0000882104-19-000089.txt : 20190807 0000882104-19-000089.hdr.sgml : 20190807 20190807163107 ACCESSION NUMBER: 0000882104-19-000089 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 102 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190807 DATE AS OF CHANGE: 20190807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDL BIOPHARMA, INC. CENTRAL INDEX KEY: 0000882104 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943023969 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19756 FILM NUMBER: 191005916 BUSINESS ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 BUSINESS PHONE: 775-832-8500 MAIL ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 FORMER COMPANY: FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE DATE OF NAME CHANGE: 19930328 10-Q 1 pdli-2019063010qdoc.htm 10-Q Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
 
 (Mark One)
ý
Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
For the quarterly period ended June 30, 2019
OR
¨
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
For transition period from               to            
Commission File Number: 000-19756
 
pdllogoa22.jpg
PDL BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
94-3023969
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices and Zip Code)

(775) 832-8500
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
Title of each class
Trading symbol
Name of each exchange on which registered
Common Stock, par value $0.01 per share
PDLI
The Nasdaq Stock Market LLC

 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  ý    No   ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes  ý    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ¨
Accelerated filer ý
Non-accelerated filer ¨
Smaller reporting company ¨
Emerging growth company ¨
 
 
 
 
 
If an emerging growth company, indicated by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)    Yes  ¨    No  ý
As of July 30, 2019, there were 114,202,671 shares of the registrant’s Common Stock outstanding.



 PDL BIOPHARMA, INC.
2019 Form 10-Q
Table of Contents
 
Page
PART I - FINANCIAL INFORMATION
 
 
 
ITEM 1.
FINANCIAL STATEMENTS (unaudited)
 
 
 
 
Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2019 and 2018
 
 
 
 
Condensed Consolidated Statements of Comprehensive (Loss) Income for the Three and Six Months Ended June 30, 2019 and 2018
 
 
 
 
Condensed Consolidated Balance Sheets at June 30, 2019 and December 31, 2018
 
 
 
 
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2019 and 2018
 
 
 
 
Notes to the Condensed Consolidated Financial Statements
 
 
 
ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
 
 
ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
 
 
ITEM 4.
CONTROLS AND PROCEDURES
 
PART II - OTHER INFORMATION
 
 
 
ITEM 1.
LEGAL PROCEEDINGS
 
 
 
ITEM 1A.
RISK FACTORS
 
 
 
ITEM 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
 
 
 
ITEM 3.
DEFAULTS UPON SENIOR SECURITIES
 
 
 
ITEM 4.
MINE SAFETY DISCLOSURES
 
 
 
ITEM 5.
OTHER INFORMATION
 
 
 
ITEM 6.
EXHIBITS
 
 
SIGNATURES
We own or have rights to certain trademarks, trade names, copyrights and other intellectual property used in our business, including PDL BioPharma and the PDL logo, each of which is considered a trademark. All other company names, product names, trade names and trademarks included in this Quarterly Report on Form 10-Q are trademarks, registered trademarks or trade names of their respective owners.

2


PART I. FINANCIAL INFORMATION

 ITEM  1.         FINANCIAL STATEMENTS

 PDL BIOPHARMA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share amounts)
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
 
 
2019
 
2018
 
2019
 
2018
Revenues
 
 
 
 
 
 
 
 
Product revenue, net
 
$
17,837

 
$
31,761

 
$
44,523

 
$
55,085

Royalty rights - change in fair value
 
(40,399
)
 
12,842

 
(28,142
)
 
23,933

Royalties from Queen et al. patents
 
6

 
1,218

 
9

 
4,001

Interest revenue
 
—

 
751

 
—

 
1,500

License and other
 
30

 
3

 
(3
)
 
574

Total revenues
 
(22,526
)
 
46,575

 
16,387

 
85,093

Operating expenses
 
 

 
 

 
 

 
 

Cost of product revenue (excluding intangible asset amortization and impairment)
 
12,348

 
14,524

 
25,158

 
25,090

Amortization of intangible assets
 
1,598

 
6,384

 
3,170

 
12,677

General and administrative
 
10,483

 
14,529

 
20,945

 
26,190

Sales and marketing
 
2,073

 
5,385

 
4,803

 
10,898

Research and development
 
886

 
684

 
1,755

 
1,477

Impairment of intangible assets
 
—

 
152,330

 
—

 
152,330

Change in fair value of contingent consideration
 
—

 
(22,135
)
 
—

 
(22,735
)
Total operating expenses
 
27,388

 
171,701

 
55,831

 
205,927

Operating loss
 
(49,914
)
 
(125,126
)
 
(39,444
)
 
(120,834
)
Non-operating income (expense), net
 
 

 
 

 
 

 
 

Interest and other income, net
 
1,650

 
1,376

 
3,524

 
3,290

Interest expense
 
(2,984
)
 
(2,811
)
 
(5,939
)
 
(6,396
)
Equity affiliate - change in fair value
 
45,487

 
—

 
45,487

 
—

Total non-operating income (expense), net
 
44,153

 
(1,435
)
 
43,072

 
(3,106
)
(Loss) income before income taxes
 
(5,761
)
 
(126,561
)
 
3,628

 
(123,940
)
Income tax (benefit) expense
 
(1,247
)
 
(14,265
)
 
1,525

 
(13,246
)
Net (loss) income
 
(4,514
)
 
(112,296
)
 
2,103

 
(110,694
)
Less: Net loss attributable to noncontrolling interests
 
(95
)
 
—

 
(158
)
 
—

Net (loss) income attributable to PDL’s shareholders
 
$
(4,419
)
 
$
(112,296
)
 
$
2,261

 
$
(110,694
)
 
 
 
 
 
 
 
 
 
Net (loss) income per share
 
 

 
 

 
 

 
 

Basic
 
$
(0.04
)
 
$
(0.76
)
 
$
0.02

 
$
(0.74
)
Diluted
 
$
(0.04
)
 
$
(0.76
)
 
$
0.02

 
$
(0.74
)
Weighted-average shares outstanding
 
 

 
 

 
 

 
 

Basic
 
118,285

 
146,923

 
123,484

 
149,186

Diluted
 
118,285

 
146,923

 
124,040

 
149,186

 
See accompanying notes.

3


PDL BIOPHARMA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
(Unaudited)
(In thousands)

 
 
Three Months Ended
 
Six Months Ended
 
 
 
June 30,
 
June 30,
 
 
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
 
 
Net (loss) income
 
$
(4,514
)
 
$
(112,296
)
 
$
2,103

 
$
(110,694
)
 
 
 
 
 
 
 
 
 
 
 
Other comprehensive loss, net of tax
 
 

 
 

 
 

 
 

 
Change in unrealized gains (losses) on investments in available-for-sale securities:
 
 
 
 
 
 
 
 
 
Change in fair value of investments in available-for-sale securities, net of tax
 
—

 
—

 
—

 
(578
)
 
Adjustment for net gains realized and included in net loss, net of tax
 
—

 
—

 
—

 
(603
)
 
Total change in unrealized gains on investments in available-for-sale securities, net of tax
 
—

 
—

 
—

 
(1,181
)
(a) 
Total other comprehensive loss, net of tax
 
—

 
—

 
—

 
(1,181
)
 
Comprehensive (loss) income
 
(4,514
)
 
(112,296
)
 
2,103

 
(111,875
)
 
Less: Comprehensive loss attributable to noncontrolling interests
 
(95
)
 
—

 
(158
)
 
—

 
Comprehensive (loss) income attributable to PDL’s shareholders
 
$
(4,419
)
 
$
(112,296
)
 
$
2,261

 
$
(111,875
)
 
 ______________________________________________
(a) Net of tax of $314 for the six months ended June 30, 2018.


See accompanying notes.

4


PDL BIOPHARMA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except per share amounts) 
 
June 30,
 
December 31,
 
2019
 
2018
 
(unaudited)
 
(Note 1)
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
284,941

 
$
394,590

Accounts receivable, net
17,872

 
21,648

Notes receivable
63,280

 
63,042

Inventory
16,263

 
18,942

Prepaid and other current assets
17,347

 
18,995

Total current assets
399,703

 
517,217

Property and equipment, net
6,914

 
7,387

Royalty rights - at fair value
315,642

 
376,510

Investment in equity affiliate
88,533

 
—

Notes receivables, long-term
547

 
771

Intangible assets, net
50,449

 
51,319

Other assets
28,673

 
10,532

Total assets
$
890,461

 
$
963,736

 
 
 
 
Liabilities and Stockholders’ Equity
 

 
 

Current liabilities:
 

 
 

Accounts payable
$
14,812

 
$
13,142

Accrued liabilities
23,499

 
39,312

Accrued income taxes
25

 
16

Total current liabilities
38,336

 
52,470

Convertible notes payable
128,520

 
124,644

Other long-term liabilities
58,181

 
56,843

Total liabilities
225,037

 
233,957

 
 
 
 
Commitments and contingencies (Note 12)


 


 
 
 
 
Stockholders’ equity:
 

 
 

Preferred stock, par value $0.01 per share, 10,000 shares authorized; no shares issued and outstanding
—

 
—

Common stock, par value $0.01 per share, 350,000 shares authorized; 115,669 and 136,513 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively
1,157

 
1,365

Additional paid-in capital
(94,465
)
 
(98,030
)
Treasury stock, at cost; 179 and 750 shares held at June 30, 2019 and December 31, 2018, respectively
(546
)
 
(2,103
)
Retained earnings
759,080

 
828,547

Total PDL stockholders’ equity
665,226

 
729,779

Noncontrolling interests
198

 
—

Total stockholders’ equity
665,424

 
729,779

Total liabilities and stockholders’ equity
$
890,461

 
$
963,736


See accompanying notes.

5


PDL BIOPHARMA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands, except share amounts)
(unaudited)

 
PDL Stockholders’ Equity
 
 
 
 
 
Common Stock
 
Treasury Stock
 
Additional
Paid-In
Capital
 
Retained Earnings
 
Accumulated
Other Comprehensive
 Income (Loss)
 
Non-controlling Interest
 
Total
Stockholders’ Equity
 
Shares
 
Amount
 
 
 
 
 
Balance at December 31, 2018
136,512,522

 
$
1,365

 
$
(2,103
)
 
$
(98,030
)
 
$
828,547

 
$
—

 
$
—

 
$
729,779

 Issuance of common stock, net of forfeitures
764,785

 
8

 
—

 
(8
)
 
—

 
—

 
—

 
—

 Stock-based compensation expense
—

 
—

 
—

 
1,169

 
—

 
—

 
—

 
1,169

Repurchase and retirement of common stock
(13,460,164
)
 
(135
)
 
613

 
—

 
(44,831
)
 
—

 
—

 
(44,353
)
Transfer of subsidiary shares to non-controlling interest
—

 
—

 
—

 
—

 
—

 
—

 
572

 
572

 Comprehensive income:


 


 
 
 


 


 


 


 
 
 Net income (loss)
—

 
—

 
—

 
—

 
6,680

 
—

 
(63
)
 
6,617

 Total comprehensive income
—

 
—

 
—

 
—

 
—

 
—

 
—

 
6,617

Balance at March 31, 2019
123,817,143

 
1,238

 
(1,490
)
 
(96,869
)
 
790,396

 
—

 
509

 
693,784

 Issuance of common stock, net of forfeitures
37,996

 
—

 
—

 
—

 
—

 
—

 
—

 
—

 Stock-based compensation expense
—

 
—

 
—

 
2,175

 
—

 
—

 
—

 
2,175

Repurchase and retirement of common stock
(8,185,970
)
 
(81
)
 
944

 
—

 
(26,897
)
 
—

 
—

 
(26,034
)
Transfer of subsidiary shares to non-controlling interest
—

 
—

 
—

 
229

 
—

 
—

 
(216
)
 
13

 Comprehensive loss:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net loss
—

 
—

 
—

 
—

 
(4,419
)
 
—

 
(95
)
 
(4,514
)
Total comprehensive loss
—

 
—

 
—

 
—

 
—

 
—

 
—

 
(4,514
)
Balance at June 30, 2019
115,669,169

 
$
1,157

 
$
(546
)
 
$
(94,465
)
 
$
759,080

 
$
—

 
$
198

 
$
665,424


 
PDL Stockholders’ Equity
 
 
 
 
 
Common Stock
 
Treasury Stock
 
Additional
Paid-In
Capital
 
Retained Earnings
 
Accumulated
Other Comprehensive
 Income (Loss)
 
Non-controlling Interest
 
Total
Stockholders’ Equity
 
Shares
 
Amount
 
 
 
 
 
Balance at December 31, 2017
153,774,756

 
$
1,538

 
$
—

 
$
(102,443
)
 
$
945,614

 
$
1,181

 
$
—

 
$
845,890

 Issuance of common stock
37,500

 
—

 
—

 
—

 
—

 
—

 
—

 
—

 Stock-based compensation expense
—

 
—

 
—

 
957

 
—

 
—

 
—

 
957

Repurchase and retirement of common stock
(1,000,000
)
 
(10
)
 
(1,188
)
 
—

 
(2,961
)
 
—

 
—

 
(4,159
)
 Comprehensive income:


 


 


 


 


 


 


 
 
Net income
—

 
—

 
—

 
—

 
1,602

 
—

 
—

 
1,602

Change in unrealized gains on investments in available-for-sale securities, net of tax
—

 
—

 
—

 
—

 
—

 
(1,181
)
 
—

 
(1,181
)
Total comprehensive income
—

 
—

 
—

 
—

 
—

 
—

 
—

 
421

Balance at March 31, 2018
152,812,256

 
1,528

 
(1,188
)
 
(101,486
)
 
944,255

 
—

 
—

 
843,109

 Issuance of common stock, net of forfeitures
324,591

 
4

 
—

 
(3
)
 
3

 
—

 
—

 
4

 Stock-based compensation expense
—

 
—

 
—

 
1,260

 
—

 
—

 
—

 
1,260

Repurchase and retirement of common stock
(7,165,415
)
 
(72
)
 
1,188

 
—

 
(20,565
)
 
—

 
—

 
(19,449
)
 Comprehensive loss:

 

 

 

 

 

 

 
 
Net loss
—

 
—

 
—

 
—

 
(112,296
)
 
—

 
—

 
(112,296
)
Total comprehensive loss
—

 
—

 
—

 
—

 
—

 
—

 
—

 
(112,296
)
Balance at June 30, 2018
145,971,432

 
$
1,460

 
$
—

 
$
(100,229
)
 
$
811,397

 
$
—

 
$
—

 
$
712,628


See accompanying notes.

6


PDL BIOPHARMA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
 
Six Months Ended June 30,
 
2019
 
2018
Cash flows from operating activities
 
 
 
Net income (loss)
$
2,103

 
$
(110,694
)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
 

 
 

Amortization of convertible notes
3,876

 
3,911

Amortization of intangible assets
3,170

 
12,677

Amortization of right-of-use assets
441

 
—

Impairment of intangible assets
—

 
152,330

Change in fair value of royalty rights - at fair value
28,142

 
(23,933
)
Change in fair value of equity affiliate
(37,907
)
 
—

Change in fair value of derivative assets
(7,577
)
 
(74
)
Change in fair value of contingent consideration
—

 
(22,735
)
Other amortization and depreciation
1,649

 
2,028

Gain on sale of available-for-sale securities
—

 
(764
)
Loss on disposal of property and equipment
—

 
66

Provision for bad debts
(7
)
 
43

Stock-based compensation expense
3,344

 
2,218

Deferred income taxes
(125
)
 
(11,276
)
Changes in assets and liabilities:
 

 
 

Accounts receivable
3,546

 
11,709

Prepaid and other current assets
1,647

 
(6,816
)
Accrued interest on notes receivable
—

 
(150
)
Inventory
1,857

 
(5,834
)
Other assets
476

 
(1,531
)
Accounts payable
1,670

 
(8,679
)
Accrued liabilities
(14,656
)
 
(11,759
)
Accrued income taxes
9

 
(1,159
)
Other long-term liabilities
167

 
666

Net cash used in operating activities
(8,175
)
 
(19,756
)
Cash flows from investing activities
 

 
 

Proceeds from sales of available-for-sale securities
—

 
4,116

Proceeds from royalty rights - at fair value
32,726

 
37,993

Purchase of intangible asset
(1,700
)
 
—

Investment in equity affiliate
(60,000
)
 
—

Purchase of property and equipment
(163
)
 
(3,915
)
Net cash (used in) provided by investing activities
(29,137
)
 
38,194

Cash flows from financing activities
 

 
 

Repayment of convertible notes
—

 
(126,447
)
Payment of contingent consideration
(1,071
)
 
—

Repurchase of Company common stock
(71,266
)
 
(23,604
)
Net cash used in financing activities
(72,337
)
 
(150,051
)
Net decrease in cash and cash equivalents
(109,649
)
 
(131,613
)
Cash and cash equivalents at beginning of the period
394,590

 
527,266

Cash and cash equivalents at end of period
$
284,941

 
$
395,653

 
 
 
 
Supplemental cash flow information
 

 
 

Cash (refunded) paid for income taxes
$
(2,693
)
 
$
3,980

Cash paid for interest
$
2,063

 
$
4,591

 
 
 
 
Supplemental schedule of non-cash investing and financing activities
 
 
 
Assets held for sale reclassified from other assets to intangible assets
$
—

 
$
1,811

See accompanying notes.

7
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)



1. Summary of Significant Accounting Policies
 
Basis of Presentation
 
The accompanying unaudited Condensed Consolidated Financial Statements of PDL Biopharma, Inc. and its subsidiaries (collectively, the “Company” or “PDL”) have been prepared in accordance with Generally Accepted Accounting Principles (United States) (“GAAP”) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments), that management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year.
 
The accompanying unaudited Condensed Consolidated Financial Statements and related financial information should be read in conjunction with the Company’s audited Consolidated Financial Statements and the related notes thereto for the year ended December 31, 2018, included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the Securities and Exchange Commission (“SEC”) on March 15, 2019. The Condensed Consolidated Balance Sheet at December 31, 2018, included herein, has been derived from the audited Consolidated Financial Statements at that date, but does not include all disclosures required by GAAP.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying Notes to the Condensed Consolidated Financial Statements. The accounting estimates that require management’s most significant, difficult and subjective judgments include the valuation of royalty rights - at fair value, product revenue recognition and allowance for customer rebates and allowances, the valuation of notes receivable and inventory, the assessment of recoverability of intangible assets and their estimated useful lives, the valuation and recognition of stock-based compensation, the recognition and measurement of current and deferred income tax assets and liabilities, and the valuation of warrants to acquire shares of common stock. Actual results could differ from those estimates.

The Condensed Consolidated Financial Statements included herein include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Based on the nature of the Company’s existing investments and how they are managed, the Company structured its operations in four segments designated as Pharmaceutical, Medical Devices, Strategic Positions and Income Generating Assets. During the second quarter of 2019 the Company made an investment in Evofem Biosciences, Inc. (“Evofem”) and added a new segment designated as Strategic Positions. This had no impact on its prior segment reporting structure.
•
The Company’s Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna® and Tekturna HCT® in the United States and Rasilez® and Rasilez HCT® in the rest of the world and an authorized generic form of Tekturna sold in the United States (collectively, the “Noden Products”). The branded prescription Noden Products were acquired from Novartis in July 2016 (the “Noden Transaction”) by the Company’s wholly-owned subsidiary, Noden Pharma DAC (“Noden DAC”). The Company, through its wholly-owned subsidiary, Noden Pharma USA Inc. (“Noden USA”) launched its authorized generic form of Tekturna in the United States in March 2019.
•
The Company’s Medical Devices segment consists of revenue derived from the LENSAR® Laser System sales made by the Company’s subsidiary, LENSAR, Inc. (“LENSAR”), which may include equipment, Patient Interface Devices (“PIDs” or “consumables”), procedure licenses, training, installation, warranty and maintenance agreements.
•
The Company’s Strategic Positions segment consists of an investment in Evofem. The Company’s investment includes shares of common stock and warrants to purchase additional shares of common stock. Evofem is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Evofem is leveraging its proprietary Multipurpose Vaginal pH Regulator (MVP-R™) platform to develop Amphora® (L-lactic acid, citric acid and potassium bitartrate) for hormone-free birth control.
•
The Company’s Income Generating Assets segment consists of revenue derived from (i) royalty rights - at fair value, (ii) notes and other long-term receivables, (iii) equity investments and (iv) royalties from issued patents in the United States and elsewhere covering the humanization of antibodies (“Queen et al. patents”).


8
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


Significant Accounting Policies

The Company’s significant accounting policies are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018. Summarized below and in Note 2, Investment in Evofem Biosciences, Inc., are the accounting pronouncements and policies adopted subsequent to December 31, 2018.

Adopted Accounting Pronouncements

Leases

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases, that supersedes Accounting Standards Codification (“ASC”) 840, Leases. Subsequently, the FASB issued several updates to ASU No. 2016-02, codified in ASC Topic 842 (“ASC 842”). The Company adopted ASC 842, Leases, on January 1, 2019 using the modified retrospective method for all leases not substantially completed as of the date of adoption. The reported results for the three and six month periods ended June 30, 2019 reflect the application of ASC 842 guidance while the reported results for the three and six month periods ended June 30, 2018 were prepared under the guidance of ASC 840, which is also referred to herein as “legacy GAAP” or the “previous guidance”. The cumulative impact of the adoption of ASC 842 was not material, therefore, the Company did not record any adjustments to retained earnings. As a result of adopting ASC 842, the Company recorded operating lease right-of-use (“ROU”) assets of $2.1 million and operating lease liabilities of $2.1 million, primarily related to corporate office leases, based on the present value of the future lease payments on the date of adoption. Changes to lessor accounting focused on conforming with certain changes made to lessee accounting and the recently adopted revenue recognition guidance. The adoption of ASC 842 did not materially change how the Company accounts for lessor arrangements.
Policy Elections and Practical Expedients Taken
For leases that commenced before the effective date of ASC 842, the Company elected the practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases.
The Company adopted a policy of expensing short-term leases, defined as 12 months or less, as incurred.
The Company has a policy to exclude from the consideration in a lessor contract all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific lease revenue-producing transaction and collected by the Company from a lessee.
General
The Company determines if an arrangement is a lease or contains an embedded lease at inception. The Company has lease arrangements with lease and non-lease components, which are accounted for separately.
Lessee arrangements
Lessee operating leases are included in Other assets, Accrued liabilities, and Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheet. The Company does not have lessee financing leases.
Operating lease ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses the implicit rate when readily determinable at lease inception. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company’s remaining lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis as operating expense in the Condensed Consolidated Statements of Operations over the lease term.
Lessor arrangements
The Company leases medical device equipment to customers in both operating lease and sales-type lease arrangements generated from its Medical Devices segment.

9
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


For sales-type leases, the Company derecognizes the carrying amount of the underlying asset and capitalizes the net investment in the lease, which consists of the total minimum lease payments receivable from the lessee, at lease inception. The Company does not estimate an unguaranteed residual value of the equipment at lease termination because the equipment transfers to the lessee upon completion of the lease. Selling profit or loss is recognized at lease inception. Initial direct costs are recognized as an expense, unless there is no selling profit or loss. If there is no selling profit or loss, initial direct costs are deferred and recognized over the lease term. The Company recognizes interest income from the lease receivable over the lease term in Interest and other income, net in the Condensed Consolidated Statements of Operations.
 
For operating leases, rental income is recognized on a straight-line basis over the lease term. The cost of customer-leased equipment is recorded within Property and equipment, net in the accompanying Condensed Consolidated Balance Sheets and depreciated over the equipment’s estimated useful life. Depreciation expense associated with the leased equipment under operating lease arrangements is reflected in Cost of product revenue in the accompanying Condensed Consolidated Statements of Operations. Some of the Company’s operating leases include a purchase option for the customer to purchase the leased asset at the end of the lease arrangement. The Company manages its risk on its investment in the equipment through pricing and the term of the leases. Lessees do not provide residual value guarantees on leased equipment. Equipment returned to the Company may be leased or sold to other customers. Initial direct costs are deferred and recognized over the lease term.

Leases are generally not cancellable until after an initial term and may or may not require the customer to purchase a minimum number of procedures and consumables throughout the contract term.

For lease arrangements with lease and non-lease components where the Company is the lessor, the Company allocates the contract’s transaction price to the lease and non-lease components on a relative standalone selling price basis using the Company’s best estimate of the standalone selling price of each distinct product or service in the contract. Allocation of the transaction price is determined at the inception of the lease arrangement. The Company’s leases primarily consist of leases with fixed lease payments. For those leases with variable lease payments, the variable lease payment is typically based upon use of the leased equipment or the purchase of procedure licenses and consumables used with the leased equipment. Non-lease components are accounted for under ASC 606, Revenue from Contracts with Customers. For additional information regarding ASC 606, see Note 15, Revenue from Contracts with Customers.
Intangibles-Goodwill and Other
In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other: Simplifying the Test for Goodwill Impairment, to simplify the subsequent measurement of goodwill by eliminating step two from the goodwill impairment test. Under the amendments, an entity will recognize an impairment charge for the amount by which the carrying value exceeds the fair value. The amendments are effective for fiscal years and interim periods within those years beginning after December 15, 2019 on a prospective basis and early adoption is permitted. The Company adopted the requirements of ASU No. 2017-04 on January 1, 2019. The adoption did not have an effect on the Company’s Consolidated Financial Statements on the adoption date.

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. The new guidance amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses. ASU No. 2016-13 has an effective date of the fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is currently evaluating the impact of this guidance on its Consolidated Financial Statements.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement. The new guidance modifies disclosure requirements related to fair value measurement. The amendments in ASU No. 2018-13 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Implementation on a prospective or retrospective basis varies by specific disclosure requirement. Early adoption is permitted. The standard also allows for early adoption of any removed or modified disclosures upon issuance of ASU No. 2018-13 while delaying adoption of the additional disclosures until their effective date. The Company is currently evaluating the impact of this guidance on the its Consolidated Financial Statement disclosures.

In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software. The new guidance reduces complexity for the accounting for costs of implementing a cloud computing service arrangement and aligns the

10
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). For public companies, the amendments in ASU No. 2018-15 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. Implementation should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The Company is currently evaluating the impact of this guidance on the Company’s Consolidated Financial Statements.

2. Investment in Evofem Biosciences, Inc.

Equity Investment in Evofem Biosciences, Inc.

On April 10, 2019, the Company entered into a securities purchase agreement with Evofem and two other purchasers, pursuant to which the Company purchased $60.0 million of Evofem securities in a private placement. The transaction was structured in two tranches.

The first tranche closed on April 11, 2019, pursuant to which the Company invested $30.0 million to purchase 6,666,667 shares of Evofem common stock at $4.50 per share and was also issued warrants to purchase up to 1,666,667 shares of Evofem common stock exercisable for seven years beginning six months after the issuance date at an exercise price of $6.38 per share.

The second tranche closed on June 10, 2019, pursuant to which the Company invested an additional $30.0 million to purchase an additional 6,666,667 shares of Evofem common stock at $4.50 per share and was also issued warrants to purchase up to an additional 1,666,667 shares of Evofem common stock with the same terms as the warrants issued in the first tranche. Following the closing of the second tranche, the Company appointed one member to Evofem’s Board of Directors and has a limited right to have one board observer participate in Evofem board meetings.

The Company has registration rights on customary terms for all Evofem shares issued under the securities purchase agreement, including the shares underlying the warrants.

As of June 30, 2019, the Company owned approximately 29% of Evofem’s common stock. The Company’s investment in Evofem qualifies for equity method accounting given its percentage ownership in Evofem and the ability to exercise significant influence. The Company elected the fair value method to account for its investment in Evofem as it believes it better reflects economic reality, the financial reporting of the investment and the current value of the asset. Changes in fair value of the Evofem equity investment are presented in Non-operating income (expense), net on the Condensed Consolidated Statements of Operations. Because the mark to market valuation will occur at the end of each quarterly reporting period, changes in fair value will vary based upon the volatility of the stock price. The Evofem equity investment is presented on the Condensed Consolidated Balance Sheet as an Investment in equity affiliate and reflects the fair value of the equity investment at the end of the reporting period.

For the three and six months ended June 30, 2019, the Company has recognized an unrealized gain of $45.5 million, of which $37.9 million was related to Evofem common stock and $7.6 million was related to Evofem warrants.

Following are condensed consolidated balance sheet data for Evofem as of June 30, 2019:
(in thousands)
 
June 30, 2019
 
 
(unaudited)
 
 
 
Current assets
 
$
52,849

Non-current assets
 
$
1,566

Current liabilities
 
$
18,623

Non-current liabilities
 
$
—

Total stockholders’ equity
 
$
35,792



11
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


Following are condensed consolidated statements of operations data for Evofem for the three and six months ended June 30, 2019:
 
Three months ended
 
Six months ended
(in thousands)
June 30, 2019
 
June 30, 2019
 
(unaudited)
 
(unaudited)
 
 
 
Revenues
$
—

 
$
—

Operating loss
$
(11,941
)
 
$
(25,573
)
Net loss
$
(35,450
)
 
$
(53,518
)

3. Cash and Cash Equivalents
 
As of June 30, 2019 and December 31, 2018 the Company had invested its excess cash balances primarily in money market funds. The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.

The following table summarizes the Company’s cash and cash equivalents by significant investment category as of June 30, 2019 and December 31, 2018:
(in thousands)
 
June 30, 2019
 
December 31, 2018
 
 
 
 
 
Cash
 
$
55,987

 
$
167,871

Money market funds
 
228,954

 
226,719

Total
 
$
284,941

 
$
394,590


The Company recognized zero and $0.8 million of gains on sales of available-for-sale securities in the three and six months ended June 30, 2018, respectively. As of June 30, 2019 and December 31, 2018 the Company had no available-for-sale securities.

4. Inventories

Inventories consisted of the following:
(in thousands)
 
June 30, 2019
 
December 31, 2018
 
 
 
 
 
Raw materials
 
$
6,023

 
$
6,214

Work in process
 
2,629

 
549

Finished goods
 
7,611

 
12,179

Total inventory
 
$
16,263

 
$
18,942


As of June 30, 2019 and December 31, 2018, the Company deferred approximately $0.1 million and $0.5 million, respectively, of costs associated with inventory transfers made under the Company’s third party logistic provider service arrangement. These costs have been recorded as Prepaid and other current assets on the Company’s Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018. The Company will recognize the cost of product sold as inventory is transferred from its third-party logistics provider to the Company’s customers.

5. Fair Value Measurements

The fair value of the Company’s financial instruments are estimates of the amounts that would be received if the Company were to sell an asset or pay to transfer a liability in an orderly transaction between market participants at the measurement date or exit price. The assets and liabilities are categorized and disclosed in one of the following three categories:

Level 1 – based on quoted market prices in active markets for identical assets and liabilities;
 

12
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


Level 2 – based on observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
 
Level 3 – based on unobservable inputs using management’s best estimate and assumptions when inputs are unavailable.

Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis

The following table presents the fair value of the Company’s financial instruments measured at fair value on a recurring basis by level within the valuation hierarchy:
 
 
June 30, 2019
 
December 31, 2018
(in thousands)
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market funds
 
$
228,954

 
$
—

 
$
—

 
$
228,954

 
$
226,719

 
$
—

 
$
—

 
$
226,719

Corporate securities(1)
 
88,533

 
—

 
—

 
88,533

 
—

 
—

 
—

 
—

Warrants(2)
 
—

 
17,013

 
—

 
17,013

 
—

 
62

 
—

 
62

Royalty rights - at fair value
 
—

 
—

 
315,642

 
315,642

 
—

 
—

 
376,510

 
376,510

Total
 
$
317,487

 
$
17,013

 
$
315,642

 
$
650,142

 
$
226,719

 
$
62

 
$
376,510

 
$
603,291

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial liabilities:
 
 

 
 

 
 
 
 

 
 

 
 

 
 
 
 

Contingent consideration, current(3)
 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
1,071

 
$
1,071

Total
 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
1,071

 
$
1,071

___________________
(1) 
Corporate securities are classified as “Investment in equity affiliate” on the Condensed Consolidated Balance Sheet.
(2) 
Warrants are included in “Other assets” on the Condensed Consolidated Balance Sheets.
(3) 
Contingent consideration, current is classified as “Accrued liabilities” on the Condensed Consolidated Balance Sheet.

There have been no transfers between levels during the periods presented in the table above. The Company recognizes transfers between levels on the date of the event or change in circumstances that caused the transfer.

Money Market Funds - The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.

Corporate Securities - Corporate securities consists of common stock shares of Evofem, a clinical-stage biopharmaceutical company listed on Nasdaq. For additional information on the Evofem investment, see Note 2, Investment in Evofem.

Warrants - Warrants consist of rights to purchase shares of common stock in Evofem and CareView Communications, Inc. (“CareView”), see Note 2, Investment in Evofem, and Note 6, Notes and Other Long-Term Receivables. The fair value of the warrants is estimated using recently quoted market prices of the underlying equity security and the Black-Scholes option pricing model.

Royalty Rights - At Fair Value

Assertio (Depomed) Royalty Agreement

On October 18, 2013, the Company entered into the Royalty Purchase and Sale Agreement (the “Assertio Royalty Agreement”) with Assertio Therapeutics, Inc. (formerly known as Depomed, Inc.), and Depo DR Sub, LLC (together, “Assertio”), whereby the Company acquired the rights to receive royalties and milestones payable on sales of five Type 2 diabetes products licensed

13
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


by Assertio in exchange for a $240.5 million cash payment. Total consideration was $241.3 million, which was comprised of the $240.5 million cash payment to Assertio and $0.8 million in transaction costs.

The rights acquired include Assertio’s royalty and milestone payments accruing from and after October 1, 2013: (a) from Santarus, Inc. (“Santarus”), which was subsequently acquired by Salix Pharmaceuticals, Inc. (“Salix”), which itself was acquired by Valeant Pharmaceuticals International, Inc. (“Valeant”), which, in July 2018, changed its name to Bausch Health Companies Inc. (“Bausch Health”) with respect to sales of Glumetza (metformin HCL extended-release tablets) in the United States; (b) from Merck & Co., Inc. with respect to sales of Janumet® XR (sitagliptin and metformin HCL extended-release tablets); (c) from Janssen Pharmaceutica N.V. with respect to potential future development milestones and sales of its approved fixed-dose combination of Invokana® (canagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor) and extended-release metformin tablets, marketed as Invokamet XR®; (d) from Boehringer Ingelheim and Eli Lilly and Company with respect to potential future development milestones and sales of the investigational fixed-dose combinations of drugs and extended-release metformin subject to Assertio’s license agreement with Boehringer Ingelheim, including its approved products, Jentadueto XR® and Synjardy XR®; and (e) from LG Life Sciences and Bausch Health for sales of extended-release metformin tablets in Korea and Canada, respectively.

In February 2013, a generic equivalent to Glumetza was approved by the U.S. Food and Drug Administration (“FDA”) and in August 2016, two additional generic equivalents to Glumetza were approved by the FDA. In February 2016, Lupin Pharmaceuticals, Inc., in August 2017, Teva Pharmaceutical Industries Ltd., and in July 2018, Sun Pharmaceutical, Inc. (“Sun”) each launched a generic equivalent approved product. In May 2017, the Company received notification that a subsidiary of Valeant had launched an authorized generic equivalent product in February 2017, and the Company received royalties on such authorized generic equivalent product under the same terms as the branded Glumetza product, retroactive to February 2017. The Company continues to monitor whether the generic competition further affects sales of Glumetza and thus royalties on such sales paid to the Company, and the impact of the launched authorized generic equivalent. Due to the uncertainty around Bausch Health’s marketing and pricing strategy, as well as Sun’s recently launched generic product and limited historical demand data after generic market entrance, the Company may need to further evaluate future cash flows in the event of more rapid reduction or increase in market share of Glumetza and its authorized generic equivalent product and/or a further erosion in net pricing.

The Company determined that its royalty purchase interest in Depo DR Sub, LLC represented a variable interest in a variable interest entity. However, the Company did not have the power to direct the activities of Depo DR Sub, LLC that most significantly impact Depo DR Sub, LLC’s economic performance and was not the primary beneficiary of Depo DR Sub, LLC; therefore, Depo DR Sub, LLC was not subject to consolidation by the Company.

On August 2, 2018, PDL Investment Holding, LLC (“PDLIH”), a wholly-owned subsidiary of the Company and assignee from the Company under the Assertio Royalty Agreement, entered into an amendment to the Assertio Royalty Agreement with Assertio. Pursuant to the amendment, PDLIH purchased all of Assertio’s remaining interests in royalty and milestone payments payable on sales of Type 2 diabetes products licensed by Assertio for $20.0 million. Prior to the amendment, the Assertio Royalty Agreement provided that the Company would have received all royalty and milestone payments due under license agreements between Assertio and its licensees until the Company received payments equal to two times the cash payment it made to Assertio, or approximately $481.0 million, after which all net payments received by Assertio would have been shared equally between the Company and Assertio. Following the amendment, the Assertio Royalty Agreement provides that the Company will receive all royalty and milestone payments due under the license agreements between Assertio and its licensees. The Company has elected to continue to follow the fair value option and carry the financial asset at fair value.

The Assertio Royalty Agreement terminates on the third anniversary following the date upon which the later of the following occurs: (a) October 25, 2021, or (b) at such time as no royalty payments remain payable under any license agreement and each of the license agreements has expired by its terms.

As of December 31, 2018, in conjunction with the amendment described above, the Company was provided the power to direct the activities of Depo DR Sub, LLC and is the primary beneficiary of Depo DR Sub, LLC; therefore, Depo DR Sub, LLC is subject to consolidation by the Company. As of June 30, 2019, Depo DR Sub, LLC did not have any assets or liabilities of value for consolidation with the Company.


14
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


In October 2018, PDL submitted notice of its intent to exercise its audit right under the Assertio Royalty Agreement with respect to Glumetza royalties for the period beginning January 1, 2016 and ending December 31, 2018. No material adjustments were identified in connection with this audit.

The financial asset acquired represents a single unit of accounting. This financial asset is classified as a Level 3 asset within the fair value hierarchy, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future commercialization for products not yet approved by regulatory agencies outside of the United States. The estimated fair value of the financial asset acquired was determined by using a discounted cash flow analysis related to the expected future cash flows to be generated by each licensed product. The discounted cash flows are based upon expected royalties from sales of licensed products over approximately an eight-year period. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. The Company periodically assesses the expected future cash flows and to the extent such payments are greater or less than its initial estimates, or the timing of such payments is materially different than the original estimates, the Company will adjust the estimated fair value of the asset. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $6.6 million, respectively. Significant judgment is required in selecting appropriate discount rates. The discount rates utilized range from 10% to 24%. Should these discount rates increase or decrease by 2.5%, the fair value of the asset could decrease by $22.2 million or increase by $26.3 million, respectively.

As of June 30, 2019, the Company’s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date for the above described royalty streams.

As of June 30, 2019, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was $263.9 million and the maximum loss exposure was $263.9 million.

Viscogliosi Brothers Royalty Agreement

On June 26, 2014, the Company entered into a Royalty Purchase and Sale Agreement (the “VB Royalty Agreement”) with Viscogliosi Brothers, LLC (“VB”), whereby VB conveyed to the Company the right to receive royalties payable on sales of a spinal implant that has received pre-market approval from the FDA held by VB and commercialized by Paradigm Spine, LLC (“Paradigm Spine”), in exchange for a $15.5 million cash payment, less fees. Paradigm Spine was acquired in March 2019 by RTI Surgical Holdings, Inc.

The royalty rights acquired include royalties accruing from and after April 1, 2014. Under the terms of the VB Royalty Agreement, the Company receives all royalty payments due to VB pursuant to certain technology transfer agreements between VB and Paradigm Spine until the Company has received payments equal to 2.3 times the cash payment made to VB, after which all rights to receive royalties will be returned to VB. VB’s ability to repurchase the royalty right for a specified amount expired on June 26, 2018.

The estimated fair value of the royalty rights at June 30, 2019, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over approximately a nine-year period. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. The Company periodically assesses the expected future cash flows and to the extent such payments are greater or less than its initial estimates, or the timing of such payments is materially different than the original estimates, the Company will adjust the estimated fair value of the asset. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.4 million, respectively. Significant judgment is required in selecting the appropriate discount rate. The discount rate utilized was 15.0%. Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $1.3 million or increase by $1.5 million, respectively.

As of June 30, 2019, the Company’s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date.


15
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


As of June 30, 2019, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was $14.4 million and the maximum loss exposure was $14.4 million.

University of Michigan Royalty Agreement

On November 6, 2014, the Company acquired a portion of all royalty payments of the Regents of the University of Michigan’s (“U-M”) worldwide royalty interest in Cerdelga® (eliglustat) for $65.6 million pursuant to the Royalty Purchase and Sale Agreement with U-M (the “U-M Royalty Agreement”). Under the terms of the U-M Royalty Agreement, the Company receives 75% of all royalty payments due under U-M’s license agreement with Genzyme Corporation, a Sanofi company (“Genzyme”) until expiration of the licensed patents, excluding any patent term extension. Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme. Cerdelga was approved in the United States in August 2014, in the European Union in January 2015, and in Japan in March 2015. In addition, marketing applications for Cerdelga are under review by other regulatory authorities. While marketing applications have been approved in the United States, the European Union and Japan, national pricing and reimbursement decisions are delayed in some countries.

The estimated fair value of the royalty right at June 30, 2019 was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over approximately a three-year period. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. An evaluation of those estimates, discount rate utilized and general market conditions affecting fair market value is performed in each reporting period. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.6 million, respectively. Significant judgment is required in selecting the appropriate discount rate. The discount rate utilized was approximately 12.8%. Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $0.9 million or increase by $1.0 million, respectively.

As of June 30, 2019, the Company’s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows.

As of June 30, 2019, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was $24.3 million and the maximum loss exposure was $24.3 million.

AcelRx Royalty Agreement

On September 18, 2015, the Company entered into a royalty interest assignment agreement (the “AcelRx Royalty Agreement”) with ARPI LLC, a wholly-owned subsidiary of AcelRx Pharmaceuticals, Inc. (“AcelRx”), whereby the Company acquired the rights to receive a portion of the royalties and certain milestone payments on sales of Zalviso® (sufentanil sublingual tablet system) in the European Union, Switzerland and Australia by AcelRx’s commercial partner, Grünenthal, in exchange for a $65.0 million cash payment. Under the terms of the AcelRx Royalty Agreement, the Company receives 75% of all royalty payments and 80% of the first four commercial milestone payments due under AcelRx’s license agreement with Grünenthal until the earlier to occur of (i) receipt by the Company of payments equal to three times the cash payments made to AcelRx and (ii) the expiration of the licensed patents. Zalviso received marketing approval by the European Commission in September 2015. Grünenthal launched Zalviso in the second quarter of 2016 and the Company started to receive royalties in the third quarter of 2016.

As of June 30, 2019, and December 31, 2018, the Company determined that its royalty rights under the AcelRx Royalty Agreement represented a variable interest in a variable interest entity. However, the Company does not have the power to direct the activities of ARPI LLC that most significantly impact ARPI LLC’s economic performance and is not the primary beneficiary of ARPI LLC; therefore, ARPI LLC is not subject to consolidation by the Company.

Due to the slower than expected adoption of the product since its initial launch relative to the Company’s estimates and the increased variance noted between the Company’s forecast model and actual results in the three months ended June 30, 2019, the Company utilized a third-party expert in the second quarter of 2019 to reassess the market and expectations for the Zalviso product. Key findings from the third-party study included: the post-surgical PCA (Patient-Controlled Analgesia) market being smaller than previously forecasted; the higher price of the product relative to alternative therapies, the product not being used as

16
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


a replacement for systemic opioids and the design of the delivery device, which is pre-filled for up to three days of treatment, which restricts its use for shorter recovery time procedures. Based on this analysis and the impact to the projected sales-based royalties and milestones, the Company wrote down the fair value of the royalty asset by $60.0 million in the second quarter of 2019.

The estimated fair value of the royalty right at June 30, 2019 was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over approximately a fourteen-year period. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. An evaluation of those estimates, discount rate utilized and general market conditions affecting fair market valuation is performed for each reporting period. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by less than $0.3 million, respectively. Significant judgment is required in selecting the appropriate discount rate. The discount rate utilized was approximately 13.4%. Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $1.2 million or increase by $1.5 million, respectively.

As of June 30, 2019, the Company’s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date.

As of June 30, 2019, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was $12.5 million and the maximum loss exposure was $12.5 million.

Kybella Royalty Agreement

On July 8, 2016, the Company entered into a royalty purchase and sales agreement with an individual, whereby the Company acquired that individual’s rights to receive certain royalties on sales of KYBELLA® by Allergan plc in exchange for a $9.5 million cash payment and up to $1.0 million in future milestone payments based upon product sales targets. The Company started to receive royalty payments during the third quarter of 2016.

The estimated fair value of the royalty right at June 30, 2019, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of a licensed product over approximately a six-year period. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. An evaluation of those estimates, discount rate utilized and general market conditions affecting fair market value is performed in each reporting period. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by less than $0.1 million, respectively. Significant judgment is required in selecting the appropriate discount rate. The discount rate utilized was approximately 14.4%. Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease or increase by less than $0.1 million, respectively.

As of June 30, 2019, the Company’s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date.

As of June 30, 2019, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was $0.6 million and the maximum loss exposure was $0.6 million.


17
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


The following tables summarize the changes in Level 3 Royalty Right Assets and the gains and losses included in earnings for the six months ended June 30, 2019:
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets
 
 
 
 
 
 
 
(in thousands)
 
Royalty Rights -
At Fair Value
Fair value as of December 31, 2018
 
 
 
$
376,510

 
 
 
 
 
 
 
 
Total net change in fair value for the period
 
 
 
 
 
 
Change in fair value of royalty rights - at fair value
 
$
(28,142
)
 
 
 
 
Proceeds from royalty rights - at fair value
 
$
(32,726
)
 
 
 
 
Total net change in fair value for the period
 
 
 
(60,868
)
 
 
 
 
 
 
 
Fair value as of June 30, 2019
 


 
$
315,642


Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets
 
 
 
 
 
 
 
 
 
Fair Value as of
 
Royalty Rights -
 
Fair Value as of
(in thousands)
 
December 31, 2018
 
Change in Fair Value
 
June 30, 2019
 
 
 
 
 
 
 
Assertio (formerly Depomed)
 
$
264,371

 
$
(459
)
 
$
263,912

VB
 
14,108

 
265

 
14,373

U-M
 
25,595

 
(1,316
)
 
24,279

AcelRx
 
70,380

 
(57,886
)
 
12,494

KYBELLA
 
2,056

 
(1,472
)
 
584

 
 
$
376,510

 
$
(60,868
)
 
$
315,642



18
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


The following table summarizes the changes in Level 3 Liabilities and the gains and losses included in earnings for the six months ended June 30, 2019:
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Liabilities
 
 
 
(in thousands)
 
Contingent Consideration
Fair value as of December 31, 2018
 
$
(1,071
)
 
 
 
 
 
 
Settlement of financial instrument(1)
 
1,071

 
 
 
 
 
Fair value as of June 30, 2019
 
$
—

______________
(1) 
Represents the final conversion consideration and earn out liability for the LENSAR acquisition of assets from Precision Eye Services.

Gains and losses from changes in Level 3 assets included in earnings for each period are presented in “Royalty rights - change in fair value” and gains and losses from changes in Level 3 liabilities included in earnings for each period are presented in “Change in fair value of anniversary payment and contingent consideration” as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
Total change in fair value for the period included in earnings for royalty right assets held at the end of the reporting period
 
$
(40,399
)
 
$
12,842

 
$
(28,142
)
 
$
23,933

 
 
 
 
 
 
 
 
 
Total change in fair value for the period included in earnings for liabilities held at the end of the reporting period
 
$
—

 
$
22,135

 
$
—

 
$
22,735


Assets/Liabilities Measured and Recorded at Fair Value on a Nonrecurring Basis

The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets consist of long-lived assets, including property and equipment and intangible assets and the shares of Alphaeon Class A common stock, received in connection with loans made to LENSAR by the Company prior to its acquisition of LENSAR. During the three months ended June 30, 2018, the Company recorded an impairment charge of $152.3 million for the Noden intangible assets related to the increased probability of a generic form of aliskiren being launched in the United States. As a result of this impairment charge, which was based on the estimated fair value of the assets, the remaining carrying value of these intangible assets was determined to be $40.1 million. The fair value calculation included level 3 inputs. The Company’s carrying value of the investment in Alphaeon as of both June 30, 2019 and December 31, 2018 is $6.6 million based on an estimated per share value of $3.84, which was established by a valuation performed when the 1.7 million shares were acquired. The value of the Company’s investment in Alphaeon is not readily determinable as Alphaeon’s shares are not publicly traded. The Company evaluates the fair value of this investment by performing a qualitative assessment each reporting period. If the results of this qualitative assessment indicate that the fair value is less than the carrying value, the investment is written down to its fair value. There have been no such write downs since the Company acquired these shares. This investment is included in Other long-term assets. For additional information on the Alphaeon investment, see Note 6, Notes and Other Long-Term Receivables.


19
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


Assets/Liabilities Not Subject to Fair Value Recognition

The following tables present the fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy:
 
 
June 30, 2019
 
December 31, 2018
(in thousands)
 
Carrying Value
 
Fair Value
Level 2
 
Fair Value
Level 3
 
Carrying Value
 
Fair Value
Level 2
 
Fair Value
Level 3
 
 
 
 
 
 
 
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
Wellstat Diagnostics note receivable
 
$
50,191

 
$
—

 
$
59,240

 
$
50,191

 
$
—

 
$
57,322

Hyperion note receivable
 
1,200

 
—

 
1,200

 
1,200

 
—

 
1,200

CareView note receivable
 
11,458

 
—

 
11,458

 
11,458

 
—

 
11,458

Total
 
$
62,849

 
$
—

 
$
71,898

 
$
62,849

 
$
—

 
$
69,980

 
 
 
 
 
 
 
 
 
 
 
 
 
Liabilities:
 
 

 
 

 
 

 
 

 
 

 
 

December 2021 Notes
 
$
128,520

 
$
157,017

 
$
—

 
$
124,644

 
$
151,356

 
$
—

Total
 
$
128,520

 
$
157,017

 
$
—

 
$
124,644

 
$
151,356

 
$
—


During the year ended December 31, 2018 the Company recorded an impairment loss of $8.2 million to the note receivable with CareView Communications, Inc. (“CareView”). There were no impairment losses on notes receivable in the three and six month periods ended June 30, 2019.

As of June 30, 2019 and December 31, 2018, the estimated fair values of the Hyperion Catalysis International, Inc. (“Hyperion”) note receivable, and CareView note receivable were determined using discounted cash flow models, incorporating expected principal and interest payments. In addition, during the year ended December 31, 2018, the fair value of the CareView note receivable also considered the recoverability of the note receivable balance utilizing third-party revenue multiples for small cap healthcare technology companies. As of June 30, 2019 and December 31, 2018, the estimated fair value of the Wellstat Diagnostics note receivable was determined by using an asset approach and discounted cash flow model related to the underlying collateral and adjusted to consider estimated costs to sell the assets.

The Company determined its notes receivable assets are Level 3 assets as the Company’s valuations utilized significant unobservable inputs, including estimates of future revenues, discount rates, expectations about settlement, terminal values, required yield and the value of underlying collateral. The Company engages a third-party valuation expert when deemed necessary to assist in evaluating its investments and the related inputs needed to estimate the fair value of certain investments.

The CareView note receivable is secured by substantially all assets of, and equity interests in CareView. The Wellstat Diagnostics note receivable is secured by substantially all assets of Wellstat Diagnostics and is supported by a guaranty from the Wellstat Diagnostics Guarantors (as defined in Note 6, Notes and Other Long-Term Receivables).

On June 30, 2019, the carrying value of one of the Company’s notes receivable assets differed from its estimated fair value. This is the result of inputs used in estimating the fair value of the collateral, including appraisals, projected cash flows of collateral assets and discount rates used when performing a discounted cash flow analysis.

The fair values of the Company’s convertible senior notes were determined using quoted market pricing.


20
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


The following table represents significant unobservable inputs used in determining the estimated fair value of impaired notes receivable investments:
Asset
 
Valuation
Technique
 
Unobservable
Input
 
June 30, 2019
 
December 31, 2018
 
 
 
 
 
 
 
 
 
Wellstat Diagnostics
 
 
 
 
 
 
 
 
Wellstat Guarantors intellectual property
 
Income Approach
 
 
 
 
 
 
 
 
 
 
Discount rate
 
12%
 
12%
 
 
 
 
Royalty amount
 
$21 million
 
$21 million
Settlement Amount
 
Income Approach
 
 
 
 
 
 
 
 
 
 
Discount rate
 
15%
 
15%
 
 
 
 
Settlement amount
 
$34 million
 
$34 million
 
 
 
 
 
 
 
 
 
Real Estate Property
 
Market Approach
 
 
 
 
 
 
 
 
 
 
Annual appreciation rate
 
4%
 
4%
 
 
 
 
Estimated realtor fee
 
6%
 
6%
 
 
 
 
Estimated disposal date
 
9/30/2019
 
9/30/2019
 
 
 
 
 
 
 
 
 
CareView
 
 
 
 
 
 
 
 
Note receivable cash flows
 
Income Approach
 
 
 
 
 
 
 
 
 
 
Discount rate
 
30%
 
30%

6. Notes and Other Long-Term Receivables

Notes and other long-term receivables included the following significant agreements:

Wellstat Diagnostics Note Receivable and Credit Agreement and Related Litigation

On November 2, 2012, the Company and Wellstat Diagnostics entered into a $40.0 million credit agreement pursuant to which the Company was to accrue quarterly interest payments at the rate of 5% per annum (payable in cash or in kind). In addition, the Company was to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics’ net revenues, generated by the sale, distribution or other use of Wellstat Diagnostics’ products, if any, commencing upon the commercialization of its products. A portion of the proceeds of the $40.0 million credit agreement were used to repay certain notes receivable which Wellstat Diagnostics entered into in March 2012.

In January 2013, the Company was informed that, as of December 31, 2012, Wellstat Diagnostics had used funds contrary to the terms of the credit agreement and breached Sections 2.1.2 and 7 of the credit agreement. The Company sent Wellstat Diagnostics a notice of default on January 22, 2013, and accelerated the amounts owed under the credit agreement. In connection with the notice of default, the Company exercised one of its available remedies and transferred approximately $8.1 million of available cash from a bank account of Wellstat Diagnostics to the Company and applied the funds to amounts due under the credit agreement. On February 28, 2013, the parties entered into a forbearance agreement whereby the Company agreed to refrain from exercising additional remedies for 120 days. During such forbearance period, the Company provided approximately $1.3 million to Wellstat Diagnostics to fund ongoing operations of the business. During the year ended December 31, 2013, approximately $8.7 million was advanced pursuant to the forbearance agreement.

On August 15, 2013, the Company entered into an amended and restated credit agreement with Wellstat Diagnostics. The Company determined that the new agreement should be accounted for as a modification of the existing agreement.

Except as otherwise described herein, the material terms of the amended and restated credit agreement are substantially the same as those of the original credit agreement, including quarterly interest payments at the rate of 5% per annum (payable in cash or in kind). In addition, the Company was to continue to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics’ net revenues. However, pursuant to the amended and restated credit agreement: (i) the

21
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


principal amount was reset to approximately $44.1 million, which was comprised of approximately $33.7 million original loan principal and interest, $1.3 million term loan principal and interest and $9.1 million forbearance principal and interest; (ii) the specified internal rates of return increased; (iii) the default interest rate was increased; (iv) Wellstat Diagnostics’ obligation to provide certain financial information increased in frequency to monthly; (v) internal financial controls were strengthened by requiring Wellstat Diagnostics to maintain an independent, third-party financial professional with control over fund disbursements; (vi) the Company waived the existing events of default; and (vii) the owners and affiliates of Wellstat Diagnostics were required to contribute additional capital to Wellstat Diagnostics upon the sale of an affiliate entity. The amended and restated credit agreement had an ultimate maturity date of December 31, 2021 (but has subsequently been accelerated as described below).

In June 2014, the Company received information from Wellstat Diagnostics showing that it was generally unable to pay its debts as they became due, constituting an event of default under the amended and restated credit agreement.

On August 5, 2014, the Company delivered a notice of default (the “Wellstat Diagnostics Borrower Notice”) to Wellstat Diagnostics, which accelerated all obligations under the amended and restated credit agreement and demanded immediate payment in full in an amount equal to approximately $53.9 million, (which amount, in accordance with the terms of the amended and restated credit agreement, included an amount that, together with interest and royalty payments already made to the Company, would generate a specified internal rate of return to the Company), plus accruing fees, costs and interest, and demanded that Wellstat Diagnostics protect and preserve all collateral securing its obligations.

On August 7, 2014, the Company delivered a notice (the “Wellstat Diagnostics Guarantor Notice”) to each of the guarantors of Wellstat Diagnostics’ obligations to the Company (collectively, the “Wellstat Diagnostics Guarantors”) under the credit agreement, which included a demand that the guarantors remit payment to the Company in the amount of the outstanding obligations. The guarantors include certain affiliates and related companies of Wellstat Diagnostics, including Wellstat Therapeutics and Wellstat Diagnostics’ stockholders.

On September 24, 2014, the Company filed an ex-parte petition for appointment of receiver with the Circuit Court of Montgomery County, Maryland (the “Wellstat Diagnostics Petition”), which was granted on the same day. Wellstat Diagnostics remained in operation during the period of the receivership with incremental additional funding from the Company. On May 24, 2017, Wellstat Diagnostics transferred substantially all of its assets to the Company pursuant to a credit bid. The credit bid reduced the outstanding balance of the loan by an immaterial amount.

On September 4, 2015, the Company filed in the Supreme Court of New York a motion for summary judgment in lieu of complaint which requested that the court enter judgment against certain of the Wellstat Diagnostics Guarantors for the total amount due on the Wellstat Diagnostics debt, plus all costs and expenses including lawyers’ fees incurred by the Company in enforcement of the related guarantees. On September 23, 2015, the Company filed in the same court an ex parte application for a temporary restraining order and order of attachment of the Wellstat Diagnostics Guarantor defendants’ assets. Although the court denied the Company’s request for a temporary restraining order at a hearing on September 24, 2015, it ordered that assets of the Wellstat Diagnostics Guarantor defendants should be held in status quo ante and only used in the normal course of business.

On July 29, 2016, the Supreme Court of New York granted the Company’s motion for summary judgment and held that the Wellstat Diagnostics Guarantor defendants are liable for all “Obligations” owed by Wellstat Diagnostics to the Company. After appeal by the Wellstat Diagnostics Guarantor defendants on February 14, 2017, the Appellate Division of the Supreme Court of New York reversed on procedural grounds a portion of the Memorandum of Decision granting the Company summary judgment in lieu of complaint, but affirmed the portion of the Memorandum of Decision denying the Wellstat Diagnostics Guarantor defendants’ motion for summary judgment in which they sought a determination that the guarantees had been released. As a result, the litigation has been remanded to the Supreme Court of New York to proceed on the Company’s claims as a plenary action. On June 21, 2017, the Supreme Court of New York ordered the Company to file a Complaint, which was filed by the Company on July 20, 2017. The Wellstat Diagnostics Guarantors filed their answer on August 9, 2017, including counterclaims against the Company alleging breach of contract, breach of fiduciary duty, and tortious interference with prospective economic advantage. This case is currently pending and in the pre-trial phase.

On October 14, 2016, the Company sent a notice of default and reference to foreclosure proceedings to certain of the Wellstat Diagnostics Guarantors which are not defendants in the New York action, but which are owners of real estate assets over which a deed of trust in favor of the Company securing the guarantee of the loan to Wellstat Diagnostics had been executed. On March

22
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


2, 2017, the Company sent a second notice to foreclose on the real estate assets, and noticed the sale for March 29, 2017. The sale was taken off the calendar by the trustee under the deed of trust and has not been re-scheduled yet. On March 6, 2017, the Company sent a letter to the Wellstat Diagnostics Guarantors seeking information in preparation for a UCC Article 9 sale of some or all of the intellectual property-related collateral of the Wellstat Diagnostics Guarantors. The Wellstat Diagnostics Guarantors did not respond to the Company’s letter, but on March 17, 2017, filed an order to show cause with the Supreme Court of New York to enjoin the Company’s sale of the real estate or enforcing its security interests in the Wellstat Diagnostics Guarantors’ intellectual property during the pendency of any action involving the guarantees at issue. On February 6, 2018, the Supreme Court of New York issued an order from the bench which enjoins the Wellstat Diagnostics Guarantors from selling, encumbering, removing, transferring or altering the collateral pending the outcome of the proceedings before it. The Supreme Court of New York also issued an order precluding the Company from foreclosing on certain of the Wellstat Diagnostics Guarantors’ collateral pending the outcome of the proceedings before it. In September of 2018, discovery in the New York action was completed. Summary judgment motions were filed by Wellstat Diagnostics and the Company in 2018 and a hearing was held on May 22, 2019. The court has not yet issued a decision on the motions.

In an unrelated litigation, Wellstat Therapeutics filed a lawsuit against BTG International, Inc. for breach of contract (the “BTG Litigation”). In September 2017, the Delaware Chancery Court found in favor of Wellstat Therapeutics and awarded a judgment of $55.8 million in damages, plus interest. In October 2017, the Company filed a motion with the Supreme Court of New York requesting a pre-judgement attachment of the award. In June 2018, the Delaware Supreme Court largely affirmed the September 2017 decision of the Delaware Chancery Court, including the $55.8 million awarded in judgment. In August of 2018, in a letter to the Company’s counsel, Wellstat Guarantors’ counsel confirmed that the Wellstat Guarantors are preserving the BTG Litigation judgment award proceeds consistent with the New York Court’s prior directions.

On October 22, 2015, certain of the Wellstat Diagnostics Guarantors filed a separate complaint against the Company in the Supreme Court of New York seeking a declaratory judgment that certain contractual arrangements entered into between the parties subsequent to Wellstat Diagnostics’ default, and which relate to a split of proceeds in the event that the Wellstat Diagnostics Guarantors voluntarily monetize any assets that are the Company’s collateral, is of no force or effect. This case has been joined for all purposes, including discovery and trial, and consolidated with the pending case filed by the Company. The Wellstat Diagnostic Guarantors filed a summary judgment motion with regard to this case, which was also heard by the court at the hearing on May 22, 2019. The court has not yet issued a decision on this motion.

Effective April 1, 2014, and as a result of the event of default, the Company determined the loan to be impaired and it ceased to accrue interest revenue. At that time and as of June 30, 2019, it has been determined that an allowance on the carrying value of the note was not necessary, as the Company believes the value of the collateral securing Wellstat Diagnostics’ obligations exceeds the carrying value of the asset and is sufficient to enable the Company to recover the current carrying value of $50.2 million. The Company continues to closely monitor the timing and expected recovery of amounts due, including litigation and other matters related to Wellstat Diagnostics Guarantors’ assets. There can be no assurance that an allowance on the carrying value of the notes receivable investment will not be necessary in a future period depending on future developments.

Hyperion Agreement

On January 27, 2012, the Company and Hyperion (which is also a Wellstat Diagnostics Guarantor) entered into an agreement whereby Hyperion sold to the Company the royalty streams accruing from January 1, 2012 through December 31, 2013 due from Showa Denko K.K. (“SDK”) related to a certain patent license agreement between Hyperion and SDK dated December 31, 2008. In exchange for the lump sum payment to Hyperion of $2.3 million, in addition to any royalties from SDK, the Company was to receive two equal payments of $1.2 million on March 5, 2013 and March 5, 2014. The first payment of $1.2 million was paid on March 5, 2013, but the second payment that was due on March 5, 2014 has not been made by Hyperion. Effective as of such date and as a result of the event of default, the Company ceased to accrue interest revenue. As of June 30, 2019, the estimated fair value of the collateral was determined to be in excess of the carrying value. There can be no assurance of realizing value from such collateral in the event of the Company’s foreclosure on the collateral.

Avinger Credit and Royalty Agreement

On April 18, 2013, the Company entered into a credit agreement with Avinger, Inc. (the “Avinger Credit and Royalty Agreement”). Under the terms of the Avinger Credit and Royalty Agreement, the Company received a low, single-digit royalty on Avinger’s net revenues until April 2018. Commencing in October 2015, after Avinger repaid $21.4 million pursuant to its note payable to the Company prior to its maturity date, the royalty on Avinger’s net revenues was reduced by 50%, subject to

23
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


certain minimum payments from the prepayment date until April 18, 2018. The Company accounted for the royalty rights in accordance with the fair value option. As of April 18, 2018, there were no further obligations owed to the Company.

CareView Credit Agreement

On June 26, 2015, the Company entered into a credit agreement with CareView, under which the Company made available to CareView up to $40.0 million in loans comprised of two tranches of $20.0 million each, subject to CareView’s attainment of specified milestones relating to the placement of CareView Systems. On October 7, 2015, the Company and CareView entered into an amendment of the credit agreement to modify certain definitions related to the first and second tranche milestones and the Company funded the first tranche of $20.0 million, net of fees, based on CareView’s attainment of the first milestone, as amended. The second $20.0 million tranche was not funded due to CareView’s failure to achieve the related funding milestones and there is no additional funding obligation due from the Company. Outstanding borrowings under the credit agreement bear interest at the rate of 13.5% per annum and are payable quarterly in arrears.

As part of the original credit agreement, the Company received a warrant to purchase approximately 4.4 million shares of common stock of CareView at an exercise price of $0.45 per share. The Company has accounted for the warrant as derivative asset with an offsetting credit as debt discount. At each reporting period the warrant is marked to market for changes in fair value.

In connection with the October 2015 amendment of the credit agreement, the Company and CareView also agreed to amend the warrant to purchase common stock agreement by reducing the warrant’s exercise price from $0.45 to $0.40 per share.

In February 2018, the Company entered into a modification agreement with CareView (the “February 2018 Modification Agreement”) whereby the Company agreed, effective December 28, 2017, to modify the credit agreement before remedies could otherwise have become available to the Company under the credit agreement in relation to certain obligations of CareView that would potentially not be met, including the requirement to make principal payments. Under the February 2018 Modification Agreement, the Company agreed that (i) a lower liquidity covenant would be applicable and (ii) principal repayment would be delayed until December 31, 2018. In exchange for agreeing to these modifications, among other things, the exercise price of the Company’s warrants to purchase 4.4 million shares of common stock of CareView was repriced from $0.40 to $0.03 per share and, subject to the occurrence of certain events, CareView agreed to grant the Company additional equity interests. As a result of the February 2018 Modification Agreement, the Company determined the loan to be impaired and it ceased to accrue interest revenue effective October 1, 2017.

In September 2018, the Company entered into an amendment to the February 2018 Modification Agreement with CareView whereby the Company agreed, effective as of September 28, 2018, that a lower liquidity covenant would be applicable. In December 2018, the Company further modified the loan by agreeing that (i) a lower liquidity covenant would be applicable, (ii) the first principal payment would be deferred until January 31, 2019, and (iii) the scheduled interest payment due December 31, 2018 would be deferred until January 31, 2019. In December 2018, and in consideration of the further modification to the credit agreement, the Company completed an impairment analysis and determined that the note was impaired and recorded an impairment loss of $8.2 million. For additional information see Note 5, Fair Value Measurements. As of March 31, 2019, the principal repayment and interest payments were deferred until April 30, 2019. The principal repayment and interest payment were subsequently deferred until May 15, 2019. In May 2019, and in consideration of additional capital raised by CareView, the Company further modified the loan by agreeing that (i) the first principal and interest payments would be deferred until September 30, 2019 and (ii) the remaining liquidity covenant would be removed. As of June 30, 2019, the Company performed an analysis and determined that no additional impairment was required and estimated the fair value of the warrants to be less than $0.1 million.

7. Leases

Lessee arrangements

The Company has operating leases for corporate offices and certain equipment. The Company’s operating leases have remaining lease terms ranging from one to eight years, some of which include options to extend the leases for up to five years, and some of which include options to terminate the leases within three years.


24
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


The components of lease expense are as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
Operating lease cost
 
$
234

 
$
324

 
$
467

 
$
609

Short-term lease cost
 
19

 
12

 
44

 
24

Total lease cost
 
$
253

 
$
336

 
$
511

 
$
633


Supplemental cash flow information related to leases is as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
 
 
 
 
 
Operating cash flows from operating leases
 
$
235

 
$
324

 
$
450

 
$
609

Right-of-use-assets obtained in exchange for lease obligations:
 
 
 
 
 
 
 
 
Operating leases
 
$
—

 
N/A
 
$
2,111

 
N/A
_______________
N/A    Not applicable

The following table presents the lease balances within the Condensed Consolidated Balance Sheet, weighted-average remaining lease term, and weighted-average discount rates related to the Company’s operating leases (in thousands):
Operating Leases
 
Classification
 
June 30, 2019
 
 
 
 
 
Operating lease ROU assets
 
Other assets
 
$
1,661

 
 
 
 
 
Operating lease liabilities, current
 
Accrued liabilities
 
$
807

Operating lease liabilities, long-term
 
Other long-term liabilities
 
891

Total operating lease liabilities
 
Total operating lease liabilities
 
$
1,698

 
 
 
 
 
Weighted-average remaining lease term
 
 
 
2.00 years

Weighted-average discount rate
 
 
 
6
%

Maturities of operating lease liabilities as of June 30, 2019 are as follows (in thousands):
Fiscal Year
 
Amount
 
 
 
2019 (Remaining six months)
 
$
472

2020
 
837

2021
 
473

2022
 
—

2023
 
—

Thereafter
 
—

Total operating lease payments
 
1,782

Less: imputed interest
 
84

Total operating lease liabilities
 
$
1,698



25
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


Future minimum operating lease payments as of December 31, 2018 were as follows (in thousands):
Fiscal Year
 
Amount
 
 
 
2019
 
$
1,140

2020
 
1,003

2021
 
559

2022
 
—

2023
 
—

Thereafter
 
—

Total
 
$
2,702


As of June 30, 2019, the Company had no additional significant operating or finance leases that had not yet commenced.

Lessor arrangements

The Company has operating and sales-type leases for medical device equipment generated from its medical devices segment. The Company’s leases have remaining lease terms of less than one year to five years, some of which include options to extend the leases on a month-to-month basis if the customer does not notify the Company of the intention to return the equipment at the end of the lease term. The Company typically does not offer options to terminate the leases before the end of the lease term.

The components of lease income are as follows:
 
 
 
 
Three Months Ended
 
Six Months Ended
 
 
 
 
June 30,
 
June 30,
(in thousands)
 
Classification
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
 
 
Sales-type lease selling price
 
Product revenue, net
 
$
—

 
$
—

 
$
—

 
$
151

Cost of underlying asset
 
 
 
—

 
—

 
—

 
58

Operating profit
 
 
 
$
—

 
$
—

 
$
—

 
$
209

 
 
 
 
 
 
 
 
 
 
 
Interest income on the lease receivable
 
Interest and other income, net
 
$
14

 
$
12

 
$
26

 
$
24

 
 
 
 
 
 
 
 
 
 
 
Initial direct costs incurred
 
Operating expense
 
$
—

 
$
—

 
$
—

 
$
8

 
 
 
 
 
 
 
 
 
 
 
Operating lease Income
 
Product revenue, net
 
$
1,355

 
$
2,840

 
$
2,592

 
$
4,125


Net investment in sales-type leases are as follows:
(in thousands)
 
Classification
 
June 30, 2019
 
December 31, 2018
 
 
 
 
 
 
 
Lease payment receivable, current
 
Accounts receivable, net and Notes receivable, current
 
$
431

 
$
533

Lease payment receivable, long-term
 
Notes receivable, long-term and Other assets
 
547

 
475

Total lease payment receivable
 
 
 
$
978

 
$
1,008


Equipment under lease is stated at cost less accumulated depreciation and is classified as “Property and equipment, net” on the Condensed Consolidated Balance Sheets. Depreciation is computed using the straight-line method over an estimated useful life of the greater of the lease term or five years to ten years. Equipment under lease is as follows:


26
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


(in thousands)
 
June 30, 2019
 
December 31, 2018
 
 
 
 
 
Equipment under lease
 
$
6,758

 
$
6,529

Less accumulated depreciation
 
(4,698
)
 
(3,665
)
Equipment under lease, net
 
$
2,060

 
$
2,864


Maturities of sales-type lease receivables as of June 30, 2019 are as follows (in thousands):
Fiscal Year
 
Amount
 
 
 
2019 (Remaining six months)
 
$
245

2020
 
394

2021
 
198

2022
 
150

2023
 
52

Thereafter
 
—

Total undiscounted cash flows
 
1,039

Present value of lease payments (recognized as lease receivables)
 
978

Difference between undiscounted and discounted cash flows
 
$
61


Maturities of operating lease receivables as of June 30, 2019 are as follows (in thousands):
Fiscal Year
 
Amount
 
 
 
2019 (Remaining six months)
 
$
1,274

2020
 
1,587

2021
 
551

2022
 
116

2023
 
29

Thereafter
 
—

Total undiscounted cash flows
 
$
3,557


8. Intangible Assets

Intangible Assets, Net

On June 8, 2018, Noden DAC entered into a Settlement Agreement (the “Settlement Agreement”) with Anchen Pharmaceuticals, Inc. and its affiliates (“Anchen”) to resolve the patent litigation relating to infringement of U.S. Patent No. 8,617,595 (the “‘595 Patent”) based on their submission of an Abbreviated New Drug Application (“ANDA”) seeking authorization from the FDA to market a generic version of aliskiren, the active ingredient in the Tekturna and Tekturna HCT drug. Under the Settlement Agreement, Anchen, the sole ANDA filer of which the Company is aware, agreed to not commercialize its generic version of aliskiren prior to March 1, 2019. Per the Settlement Agreement, Anchen may commercialize their formulation of aliskiren, but is not permitted to commercialize a copy of Tekturna.

Accordingly, management evaluated the ongoing value of the Noden DAC asset group based upon the probability of Anchen’s market entry of a generic version of aliskiren in the United States and the associated cash flows and conducted a test for impairment. Due to the increased probability of a generic version of aliskiren being launched in the United States, the Company revised its estimates of future cash flows and as a result of this analysis, determined that the sum of undiscounted cash flows was not greater than the carrying value of the assets. Therefore, the Company performed a discounted cash flow analysis to estimate the fair value of the asset group in accordance with ASC Topic 360, Impairment or Disposal of Long-lived Assets. The cash flows used in this analysis are those expected to be generated by market participants, discounted to reflect an appropriate

27
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


amount of risk, which was determined to be 21%. The Company concluded that the Noden DAC acquired product rights and customer relationship long-lived assets, with a carrying amount of $192.5 million, were no longer recoverable and wrote them down to their estimated fair value of $40.1 million, resulting in an impairment charge of $152.3 million in the second quarter of 2018. This write-down is included in “Impairment of intangible assets” in the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows.

On March 4, 2019, the Company announced the U.S. commercial launch of an authorized generic form of Tekturna, with the same drug formulation as Tekturna. The Company performed an impairment assessment of the Noden asset group at this time by estimating the undiscounted future cash flows with respect to the asset against its carrying value and concluded a further impairment was not required.

On March 22, 2019, the FDA approved Anchen’s generic form of aliskiren. The Company performed an impairment assessment of the Noden asset group at this time and concluded no further impairment was required.

Future events, such as FDA approval of additional generic forms of aliskiren, or pricing or market share pressure resulting from existing generic competition, may be further indicators of impairment which may require the Company to perform additional impairment testing.

In April 2019, LENSAR acquired certain intellectual property from a third-party for $2.0 million in cash and obligations to pay a $0.3 million milestone payment and royalties upon the completion of certain events.

The components of intangible assets as of June 30, 2019 and December 31, 2018 were as follows:
 
 
June 30, 2019
 
December 31, 2018
(in thousands)
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
 
 
 
 
 
 
 
 
 
 
 
 
Finite-lived intangible assets:
 
 
 
 
 
 
 
 
 
 
 
 
Acquired products rights(1)
 
$
36,143

 
$
(4,517
)
 
$
31,626

 
$
36,143

 
$
(2,258
)
 
$
33,885

Customer relationships(1) (2) (4)
 
8,028

 
(1,209
)
 
6,819

 
8,028

 
(782
)
 
7,246

Acquired technology(2) (3) (5)
 
13,311

 
(1,630
)
 
11,681

 
11,011

 
(1,203
)
 
9,808

Acquired trademarks(2)
 
570

 
(247
)
 
323

 
570

 
(190
)
 
380

 
 
$
58,052

 
$
(7,603
)
 
$
50,449

 
$
55,752

 
$
(4,433
)
 
$
51,319

________________
(1) 
The Company acquired certain intangible assets as part of the Noden transaction. They are being amortized on a straight-line basis over a weighted-average period of eight years.
(2)
The Company acquired certain intangible assets as part of its acquisition of LENSAR in May 2017. They are being amortized on a straight-line basis over a weighted-average period of 15 years. The intangible assets for customer relationships are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained.
(3) 
The Company acquired certain intangible assets as part of the foreclosure on certain of Direct Flow Medical assets. They are being amortized on a straight-line basis over a weighted-average period of 10 years.
(4)
LENSAR acquired certain intangible assets for customer relationships from Precision Eye Services, which are being amortized using a double-declining method over a period of 20 years.
(5)
LENSAR acquired certain intangible assets from a third-party, which are being amortized on a straight-line basis over a period of 15 years.

For the three and six months ended June 30, 2019 amortization expense was $1.6 million and $3.2 million, respectively, and for the three and six months ended June 30, 2018 amortization expense was $6.4 million and $12.7 million, respectively.


28
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


Based on the intangible assets recorded at June 30, 2019, and assuming no subsequent additions to or impairment of the underlying assets, the remaining amortization expense is expected to be as follows (in thousands):
Fiscal Year
 
Amount
 
 
 
2019 (Remaining six months)
 
$
3,212

2020
 
6,394

2021
 
6,362

2022
 
6,257

2023
 
6,194

Thereafter
 
22,030

Total remaining amortization expense
 
$
50,449


9. Accrued Liabilities

Accrued liabilities consist of the following:
(in thousands)
 
June 30,
2019
 
December 31,
2018
 
 
 
 
 
Accrued rebates, chargebacks and other revenue reserves
 
$
8,248

 
$
20,133

Deferred revenue
 
4,800

 
8,811

Compensation
 
5,017

 
4,468

Interest
 
344

 
344

Legal
 
314

 
623

Other
 
4,776

 
4,933

Total
 
$
23,499

 
$
39,312


The following table provides a summary of activity with respect to the Company’s sales allowances and accruals for the six months ended June 30, 2019:
(in thousands)
 
Discount and Distribution Fees
 
Government Rebates and Chargebacks
 
Assistance and Other Discounts
 
Product Returns
 
Total
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2018
 
$
3,094

 
$
8,901

 
$
3,457

 
$
4,681

 
$
20,133

Allowances for current period sales
 
3,069

 
6,455

 
2,962

 
951

 
13,437

Allowances for prior period sales
 
—

 
1,841

 
120

 
—

 
1,961

Credits/payments for current period sales
 
(1,544
)
 
(4,929
)
 
(2,401
)
 
(232
)
 
(9,106
)
Credits/payments for prior period sales
 
(3,044
)
 
(9,910
)
 
(3,005
)
 
(2,218
)
 
(18,177
)
Balance at June 30, 2019
 
$
1,575

 
$
2,358

 
$
1,133

 
$
3,182

 
$
8,248


10. Convertible Senior Notes
  
 
 
 
 
Principal Balance Outstanding
 
Carrying Value
 
 
 
 
June 30,
 
June 30,
 
December 31,
Description
 
Maturity Date
 
2019
 
2019
 
2018
(in thousands)
 
 
 
 
 
 
 
 
Convertible Senior Notes
 
 
 
 
 
 
 
 
December 2021 Notes
 
December 1, 2021
 
$
150,000

 
$
128,520

 
$
124,644

Total
 
 
 
 

 
$
128,520

 
$
124,644


29
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)



February 2018 Notes

On February 12, 2014, the Company issued $300.0 million in aggregate principal amount, at par, of the February 2018 Notes in an underwritten public offering, for net proceeds of $290.2 million. The February 2018 Notes were due February 1, 2018. In November 2015, $53.6 million in aggregate principal amount of the February 2018 Notes were repurchased and in November 2016 an additional $120.0 million in aggregate principal amount of the February 2018 Notes were repurchased in open market transactions. In connection with these repurchases, the Company unwound a corresponding portion of the purchased call options and warrants related to the notes.

On February 1, 2018, upon maturity of the February 2018 Notes, the Company repaid a total cash amount of $129.0 million to the custodian, The Bank of New York Mellon Trust Company, N.A., which was comprised of $126.4 million in principal amount and $2.6 million in accrued interest, to retire the February 2018 Notes.

Interest expense for the February 2018 Notes on the Company’s Condensed Consolidated Statements of Operations was as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2018
 
2018
 
 
 
 
 
Contractual coupon interest
 
$
—

 
$
421

Amortization of debt issuance costs
 
—

 
88

Amortization of debt discount
 
—

 
293

Total
 
$
—

 
$
802


December 2021 Notes

On November 22, 2016, the Company issued $150.0 million in aggregate principal amount, at par, of the December 2021 Notes in an underwritten public offering, for net proceeds of $145.7 million. The December 2021 Notes are due December 1, 2021, and the Company pays interest at 2.75% on the December 2021 Notes semiannually in arrears on June 1 and December 1 of each year, beginning June 1, 2017. A portion of the proceeds from the December 2021 Notes, net of amounts used for the capped call transaction described below, was used to extinguish $120.0 million of the February 2018 Notes.

Upon the occurrence of a fundamental change, as defined in the indenture entered into in connection with the December 2021 Notes (the “December 2021 Notes Indenture”), holders have the option to require the Company to repurchase their December 2021 Notes at a purchase price equal to 100% of the principal, plus accrued interest.

The December 2021 Notes are convertible under any of the following circumstances:
•
During any fiscal quarter (and only during such fiscal quarter) commencing after the fiscal quarter ended June 30, 2017, if the last reported sale price of Company common stock for at least 20 trading days (whether or not consecutive), in the period of 30 consecutive trading days, ending on, and including, the last trading day of the immediately preceding fiscal quarter, exceeds 130% of the conversion price for the notes on each applicable trading day;
•
During the five business-day period immediately after any five consecutive trading-day period, which the Company refers to as the measurement period, in which the trading price per $1,000 principal amount of notes for each trading day of that measurement period was less than 98% of the product of the last reported sale price of Company common stock and the conversion rate for the notes for each such trading day; or
•
Upon the occurrence of specified corporate events as described in the December 2021 Notes Indenture.

The initial conversion rate for the December 2021 Notes is 262.2951 shares of the Company’s common stock per $1,000 principal amount of December 2021 Notes, which is equivalent to an initial conversion price of approximately $3.81 per share of common stock, subject to adjustments upon the occurrence of certain specified events as set forth in the December 2021 Notes Indenture.

30
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)



In accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion, the Company was required to separately account for the liability component of the instrument in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. As a result, the Company separated the principal balance of the December 2021 Notes between the fair value of the debt component and the fair value of the common stock conversion feature. Using an assumed borrowing rate of 9.5%, which represented the estimated market interest rate for a similar nonconvertible instrument available to the Company on the date of issuance, the Company recorded a total debt discount of $4.3 million, allocated $23.8 million to additional paid-in capital and allocated $12.8 million to deferred tax liability. The discount is being amortized to interest expense over the term of the December 2021 Notes and increases interest expense during the term of the December 2021 Notes from the 2.75% cash coupon interest rate to an effective interest rate of 3.4%. As of June 30, 2019, the remaining discount amortization period is 2.4 years.

The carrying value and unamortized discount of the December 2021 Notes were as follows:
(in thousands)
 
June 30, 2019
 
December 31, 2018
 
 
 
 
 
Principal amount of the December 2021 Notes
 
$
150,000

 
$
150,000

Unamortized discount of liability component
 
(21,480
)
 
(25,356
)
Net carrying value of the December 2021 Notes
 
$
128,520

 
$
124,644


Interest expense for the December 2021 Notes on the Company’s Condensed Consolidated Statements of Operations was as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
Contractual coupon interest
 
$
1,032

 
$
1,031

 
$
2,063

 
$
2,062

Amortization of debt issuance costs
 
20

 
19

 
40

 
38

Amortization of debt discount
 
138

 
135

 
276

 
269

Amortization of conversion feature
 
1,794

 
1,626

 
3,560

 
3,225

Total
 
$
2,984

 
$
2,811

 
$
5,939

 
$
5,594


As of June 30, 2019, the December 2021 Notes are not convertible.

Capped Call Transaction

In connection with the offering of the December 2021 Notes, the Company entered into a privately-negotiated capped call transaction with an affiliate of the underwriter of such issuance. The aggregate cost of the capped call transaction was $14.4 million. The capped call transaction is generally expected to reduce the potential dilution upon conversion of the December 2021 Notes and/or partially offset any cash payments the Company is required to make in excess of the principal amount of converted December 2021 Notes in the event that the market price per share of the Company’s common stock, as measured under the terms of the capped call transaction, is greater than the strike price of the capped call transaction. This initially corresponds to the approximate $3.81 per share conversion price of the December 2021 Notes and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of the December 2021 Notes. The cap price of the capped call transaction was initially $4.88 per share, and is subject to certain adjustments under the terms of the capped call transaction. The Company will not be required to make any cash payments to the option counterparty upon the exercise of the options that are a part of the capped call transaction, but the Company will be entitled to receive from it an aggregate amount of cash and/or number of shares of the Company’s common stock, based on the settlement method election chosen for the related convertible senior notes, with a value equal to the amount by which the market price per share of the Company’s common stock, as measured under the terms of the capped call transaction, is greater than the strike price of the capped call transaction during the relevant valuation period under the capped call transaction, with such number of shares of the Company’s common stock and/or amount of cash subject to the cap price.


31
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


The Company evaluated the capped call transaction under authoritative accounting guidance and determined that it should be accounted for as separate transaction and classified as a net reduction to additional paid-in capital within stockholders’ equity with no recurring fair value measurement recorded.

11. Other Long-Term Liabilities

Other long-term liabilities consist of the following:
 
 
June 30,
 
December 31,
(in thousands)
 
2019
 
2018
 
 
 
 
 
Uncertain tax positions
 
$
32,402

 
$
31,706

Deferred tax liabilities
 
13,803

 
13,847

Accrued lease guarantee
 
10,700

 
10,700

Long-term incentive accrual
 
146

 
125

Other
 
1,130

 
465

Total
 
$
58,181

 
$
56,843

 

12. Commitments and Contingencies

Lease Guarantee

In connection with the spin-off (the “Spin-Off”) by the Company of Facet Biotech Corporation (“Facet”), the Company entered into amendments to the leases for the Company’s former facilities in Redwood City, California, under which Facet was added as a co-tenant, and a Co-Tenancy Agreement, under which Facet agreed to indemnify the Company for all matters related to the leases attributable to the period after the Spin-Off date. In April 2010, Abbott Laboratories acquired Facet and later renamed the entity AbbVie Biotherapeutics, Inc. (“AbbVie”). If AbbVie were to default under its lease obligations, the Company could be held liable by the landlord as a co-tenant and, thus, the Company has in substance guaranteed the payments under the lease agreements for the Redwood City facilities. As of June 30, 2019, the total lease payments for the duration of the guarantee, which runs through December 2021, are approximately $28.2 million.

The Company prepared a discounted, probability weighted cash flow analysis to calculate the estimated fair value of the lease guarantee as of the Spin-Off. The Company was required to make assumptions regarding the probability of Facet’s default on the lease payment, the likelihood of a sublease being executed and the times at which these events could occur. These assumptions are based on information that the Company received from real estate brokers and the then-current economic conditions, as well as expectations of future economic conditions. The fair value of this lease guarantee was charged to additional paid-in capital upon the Spin-Off and any future adjustments to the carrying value of the obligation will also be recorded in additional paid-in capital.

The Company has recorded a liability of $10.7 million on its Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018, related to this guarantee. In future periods, the Company may adjust this liability for any changes in the ultimate outcome of this matter that are both probable and estimable.

Purchase Obligations

Noden DAC and Novartis entered into a supply agreement pursuant to which Novartis will manufacture and supply to Noden DAC a bulk tableted form of the Noden Products and active pharmaceutical ingredient (“API”). In May 2019, Noden DAC and Novartis entered into an amended supply agreement pursuant to which Novartis will supply to Noden DAC a bulk tableted form of the Noden Products through 2020 and API through June 2021. The supply agreement may be terminated by either party for material breach that remains uncured for a specified time period. Under the terms of the amended supply agreement, Noden DAC is committed to purchase certain quantities of bulk product and API that would amount to approximately $90.9 million through June 2021, of which $53.1 million is committed over the next twelve months, which are guaranteed by the Company. While the supply agreement provides that the parties will agree to reasonable accommodations with respect to changes in firm orders, the Company expects that Noden DAC will meet the requirements of the supply agreement, unless otherwise negotiated.


32
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


LENSAR entered into various supply agreements for the manufacture and supply of certain components. The supply agreements commit LENSAR to a minimum purchase obligation of approximately $6.3 million over the next twenty-four months, of which $4.9 million is due in the next twelve months. LENSAR expects to meet these requirements.

Escrow Receivable

On April 1, 2014, the Company entered into a note purchase agreement with Accel 300, LLC (“Accel 300”), a wholly-owned subsidiary of kaléo, Inc. (“kaléo”), pursuant to which the Company acquired $150.0 million of secured notes due 2029 (the “kaléo Note”). The kaléo Note was issued pursuant to an indenture between Accel 300 and U.S. Bank, National Association, as trustee, and was secured by 20% of net sales of its first approved product, Auvi-Q® (epinephrine auto-injection, USP) (known as Allerject® in Canada) and 10% of net sales of kaléo’s second proprietary auto-injector based product, EVZIO (naloxone hydrochloride injection) (the “kaléo Revenue Interests”), and a pledge of kaléo’s equity ownership in Accel 300. On September 21, 2017, the Company entered into an agreement (the “kaléo Note Sale Agreement”) with MAMKangaroo Lender, LLC, a Delaware limited liability company (the kaléo Purchaser”), pursuant to which the Company sold its entire interest in the kaléo Note for an aggregate cash purchase price of $141.7 million.

Pursuant to the terms of the kaléo Note Sale Agreement, $1.4 million of the aggregate purchase price was deposited into an escrow account as a potential payment against certain contingencies. The escrow period ended on March 20, 2019 and the escrow agent released the entire $1.4 million to the Company.

13. Stockholders’ Equity

Stock Repurchase Program

On September 25, 2017, the Company announced that its board of directors authorized the repurchase of issued and outstanding shares of the Company’s common stock having an aggregate value of up to $25.0 million pursuant to a share repurchase program. The repurchases under the share repurchase program were made from time to time in the open market or in privately negotiated transactions and were funded from the Company’s working capital. All shares of common stock repurchased under this share repurchase program were retired and restored to authorized but unissued shares of common stock. The Company repurchased 8.7 million shares of its common stock under the share repurchase program during the fiscal year ended December 31, 2018, for an aggregate purchase price of $25.0 million, or an average cost of $2.86 per share, including trading commissions.

On September 24, 2018, the Company announced that its board of directors authorized the repurchase of issued and outstanding shares of the Company’s common stock having an aggregate value of up to $100.0 million pursuant to a share repurchase program. The Company repurchased 21.1 million shares of its common stock under this share repurchase program during the six months ended June 30, 2019, for an aggregate purchase price of $70.4 million, or an average cost of $3.34 per share, including trading commissions. Since the inception of this share repurchase program through June 30, 2019, the Company has repurchased 29.7 million shares for an aggregate purchase price of $95.9 million, or an average cost of $3.22 per share, including trading commissions. As of June 30, 2019, the Company had 178,700 shares held in treasury stock at a total cost of $0.5 million. Those shares were settled and retired on July 5, 2019. All shares of common stock repurchased under this share repurchase program were retired and restored to authorized but unissued shares of common stock. This program was completed in July 2019 as further discussed in Note 20, Subsequent Events.

14. Stock-Based Compensation

The Company grants restricted stock awards and stock options pursuant to a stockholder approved stock-based incentive plan.

33
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)



The following table summarizes the Company’s stock option and restricted stock award activity during the six months ended June 30, 2019:
 
 
Stock Options
 
Restricted Stock Awards
(in thousands, except per share amounts)
 
Number of Shares Outstanding
 
Weighted Average Exercise Price
 
Number of Shares Outstanding
 
Weighted Average Grant-date Fair Value Per Share
 
 
 
 
 
 
 
 
 
Balance at December 31, 2018
 
7,869

 
$
2.82

 
883

 
$
2.87

Granted
 
5,666

 
$
3.61

 
851

 
$
3.66

Exercised or vested
 
—

 
$
—

 
(335
)
 
$
2.69

Forfeited or canceled
 
—

 
$
—

 
(49
)
 
$
2.52

Balance at June 30, 2019
 
13,535

 
$
3.15

 
1,350

 
$
3.43


 15. Revenue from Contracts with Customers

Revenue

Nature of Goods and Services

The following is a description of principal activities - separated by reportable segments - from which the Company generates its revenue. For more detailed information about reportable segments, see Note 16, Segment Information.

Pharmaceutical

The Company’s Pharmaceutical segment consists of revenue derived from the branded prescription Noden Products and the authorized generic launched in March 2019.

The agreement between Novartis and Noden DAC provides for various transition periods for development and commercialization activities relating to the Noden Products. Initially, Novartis distributed the Noden Products on behalf of Noden DAC worldwide and Noden DAC received a profit transfer on such sales. Generally, the profit transfer to Noden DAC was defined as gross revenues less product cost and a low single-digit percentage fee to Novartis. The profit transfer terminated upon the transfer of the marketing authorization from Novartis to Noden DAC in each country. In the United States, the duration of the profit transfer ran from July 1, 2016 through October 4, 2016. Outside the United States, the profit transfer ended in the first quarter of 2018.

Prior to the transfer of the marketing authorization, revenue was presented on a “net” basis; after the transfer of the marketing authorization, revenue is presented on a “gross” basis, meaning product costs are reported separately and there is no fee to Novartis. Except for the sales outside of the United States preceding the final profit transfer that occurred in the first quarter of 2018, revenues of the Noden Products for the periods herein are presented on a gross basis.

Noden USA launched an authorized generic of Tekturna in the United States in March 2019.

The Pharmaceutical segment principally generates revenue from products sold to wholesalers and distributors. Customer orders are generally fulfilled within a few days of receipt resulting in minimal order backlog. Contractual performance obligations are usually limited to transfer of the product to the customer. The transfer occurs either upon shipment or upon receipt of the product in certain countries outside the United States after considering when the customer obtains control of the product. In addition, for some non-U.S. countries, the Company sells product on a consignment basis where control is not transferred until the customer resells the product to an end user. At these points, customers are able to direct the use of and obtain substantially all of the remaining benefits of the product.

Sales to customers are initially invoiced at contractual list prices. Payment terms are typically 30 to 90 days based on customary practice in each country. Revenue is reduced from the list price at the time of recognition for expected chargebacks, discounts,

34
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


rebates, sales allowances and product returns, which are collectively referred to as gross-to-net adjustments. These reductions are attributed to various commercial agreements, managed healthcare organizations and government programs such as Medicare, Medicaid, and the 340B Drug Pricing Program containing various pricing implications such as mandatory discounts, pricing protection below wholesaler list price and other discounts when Medicare Part D beneficiaries are in the coverage gap. These various reductions in the transaction price have been estimated using either a most likely amount, in the case of prompt pay discounts, or expected value method for all other variable consideration and have been reflected as liabilities and are settled through cash payments, typically within time periods ranging from a few months to one year. Significant judgment is required in estimating gross-to-net adjustments considering legal interpretations of applicable laws and regulations, historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, processing time lags and inventory levels in the distribution channel.

For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front license fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.

Medical Devices

The Medical Devices segment principally generates revenue from the sale and lease of the LENSAR® Laser System, which may include equipment, PIDs or consumables, procedure licenses, training, installation, warranty and maintenance agreements.

For bundled packages, the Company accounts for individual products and services separately if they are distinct - i.e. if a product or service is separately identifiable from other items in the bundled package and if the customer can benefit from it on its own or with other resources that are readily available to the customer. The LENSAR® Laser System, standard warranty training and installation services are one performance obligation. All other elements are separate performance obligations. PIDs, procedure licenses, warranty and maintenance services are also sold on a stand-alone basis.

As the Company both sells and leases the LENSAR® Laser System, the consideration (including any discounts) is first allocated between lease and non-lease components and then allocated between the separate products and services based on their stand-alone selling prices. The stand-alone selling prices for the PIDs and procedure licenses are determined based on the prices at which the Company separately sells the PIDs and procedure licenses. The LENSAR® Laser System and warranty stand-alone selling prices are determined using the expected cost plus a margin approach.

For LENSAR® Laser System sales, the Company recognizes Product revenue when a customer takes possession of the system. This usually occurs after the customer signs a contract, LENSAR installs the system, and LENSAR performs the requisite training for use of the system. For LENSAR® Laser System leases, the Company recognized Product revenue over the length of the lease in accordance with ASC Topic 840, Leases, through December 31, 2018 and recognized Product revenue in accordance with ASC Topic 842, Leases, after January 1, 2019. For additional information regarding accounting for leases, see Note 7, Leases.

The LENSAR® Laser System requires both a consumable and a procedure license to perform each procedure. The Company recognizes Product revenue for PIDs when the customer takes possession of the PID. PIDs are sold by the case. The Company recognizes Product revenue for procedure licenses when a customer purchases a procedure license from the web portal. Typically, consideration for PIDs and procedure licenses is considered fixed consideration except for certain customer agreements that provide for tiered volume discount pricing which is considered variable consideration.

The Company offers an extended warranty that provides additional services beyond the standard warranty. The Company recognizes Product revenue from the sale of extended warranties over the warranty period. Customers have the option of renewing the warranty period, which is considered a new and separate contract.

Income Generating Assets

For licenses of intellectual property, if the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front

35
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.

In January 2018, DFM, LLC, a wholly-owned subsidiary of the Company, granted an exclusive license related to certain Direct Flow Medical, Inc. assets in exchange for $0.5 million in cash and up to $2.0 million in royalty payments. The $0.5 million payment was accounted for in accordance with ASC 606 under which the full cash payment was recognized as revenue in the first quarter of 2018 as DFM, LLC had fulfilled its performance obligation under the agreement.

Disaggregation of Revenue

The Company disaggregates its revenue from contracts with customers by segment and geographic location as the Company believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. In the following table, revenue is disaggregated by segment and primary geographical market for the three and six months ended June 30, 2019 and 2018:
 
 
Three Months Ended
 
Three Months Ended
 
 
June 30, 2019
 
June 30, 2018
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Medical Devices
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
Primary geographical markets:
 
 
 
 
 
 
 
 
North America
 
$
2,203

 
$
3,038

 
$
615

 
$
10,776

Europe
 
705

 
5,454

 
679

 
6,371

Asia
 
3,093

 
1,923

 
1,643

 
8,732

Other
 
66

 
—

 
107

 
—

Total revenue from contracts with customers(1)
 
$
6,067

 
$
10,415

 
$
3,044

 
$
25,879


 
 
Six Months Ended
 
Six Months Ended
 
 
June 30, 2019
 
June 30, 2018
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Medical Devices
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
Primary geographical markets:
 
 
 
 
 
 
 
 
North America
 
$
4,287

 
$
15,176

 
$
2,319

 
$
21,707

Europe
 
1,722

 
11,036

 
1,294

 
12,362

Asia
 
5,362

 
4,163

 
2,757

 
10,152

Other
 
185

 
—

 
220

 
—

Total revenue from contracts with customers(1)
 
$
11,556

 
$
30,375

 
$
6,590

 
$
44,221

_______________
(1)
The tables above do not include lease revenue from the Company’s Medical Devices segment. For the three-month periods ended June 30, 2019 and 2018, revenue accounted for under Topic 842 and 840, Leases, was $1.4 million and $2.8 million, respectively and for the six-month periods ended June 30, 2019 and 2018 was $2.6 million and $4.3 million, respectively. For additional information, see Note 7, Leases.


36
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


Contract Balances

The following table provides information about receivables, contract assets and contract liabilities from contracts with customers:
(in thousands)
 
June 30, 2019
 
December 31, 2018
 
 
 
 
 
Receivables, net
 
$
17,872

 
$
20,655

Contract assets
 
$
3,214

 
$
2,595

Contract liabilities
 
$
4,856

 
$
8,938


Receivables, Net—Receivables, net, include amounts billed and due from customers. The amounts due are stated at their net estimated realizable value and are classified as current or noncurrent based on the timing of when the Company expects to receive payment. The Company maintains an allowance for doubtful accounts to provide for the estimated amount of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and collateral to the extent applicable.

Contract assets—The Company’s contract assets represent revenue recognized for performance obligations completed before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. The Company classifies contract assets in Prepaid and other current assets in the Company’s Condensed Consolidated Balance Sheets based on the timing of when it expects to receive payment.
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Total
 
 
 
 
 
 
 
Contract assets at December 31, 2018
 
$
—

 
$
2,595

 
$
2,595

Contract assets recognized
 
—

 
4,638

 
4,638

Payments received
 
—

 
(4,019
)
 
(4,019
)
Contract assets at June 30, 2019
 
$
—

 
$
3,214

 
$
3,214


Contract Liabilities—The Company’s contract liabilities consist of deferred revenue for products sold to customers for which the performance obligation has not been completed by the Company. The Company classifies deferred revenue as current or noncurrent based on the timing of when it expects to recognize revenue. The noncurrent portion of deferred revenue is included in Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheets.
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Total
 
 
 
 
 
 
 
Contract liabilities at December 31, 2018
 
$
1,167

 
$
7,771

 
$
8,938

Contract liabilities recognized
 
537

 
2,855

 
3,392

Amounts recognized into revenue
 
(645
)
 
(6,829
)
 
(7,474
)
Contract liabilities at June 30, 2019
 
$
1,059

 
$
3,797

 
$
4,856


Transaction Price Allocated to Future Performance Obligations

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.
 
 
Six Months Ended
 
 
 
 
(in thousands)
 
December 31, 2019
 
Thereafter
 
Total
 
 
 
 
 
 
 
Pharmaceutical product sales
 
$
116

 
$
2,326

 
$
2,442

Medical device sales
 
$
2,347

 
$
3,986

 
$
6,333



37
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with original expected lengths of one year or less or (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for the products delivered or services performed.

16. Segment Information

In connection with its investment in Evofem in the second quarter of 2019, the Company added a fourth reportable segment, “Strategic Positions.”

Information regarding the Company’s segments for the three and six months ended June 30, 2019 and 2018 is as follows:
Revenues by segment
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
$
10,415

 
$
25,879

 
$
30,375

 
$
44,221

Medical Devices
 
7,422

 
5,882

 
14,148

 
10,864

Strategic Positions
 
—

 
—

 
—

 
—

Income Generating Assets
 
(40,363
)
 
14,814

 
(28,136
)
 
30,008

Total revenues
 
$
(22,526
)
 
$
46,575

 
$
16,387

 
$
85,093


(Loss) income by segment
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
$
(345
)
 
$
(111,335
)
 
$
5,300

 
$
(113,048
)
Medical Devices
 
(1,678
)
 
(1,904
)
 
(2,893
)
 
(2,491
)
Strategic Positions
 
19,044

 
—

 
19,044

 
—

Income Generating Assets
 
(21,440
)
 
943

 
(19,190
)
 
4,845

Total net (loss) income
 
$
(4,419
)
 
$
(112,296
)
 
$
2,261

 
$
(110,694
)

Information regarding the Company’s segments as of June 30, 2019 and December 31, 2018 is as follows:
Long-lived assets by segment
 
 
 
 
(in thousands)
 
June 30,
2019
 
December 31,
2018
 
 
 
 
 
Pharmaceutical
 
$
4,082

 
$
3,682

Medical Devices
 
2,681

 
3,545

Strategic Positions
 
—

 
—

Income Generating Assets
 
151

 
160

Total long-lived assets
 
$
6,914

 
$
7,387


The operations for the Pharmaceutical and Medical Devices segments are primarily located in Italy, Ireland and the United States, respectively.


38
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


17. Concentration of Credit Risk

Product Line Concentration

The percentage of total revenue recognized, which individually accounted for 10% or more of the Company’s total revenues in one or more of the periods presented below, was as follows:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
2019(1)
 
2018
 
2019(1)
 
2018
Noden
 
28%
 
56%
 
41%
 
52%
Assertio
 
49%
 
20%
 
39%
 
20%
LENSAR
 
20%
 
13%
 
19%
 
13%
___________________ 
(1)
For the three and six months ended June 30, 2019, the AcelRx royalty asset decrease in fair value of $60.0 million and $57.9 million, respectively, are excluded from total revenue when calculating product line concentration.

18. Income Taxes
 
Income tax (benefit) expense for the three months ended June 30, 2019 and 2018, was $(1.2) million and $(14.3) million, respectively, and for the six months ended June 30, 2019 and 2018, was $1.5 million and $(13.2) million, respectively, which resulted primarily from applying the federal statutory income tax rate to income before income taxes. The Company’s effective tax rate for the current period differs from the U.S. federal statutory rate of 21% due primarily to the effect of state income taxes and non-deductible executive compensation, less the foreign tax rate differential associated with the Company’s Noden DAC operations in Ireland.

The uncertain tax positions did not change during the three or six months ended June 30, 2019 and 2018.

The Company’s income tax returns are subject to examination by U.S. federal, foreign, state and local tax authorities for tax years 2000 forward. The Company is currently under audit by the California Franchise Tax Board (the “CFTB”) for the tax years 2009 through 2015 and the Internal Revenue Service (the “IRS”) for the tax year 2016. The timing of the resolutions to these audits and the amount to be ultimately paid, if any, is uncertain. The outcome of these audits could result in the payment of tax amounts that differ from the amounts the Company has reserved for uncertain tax positions for the periods under audit resulting in incremental expense or a reversal of the Company’s reserves in a future period. At this time, the Company does not anticipate a material change in the unrecognized tax benefits related to the CFTB or IRS audits that would affect the effective tax rate or deferred tax assets over the next 12 months.


39
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)


19. Net (Loss) Income per Share
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
Net (Loss) Income per Basic and Diluted Share
 
2019
 
2018
 
2019
 
2018
 (in thousands, except per share amounts)
 
 
 
 
 
 
 
 
Numerator
 
 
 
 
 
 
 
 
(Loss) income attributable to PDL’s shareholders used to compute net (loss) income per basic and diluted share
 
$
(4,419
)
 
$
(112,296
)
 
$
2,261

 
$
(110,694
)
 
 
 
 
 
 
 
 
 
Denominator
 
 

 
 

 
 
 
 
Total weighted-average shares used to compute net (loss) income attributable to PDL’s shareholders, per basic share
 
118,285

 
146,923

 
123,484

 
149,186

Restricted stock
 
—

 
—

 
507

 
—

Stock options
 
—

 
—

 
49

 
—

Shares used to compute net (loss) income attributable to PDL’s shareholders, per diluted share
 
118,285

 
146,923

 
124,040

 
149,186

 
 
 
 
 
 
 
 
 
Net (loss) income attributable to PDL’s shareholders per share - basic
 
$
(0.04
)
 
$
(0.76
)
 
$
0.02

 
$
(0.74
)
Net (loss) income attributable to PDL’s shareholders per share - diluted
 
$
(0.04
)
 
$
(0.76
)
 
$
0.02

 
$
(0.74
)

The Company computes net (loss) income per diluted share using the sum of the weighted-average number of common and common equivalent shares outstanding. Common equivalent shares used in the computation of net (loss) income per diluted share include shares that may be issued pursuant to outstanding stock options and restricted stock awards, the 4.0% Convertible Senior Notes due February 1, 2018 (the “February 2018 Notes”) that were repaid on February 1, 2018, and the 2.75% Convertible Senior Notes due December 1, 2021 (the “December 2021 Notes”), in each case, on a weighted-average basis for the period that the notes were outstanding, including, if applicable, the underlying shares using the treasury stock method.

December 2021 Notes Capped Call Potential Dilution

In November 2016, the Company issued $150.0 million in aggregate principal of the December 2021 Notes, which provide in certain situations for the conversion of the outstanding principal amount of the December 2021 Notes into shares of the Company’s common stock at a predefined conversion rate. In conjunction with the issuance of the December 2021 Notes, the Company entered into a capped call transaction with a hedge counterparty. The capped call transaction is expected generally to reduce the potential dilution, and/or offset, to an extent, the cash payments the Company may choose to make in excess of the principal amount, upon conversion of the December 2021 Notes. The Company has excluded the capped call transaction from the net (loss) income per diluted share computation as such securities would have an anti-dilutive effect and those securities should be considered separately rather than in the aggregate in determining whether their effect on net (loss) income per diluted share would be dilutive or anti-dilutive. For additional information regarding the conversion rates and the capped call transaction related to the Company’s December 2021 Notes, see Note 10, Convertible Senior Notes.

Anti-Dilutive Effect of Restricted Stock Awards and Stock Options

For the three months ended June 30, 2019 and 2018, the Company excluded approximately 1.1 million and 1.0 million shares underlying restricted stock awards, respectively, and for the six months ended June 30, 2019 and 2018, the Company excluded approximately 0.8 million and 1.1 million shares underlying restricted stock awards, respectively, in each case calculated on a weighted-average basis, from its net (loss) income per diluted share calculations because their effect was anti-dilutive.

For the three months ended June 30, 2019 and 2018, the Company excluded approximately 12.7 million and 4.9 million shares underlying outstanding stock options, respectively, and for the six months ended June 30, 2019 and 2018, the Company excluded approximately 10.4 million and 4.9 million shares underlying outstanding stock options, respectively, in each case calculated on a weighted-average basis, from its net (loss) income per diluted share calculations because their effect was anti-dilutive.

40
PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)



20. Subsequent Events

Share Repurchase Program

Subsequent to June 30, 2019, the Company repurchased approximately 1.3 million shares of its common stock at a weighted-average price of $3.17 per share for a total of $4.1 million. These purchases concluded this share repurchase program. The amounts repurchased by the Company under the $100.0 million share repurchase program authorized by the Company’s board of directors totaled 31.0 million shares of its common stock for an aggregate purchase price of $100.0 million, or an average cost of $3.22 per share, including trading commissions.


41


ITEM 2.             MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are “forward-looking statements” for purposes of these provisions, including any projections of earnings, revenues or other financial items, any statements of the plans and objectives of management for future operations, including any statements concerning new licensing, any statements regarding future economic conditions or performance, and any statement of assumptions underlying any of the foregoing. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, forward-looking statements can be identified by the use of terminology such as “may,” “will,” “intends,” “plans,” “believes,” “anticipates,” “expects,” “estimates,” “predicts,” “potential,” “continue” or “opportunity,” or the negative thereof or other comparable terminology. The forward-looking statements in this quarterly report are only predictions. Although we believe that the expectations presented in the forward-looking statements contained herein are reasonable at the time they were made, there can be no assurance that such expectations or any of the forward-looking statements will prove to be correct. These forward-looking statements, including with regards to our future financial condition and results of operations, are subject to inherent risks and uncertainties, including but not limited to the risk factors set forth below or incorporated by reference herein, and for the reasons described elsewhere in this Quarterly Report on Form 10-Q. All forward-looking statements and reasons why results may differ included in this Quarterly Report on Form 10-Q are made as of the date hereof. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

OVERVIEW

We seek to provide a significant return for our stockholders by entering into strategic transactions involving innovative late clinical-stage or early commercial-stage therapeutics with attractive revenue growth potential. Our leadership team has extensive experience in acquiring, commercializing and managing the life cycle of therapeutic products domestically and internationally across a number of indications and modalities. We intend to leverage this experience by pursuing the acquisition, growth and potential monetization of pharmaceutical products and companies.

Historically, we generated a substantial portion of our revenues through the license agreements related to patents covering the humanization of antibodies, which we refer to as the Queen et al. patents. In 2012, we began providing alternative sources of capital through royalty monetizations and debt facilities, and, in 2016, we began acquiring commercial-stage products and launching specialized companies dedicated to the commercialization of these products. As a result of the nature of these investments and how they are managed, we structured our operations in three segments designated as Pharmaceutical, Medical Devices and Income Generating Assets.

On April 10, 2019, the Company entered into a securities purchase agreement with Evofem Biosciences, Inc. (“Evofem”), pursuant to which it invested $60 million in a private placement of securities. The transaction was structured in two tranches. The first tranche comprised $30 million, which was funded on April 11, 2019. The Company had the right to invest an additional $30 million in a second tranche, which it did on June 10, 2019, alongside two existing Evofem shareholders, who each invested an additional $10 million. These investments are expected to provide funding for Evofem's pre-commercial activities for Amphora®, its investigational, non-hormonal, on-demand prescription contraceptive gel for women. After completing the second tranche, we obtained the right to appoint one member to Evofem's Board of Directors and a limited right to have one non-voting observer participate in Evofem board meetings. We believe this investment provides the Company the ability to take a significant position in a promising company at a critical stage of development where we can provide meaningful contributions through our capital and expertise. As a result of this investment the Company established a fourth segment, “Strategic Positions.”

Prospectively, we will continue to evaluate additional opportunities. We are targeting pharmaceutical products and companies focused on the U.S. market. We are open to various forms of transactions: acquisitions, licensing, joint-ventures or significant equity positions, but it is important to us to be able to be actively engaged in the management of these assets. With our expected focus on consummating strategic transactions involving late clinical-stage or early commercial-stage therapeutics with

42


attractive revenue growth potential, we anticipate that over time more of our revenues will come from our Pharmaceutical segment and, to a lesser extent, our Medical Devices segment, and less of our revenues will come from our Income Generating Assets segment.

Our Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna® and Tekturna HCT® in the United States, Rasilez® and Rasilez HCT® in the rest of the world and revenue generated from the sale of an authorized generic of Tekturna in the United States (collectively, the “Noden Products”).

Our Medical Devices segment consists of revenue from the sale and lease of the LENSAR® Laser System, which may include equipment, Patient Interface Devices (“PIDs”), procedure licenses, training, installation, warranty and maintenance agreements.

Our Strategic Positions segment consists of an investment in Evofem. Our investment includes shares of common stock and warrants to purchase additional shares of common stock. Evofem is a pre-commercial company and, as such, is not yet engaged in revenue-generating activities.

Our Income Generating Assets segment consists of revenue derived from (i) notes and other long-term receivables, (ii) royalty rights and hybrid notes/royalty receivables, (iii) equity investments and (iv) royalties from issued patents in the United States and elsewhere covering the humanization of antibodies, which we refer to as the Queen et al. patents.

Pharmaceutical

Our goal is to deliver shareholder value through the acquisition, growth and potential monetization of a portfolio of actively managed pharmaceutical assets. We are focused on investing in late clinical-stage or early commercial-stage pharmaceutical products and companies with attractive revenue growth potential. Our acquisition strategy focuses on our ability to add value to these assets by giving them access to our capital and commercialization expertise. We have a leadership team with a proven track record of consummating deals and putting businesses on the path to growth and profitability, and we have a strong, liquid balance sheet that can be deployed to finance the right transactions. Our goal is to build growing, profitable revenues from a balanced portfolio of operating companies’ cash flows and, when appropriate, to capture further market value through optimally timed exit strategies.

Noden

On July 1, 2016, our subsidiary, Noden Pharma DAC, entered into an asset purchase agreement (“Noden Purchase Agreement”) whereby it purchased from Novartis Pharma AG (“Novartis”) the exclusive worldwide rights to manufacture, market, and sell the Noden Products and certain related assets and assumed certain related liabilities (the “Noden Transaction”). Noden Pharma DAC and Noden Pharma USA, Inc., together, and including their respective subsidiaries represent deployed capital of $191.2 million.

Tekturna (or Rasilez outside of the United States) contains aliskiren, a direct renin inhibitor, for the treatment of hypertension. While indicated as a first line treatment, it is more commonly used as a third line treatment in those patients who are intolerant of angiotensin-receptor blockers (“ARBs”) or angiotensin converting enzyme inhibitors (“ACEIs”). Studies indicate that approximately 12% of hypertension patients are ARB/ACEI inhibitor-intolerant. It is not indicated for use with ARBs and ACEIs in patients with diabetes or renal impairment and is contraindicated for use by pregnant women. On March 4, 2019, we announced the U.S. commercial launch of an authorized generic (“AG”) form of Tekturna, aliskiren hemifumarate 150 mg and 300 mg tablets with the same drug formulation as Tekturna. The AG launch is being carried out by Prasco, LLC d/b/a Prasco Laboratories.

Tekturna HCT is a combination of aliskiren and hydrochlorothiazide, a diuretic, for the treatment of hypertension in patients not adequately controlled by monotherapy and as an initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals. It is not indicated for use with ACEIs and ARBs in patient with diabetes or renal impairment, or for use in patients with known anuria or hypersensitivity to sulfonamide derived drugs and is contraindicated for use by pregnant women.

The Noden Products are protected by multiple patents worldwide, which specifically cover the composition of matter, the pharmaceutical formulations and methods of production. In the United States, the FDA Orange Book lists one patent, U.S. patent No. 5,559,111 (the “’111 Patent”), which covers compositions of matter comprising aliskiren. The ‘111 Patent expired on January 21, 2019, and was previously extended for six months through a pediatric extension. In addition, the Food and Drug

43


Administration (the “FDA”) Orange Book for Tekturna lists U.S. Patent No. 8,617,595, which covers certain compositions comprising aliskiren, together with other formulation components, and will expire on February 19, 2026. The FDA Orange Book for Tekturna HCT lists U.S. patent No. 8,618,172, which covers certain compositions comprising aliskiren, together with other formulation components, and will expire on July 13, 2028. In Europe, European patent No. 678 503B (the “’503B Patent”) expired in 2015. However, numerous Supplementary Protection Certificates (“SPCs”) have been granted which are based on the ‘503B Patent and which will provide for extended protection. These SPCs generally expire in April of 2020.

The agreement between Novartis and Noden provides for various transition periods for development and commercialization activities relating to the Noden Products. Initially, Novartis distributed the Noden Products on behalf of Noden worldwide and Noden received a profit transfer on such sales. Generally, the profit transfer to Noden was defined as gross revenues less product cost and a low single-digit percentage fee to Novartis. The profit transfer terminated upon the transfer of the marketing authorization from Novartis to Noden in each country. In the United States, the duration of the profit transfer ran from July 1, 2016 through October 4, 2016. Outside the United States, the profit transfer ended in the first quarter of 2018.

Prior to the transfer of the marketing authorization, revenue was presented on a “net” basis; after the transfer of the marketing authorization, revenue is presented on a “gross” basis, meaning product costs are reported separately and there is no fee to Novartis. Except for the sales outside of the United States preceding the final profit transfer that occurred in the first quarter of 2018, revenues of the Noden Products for the periods herein are presented on a gross basis.

Medical Devices

LENSAR

In December 2016, LENSAR filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code (the “Chapter 11 case”). With our support, LENSAR filed a Chapter 11 plan of reorganization under which LENSAR would issue 100% of its equity interests to us in exchange for the cancellation of our claims as a secured creditor in the Chapter 11 case. On May 11, 2017, pursuant to the Chapter 11 plan of reorganization, most of LENSAR’s outstanding debt owed to us was converted to equity and LENSAR became our operating subsidiary. LENSAR represents deployed capital of $47.0 million.

LENSAR is a medical device company focused on the next generation femtosecond cataract laser technology for refractive cataract surgery. Femtosecond cataract surgery uses advanced laser technology as compared to conventional phacoemulsification cataract surgery which uses an ultrasonic device. Cataract surgery is the highest volume surgical procedure performed worldwide with over 27 million surgeries estimated to have been performed in 2018, the majority of which use the conventional phacoemulsification technique. The LENSAR® Laser System offers cataract surgeons automation and customization for their astigmatism treatment planning and other essential steps of the refractive cataract surgery procedure with the highest levels of precision, accuracy, and efficiency. These features assist surgeons in managing their astigmatism treatment plans for optimal overall visual outcomes.

The LENSAR® Laser System has been approved by the FDA for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions. The LENSAR Laser with Augmented Reality™ provides an accurate 3-D model of the relevant anatomical features of each patient’s anterior segment, allowing precise laser delivery and to enhance the surgical confidence in performing accurate corneal incisions, precise size, shape and location of free-floating capsulotomies, and efficient lens fragmentation for all grades. The LENSAR® Laser System - fs 3D (LLS-fs 3D) with Streamline™ includes the integration with various pre-op diagnostic devices, automated Iris Registration with automatic cyclorotation adjustment, IntelliAxis-C™ (corneal) and IntelliAxis-L™ (lens) markers for simple alignment without errors associated with manually marking the eye, of Toric IOLs as well as treatment planning tools for precision guided laser treatments. The corneal incision-only mode, expanded remote diagnostics capabilities, additional pre-programmable preferences, thoughtful ergonomics, and up to 20 seconds faster laser treatment times with Streamline allow for seamless integration and maximum surgical efficiency.

LENSAR has developed the LENSAR® Laser System, which is the only femtosecond cataract laser built specifically for refractive cataract surgery. The LENSAR® Laser System is protected by over 60 granted patents in the United States and the rest of the world and over 45 pending patent applications in the United States and rest of the world.


44


Strategic Positions

Evofem

As described above, in the second quarter of 2019 the Company invested $60.0 million in Evofem, representing approximately a 29% ownership interest in the company. In connection with this investment the Company appointed one board member and one observer to Evofem’s board of directors. Evofem is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Evofem is leveraging its proprietary Multipurpose Vaginal pH Regulator (MVP-R™) platform to develop Amphora® (L-lactic acid, citric acid and potassium bitartrate) for hormone-free birth control. Evofem plans to resubmit the Amphora New Drug Application for prevention of pregnancy in the fourth quarter of 2019.

Income Generating Assets

We have pursued income generating assets when such assets could be acquired on terms that we believed would allow us to increase return to our stockholders. The income generating assets typically consisted of (i) notes and other long-term receivables, (ii) royalty rights and hybrid notes/royalty receivables, (iii) equity investments and (iv) royalties from the Queen et. al patents. We previously focused our income generating asset acquisition strategy on commercial-stage therapies and medical devices having strong economic fundamentals. We have consummated fifteen transactions in this segment, eight of which are active and outstanding:
Investment
 
Investment Type
 
Deployed Capital (4)
(in millions)
 
 
 
 
 
Assertio(1)
 
Royalty
 
$
260.5

The Regents of the University of Michigan (“U-M”)
 
Royalty
 
$
65.6

AcelRx Pharmaceuticals, Inc. (“AcelRx”)
 
Royalty
 
$
65.0

Viscogliosi Brothers, LLC (“VB”)
 
Royalty
 
$
15.5

KYBELLA®
 
Royalty
 
$
9.5

CareView Communications, Inc. (“CareView”)
 
Debt
 
$
20.0

Direct Flow Medical, Inc. (“DFM”)(2)
 
Debt
 
$
59.0

Wellstat Diagnostics(3)
 
Royalty/debt hybrid
 
$
44.0

______________
(1) 
Assertio Therapeutics, Inc., formerly Depomed, Inc.
(2) 
DFM ceased operations in December 2016 and we subsequently foreclosed upon and obtained most of the assets of DFM and impaired them by $51.1 million. Since taking over the DFM assets, we have collected $8.7 million in cash and, as of June 30, 2019 an intangible asset with a carrying value of $1.6 million remains on our books. For further detail see Note 8, Intangible Assets.
(3) 
Wellstat Diagnostics, LLC (also known as Defined Diagnostic, LLC) (“Wellstat Diagnostics”).
(4) 
Excludes transaction costs.

Royalty Rights - At Fair Value

We have entered into various royalty purchase agreements with counterparties, whereby the counterparty conveys to us the right to receive royalties that are typically payable on sales revenue generated by the sale, distribution or other use of the counterparties’ products.

We record the royalty rights at fair value using discounted cash flows related to the expected future cash flows to be received. We use significant judgment in determining our valuation inputs, including estimates as to the probability and timing of future sales of the licensed product. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from our estimates. A third-party expert is generally engaged to assist us with the development of our estimate of the expected future cash flows. At each reporting period, an evaluation is performed to assess those estimates, discount rates utilized and general market conditions affecting fair market value.

45



While we currently maintain this portfolio of royalty rights, our intention is to no longer pursue these transactions while we focus on acquiring additional pharmaceutical products or companies. At June 30, 2019, we had a total of five royalty rights transactions outstanding.

Notes and Other Long-Term Receivables

We have entered into credit agreements with borrowers across the healthcare industry, under which we made available cash loans to be used by the borrower. Obligations under these credit agreements are typically secured by a pledge of substantially all the assets of the borrower and any of its subsidiaries. While we currently maintain this portfolio of notes receivable, our intention is to no longer pursue these types of transactions. At June 30, 2019, we had two notes receivable transactions outstanding.

Equity Investments

In the past, we have received equity instruments, including shares of stock or warrants to acquire shares of stock, in connection with credit agreements we entered into with borrowers in the healthcare industry. Our investment objective with respect to these equity investments is to maximize our return through capital appreciation and, when appropriate, to capture the value through optimally timed exit strategies.

Royalties from Queen et al. patents

We have been issued patents in the United States and elsewhere, covering the humanization of antibodies, which we refer to as our Queen et al. patents. Our Queen et al. patents, for which final patent expiry was in December 2014, covered, among other things, humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies and methods of producing humanized antibodies.

We previously entered into licensing agreements under our Queen et al. patents with numerous entities that are independently developing or have developed humanized antibodies. Under our licensing agreements, we are entitled to receive a flat-rate royalty based upon our licensees’ net sales of covered antibodies, although the royalties under these agreements have substantially ended.

Economic and Industry-wide Factors
 
Various economic and industry-wide factors are relevant to our business, including changes to laws and interpretation of those laws that protect our intellectual property rights, our licensees’ ability to obtain or retain regulatory approval for products licensed under our patents, fluctuations in foreign currency exchange rates, the ability to attract, retain and integrate qualified personnel, as well as overall global economic conditions. We actively monitor economic, industry and market factors affecting our business; however, we cannot predict the impact such factors may have on our future results of operations, liquidity and cash flows. See also the risk factors included in “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 for additional factors that may impact our business and results of operations.

Critical Accounting Policies and Use of Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on our historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

In February 2016, the FASB issued ASU No. 2016-02, Leases, that supersedes Accounting Standards Codification (“ASC”) 840, Leases. Subsequently, the FASB issued several updates to ASU No. 2016-02, codified in ASC Topic 842 (“ASC 842”)
Effective January 1, 2019, we adopted the requirements of ASC 842 using the modified retrospective method for all leases not substantially completed as of the date of adoption. The reported results for the three and six month periods ended June 30, 2019

46


reflect the application of ASC 842 guidance while the reported results for the three and six month periods ended June 30, 2018 were prepared under the guidance of ASC 840, which is also referred to herein as “legacy GAAP” or the “previous guidance”. The adoption did not have an effect on the Condensed Consolidated Statements of Operations. However, the new standard required us to establish liabilities and corresponding right-of-use assets on our Consolidated Balance Sheet for operating leases that exist as of January 1, 2019. The cumulative impact of the adoption of ASC 842 was not material, therefore, we did not record any adjustments to retained earnings.

During the three months ended June 30, 2019, we acquired shares of common stock and warrants to acquire additional shares of common stock of Evofem. As of June 30, 2019, we owned approximately 29% of Evofem’s common stock. Our investment in Evofem qualifies for equity method accounting given our percentage ownership in Evofem and our ability to exercise significant influence. We elected the fair value method to account for our investment in Evofem as we believe it better reflects economic reality, the financial reporting of the investment and the current value of the asset. The mark to market valuation of our investment, and resulting changes in fair value, will occur at the end of each quarterly reporting period and will vary based upon the volatility of the stock price.

During the six months ended June 30, 2019, there have not been any other significant changes to our critical accounting policies and estimates from those presented in Part II, Item 7 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, that are of significance, or potential significance, to us.

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. The new guidance amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses. ASU No. 2016-13 has an effective date of the fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. We are currently evaluating the impact of this guidance on our Consolidated Financial Statements.

In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software. The new guidance reduces complexity for the accounting for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). For public companies, the amendments in ASU No. 2018-15 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. Implementation should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We are currently evaluating the impact of this guidance on our Consolidated Financial Statements.

Operating Results

Three and six months ended June 30, 2019, compared to three and six months ended June 30, 2018

Revenues

 
 
Three Months Ended
 
Change from Prior
 
Six Months Ended
 
Change from Prior
 
 
June 30,
 
 
June 30,
 
(dollars in thousands)
 
2019
 
2018
 
Year %
 
2019
 
2018
 
Year %
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues
 
 
 
 
 
 
 
 
 
 
 
 
Product revenue, net(1)
 
$
17,837

 
$
31,761

 
(44%)
 
$
44,523

 
$
55,085

 
(19%)
Royalty rights - change in fair value
 
(40,399
)
 
12,842

 
(415%)
 
(28,142
)
 
23,933

 
(218%)
Royalties from Queen et al. patents
 
6

 
1,218

 
(100%)
 
9

 
4,001

 
(100%)
Interest revenue
 
—

 
751

 
N/M
 
—

 
1,500

 
N/M
License and other
 
30

 
3

 
900%
 
(3
)
 
574

 
(101%)
Total revenues
 
$
(22,526
)
 
$
46,575

 
(148%)
 
$
16,387

 
$
85,093

 
(81%)
________________________

47


N/M    Not meaningful

(1)
Our Product revenue, net includes revenue from our Pharmaceutical segment and Medical Devices segment. We record Product revenue for our Pharmaceutical segment net of estimated product returns, pricing discounts, including rebates offered pursuant to mandatory federal and state government programs, chargebacks, prompt pay discounts, distribution fees and co-pay assistance for product sales each period. Revenue from LENSAR product sales include LENSAR® Laser Systems, disposable consumables, procedures, training, installation, warranty and maintenance services.

Three Months Ended June 30, 2019

Total revenues were $(22.5) million for the three months ended June 30, 2019, compared with $46.6 million for the three months ended June 30, 2018. Our total revenues decreased by 148%, or $69.1 million, for the three months ended June 30, 2019, when compared to the same period of 2018. The decrease was primarily due to:
•
lower royalty asset revenues,
•
a $15.5 million decline in product revenue from our Pharmaceutical segment, of which $7.7 million and $7.8 million is attributable to the United States and rest of world, respectively,
•
a decline in interest revenue from the CareView note receivable asset, and
•
lower royalties from the Queen et al. patents, partially offset by
•
$1.5 million in higher product revenues from our Medical Devices segment, and
•
higher license and other revenue.

Revenue from our Pharmaceutical segment for the three months ended June 30, 2019 was $10.4 million, a decrease of 60%, compared to the same period in the prior year. The decrease in revenue from our Pharmaceutical segment reflects lower net revenues in the United States and the rest of the world. The decrease in revenue from our Pharmaceutical segment in the United States for the three months ended June 30, 2019 reflects limited sales of our authorized generic due to the initial inventory stocking that occurred in the third month of the prior quarter when the authorized generic of Tekturna was launched. Additionally, the availability of our authorized generic in the market in the three months ended June 30, 2019 and sales from a third-party generic of aliskiren that was launched late in the first quarter impacted sales of the branded product in the three months ended June 30, 2019. The decrease in revenue for the rest of the world is due to the initial inventory stock in Japan in the three months ended June 30, 2018 and lower sales volume of Rasilez in other territories.

Revenue from our Medical Devices segment for the three months ended June 30, 2019 was $7.4 million, an increase of 26%, compared to the same period in the prior year. The increase in revenue from our Medical Devices segment reflects higher net revenues in both North America and the rest of the world, with the majority of the increase outside of North America.

Revenue from our Income Generating Assets segment for the three months ended June 30, 2019 were $(40.4) million, a decrease of 372%, compared to the same period in the prior year. The decrease was primarily due to:
•
lower royalty asset revenues primarily due to a $60.0 million decrease in fair value of the AcelRx royalty asset,
•
decrease in revenue from the Queen et al. patents, and
•
decrease in interest revenue from our CareView note receivable, partially offset by
•
higher license and other revenue.

The adjustment to the fair value of the AcelRx royalty asset is due to the slower than expected adoption of Zalviso® (sufentanil sublingual tablet system) since its initial launch relative to our estimates and the increased variance noted between our forecast model and actual results in the three months ended June 30, 2019. We engaged a third-party expert in the second quarter of 2019 to reassess the market and expectations for the product. Key findings from the third-party study included: the post-surgical PCA (Patient-Controlled Analgesia) market being smaller than previously forecasted; the higher price of the product relative to alternative therapies, the product not being used as a replacement for systemic opioids and the design of the delivery device, which is pre-filled for up to three days of treatment, which restricts its use for shorter recovery time procedures. Based on this analysis, and the impact to the projected sales-based royalties and milestones, we wrote down the fair value of the royalty asset by $60.0 million in the three months ended June 30, 2019.


48


The following tables provides a summary of activity with respect to our royalty rights - change in fair value for the three months ended June 30, 2019 and 2018:
 
 
Three Months Ended June 30, 2019
 
 
 
 
Change in
 
Royalty Rights -
(in thousands)
 
Cash Royalties
 
Fair Value
 
Change in Fair Value
 
 
 
 
 
 
 
Assertio
 
$
18,415

 
$
93

 
$
18,508

VB
 
227

 
137

 
364

U-M
 
1,371

 
(780
)
 
591

AcelRx
 
93

 
(59,974
)
 
(59,881
)
KYBELLA
 
—

 
19

 
19

Total
 
$
20,106

 
$
(60,505
)
 
$
(40,399
)

 
 
Three Months Ended June 30, 2018
 
 
 
 
Change in
 
Royalty Rights -
(in thousands)
 
Cash Royalties
 
Fair Value
 
Change in Fair Value
 
 
 
 
 
 
 
Assertio
 
$
17,690

 
$
(8,537
)
 
$
9,153

VB
 
263

 
147

 
410

U-M
 
1,288

 
(433
)
 
855

AcelRx
 
68

 
2,302

 
2,370

Avinger
 
61

 
(101
)
 
(40
)
KYBELLA
 
—

 
94

 
94

Total
 
$
19,370

 
$
(6,528
)
 
$
12,842


Six Months Ended June 30, 2019

Total revenues were $16.4 million for the six months ended June 30, 2019, compared with $85.1 million for the six months ended June 30, 2018. Our total revenues decreased by 81%, or $68.7 million, for the six months ended June 30, 2019, when compared to the same period of 2018. The decrease was primarily due to:
•
lower royalty asset revenues,
•
lower product revenues from our Pharmaceutical segment,
•
lower royalties from the Queen et al. patents, and
•
a decline in interest revenue from the CareView note receivable asset, partially offset by
•
higher product revenues from our Medical Devices segment.

Revenue from our Pharmaceutical segment for the six months ended June 30, 2019 was $30.4 million, a decrease of 31%, compared to the same period in the prior year. The decrease in revenue from our Pharmaceutical segment reflects lower net revenues in the United States and the rest of the world. The decrease in revenue from our Pharmaceutical segment in the United States for the three months ended June 30, 2019 reflects the introduction of our authorized generic of Tekturna and a third-party generic of aliskiren in the current six-month period. The decrease in revenue for the rest of the world is due to the initial inventory stock in Japan in the three months ended June 30, 2018 and lower sales volume of Rasilez in other territories.



49


The following table provides a summary of activity with respect to our sales allowances and accruals for the six months ended June 30, 2019:
(in thousands)
 
Discount and Distribution Fees
 
Government Rebates and Chargebacks
 
Assistance and Other Discounts
 
Product Returns
 
Total
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2018
 
$
3,094

 
$
8,901

 
$
3,457

 
$
4,681

 
$
20,133

Allowances for current period sales
 
3,069

 
6,455

 
2,962

 
951

 
13,437

Allowances for prior period sales
 
—

 
1,841

 
120

 
—

 
1,961

Credits/payments for current period sales
 
(1,544
)
 
(4,929
)
 
(2,401
)
 
(232
)
 
(9,106
)
Credits/payments for prior period sales
 
(3,044
)
 
(9,910
)
 
(3,005
)
 
(2,218
)
 
(18,177
)
Balance at June 30, 2019
 
$
1,575

 
$
2,358

 
$
1,133

 
$
3,182

 
$
8,248


Revenue from our Medical Devices segment for the six months ended June 30, 2019 was $14.1 million, an increase of 30%, compared to the same period in the prior year. The increase in revenue from our Medical Devices segment reflects higher net revenues in both North America and the rest of the world, with the majority of the increase outside of North America.

Revenue from our Income Generating Assets segment for the six months ended June 30, 2019 was $(28.1) million, a decrease of 194%, compared to the same period in the prior year. The decrease was primarily due to:
•
lower royalty asset revenues primarily due to the decrease in fair value of the AcelRx royalty asset in the three months ended June 30, 2019 discussed above,
•
a decrease in revenue from the Queen et al. patents, and
•
no interest revenue recognized from our CareView note receivable.

The following tables provides a summary of activity with respect to our royalty rights - change in fair value for the six months ended June 30, 2019 and 2018:
 
 
Six Months Ended June 30, 2019
 
 
 
 
 
 
 
 
 
 
 
Change in
 
Royalty Rights -
(in thousands)
 
Cash Royalties
 
Fair Value
 
Change in Fair Value
 
 
 
 
 
 
 
Assertio
 
$
29,383

 
$
(459
)
 
$
28,924

VB
 
494

 
265

 
759

U-M
 
2,638

 
(1,316
)
 
1,322

AcelRx
 
161

 
(57,886
)
 
(57,725
)
KYBELLA
 
50

 
(1,472
)
 
(1,422
)
Total
 
$
32,726

 
$
(60,868
)
 
$
(28,142
)

 
 
Six Months Ended June 30, 2018
 
 
 
 
 
 
 
 
 
 
 
Change in
 
Royalty Rights -
(in thousands)
 
Cash Royalties
 
Fair Value
 
Change in Fair Value
 
 
 
 
 
 
 
Assertio
 
$
34,597

 
$
(17,967
)
 
$
16,630

VB
 
543

 
284

 
827

U-M
 
2,284

 
(620
)
 
1,664

AcelRx
 
120

 
4,539

 
4,659

Avinger
 
366

 
(396
)
 
(30
)
KYBELLA
 
83

 
100

 
183

Total
 
$
37,993

 
$
(14,060
)
 
$
23,933



50


Operating Expenses

 
 
Three Months Ended
 
Change from Prior
 
Six Months Ended
 
Change from Prior
 
 
June 30,
 
 
June 30,
 
(dollars in thousands)
 
2019
 
2018
 
Year %
 
2019
 
2018
 
Year %
 
 
 
 
 
 
 
 
 
 
 
 
 
Cost of product revenue, (excluding intangible amortization and impairment)
 
$
12,348

 
$
14,524

 
(15)%
 
$
25,158

 
$
25,090

 
—%
Amortization of intangible assets
 
1,598

 
6,384

 
(75)%
 
3,170

 
12,677

 
(75)%
General and administrative
 
10,483

 
14,529

 
(28)%
 
20,945

 
26,190

 
(20)%
Sales and marketing
 
2,073

 
5,385

 
(62)%
 
4,803

 
10,898

 
(56)%
Research and development
 
886

 
684

 
30%
 
1,755

 
1,477

 
19%
Impairment of intangible assets
 
—

 
152,330

 
N/M
 
—

 
152,330

 
N/M
Change in fair value of acquisition-related contingent consideration
 
—

 
(22,135
)
 
N/M
 
—

 
(22,735
)
 
N/M
Total operating expenses
 
$
27,388

 
$
171,701

 
(84)%
 
$
55,831

 
$
205,927

 
(73)%
Percentage of total revenues
 
N/M

 
369
%
 
 
 
341
%
 
242
%
 
 
_______________________
N/M    Not meaningful

Three Months Ended June 30, 2019

Total operating expenses were $27.4 million for the three months ended June 30, 2019, compared with $171.7 million for the three months ended June 30, 2018. Our operating expenses decreased 84%, or $144.3 million, for the three month period ended June 30, 2019, when compared to the three-month period ended June 30, 2018. The decrease was primarily a result of:
•
the absence of the $152.3 million Noden intangible asset impairment recorded in the second quarter of 2018,
•
lower amortization of intangible assets after the impairment of the Noden intangible assets,
•
lower general and administrative expenses of $4.0 million, or 28%, primarily due to lower professional fees,
•
lower sales and marketing expenses, reflecting the cost savings from the change in our marketing strategies for the Noden Products to a non-personal promotion strategy in anticipation of a third-party generic launch of aliskiren, and
•
lower cost of product revenue, due to lower sales at Noden, partially offset by
•
the favorable adjustment to the fair value of the contingent consideration recorded in the three-month period ended June 30, 2018 with no corresponding adjustment in the three-month period ended June 30, 2019, and
•
higher research and development in our Medical Devices segment.


51


General and administrative expenses for the three months ended June 30, 2019 and 2018 are summarized in the table below:
 
 
Three Months Ended June 30, 2019
 
Three Months Ended June 30, 2018
(in thousands)
 
Pharmaceutical
 
Medical Device
 
Income Generating Assets
 
Total
 
Pharmaceutical
 
Medical Device
 
Income Generating Assets
 
Total
Compensation
 
$
513

 
$
987

 
$
4,336

 
$
5,836

 
$
457

 
$
935

 
$
3,894

 
$
5,286

Salaries and Wages (including taxes)
 
385

 
453

 
1,543

 
2,381

 
371

 
414

 
1,525

 
2,310

Bonuses (including accruals)
 
67

 
247

 
724

 
1,038

 
67

 
402

 
1,144

 
1,613

Equity
 
61

 
287

 
2,069

 
2,417

 
19

 
119

 
1,225

 
1,363

Asset management
 
—

 
—

 
234

 
234

 
—

 
—

 
764

 
764

Business development
 
—

 
—

 
468

 
468

 
28

 
—

 
869

 
897

Accounting and tax services
 
531

 
37

 
679

 
1,247

 
619

 
4

 
1,652

 
2,275

Other professional services
 
443

 
428

 
462

 
1,333

 
202

 
69

 
729

 
1,000

Other
 
9

 
271

 
1,085

 
1,365

 
2,530

 
522

 
1,255

 
4,307

Total general and administrative
 
$
1,496

 
$
1,723

 
$
7,264

 
$
10,483

 
$
3,836

 
$
1,530

 
$
9,163

 
$
14,529

________________
No general and administrative expenses were attributable to the Strategic Positions segment for the three months ended June 30, 2019.

The reduction in other general and administrative expenses in the Pharmaceutical segment for the three months ended June 30, 2019 were reduced by $1.1 million due to a change in foreign currency exchange rates as compared to the three month period ended June 30, 2018.

Six Months Ended June 30, 2019

Total operating expenses were $55.8 million for the six months ended June 30, 2019, compared with $205.9 million for the six months ended June 30, 2018. Our operating expenses decreased 73%, or $150.1 million, for the six month period ended June 30, 2019, when compared to the six-month period ended June 30, 2018. The decrease was primarily a result of:
•
the absence of the $152.3 million Noden intangible asset impairment recorded in the second quarter of 2018,
•
lower amortization expense for the Noden intangible assets as a result of the impairment recorded,
•
lower general and administrative expenses of $5.2 million, or 20%, primarily due to lower professional fees, and
•
lower sales and marketing expenses, reflecting the cost savings from the change in our marketing strategies for the Noden Products, partially offset by
•
the favorable adjustment to the Noden acquisition related contingent consideration which was reduced in the second quarter of 2018.


52


General and administrative expenses for the six months ended June 30, 2019 and 2018 are summarized in the table below:
 
 
Six Months Ended June 30, 2019
 
Six Months Ended June 30, 2018
(in thousands)
 
Pharmaceutical
 
Medical Device
 
Income Generating Assets
 
Total
 
Pharmaceutical
 
Medical Device
 
Income Generating Assets
 
Total
Compensation
 
$
1,005

 
$
1,943

 
$
7,784

 
$
10,732

 
$
897

 
$
1,623

 
$
7,218

 
$
9,738

Salaries and Wages (including taxes)
 
769

 
972

 
3,190

 
4,931

 
740

 
849

 
2,843

 
4,432

Bonuses (including accruals)
 
147

 
570

 
1,429

 
2,146

 
128

 
456

 
2,217

 
2,801

Equity
 
89

 
401

 
3,165

 
3,655

 
29

 
318

 
2,158

 
2,505

Asset management
 
—

 
—

 
684

 
684

 
—

 
—

 
2,267

 
2,267

Business development
 
—

 
—

 
597

 
597

 
28

 
—

 
1,269

 
1,297

Accounting and tax services
 
787

 
40

 
1,648

 
2,475

 
926

 
6

 
2,908

 
3,840

Other professional services
 
952

 
702

 
803

 
2,457

 
1,933

 
192

 
946

 
3,071

Other
 
901

 
854

 
2,245

 
4,000

 
2,617

 
840

 
2,520

 
5,977

Total general and administrative
 
$
3,645

 
$
3,539

 
$
13,761

 
$
20,945

 
$
6,401

 
$
2,661

 
$
17,128

 
$
26,190

________________
No general and administrative expenses were attributable to the Strategic Positions segment for the six months ended June 30, 2019.

Non-operating Income (Expense), Net

 
 
Three Months Ended
 
Change from Prior
 
Six Months Ended
 
Change from Prior
 
 
June 30,
 
 
June 30,
 
(dollars in thousands)
 
2019
 
2018
 
Year %
 
2019
 
2018
 
Year %
 
 
 
 
 
 
 
 
 
 
 
 
 
Interest and other income, net
 
$
1,650

 
$
1,376

 
20%
 
$
3,524

 
$
3,290

 
7%
Interest expense
 
(2,984
)
 
(2,811
)
 
6%
 
(5,939
)
 
(6,396
)
 
(7%)
Equity affiliate - change in fair value
 
45,487

 
—

 
N/M
 
45,487

 
—

 
N/M
Total revenues
 
$
44,153

 
$
(1,435
)
 
(3,177%)
 
$
43,072

 
$
(3,106
)
 
(1,487%)
________________________
N/M    Not meaningful

Three Months Ended June 30, 2019

Non-operating income (expense), net, increased for the three months ended June 30, 2019, as compared to the same period in 2018, primarily due to:
•
the unrealized gain on the value of our investment in common stock and warrants of Evofem, and
•
an increase in interest income from investments as compared to the prior year comparable period, partially offset by
•
an increase in interest expense associated with the amortization of the conversion feature on our 2021 convertible notes.

Six Months Ended June 30, 2019

Non-operating income (expense), net, increased for the six months ended June 30, 2019, as compared to the same period in 2018, primarily due to:
•
the unrealized gain on the value of our investment in common stock and warrants of Evofem,
•
the reduction in interest expense after the February 2018 Notes were repaid, and
•
an increase in interest income from investments as compared to the prior year comparable period, partially offset by

53


•
the gain on available-for-sale investments recorded in the six-month period ended June 30, 2018 for which no such gain was recognized in the six-month period ended June 30, 2019.


Income Taxes

Income tax (benefit) expense for the three months ended June 30, 2019 and 2018, was $(1.2) million and $(14.3) million, respectively, and for the six months ended June 30, 2019 and 2018, was $1.5 million and $(13.2) million respectively, which resulted primarily from applying the federal statutory income tax rate to income before income taxes. Our effective tax rate for the current period differs from the U.S. federal statutory rate of 21% due primarily to the effect of state income taxes and non-deductible executive compensation, less the foreign tax rate differential associated with our operations of Noden DAC in Ireland.

The uncertain tax positions did not change during the three or six months ended June 30, 2019 and 2018.

Our income tax returns are subject to examination by U.S. federal, foreign, state and local tax authorities for tax years 2000 forward. We are currently under audit by the California Franchise Tax Board (the “CFTB”) for the tax years 2009 through 2015 and the Internal Revenue Service (the “IRS”) for the tax year 2016. The timing of the audit resolution and the amount to be ultimately paid, if any, is uncertain. The outcome of these audits could result in the payment of tax amounts that differ from the amounts we have reserved for uncertain tax positions for the periods under audit resulting in incremental expense or a reversal of the reserves in a future period. At this time, we do not anticipate a material change in the unrecognized tax benefits related to the CFTB or IRS audits that would affect the effective tax rate or deferred tax assets over the next 12 months.

Net (Loss) Income Per Share
 
Net (loss) income per share for the three and six months ended June 30, 2019 and 2018, is presented below:
 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
Net (loss) income per share - basic
$
(0.04
)
 
$
(0.76
)
 
$
0.02

 
$
(0.74
)
Net (loss) income per share - diluted
$
(0.04
)
 
$
(0.76
)
 
$
0.02

 
$
(0.74
)
Weighted-average basic and diluted shares used in the computation of Net (loss) income per share are as follows (in thousands):
 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
Basic
118,285

 
146,923

 
123,484

 
149,186

Diluted
118,285

 
146,923

 
124,040

 
149,186


Liquidity and Capital Resources

We finance our operations primarily through royalty and other license-related revenues, public and private placements of debt and equity securities, interest income on invested capital and revenues from pharmaceutical and medical device product sales. We currently have 19 full-time employees at PDL managing our intellectual property, our asset acquisitions, operations and other corporate activities as well as providing for certain essential reporting and management functions of a public company. In addition, we have 15 full-time employees at our operating subsidiary, Noden, who manage the Pharmaceutical segment business and operations, and 73 full time employees at our operating subsidiary, LENSAR, who manage the Medical Devices segment business and operations.

Our future capital requirements are difficult to forecast and will depend upon many factors, including our ability to identify and acquire pharmaceutical products or companies, the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, the resources we devote to developing and supporting our products and those

54


of our strategic partners through additional investments and other factors. Additionally, we will continue to evaluate possible acquisitions of new pharmaceutical products or companies, which may require the use of cash or additional financing.

The general cash needs of our Pharmaceutical, Medical Devices and Income Generating Assets segments can vary significantly. In our Pharmaceutical segment, cash needs tend to be driven primarily by material purchases and capital expenditures. In our Medical Devices segment, the primary factor determining cash needs is the funding of our operations and enhancing our product offerings through research and development. The cash needs of our Income Generating Assets segment tend to be driven by legal and professional service fees as well as the funding of potential repurchases of our common stock.

We had cash and cash equivalents in the aggregate of $284.9 million and $394.6 million at June 30, 2019 and December 31, 2018, respectively, representing a decrease of $109.6 million. The decrease was primarily attributable to:
•
the repurchase of common stock for $71.3 million,
•
the investment in Evofem of $60.0 million, and
•
cash used for operating activities of $8.2 million, partially offset by
•
proceeds from royalty right payments of $32.7 million.

On September 24, 2018, we announced that our board of directors authorized the repurchase of issued and outstanding shares of our common stock having an aggregate value of up to $100.0 million pursuant to a share repurchase program. We repurchased 8.0 million shares of our common stock under this share repurchase program during the three months ended June 30, 2019, for an aggregate purchase price of $26.0 million, or an average cost of $3.27 per share, including trading commissions. Since the inception of this share repurchase program through June 30, 2019 we have repurchased 29.7 million shares for an aggregate purchase price of $95.9 million, or an average cost of $3.22 per share, including trading commissions.

Subsequent to June 30, 2019, we repurchased approximately 1.3 million shares of our common stock at a weighted-average price of $3.17 per share for a total of $4.1 million. These purchases concluded this share repurchase program. The amounts repurchased by us under the $100.0 million share repurchase program authorized by our board of directors totaled approximately 31.0 million shares of our common stock for an aggregate purchase price of $100.0 million, or an average cost of $3.22 per share, including trading commissions.

All shares of common stock repurchased under this share repurchase program were retired and restored to authorized but unissued shares of common stock.

We believe that cash on hand and cash from future revenues from acquired pharmaceutical products, medical devices and/or income generating assets, net of operating expenses, debt service and income taxes, will be sufficient to fund our operations over the next several years. Our continued success is dependent on our ability to acquire new pharmaceutical products or companies, and the timing of these transactions, in order to provide recurring cash flows going forward that support our business model, and service our debt.

We continuously evaluate alternatives to create value for our stockholders, including, for example, by investing in late clinical-stage or early commercial-stage therapeutics with attractive revenue growth potential, selling certain assets through optimally timed exit strategies, buying back our convertible notes, repurchasing our common stock or potentially selling our company.

We may consider additional debt or equity financings to support growth if cash flows from our existing business are not sufficient to fund future pharmaceutical product or company acquisitions.

Off-Balance Sheet Arrangements

As of June 30, 2019, we did not have any off-balance sheet arrangements, as defined under SEC Regulation S-K Item 303(a)(4)(ii).


55


Contractual Obligations

Convertible Senior Notes

As of June 30, 2019, our outstanding notes consisted of our December 2021 Notes, which in the aggregate totaled $150.0 million in principal.

We expect that our debt service obligations over the next several years will consist of interest payments and repayment of our December 2021 Notes. We may further seek to exchange, repurchase or otherwise acquire the convertible senior notes in the open market in the future, which could adversely affect the amount or timing of any distributions to our stockholders. We would make such exchanges or repurchases only if we deemed it to be in our stockholders’ best interest. We may finance such repurchases with cash on hand and/or with public or private equity or debt financings if we deem such financings to be available on favorable terms.

Guarantees

Redwood City Lease Guarantee

In connection with the Spin-Off of Facet, we entered into amendments to the leases for our former facilities in Redwood City, California, under which Facet was added as a co-tenant, and a Co-Tenancy Agreement, under which Facet agreed to indemnify us for all matters related to the leases attributable to the period after the Spin-Off date. In April 2010, Abbott Laboratories acquired Facet and later renamed the entity AbbVie Biotherapeutics, Inc. (“AbbVie”). If AbbVie were to default under its lease obligations, we could be held liable by the landlord as a co-tenant and, thus, we have in substance guaranteed the payments under the lease agreements for the Redwood City facilities. As of June 30, 2019, the total lease payments for the duration of the guarantee, which runs through December 2021, are approximately $28.2 million. For additional information regarding our lease guarantee, see Note 12, Commitments and Contingencies.

Purchase Obligation

Noden DAC and Novartis entered into a supply agreement pursuant to which Novartis will manufacture and supply to Noden DAC a bulk tableted form of the Noden Products and the active pharmaceutical ingredient (“API”). In May 2019, Noden DAC and Novartis entered into an amended supply agreement pursuant to which Novartis will supply to Noden DAC a bulk tableted form of the Noden Products through 2020 and API through June 2021. The supply agreement may be terminated by either party for material breach that remains uncured for a specified time period. Under the terms of the amended supply agreement, Noden DAC is committed to purchase certain quantities of bulk product and API that would amount to approximately $90.9 million through June 2021, of which $53.1 million is committed over the next twelve months, which are guaranteed by the Company. While the supply agreement provides that the parties will agree to reasonable accommodations with respect to changes in firm orders, we expect that Noden DAC will meet the requirements of the supply agreement, unless otherwise negotiated.

LENSAR entered into various supply agreements for the manufacture and supply of certain components. The supply agreement commits LENSAR to a minimum purchase obligation of approximately $6.3 million over the next twenty-four months, of which $4.9 million is committed over the next twelve months. We expect that LENSAR will meet this requirement.


56


ITEM 3.      QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
As of June 30, 2019, there have been no material changes in our market risk from that described in “Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018.


57


ITEM 4.        CONTROLS AND PROCEDURES
 
Evaluation of Disclosure Controls and Procedures
 
The Company’s management has evaluated, with the participation of the chief executive officer and the chief financial officer, the effectiveness of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based on this evaluation, management concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2019.
 
Changes in Internal Control over Financial Reporting

During the quarter ended June 30, 2019, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.



58


PART II. OTHER INFORMATION

ITEM 1.           LEGAL PROCEEDINGS

The information set forth in Note 12, Commitments and Contingencies, to our Notes to Condensed Consolidated Financial Statements included in Part I, Item 1, of this Quarterly Report on Form 10-Q is incorporated by reference herein.

ITEM 1A.        RISK FACTORS

Except for the additional risk factors set forth below, there have been no material changes to the risk factors included in “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018.

Our strategic investment in Evofem Biosciences, Inc. (“Evofem”) is subject to risks, and any other strategic investments that we may make from time to time may be subject to risks.

On April 10, 2019, we entered into a securities purchase agreement with Evofem, pursuant to which we invested $60.0 million in a private placement of securities representing approximately 29% ownership interest in Evofem. Our investment in Evofem is subject to a number of risks and uncertainties. Evofem has no products approved for commercialization, has never generated any material amount of revenue from product sales and may never be profitable. The ability for Evofem to generate revenue and achieve profitability depends on its ability, alone or with strategic collaborators, to successfully complete the development of, and obtain necessary regulatory and marketing approvals to commercialize one or more of its current or future product candidates.

Further, we have elected the fair value method to account for our investment in Evofem as we believe it better reflects economic reality, the financial reporting of the investment and the current value of the asset. Because the mark to market valuation will occur at the end of each quarterly reporting period, changes in fair value will vary based upon the volatility of the stock price, and such changes in fair value could have a material and adverse impact on our results of operations.

In addition, applicable securities law restrictions and other factors may result in an inability to liquidate our investment in Evofem. In addition, we may from time to time make strategic investments in other entities. Any such strategic investments will also be subject to risks and uncertainties that may cause us to lose some or all of any such investments.

We may not achieve the expected benefits from our strategic investment in Evofem.

We may not achieve some or all or the benefits that we expect to achieve from our investment in Evofem. Our investment in Evofem is expected to provide funding for Evofem's pre-commercial activities for Amphora®, its investigational, non-hormonal, on-demand prescription contraceptive gel for women, although there can be no assurance that our investment will guarantee its success.

In addition, we have limited control over the business and operation of Evofem. Although we are entitled to appoint one member of Evofem’s board of directors, as a minority shareholder, our influence on Evofem will be limited, and it is possible that Evofem may take actions that are not in our interest. If Evofem fails to conduct its business in a compliant manner, incurs an excessive amount of debt or goes bankrupt, or the business operations decline, the value of our investment may be harmed. Further, as we have limited control over the business and operation of Evofem, we will have limited oversight and control over the use of proceeds from our investment. If funds are not used efficiently or appropriately, the value of our investment may be harmed.

To the extent that we do not achieve the expected benefits from our investment, our business, financial condition and results of operations may be materially and adversely affected.


59


Our strategic investment in Evofem will depend heavily on whether Evofem can successfully develop, gain approval for and commercialize its lead product candidate, Amphora, for prevention of pregnancy. Failure of Evofem to successfully develop, gain approval or commercialize Amphora for prevention of pregnancy would likely cause its business to fail, which would diminish the value of our investment in Evofem.

Our investment in Evofem is substantially dependent on Evofem’s ability to successfully develop and commercialize Amphora for the prevention of pregnancy. Evofem’s second Phase 3 clinical trial intended to demonstrate efficacy for prevention of pregnancy had its last patient exit the study on November 8, 2018, and it released top-line results from this trial on December 17, 2018. The success of Evofem and the related return on our investment in Evofem depends almost entirely on the successful clinical development and regulatory approval of Amphora for prevention of pregnancy, which may never occur. Evofem intends to resubmit an NDA for Amphora for this indication in 2019, however the FDA may not approve Amphora for this indication and numerous factors may delay its ability to resubmit the NDA in a timely manner. Evofem has never received regulatory approval for any product. Even though Evofem was able to successfully complete its clinical trial for Amphora for prevention of pregnancy, it may be unable to obtain regulatory approval for Amphora for prevention of pregnancy. The commercial success of Amphora will also depend in significant measure upon Evofem’s ability to obtain marketing approval from the FDA or other regulatory authorities including an indication and labeling of sufficient scope to be commercially meaningful. Failure to achieve marketing approval from the FDA or other regulatory authorities of a commercially meaningful indication and labeling may substantially limit Evofem’s ability to market and promote Amphora. In addition, to obtain marketing approval of Amphora on schedule, manufacturing facilities operated by third parties with which Evofem has contracted for the purpose of the supply of Amphora will need to pass a regulatory inspection. Failure of the FDA to approve manufacture of Amphora at such third party facilities may delay approval, and consequently affect the value of our investment in Evofem. Evofem will also likely incur significant costs associated with launching and Amphora, including the development of a successful commercial team and strategy. The failure of Evofem to successfully develop, gain marketing approval and commercialize Amphora would have a material adverse impact on our investment in their company.

Our Strategic Positions business is subject to liquidity risks.

Investments we make in our Strategic Positions segment are, and will likely continue to be, in the form of securities that are subject to liquidity risks. Future strategic investments may be in companies that are not publicly traded. In many cases, there may be a prohibition by contract or by applicable laws from selling such securities for a period of time or there may not be a public market for such securities. Even if the securities are publicly traded, large holdings of securities can often be disposed of only over a substantial length of time, exposing the investment returns to risks of downward movement in market prices during the disposition period. Accordingly, under certain conditions, we may be forced to either sell securities at lower prices than we had expected or defer sales that we had planned to make, potentially for a considerable period of time. Investing in these securities can involve a high degree of risk, and we may lose some or all of the principal amount of such strategic investments.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

There were no unregistered sales of equity securities during the period covered by this report.

Issuer Purchases of Equity Securities

The following table contains information relating to the repurchases of our common stock made by us in the three months ended June 30, 2019 (in thousands, except per share amounts):
Fiscal Period
 
Total Number of Shares Repurchased
 
Average Price Paid Per Share
 
Total Number of Shares Purchased As Part of a Publicly Announced Program
 
Approximate Dollar Amount of Shares That May Yet be Purchased Under the Program
 
April 1, 2019
to
April 30, 2019
 
2,762

 
$
3.77

 
24,546

 
$
19,711

(1) 
May 1, 2019
to
May 31, 2019
 
2,207

 
$
3.01

 
26,753

 
13,069

 
June 1, 2019
to
June 30, 2019
 
2,996

 
$
3.00

 
29,749

 
4,079

 
Total for the three months ended June 30, 2019
 
7,965

 
$
3.27

 
29,749

 
$
4,079

 

60


____________________
(1) On September 24, 2018, we announced that our board of directors authorized the repurchase of issued and outstanding shares of our common stock having an aggregate value of up to $100.0 million pursuant to a share repurchase program. All shares of common stock repurchased under our share repurchase program were retired and restored to authorized but unissued shares of common stock.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION

In May 2019, Noden DAC and Novartis entered into an amended supply agreement pursuant to which Novartis will supply to Noden DAC a bulk tableted form of the Noden Products through 2020 and API through June 2021. The supply agreement may be terminated by either party for material breach that remains uncured for a specified time period. Under the terms of the amended supply agreement, Noden DAC is committed to purchase certain quantities of bulk product and API that would amount to approximately $90.9 million through June 2021, of which $53.1 million is committed over the next twelve months, which are guaranteed by the Company. While the supply agreement provides that the parties will agree to reasonable accommodations with respect to changes in firm orders, we expect that Noden DAC will meet the requirements of the supply agreement, unless otherwise negotiated.


ITEM 6.    EXHIBITS


61


Exhibit Number
Exhibit Title
 
 
3.1
Restated Certificate of Incorporation effective March 23, 1993 (incorporated by reference to Exhibit 3.1 to Annual Report on Form 10-K filed March 31, 1993)
 
 
3.2
 
 
3.3
 
 
3.4
 
 
3.5
 
 
3.6
 
 
10.1*
 
 
10.2
 
 
10.3*
 
 
10.4†
 
 
31.1#
 
 
31.2#
 
 
32.1#+
 
 
101.INS
XBRL Instance Document
101.SCH
XBRL Taxonomy Extension Schema
101.CAL
XBRL Taxonomy Extension Calculation Linkbase
101.DEF
XBRL Taxonomy Extension Definition Linkbase
101.LAB
XBRL Taxonomy Extension Label Linkbase
101.PRE
XBRL Taxonomy Extension Presentation Linkbase
 
 
#
Filed herewith.
*
Management contract or compensatory plan or arrangement.
+
This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.
†
Certain information in this exhibit has been omitted for confidentiality purposes.

62


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
Dated:
August 7, 2019
 
PDL BIOPHARMA, INC. (REGISTRANT)
 
 
 
 
 
 
 
/s/    Dominique Monnet
 
Dominique Monnet
 
President and Chief Executive Officer
(Principal Executive Officer)
 


/s/    Peter S. Garcia
 
Peter S. Garcia
 
Vice President and Chief Financial Officer (Principal Financial Officer)
 


/s/    Edward A. Imbrogno
 
Edward A. Imbrogno
 
Vice President, Finance and Chief Accounting Officer (Principal Accounting Officer)
 


63
 EX-10.4 2 pdli-2019063010qex104.htm SETTLEMENT LETTER AND SUPPLY AGREEMENT AMENDMENT Exhibit




CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE PDL BIOPHARMA, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO PDL BIOPHARMA, INC. IF PUBLICLY DISCLOSED.

May 30, 2019

Noden Pharma DAC
16A D’Olier Street
Dublin 2, Ireland

Novartis Pharma AG
Lichtstrasse 35
CH‑4056 Basel, Switzerland

Settlement Letter and Supply Agreement Amendment regarding Supply of Tekturna
Reference is made to the Supply Agreement, dated May 24th, 2016 (the “SA”) and the Asset Purchase Agreement, dated May 24, 2016, between Novartis Pharma AG, a company organized under the laws of Switzerland and located at Lichtstrasse 35, 4056 Basel, Switzerland (“Novartis”) and Noden Pharma DAC, a company organized under the laws of Ireland and located at 16A D’Olier Street, Dublin, 2, Ireland (“Purchaser”). Novartis and Purchaser are each referred to individually as a “Party” and together as the “Parties.” Capitalized terms used in this letter agreement (this “Letter Agreement”) shall have the same meaning as ascribed to them in the SA, unless the context requires otherwise.

WHEREAS, under Clause 2.5(a) and Annex F of the Supply Agreement, Novartis and Purchaser have agreed to a certain minimum quantity of API to be manufactured and supplied to Purchaser. The minimum quantity in the year 2020 was supplemented by an additional order of API from Purchaser received and accepted by Novartis on November 3, 2017.

WHEREAS, Purchaser wishes to have the API delivered over a longer period than agreed in the current Annex F and in order to extend the Supply Period for the Product and Novartis is willing to amend the current Supply Period obligations in accordance with this Letter Agreement.

WHEREAS, Purchaser’s parent company PDL BioPharma, Inc (“PDL”) will provide a Parent Guarantee to secure future payments due by Purchaser to Novartis under the SA, as amended herein.

WHEREAS, the Parties would like to clarify the estimated quantity of certain remaining materials to be either transferred to Purchaser or destroyed at the end of the last API manufacturing campaign and how the costs for such materials are allocated between the Parties.

NOW, THEREFORE, the Parties hereby agree as follows:

1.
Amendment of the definition of “Supply Period”

The Parties agree to amend the definition of Supply Period in the SA,
“Supply Period” means the period under which Novartis continues to supply and Purchaser continues to purchase (i) with respect to the Product, the Product until the end of the Phase 2 Period and (ii) with respect to the API, the API until [ * * * ] as specified in Annex F or, if earlier than [ * * * ] and not agreed otherwise by

* * * Certain Confidential Information Omitted



the Parties , with the first commercial supply of Finished Product to a Third Party containing API, which has been manufactured by a Third Party Manufacturer.”
by deleting it and replacing it with the following:
““Supply Period” means the period under which Novartis continues to supply and Purchaser continues to purchase:
(i)
with respect to the Product, until [ * * * ] and
(ii)
with respect to the API, until [ * * * ].”

2.
Amendment of Annex F of the SA is amended to cover an updated 2019-2021 API delivery schedule.

The Parties agree to delete Annex F of the SA in its entirety and replace with a new version of Annex F attached to this Letter Agreement as Appendix 1.
For the avoidance of doubt, any supply for the past as per the now deleted Annex F of the SA for the years 2016, 2017 and 2018 has, as of the date of this Letter Agreement, been concluded and was therefore deleted from the updated Annex F in Appendix 1.
Therefore, Appendix 1 describes the agreed and amended 2019 to 2021 API delivery schedule. The respective deliveries are intended to take place at the beginning of the respective quarter of each calendar year or as otherwise agreed by the Parties.
The total quantity of API shown in Appendix 1 over the 2019 to 2021 period [ * * * ] is the quantity of API planned to be manufactured by Novartis. As the manufacturing yield may vary and impact the quantity available, the Parties will mutually discuss the absolute and final quantity of such API to be delivered to Purchaser, such discussions to occur prior to the end of [ * * * ]. It is also understood that such final API quantity may vary and Purchaser shall be required to purchase all such API manufactured by Novartis even if in excess of [ * * * ]. Furthermore, the manufactured quantity of API could also be lower than [ * * * ]. In such case, Novartis will have no obligation to produce any additional quantity of API and Purchaser will accept such lower quantity as in conformance with Novartis’ obligations under the SA and this Letter Agreement. 
Notwithstanding the above commitments of the Parties, while the Parties acknowledge that the estimated [ * * * ] of API noted above is subject to revision, in no event will Novartis produce, or will Purchaser be required to purchase, in excess of [ * * * ] of API (or Product comprising an equivalent amount of such API), and in no event will Novartis produce, or will Purchaser be required to accept, less than [ * * * ] of API (or Product comprising an equivalent amount of such API).
It is further understood that the [ * * * ] of API set out in Appendix 1 will be supplied either as API or as Product (which as defined under the SA can be Finished Product or Drug Product) as per Purchaser’s ordering in accordance with the terms of the SA. For 2019 through 2021, if in any quarter, the quantity of API ordered by Purchaser to be supplied as Product is below the respective amounts described in Appendix 1, Novartis reserves the right to supply the remaining difference as API to Purchaser in the current quarter or the subsequent quarter, or as mutually agreed between the Parties in good faith.
For the avoidance of doubt, all other payment and delivery terms will remain as stated in the SA.
3.
Remaining Materials after the last API Manufacturing Campaign.

The Parties acknowledge that there have been some discussions among them with regards to certain potential amounts of Inventory under Section 7 of the SA as well as the possibility of write-off costs under Section 4.3(b) of the SA which would be left at the end of the term of the SA, such materials including all materials from all sites involved in the supply of Product and/or API by Novartis (together the “Remaining Materials”).  
The Parties agree that they want to settle such discussions with a lump-sum all-inclusive payment made by Purchaser to Novartis of [ * * * ].

* * * Certain Confidential Information Omitted



The Parties expect that payment for the Remaining Materials will be a one-time payment (as a full and final settlement in this regard) made by the end of Q2 2019. Such payment shall be made upon Novartis issuing an invoice for such Remaining Materials, the invoice to be paid within 45 (forty-five) days, with no setoffs, in accordance with the payment terms of the SA. The Parties shall agree in good faith on the best way to transfer or destroy the Remaining Materials , in good time ahead of 2020.
4.
Other Amendments to the Supply Agreement.

The SA is hereby amended to be a non-exclusive supply purchase obligation on the part of Purchaser.  Except for the obligations provided for in this Letter Agreement with regard to the purchase of API and Product as provided for in Appendix 1 and with respect to Remaining Materials, Purchaser shall not be obligated to purchase its requirements from Novartis with respect to API and/or Product, and shall be free to contract, obtain and purchase from any other source in its sole discretion.
Novartis agrees that the price of API and Product shall not vary from the prices provided in the Supply Price Letter Agreements dated May 24, 2016, November 28, 2017, February 12, 2018, February 16, 2018, and September 14, 2018, for the duration of its supply obligations.
Novartis will remain responsible for maintaining any routine stability program under ICH conditions, as required, until the termination or expiration of the Supply Agreement. Purchaser agrees that as of July 1st 2019, Novartis shall continue maintaining any routine stability program required under ICH conditions until the end of the shelf-life of the Products and the retesting period of the API supplied to Purchaser in exchange for payment of service fees by Purchaser amounting to [ * * * ] per man-hour required to perform stability testing and reporting.
All other terms and conditions of the SA, and except as specifically modified herein, shall remain in force as provided therein.
5.
Parent Guarantee from PDL.

Appendix 2 contains the Parent Guarantee as agreed between Novartis and PDL. Novartis’ signature to this Agreement is conditional to PDL executing the Parent Guarantee.
6.
Release

a.
Release of Claims.  This Agreement is in full and final settlement of, and each Party hereby releases and forever discharges, all actions, claims, rights, demands and set-offs, whether or not presently known to the parties or to the law, and whether in law or equity, that it or any of its affiliates or their assigns, transferees, representatives, principals, agents, officers and directors ever had, may have or hereafter can, shall or may have against the other Party or any of its affiliates, assigns, transferees, representatives, principals, agents, officers or directors arising out of or resulting from  the modification of Appendix 1 and the supply obligations of the Parties which are subject matter of this Letter Agreement (collectively, the “Released Claims”).

b.
Covenant Not to Sue.  Each Party agrees, on behalf of itself and its affiliates, assigns, transferees, representatives, principals, agents, officers and directors, not to sue, commence, voluntarily aid in any way, prosecute or cause to be commenced or prosecuted against the other Party or its affiliates or their assigns, transferees, representatives, principals, agents, officers or directors, any action, suit or other proceeding concerning the Released Claims.

7.
Confidentiality.

Clause 17.1 of the APA is incorporated by reference herein, mutatis mutandis.
Miscellaneous. 

Clause of Article 18 of the APA are incorporated herein by reference, mutatis mutandis.  This Letter Agreement shall terminate and have no further force or effect in the event the APA is terminated in accordance with its terms. In the event that there is any conflict or inconsistency between the terms and conditions of the APA and those of this Letter Agreement, the terms and conditions of the APA shall control and govern the rights and obligations of the parties.

* * * Certain Confidential Information Omitted




NODEN PHARMA DAC
 
 
 
 
 
By: /s/ Alan Markey
 
 
Name: Alan Markey
 
 
Title: Chief Executive Officer
 
 
Date: May 30, 2019
 
 
 
 
 
NOVARTIS PHARMA AG
 
 
 
 
 
By: /s/ Alan Dy
 
By: /s/ Shilpi Ghosh
Name: Alan Dy
 
Name: Shilpi Ghosh
Title: Global Head - SCM
 
Title: Head – Key Account Management
Date: May 21, 2019
 
Date: May 21, 2019
 
 
 
 
 
 
 
 
 
 
 
 













* * * Certain Confidential Information Omitted












Appendix 1
Annex F
API Schedule
[ * * * ]







Appendix 2
Parent Guarantee



Appendix 3
Supply price letters




* * * Certain Confidential Information Omitted

 EX-31.1 3 pdli-2019063010qex311.htm CERTIFICATION Exhibit
Exhibit 31.1

CERTIFICATIONS
 
I, Dominique Monnet, Chief Executive Officer, of PDL BioPharma, Inc., certify that:

(1) I have reviewed this Quarterly Report on Form 10-Q of PDL BioPharma, Inc.;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:
August 7, 2019
 
 
 
 
/s/ Dominique Monnet
 
Dominique Monnet
President and Chief Executive Officer
(Principal Executive Officer)
 


 EX-31.2 4 pdli-2019063010qex312.htm CERTIFICATION Exhibit


Exhibit 31.2

CERTIFICATIONS
 
I, Peter S. Garcia, Vice President and Chief Financial Officer, of PDL BioPharma, Inc., certify that:

(1) I have reviewed this Quarterly Report on Form 10-Q of PDL BioPharma, Inc.;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:
August 7, 2019
 
 
 
 
/s/ Peter S. Garcia
 
Peter S. Garcia
Vice President and Chief Financial Officer
(Principal Financial Officer)
 



 EX-32.1 5 pdli-2019063010qex321.htm CERTIFICATION Exhibit
Exhibit 32.1

CERTIFICATIONS

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350), Dominique Monnet, President and Chief Executive Officer of PDL BioPharma, Inc. (the “Company”), and Peter S. Garcia, Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of their knowledge:

(1) The Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and

(2) The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: August 7, 2019
 
By:
 
 
 
/s/ DOMINIQUE MONNET
 
 
Dominique Monnet
 
 
President and Chief Executive Officer
 
 
(Principal Executive Officer)
 
 
 
 
 
 
 
By:
 
 
 
/s/ PETER S. GARCIA
 
 
Peter S. Garcia
 
 
Vice President and Chief Financial Officer
 
 
(Principal Financial Officer)
_________________________________________
(1)
This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of PDL BioPharma, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to PDL BioPharma, Inc. and will be retained by PDL BioPharma, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.




 EX-101.INS 6 pdli-20190630.xml XBRL INSTANCE DOCUMENT 0000882104 2019-01-01 2019-06-30 0000882104 2019-07-30 0000882104 2019-04-01 2019-06-30 0000882104 2018-01-01 2018-06-30 0000882104 2018-04-01 2018-06-30 0000882104 pdli:LicenseandotherMember 2019-04-01 2019-06-30 0000882104 pdli:AcquiredrightsMember 2018-01-01 2018-06-30 0000882104 pdli:ProductRevenueMember 2018-04-01 2018-06-30 0000882104 pdli:LicenseandotherMember 2018-01-01 2018-06-30 0000882104 pdli:Queenetal.patentsMember 2018-01-01 2018-06-30 0000882104 pdli:ProductRevenueMember 2019-01-01 2019-06-30 0000882104 pdli:Queenetal.patentsMember 2018-04-01 2018-06-30 0000882104 pdli:ProductRevenueMember 2018-01-01 2018-06-30 0000882104 pdli:AcquiredrightsMember 2018-04-01 2018-06-30 0000882104 pdli:ProductRevenueMember 2019-04-01 2019-06-30 0000882104 pdli:LicenseandotherMember 2018-04-01 2018-06-30 0000882104 pdli:AcquiredrightsMember 2019-01-01 2019-06-30 0000882104 pdli:LicenseandotherMember 2019-01-01 2019-06-30 0000882104 pdli:Queenetal.patentsMember 2019-01-01 2019-06-30 0000882104 pdli:AcquiredrightsMember 2019-04-01 2019-06-30 0000882104 pdli:Queenetal.patentsMember 2019-04-01 2019-06-30 0000882104 2018-12-31 0000882104 2019-06-30 0000882104 us-gaap:RetainedEarningsMember 2018-03-31 0000882104 2018-03-31 0000882104 us-gaap:TreasuryStockMember 2018-03-31 0000882104 2018-01-01 2018-03-31 0000882104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000882104 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0000882104 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000882104 us-gaap:CommonStockMember 2018-03-31 0000882104 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000882104 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0000882104 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0000882104 us-gaap:CommonStockMember 2017-12-31 0000882104 2017-12-31 0000882104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000882104 2018-06-30 0000882104 us-gaap:TreasuryStockMember 2017-12-31 0000882104 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000882104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000882104 us-gaap:CommonStockMember 2018-06-30 0000882104 us-gaap:RetainedEarningsMember 2017-12-31 0000882104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000882104 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000882104 2019-03-31 0000882104 us-gaap:TreasuryStockMember 2019-03-31 0000882104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000882104 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000882104 2019-01-01 2019-03-31 0000882104 us-gaap:RetainedEarningsMember 2018-12-31 0000882104 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000882104 us-gaap:CommonStockMember 2018-12-31 0000882104 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000882104 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000882104 us-gaap:CommonStockMember 2019-06-30 0000882104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000882104 us-gaap:NoncontrollingInterestMember 2019-04-01 2019-06-30 0000882104 us-gaap:TreasuryStockMember 2019-06-30 0000882104 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000882104 us-gaap:RetainedEarningsMember 2019-03-31 0000882104 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000882104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000882104 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000882104 us-gaap:CommonStockMember 2019-03-31 0000882104 us-gaap:RetainedEarningsMember 2019-06-30 0000882104 us-gaap:TreasuryStockMember 2018-12-31 0000882104 2019-01-02 0000882104 pdli:EvofemMember us-gaap:CommonStockMember 2019-01-01 2019-06-30 0000882104 pdli:EvofemMember 2019-04-11 0000882104 pdli:EvofemMember 2019-01-01 2019-06-30 0000882104 pdli:EvofemMember 2019-06-30 0000882104 pdli:EvofemMember 2019-06-10 0000882104 pdli:EvofemMember 2019-04-01 2019-06-30 0000882104 pdli:EvofemMember us-gaap:WarrantMember 2019-01-01 2019-06-30 0000882104 pdli:EvofemMember us-gaap:OtherNoncurrentAssetsMember 2019-06-30 0000882104 pdli:EvofemMember us-gaap:OtherCurrentLiabilitiesMember 2019-06-30 0000882104 pdli:EvofemMember us-gaap:OtherNoncurrentLiabilitiesMember 2019-06-30 0000882104 pdli:EvofemMember us-gaap:StockholdersEquityTotalMember 2019-06-30 0000882104 pdli:EvofemMember us-gaap:OtherCurrentAssetsMember 2019-06-30 0000882104 pdli:EvofemMember pdli:IncomeLossMember 2019-01-01 2019-06-30 0000882104 pdli:EvofemMember us-gaap:OperatingIncomeLossMember 2019-01-01 2019-06-30 0000882104 pdli:EvofemMember pdli:IncomeLossMember 2019-04-01 2019-06-30 0000882104 pdli:EvofemMember us-gaap:OperatingIncomeLossMember 2019-04-01 2019-06-30 0000882104 pdli:EvofemMember us-gaap:RevenueFromContractWithCustomerMember 2019-04-01 2019-06-30 0000882104 pdli:EvofemMember us-gaap:RevenueFromContractWithCustomerMember 2019-01-01 2019-06-30 0000882104 pdli:EvofemMember us-gaap:WarrantMember 2019-04-01 2019-06-30 0000882104 pdli:EvofemMember us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000882104 us-gaap:CashAndCashEquivalentsMember 2018-12-31 0000882104 us-gaap:MoneyMarketFundsMember 2018-12-31 0000882104 us-gaap:MoneyMarketFundsMember 2019-06-30 0000882104 us-gaap:CashAndCashEquivalentsMember 2019-06-30 0000882104 pdli:DepomedMember srt:MaximumMember 2019-06-30 0000882104 pdli:DepomedMember 2019-06-30 0000882104 pdli:DepomedMember 2013-10-18 0000882104 pdli:UniversityofMichiganMember 2019-06-30 0000882104 pdli:KybellaMember 2019-04-01 2019-06-30 0000882104 pdli:AcelRxMember 2019-04-01 2019-06-30 0000882104 pdli:KybellaMember 2019-06-30 0000882104 pdli:AcelRxMember 2015-09-18 0000882104 pdli:NodenMember 2018-06-30 0000882104 pdli:AcelRxMember 2019-06-30 0000882104 pdli:VBMember 2019-06-30 0000882104 2018-01-01 2018-12-31 0000882104 2014-11-06 0000882104 2018-08-03 0000882104 pdli:VBMember 2014-06-26 0000882104 pdli:KybellaMember 2016-07-07 2016-07-08 0000882104 pdli:DepomedMember srt:MinimumMember 2019-06-30 0000882104 pdli:KybellaMember 2016-07-09 0000882104 pdli:DepomedMember 2019-04-01 2019-06-30 0000882104 pdli:VBMember 2019-04-01 2019-06-30 0000882104 pdli:AlphaeonMember 2015-12-31 0000882104 pdli:DepomedMember 2019-01-01 2019-06-30 0000882104 pdli:VBMember 2019-01-01 2019-06-30 0000882104 pdli:AcelRxMember 2019-01-01 2019-06-30 0000882104 2018-08-02 2018-08-02 0000882104 pdli:AlphaeonMember 2015-12-15 0000882104 pdli:UniversityofMichiganMember 2019-04-01 2019-06-30 0000882104 us-gaap:FairValueInputsLevel2Member 2019-06-30 0000882104 pdli:HyperionMember 2019-06-30 0000882104 pdli:CareViewMember 2018-12-31 0000882104 pdli:HyperionMember 2018-12-31 0000882104 pdli:HyperionMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000882104 pdli:CareViewMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000882104 pdli:WellstatNoteReceivableMember 2019-06-30 0000882104 pdli:HyperionMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000882104 pdli:CareViewMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000882104 pdli:WellstatNoteReceivableMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000882104 pdli:December2021NotesMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000882104 pdli:HyperionMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000882104 pdli:December2021NotesMember 2018-12-31 0000882104 pdli:CareViewMember 2019-06-30 0000882104 pdli:December2021NotesMember 2019-06-30 0000882104 pdli:WellstatNoteReceivableMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000882104 pdli:WellstatNoteReceivableMember 2018-12-31 0000882104 pdli:CareViewMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000882104 pdli:CareViewMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000882104 us-gaap:FairValueInputsLevel2Member 2018-12-31 0000882104 pdli:December2021NotesMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000882104 us-gaap:FairValueInputsLevel3Member 2018-12-31 0000882104 pdli:HyperionMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000882104 us-gaap:FairValueInputsLevel3Member 2019-06-30 0000882104 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000882104 us-gaap:EquitySecuritiesMember 2019-06-30 0000882104 pdli:ContingentConsiderationMember 2018-12-31 0000882104 us-gaap:FairValueInputsLevel1Member 2018-12-31 0000882104 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000882104 us-gaap:EquitySecuritiesMember 2018-12-31 0000882104 us-gaap:MoneyMarketFundsMember 2019-06-30 0000882104 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000882104 us-gaap:FairValueInputsLevel1Member 2019-06-30 0000882104 us-gaap:MoneyMarketFundsMember 2018-12-31 0000882104 pdli:ContingentConsiderationMember 2019-06-30 0000882104 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000882104 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000882104 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000882104 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000882104 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000882104 pdli:WellstatDiagnosticsMember srt:MinimumMember us-gaap:MeasurementInputDiscountRateMember 2018-12-31 0000882104 pdli:WellstatDiagnosticsMember us-gaap:IntellectualPropertyMember us-gaap:MeasurementInputDiscountRateMember 2018-12-31 0000882104 pdli:CareViewMember pdli:NotereceivablecashflowsMember 2018-12-31 0000882104 pdli:WellstatDiagnosticsMember pdli:EstimatedrealtorfeeMember 2018-12-31 0000882104 pdli:WellstatDiagnosticsMember srt:MaximumMember us-gaap:MeasurementInputDiscountRateMember 2019-06-30 0000882104 pdli:WellstatDiagnosticsMember pdli:RealestateappreciationMember 2019-06-30 0000882104 pdli:WellstatDiagnosticsMember pdli:EstimatedrealtorfeeMember 2019-06-30 0000882104 pdli:WellstatDiagnosticsMember srt:MaximumMember us-gaap:MeasurementInputDiscountRateMember 2018-12-31 0000882104 pdli:WellstatDiagnosticsMember pdli:OtherMember us-gaap:MeasurementInputDiscountRateMember 2019-06-30 0000882104 pdli:CareViewMember pdli:NotereceivablecashflowsMember 2019-06-30 0000882104 pdli:WellstatDiagnosticsMember pdli:RealestateappreciationMember 2018-12-31 0000882104 pdli:WellstatDiagnosticsMember us-gaap:IntellectualPropertyMember us-gaap:MeasurementInputDiscountRateMember 2019-06-30 0000882104 pdli:WellstatDiagnosticsMember srt:MinimumMember us-gaap:MeasurementInputDiscountRateMember 2019-06-30 0000882104 pdli:WellstatDiagnosticsMember pdli:OtherMember us-gaap:MeasurementInputDiscountRateMember 2018-12-31 0000882104 pdli:RoyaltyrightMember 2018-12-31 0000882104 pdli:RoyaltyrightMember 2019-01-01 2019-06-30 0000882104 pdli:RoyaltyrightMember 2019-06-30 0000882104 pdli:RoyaltyrightMember pdli:AcelRxMember 2019-06-30 0000882104 pdli:RoyaltyrightMember pdli:AcelRxMember 2019-01-01 2019-06-30 0000882104 pdli:RoyaltyrightMember pdli:VBMember 2019-01-01 2019-06-30 0000882104 pdli:RoyaltyrightMember pdli:UniversityofMichiganMember 2019-01-01 2019-06-30 0000882104 pdli:RoyaltyrightMember pdli:DepomedMember 2019-01-01 2019-06-30 0000882104 pdli:RoyaltyrightMember pdli:KybellaMember 2019-06-30 0000882104 pdli:RoyaltyrightMember pdli:VBMember 2019-06-30 0000882104 pdli:RoyaltyrightMember pdli:KybellaMember 2018-12-31 0000882104 pdli:RoyaltyrightMember pdli:DepomedMember 2018-12-31 0000882104 pdli:RoyaltyrightMember pdli:UniversityofMichiganMember 2018-12-31 0000882104 pdli:RoyaltyrightMember pdli:KybellaMember 2019-01-01 2019-06-30 0000882104 pdli:RoyaltyrightMember pdli:AcelRxMember 2018-12-31 0000882104 pdli:RoyaltyrightMember pdli:UniversityofMichiganMember 2019-06-30 0000882104 pdli:RoyaltyrightMember pdli:VBMember 2018-12-31 0000882104 pdli:RoyaltyrightMember pdli:DepomedMember 2019-06-30 0000882104 pdli:AvingerMember pdli:RoyaltyAgreementMember 2013-07-01 2018-04-30 0000882104 pdli:WellstatDiagnosticsMember pdli:CreditAgreementMember 2013-01-01 2013-12-31 0000882104 pdli:WellstatDiagnosticsMember pdli:AdditionalLoanMember 2013-06-28 0000882104 pdli:AvingerMember 2015-09-22 2015-09-22 0000882104 pdli:HyperionMember 2012-01-27 0000882104 pdli:CareViewMember 2015-10-07 0000882104 pdli:CareViewMember 2015-06-26 0000882104 pdli:WellstatDiagnosticsMember pdli:CreditAgreementMember 2012-11-02 0000882104 pdli:CareViewMember 2015-06-26 2015-06-26 0000882104 pdli:WellstatDiagnosticsMember pdli:CreditAgreementMember 2013-01-01 2013-01-31 0000882104 pdli:WellstatDiagnosticsMember 2019-06-30 0000882104 pdli:WellstatDiagnosticsMember pdli:CreditAgreementMember 2013-08-13 2013-08-15 0000882104 pdli:WellstatDiagnosticsMember pdli:InitialLoanMember 2013-08-13 2013-08-15 0000882104 pdli:WellstatDiagnosticsMember pdli:TermloanandinterestMember 2013-08-13 2013-08-15 0000882104 pdli:WellstatDiagnosticsMember pdli:ForbearanceprincipalandinterestMember 2013-08-13 2013-08-15 0000882104 pdli:WellstatDiagnosticsMember pdli:CreditAgreementMember 2013-02-27 2013-02-28 0000882104 pdli:WellstatDiagnosticsMember 2013-08-15 0000882104 pdli:HyperionMember 2013-03-05 0000882104 pdli:CareViewMember 2019-06-30 0000882104 pdli:WellstatDiagnosticsMember 2014-09-30 0000882104 pdli:CareViewMember 2018-02-02 0000882104 us-gaap:EquipmentLeasedToOtherPartyMember 2019-06-30 0000882104 us-gaap:EquipmentLeasedToOtherPartyMember 2018-12-31 0000882104 srt:MaximumMember 2019-06-30 0000882104 srt:MinimumMember 2019-06-30 0000882104 srt:MaximumMember us-gaap:EquipmentLeasedToOtherPartyMember 2019-01-01 2019-06-30 0000882104 srt:MinimumMember us-gaap:EquipmentLeasedToOtherPartyMember 2019-01-01 2019-06-30 0000882104 pdli:LENSARMember pdli:ThirdpartyMember 2019-01-01 2019-06-30 0000882104 pdli:NodenMember 2018-06-29 0000882104 pdli:LENSARMember pdli:OriginalacquisitionMember 2019-01-01 2019-06-30 0000882104 pdli:DirectFlowMember 2019-01-01 2019-06-30 0000882104 pdli:NodenMember 2018-06-30 0000882104 pdli:LENSARMember pdli:CashpaidMember pdli:ThirdpartyMember 2019-04-22 0000882104 pdli:NodenMember 2019-01-01 2019-06-30 0000882104 pdli:LENSARMember pdli:MilestoneMember pdli:ThirdpartyMember 2019-04-22 0000882104 pdli:LENSARMember pdli:PrecisionEyeServicesMember 2019-01-01 2019-06-30 0000882104 us-gaap:PatentedTechnologyMember 2019-06-30 0000882104 us-gaap:TrademarksMember 2018-12-31 0000882104 us-gaap:CustomerRelationshipsMember 2019-06-30 0000882104 us-gaap:PatentedTechnologyMember 2018-12-31 0000882104 us-gaap:TrademarksMember 2019-06-30 0000882104 us-gaap:ContractualRightsMember 2018-12-31 0000882104 us-gaap:ContractualRightsMember 2019-06-30 0000882104 us-gaap:CustomerRelationshipsMember 2018-12-31 0000882104 pdli:ProductReturnsMember 2019-01-01 2019-06-30 0000882104 pdli:GovernmentRebatesandChargebacksMember 2019-01-01 2019-06-30 0000882104 pdli:DiscountandDistributionFeesMember 2019-01-01 2019-06-30 0000882104 pdli:AssistanceandOtherDiscountsMember 2019-01-01 2019-06-30 0000882104 pdli:December2021NotesMember 2019-01-01 2019-06-30 0000882104 pdli:December2021NotesMember 2018-04-01 2018-06-30 0000882104 pdli:December2021NotesMember 2019-04-01 2019-06-30 0000882104 pdli:December2021NotesMember 2018-01-01 2018-06-30 0000882104 pdli:February2018NotesMember 2018-01-01 2018-06-30 0000882104 pdli:February2018NotesMember 2018-04-01 2018-06-30 0000882104 pdli:December2021NotesMember 2016-11-22 0000882104 pdli:February2018NotesMember 2014-02-12 0000882104 pdli:PurchasedCallOptionsMember 2019-06-30 0000882104 pdli:February2018NotesMember 2018-02-01 2018-02-02 0000882104 pdli:December2021NotesMember 2016-11-20 2016-11-21 0000882104 pdli:February2018NotesMember 2016-11-22 0000882104 pdli:February2018NotesMember 2015-11-20 0000882104 pdli:February2018NotesMember 2014-02-10 2014-02-11 0000882104 pdli:NexttwentyfourmonthsMemberMember pdli:NodenMember 2019-06-30 0000882104 pdli:NexttwentyfourmonthsMemberMember pdli:LENSARMember 2019-06-30 0000882104 pdli:NexttwelvemonthsMember pdli:NodenMember 2019-06-30 0000882104 pdli:NexttwelvemonthsMember pdli:LENSARMember 2019-06-30 0000882104 pdli:KaleoNoteReceivableMember 2014-04-01 0000882104 pdli:KaleoNoteReceivableMember 2017-09-20 2017-09-21 0000882104 2018-03-01 2018-07-05 0000882104 2018-10-01 2019-06-30 0000882104 2017-09-25 0000882104 2018-09-21 0000882104 us-gaap:EmployeeStockOptionMember 2018-12-31 0000882104 us-gaap:RestrictedStockMember 2019-06-30 0000882104 us-gaap:RestrictedStockMember 2019-01-01 2019-06-30 0000882104 us-gaap:EmployeeStockOptionMember 2019-06-30 0000882104 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0000882104 us-gaap:RestrictedStockMember 2018-12-31 0000882104 srt:AsiaMember pdli:MedicaldevicesMember 2018-01-01 2018-06-30 0000882104 srt:EuropeMember pdli:MedicaldevicesMember 2018-01-01 2018-06-30 0000882104 srt:NorthAmericaMember pdli:MedicaldevicesMember 2018-01-01 2018-06-30 0000882104 us-gaap:NonUsMember pdli:MedicaldevicesMember 2018-01-01 2018-06-30 0000882104 srt:EuropeMember pdli:PharmaceuticalMember 2018-01-01 2018-06-30 0000882104 pdli:MedicaldevicesMember 2019-01-01 2019-06-30 0000882104 pdli:PharmaceuticalMember 2018-01-01 2018-06-30 0000882104 pdli:MedicaldevicesMember 2018-01-01 2018-06-30 0000882104 us-gaap:NonUsMember pdli:PharmaceuticalMember 2018-01-01 2018-06-30 0000882104 pdli:PharmaceuticalMember 2019-01-01 2019-06-30 0000882104 srt:AsiaMember pdli:PharmaceuticalMember 2018-01-01 2018-06-30 0000882104 srt:NorthAmericaMember pdli:PharmaceuticalMember 2018-01-01 2018-06-30 0000882104 pdli:PharmaceuticalMember 2019-06-30 0000882104 pdli:MedicaldevicesMember 2019-06-30 0000882104 srt:EuropeMember pdli:PharmaceuticalMember 2018-04-01 2018-06-30 0000882104 srt:NorthAmericaMember pdli:MedicaldevicesMember 2018-04-01 2018-06-30 0000882104 pdli:PharmaceuticalMember 2018-04-01 2018-06-30 0000882104 pdli:MedicaldevicesMember 2018-04-01 2018-06-30 0000882104 us-gaap:NonUsMember pdli:MedicaldevicesMember 2018-04-01 2018-06-30 0000882104 srt:AsiaMember pdli:PharmaceuticalMember 2018-04-01 2018-06-30 0000882104 us-gaap:NonUsMember pdli:PharmaceuticalMember 2018-04-01 2018-06-30 0000882104 pdli:PharmaceuticalMember 2019-04-01 2019-06-30 0000882104 pdli:MedicaldevicesMember 2019-04-01 2019-06-30 0000882104 srt:AsiaMember pdli:MedicaldevicesMember 2018-04-01 2018-06-30 0000882104 srt:NorthAmericaMember pdli:PharmaceuticalMember 2018-04-01 2018-06-30 0000882104 srt:EuropeMember pdli:MedicaldevicesMember 2018-04-01 2018-06-30 0000882104 pdli:MedicaldevicesMember 2018-12-31 0000882104 pdli:PharmaceuticalMember 2018-12-31 0000882104 pdli:LicenseandotherMember 2018-01-07 2018-01-08 0000882104 srt:MaximumMember 2019-01-01 2019-06-30 0000882104 srt:MinimumMember 2019-01-01 2019-06-30 0000882104 2018-01-06 0000882104 pdli:IncomegeneratingassetsMember 2018-04-01 2018-06-30 0000882104 pdli:IncomegeneratingassetsMember 2019-01-01 2019-06-30 0000882104 pdli:StrategicpositionsMember 2019-01-01 2019-06-30 0000882104 pdli:IncomegeneratingassetsMember 2019-04-01 2019-06-30 0000882104 pdli:StrategicpositionsMember 2018-04-01 2018-06-30 0000882104 pdli:IncomegeneratingassetsMember 2018-01-01 2018-06-30 0000882104 pdli:StrategicpositionsMember 2019-04-01 2019-06-30 0000882104 pdli:StrategicpositionsMember 2018-01-01 2018-06-30 0000882104 pdli:IncomegeneratingassetsMember 2019-06-30 0000882104 pdli:IncomegeneratingassetsMember 2018-12-31 0000882104 pdli:StrategicpositionsMember 2018-12-31 0000882104 pdli:StrategicpositionsMember 2019-06-30 0000882104 pdli:RoyaltyrightMember pdli:AcelRxMember 2019-04-01 2019-06-30 0000882104 pdli:NodenMember 2018-04-01 2018-06-30 0000882104 pdli:LENSARMember 2019-04-01 2019-06-30 0000882104 pdli:LENSARMember 2018-01-01 2018-06-30 0000882104 pdli:LENSARMember 2019-01-01 2019-06-30 0000882104 pdli:NodenMember 2019-04-01 2019-06-30 0000882104 pdli:NodenMember 2018-01-01 2018-06-30 0000882104 pdli:DepomedMember 2019-01-01 2019-06-30 0000882104 pdli:DepomedMember 2018-04-01 2018-06-30 0000882104 pdli:NodenMember 2019-01-01 2019-06-30 0000882104 pdli:DepomedMember 2018-01-01 2018-06-30 0000882104 pdli:LENSARMember 2018-04-01 2018-06-30 0000882104 pdli:DepomedMember 2019-04-01 2019-06-30 0000882104 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0000882104 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0000882104 us-gaap:RestrictedStockMember 2018-01-01 2018-06-30 0000882104 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0000882104 us-gaap:RestrictedStockMember 2018-04-01 2018-06-30 0000882104 us-gaap:RestrictedStockMember 2019-04-01 2019-06-30 0000882104 us-gaap:OptionOnSecuritiesMember 2018-01-01 2018-06-30 0000882104 pdli:December2021NotesMember 2015-11-20 0000882104 pdli:February2018NotesMember 2018-03-31 0000882104 us-gaap:OptionOnSecuritiesMember 2019-01-01 2019-06-30 0000882104 us-gaap:OptionOnSecuritiesMember 2018-04-01 2018-06-30 0000882104 us-gaap:RestrictedStockMember 2019-01-01 2019-06-30 0000882104 us-gaap:RestrictedStockMember 2018-01-01 2018-06-30 0000882104 us-gaap:OptionOnSecuritiesMember 2019-04-01 2019-06-30 0000882104 us-gaap:RestrictedStockMember 2018-04-01 2018-06-30 0000882104 us-gaap:RestrictedStockMember 2019-04-01 2019-06-30 0000882104 us-gaap:SubsequentEventMember 2019-07-01 2019-08-07 0000882104 us-gaap:SubsequentEventMember 2018-10-01 2019-08-07 iso4217:USD iso4217:USD xbrli:shares xbrli:pure xbrli:shares false --12-31 Q2 2019 2019-06-30 10-Q 0000882104 114202671 Yes false Accelerated Filer PDL BIOPHARMA, INC. false false 6.38 20133000 8248000 52849000 18623000 1566000 0 35792000 -35450000 -11941000 0 -53518000 -25573000 0 13437000 2962000 3069000 6455000 951000 1961000 120000 0 1841000 0 19000 0 38000 88000 20000 40000 441000 1811000 0 3457000 1133000 1 1 P14Y P8Y P6Y P3Y P9Y 240500000 65600000 0 0 0 0 22135000 22735000 0 0 -23933000 28142000 12842000 23933000 -40399000 -28142000 -28142000 -22135000 -22735000 0 0 40000000 8700000 4019000 0 4019000 4638000 0 4638000 3 2 2.3 30 0 4.50 4.50 0.05 0.98 1.30 23800000 12800000 3094000 1575000 0.095 0.21 P120D 2000000 8901000 2358000 0.05 0.135 751000 1500000 0 0 3.84 0.29 P3Y 1000000 P12M 2800000 4300000 1400000 2600000 P90D P30D 2 4 9106000 2401000 1544000 4929000 232000 18177000 3005000 3044000 9910000 2218000 0.80 0.75 0.75 1200000 1000 8100000 4681000 3182000 241300000 15500000 65000000 9500000 20000000 1188000 613000 944000 0.50 1.00 481000000 800000 376510000 376510000 315642000 12500000 263900000 600000 24300000 14400000 315642000 1200000 22200000 900000 1300000 1500000 26300000 100000 1000000 1500000 0.025 300000 6600000 100000 600000 400000 6666667 30000000 20000000 30000000 20000000 1666667 1666667 21648000 17872000 13142000 14812000 20655000 17872000 1400000 125000 146000 16000 25000 39312000 23499000 623000 314000 10700000 10700000 P10Y P15Y P20Y P15Y -98030000 -94465000 229000 957000 1260000 1169000 2175000 135000 0 269000 293000 138000 276000 3911000 3876000 6384000 12677000 1598000 3170000 4900000 1000000 4900000 1100000 12700000 1100000 0 0 8200000 0 0 963736000 890461000 517217000 399703000 603291000 226719000 62000 376510000 650142000 317487000 17013000 315642000 0 800000 0 0 -22735000 0 0 0 3665000 4698000 475000 547000 527266000 395653000 394590000 167871000 226719000 284941000 55987000 228954000 226719000 226719000 0 228954000 228954000 0 -131613000 -109649000 0.45 0.40 0.03 4400000 0.01 0.01 350000000 350000000 136513000 123817000 136513000 123817000 1365000 1157000 421000 -112296000 -111875000 -4419000 2261000 -112296000 -111875000 6617000 -4514000 2103000 0.20 0.13 0.56 0.20 0.13 0.52 0.49 0.20 0.28 0.39 0.19 0.41 2595000 0 2595000 3214000 0 3214000 8938000 4856000 1059000 3797000 124644000 128520000 300000000 150000000 150000000 124644000 128520000 0 58000 0 0 14524000 25090000 12348000 25158000 1626000 3225000 1794000 3560000 4.88 3.81 262.2951 P2Y5M5D 150000000 150000000 0.034 0.040 0.0275 0.0275 0.028 2021-12-01 2600000 126400000 53600000 120000000 25356000 21480000 4300000 500000 100000 -11276000 -125000 8811000 4800000 13847000 13803000 2028000 1649000 -0.76 -0.74 -0.04 0.02 -0.76 -0.74 -0.04 0.02 4468000 5017000 37907000 0 0 0 0 -59974000 -60868000 -57886000 -459000 -1472000 -1316000 265000 376510000 70380000 264371000 2056000 25595000 14108000 34000000 21000000 315642000 12494000 263912000 584000 24279000 14373000 34000000 21000000 1071000 1071000 0 74000 7577000 44100000 9100000 33700000 1300000 P8Y 4433000 2258000 782000 1203000 190000 7603000 4517000 1209000 1630000 247000 22030000 3212000 6194000 6257000 6362000 6394000 40100000 55752000 36143000 8028000 11011000 570000 58052000 36143000 8028000 13311000 570000 192500000 2000000 300000 51319000 33885000 7246000 9808000 380000 50449000 31626000 6819000 11681000 323000 55800000 0 0 45487000 45487000 37900000 7600000 45487000 45487000 37900000 7600000 764000 0 -66000 0 14529000 26190000 10483000 20945000 152300000 28200000 152330000 152330000 152300000 0 0 -126561000 -123940000 -5761000 3628000 -14265000 -13246000 -1247000 1525000 3980000 -2693000 -8679000 1670000 -11709000 -3546000 -1159000 9000 -11759000 -14656000 5834000 -1857000 150000 0 666000 167000 1531000 -476000 6816000 -1647000 0 0 0 0 0 0 49000 507000 40100000 51319000 50449000 2811000 6396000 2984000 5939000 2811000 0 5594000 802000 2984000 5939000 1031000 0 2062000 421000 1032000 2063000 4591000 2063000 344000 344000 12179000 7611000 18942000 16263000 6214000 6023000 549000 2629000 1376000 3290000 1650000 3524000 6600000 60000000 1700000 6666667 0 88533000 0 0 0 88533000 88533000 0 336000 633000 253000 511000 P5Y 3557000 116000 1274000 29000 0 551000 1587000 P8Y P1Y 233957000 225037000 963736000 890461000 52470000 38336000 0 0 1071000 0 0 0 56843000 58181000 31706000 32402000 0.15 0.12 0.06 0.04 0.15 0.12 0.06 0.04 0.21 0.30 0.30 0.134 0.24 0.10 0.144 0.128 0.150 151356000 151356000 157017000 157017000 -216000 -150051000 -72337000 38194000 -29137000 -19756000 -8175000 1602000 1602000 -112296000 943000 -1904000 -111335000 0 -112296000 -110694000 4845000 -2491000 -113048000 0 6680000 -4419000 -21440000 -1678000 -345000 19044000 -4419000 2261000 -19190000 -2893000 5300000 19044000 0 0 -63000 -95000 -158000 -112296000 -110694000 -4419000 2261000 572000 13000 7387000 160000 3545000 3682000 0 6914000 151000 2681000 4082000 0 -1435000 -3106000 44153000 43072000 62849000 11458000 1200000 50191000 62849000 11458000 1200000 50191000 63042000 63280000 771000 547000 124644000 124644000 128520000 128520000 0 11458000 0 1200000 57322000 69980000 0 11458000 0 1200000 59240000 71898000 53900000 2300000 40000000 1300000 150000000 50200000 4 171701000 205927000 27388000 55831000 -125126000 -120834000 -49914000 -39444000 2840000 4125000 1355000 2592000 2100000 2100000 2702000 1140000 0 0 559000 1003000 0 0 8000 0 0 4933000 4776000 10532000 28673000 -1181000 -1181000 0 -1181000 0 0 0 -1181000 0 0 0 0 -95000 -158000 0 603000 0 0 0 -578000 0 0 0 0 0 465000 1130000 0 0 0 0 509000 198000 0 1071000 -37993000 -32726000 -32726000 23604000 71266000 0 1700000 60000000 3915000 163000 0.01 0.01 10000000 10000000 0 0 0 0 0 0 18995000 17347000 21400000 141700000 290200000 145700000 14400000 4116000 0 -112296000 -110694000 6617000 -4514000 2103000 6529000 6758000 7387000 2864000 6914000 2060000 P10Y P5Y 43000 -7000 4900000 53100000 6300000 90900000 129000000 126447000 0 684000 1477000 886000 1755000 3000 828547000 759080000 1643000 8732000 679000 6371000 615000 10776000 107000 0 3044000 25879000 2757000 10152000 1294000 12362000 2319000 21707000 220000 0 6590000 44221000 6067000 10415000 11556000 30375000 31761000 55085000 17837000 44523000 6333000 2442000 500000 46575000 12842000 3000 1218000 14814000 5882000 25879000 0 85093000 23933000 574000 4001000 30008000 10864000 44221000 0 -22526000 60000000 -40399000 30000 6000 -40363000 7422000 10415000 0 16387000 -28142000 -3000 9000 -28136000 14148000 30375000 0 1008000 978000 1039000 52000 150000 533000 431000 245000 0 198000 394000 61000 12000 24000 14000 26000 0 151000 0 0 0 209000 0 0 5385000 10898000 2073000 4803000 2218000 3344000 2.52 851000 3.66 883000 1350000 2.87 3.43 335000 2.69 49000 5666000 7869000 13535000 2.82 3.15 0 3.61 153774756 152812256 145971432 136512522 123817143 115669169 37500 324591 764785 37996 0 4000 3000 4000 8000 8000 25000000 100000000 1000000 7165415 13460164 8185970 4159000 19449000 44353000 26034000 8700000 29700000 1300000 31000000 21100000 25000000 95900000 4100000 100000000 70400000 845890000 1181000 -102443000 1538000 945614000 0 843109000 0 -101486000 1528000 944255000 -1188000 712628000 0 -100229000 1460000 729779000 0 -98030000 1365000 828547000 -2103000 0 -96869000 1238000 790396000 -1490000 665226000 0 -94465000 1157000 759080000 -546000 729779000 693784000 665424000 2.86 3.22 3.17 3.22 3.34 178700 2961000 20565000 44831000 26897000 10000 72000 135000 81000 2103000 546000 1188000 12500000 263900000 600000 24300000 14400000 62000 62000 17013000 100000 17013000 0 P7Y 146923000 149186000 118285000 124040000 146923000 149186000 118285000 123484000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following are condensed consolidated balance sheet data for Evofem as of June 30, 2019:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,849</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,566</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,623</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,792</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following are condensed consolidated statements of operations data for Evofem for the three and </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three months ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six months ended</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,941</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,573</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,450</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(53,518</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2. Investment in Evofem Biosciences, Inc.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Investment in Evofem Biosciences, Inc.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 10, 2019, the Company entered into a securities purchase agreement with Evofem and two other purchasers, pursuant to which the Company purchased </font><font style="font-family:inherit;font-size:10pt;">$60.0 million</font><font style="font-family:inherit;font-size:10pt;"> of Evofem securities in a private placement. The transaction was structured in two tranches. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The first tranche closed on April 11, 2019, pursuant to which the Company invested </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> to purchase </font><font style="font-family:inherit;font-size:10pt;">6,666,667</font><font style="font-family:inherit;font-size:10pt;"> shares of Evofem common stock at </font><font style="font-family:inherit;font-size:10pt;">$4.50</font><font style="font-family:inherit;font-size:10pt;"> per share and was also issued warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;">1,666,667</font><font style="font-family:inherit;font-size:10pt;"> shares of Evofem common stock exercisable for </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> years beginning six months after the issuance date at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$6.38</font><font style="font-family:inherit;font-size:10pt;"> per share. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The second tranche closed on June 10, 2019, pursuant to which the Company invested an additional </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> to purchase an additional </font><font style="font-family:inherit;font-size:10pt;">6,666,667</font><font style="font-family:inherit;font-size:10pt;"> shares of Evofem common stock at </font><font style="font-family:inherit;font-size:10pt;">$4.50</font><font style="font-family:inherit;font-size:10pt;"> per share and was also issued warrants to purchase up to an additional </font><font style="font-family:inherit;font-size:10pt;">1,666,667</font><font style="font-family:inherit;font-size:10pt;"> shares of Evofem common stock with the same terms as the warrants issued in the first tranche. Following the closing of the second tranche, the Company appointed </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> member to Evofem&#8217;s Board of Directors and has a limited right to have </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> board observer participate in Evofem board meetings. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has registration rights on customary terms for all Evofem shares issued under the securities purchase agreement, including the shares underlying the warrants.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of June 30, 2019, the Company owned approximately </font><font style="font-family:inherit;font-size:10pt;">29%</font><font style="font-family:inherit;font-size:10pt;"> of Evofem&#8217;s common stock. The Company&#8217;s investment in Evofem qualifies for equity method accounting given its percentage ownership in Evofem and the ability to exercise significant influence. The Company elected the fair value method to account for its investment in Evofem as it believes it better reflects economic reality, the financial reporting of the investment and the current value of the asset. Changes in fair value of the Evofem equity investment are presented in Non-operating income (expense), net on the Condensed Consolidated Statements of Operations. Because the mark to market valuation will occur at the end of each quarterly reporting period, changes in fair value will vary based upon the volatility of the stock price. The Evofem equity investment is presented on the Condensed Consolidated Balance Sheet as an Investment in equity affiliate and reflects the fair value of the equity investment at the end of the reporting period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three and six months ended June 30, 2019, the Company has recognized an unrealized gain of </font><font style="font-family:inherit;font-size:10pt;">$45.5</font><font style="font-family:inherit;font-size:10pt;"> million, of which </font><font style="font-family:inherit;font-size:10pt;">$37.9</font><font style="font-family:inherit;font-size:10pt;"> million was related to Evofem common stock and </font><font style="font-family:inherit;font-size:10pt;">$7.6</font><font style="font-family:inherit;font-size:10pt;"> million was related to Evofem warrants.</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following are condensed consolidated balance sheet data for Evofem as of June 30, 2019:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,849</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,566</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,623</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,792</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following are condensed consolidated statements of operations data for Evofem for the three and </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three months ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six months ended</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,941</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,573</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,450</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(53,518</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of activity with respect to the Company&#8217;s sales allowances and accruals for the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Discount and Distribution Fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Government Rebates and Chargebacks</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assistance and Other Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Product Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,094</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,681</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowances for current period sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,069</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,455</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,962</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">951</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowances for prior period sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,961</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credits/payments for current period sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,544</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,929</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,401</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(232</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,106</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credits/payments for prior period sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,044</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,177</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,575</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,358</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,133</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,182</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ollows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:679px;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:342px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total change in fair value for the period included in earnings for royalty right assets held at the end of the reporting period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,399</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total change in fair value for the period included in earnings for liabilities held at the end of the reporting period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Assets/Liabilities Measured and Recorded at Fair Value on a Nonrecurring Basis</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets consist of long-lived assets, including property and equipment and intangible assets and the shares of Alphaeon Class A common stock, received in connection with loans made to LENSAR by the Company prior to its acquisition of LENSAR. During the three months ended June 30, 2018, the Company recorded an impairment charge of </font><font style="font-family:inherit;font-size:10pt;">$152.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the Noden intangible assets related to the increased probability of a generic form of aliskiren being launched in the United States. As a result of this impairment charge, which was based on the estimated fair value of the assets, the remaining carrying value of these intangible assets was determined to be </font><font style="font-family:inherit;font-size:10pt;">$40.1 million</font><font style="font-family:inherit;font-size:10pt;">. The fair value calculation included level 3 inputs. The Company&#8217;s carrying value of the investment in Alphaeon as of both </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> is </font><font style="font-family:inherit;font-size:10pt;">$6.6 million</font><font style="font-family:inherit;font-size:10pt;"> based on an estimated per share value of </font><font style="font-family:inherit;font-size:10pt;">$3.84</font><font style="font-family:inherit;font-size:10pt;">, which was established by a valuation performed when the </font><font style="font-family:inherit;font-size:10pt;">1.7 million</font><font style="font-family:inherit;font-size:10pt;"> shares were acquired. The value of&#160;the Company&#8217;s investment in Alphaeon is not readily determinable as Alphaeon&#8217;s shares are not publicly traded. The Company evaluates the fair value of this investment by performing a qualitative assessment each reporting period. If the results of this qualitative assessment indicate that the fair value is less than the carrying value, the investment is written down to its fair value. There have been no such write downs since the Company acquired these shares. This investment is included in Other long-term assets. For additional information on the Alphaeon investment, see Note 6, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Notes and Other Long-Term Receivables</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Assets/Liabilities Not Subject to Fair Value Recognition</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present the fair value of assets and liabilities not subject to fair value recognition by level within the valuation h</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying value and unamortized discount of the December 2021 Notes were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount of the December 2021 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized discount of liability component</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,480</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,356</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net carrying value of the December 2021 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,520</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,644</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense for the December 2021 Notes on the Company&#8217;s Condensed Consolidated Statements of Operations was as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual coupon interest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,032</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,062</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of conversion feature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,794</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,626</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,984</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,811</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,939</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,594</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense for the February 2018 Notes on the Company&#8217;s Condensed Consolidated Statements of Operations was as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual coupon interest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">421</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">293</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">802</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">. Accrued Liabilities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued rebates, chargebacks and other revenue reserves</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,800</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,811</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,468</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">344</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">344</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,776</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,933</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,499</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,312</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of activity with respect to the Company&#8217;s sales allowances and accruals for the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Discount and Distribution Fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Government Rebates and Chargebacks</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assistance and Other Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Product Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,094</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,681</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowances for current period sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,069</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,455</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,962</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">951</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowances for prior period sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,961</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credits/payments for current period sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,544</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,929</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,401</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(232</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,106</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credits/payments for prior period sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,044</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,177</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,575</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,358</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,133</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,182</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited Condensed Consolidated Financial Statements of PDL Biopharma, Inc. and its subsidiaries (collectively, the &#8220;Company&#8221; or &#8220;PDL&#8221;) have been prepared in accordance with Generally Accepted Accounting Principles (United States) (&#8220;GAAP&#8221;) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments), that management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited Condensed Consolidated Financial Statements and related financial information should be read in conjunction with the Company&#8217;s audited Consolidated Financial Statements and the related notes thereto for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 15, 2019. The Condensed Consolidated Balance Sheet at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, included herein, has been derived from the audited Consolidated Financial Statements at that date, but does not include all disclosures required by GAAP.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying Notes to the Condensed Consolidated Financial Statements. The accounting estimates that require management&#8217;s most significant, difficult and subjective judgments include the valuation of royalty rights - at fair value, product revenue recognition and allowance for customer rebates and allowances, the valuation of notes receivable and inventory, the assessment of recoverability of intangible assets and their estimated useful lives, the valuation and recognition of stock-based compensation, the recognition and measurement of current and deferred income tax assets and liabilities, and the valuation of warrants to acquire shares of common stock. Actual results could differ from those estimates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Condensed Consolidated Financial Statements included herein include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the nature of the Company&#8217;s existing investments and how they are managed, the Company structured its operations in </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> segments designated as Pharmaceutical, Medical Devices, Strategic Positions and Income Generating Assets. During the second quarter of 2019 the Company made an investment in Evofem Biosciences, Inc. (&#8220;Evofem&#8221;) and added a new segment designated as Strategic Positions. This had no impact on its prior segment reporting structure. </font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> and Tekturna HCT</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> in the United States and Rasilez</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> and Rasilez HCT</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> in the rest of the world and an authorized generic form of Tekturna sold in the United States (collectively, the &#8220;Noden Products&#8221;). The branded prescription Noden Products were acquired from Novartis in July 2016 (the &#8220;Noden Transaction&#8221;) by the Company&#8217;s wholly-owned subsidiary, Noden Pharma DAC (&#8220;Noden DAC&#8221;). The Company, through its wholly-owned subsidiary, Noden Pharma USA Inc. (&#8220;Noden USA&#8221;) launched its authorized generic form of Tekturna in the United States in March 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Medical Devices segment consists of revenue derived from the LENSAR</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Laser System sales made by the Company&#8217;s subsidiary, LENSAR, Inc. (&#8220;LENSAR&#8221;), which may include equipment, Patient Interface Devices (&#8220;PIDs&#8221; or &#8220;consumables&#8221;), procedure licenses, training, installation, warranty and maintenance agreements. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Strategic Positions segment consists of an investment in Evofem. The Company&#8217;s investment includes shares of common stock and warrants to purchase additional shares of common stock. Evofem is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Evofem is leveraging its proprietary Multipurpose Vaginal pH Regulator (MVP-R&#8482;) platform to develop Amphora&#174; (L-lactic acid, citric acid and potassium bitartrate) for hormone-free birth control.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Income Generating Assets segment consists of revenue derived from (i) royalty rights - at fair value, (ii) notes and other long-term receivables, (iii) equity investments and (iv) royalties from issued patents in the United States and elsewhere covering the humanization of antibodies (&#8220;Queen et al. patents&#8221;).</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Accounting Policies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s significant accounting policies are described in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended&#160;December&#160;31, 2018. Summarized below and in Note 2, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investment in Evofem Biosciences, Inc.,</font><font style="font-family:inherit;font-size:10pt;"> are the accounting pronouncements and policies adopted subsequent to December 31, 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3. Cash and Cash Equivalents</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;color:#ff0000;"> </font><font style="font-family:inherit;font-size:10pt;">the Company had invested its excess cash balances primarily in money market funds. The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the Company&#8217;s cash and cash equivalents by significant investment category as of&#160;</font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and&#160;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,987</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,954</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,719</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">284,941</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">394,590</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> of gains on sales of available-for-sale securities in the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;color:#ff0000;"> </font><font style="font-family:inherit;font-size:10pt;">the Company had no available-for-sale securities.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12. Commitments and Contingencies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lease Guarantee</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the spin-off (the &#8220;Spin-Off&#8221;) by the Company of Facet Biotech Corporation (&#8220;Facet&#8221;), the Company entered into amendments to the leases for the Company&#8217;s former facilities in Redwood City, California, under which Facet was added as a co-tenant, and a Co-Tenancy Agreement, under which Facet agreed to indemnify the Company for all matters related to the leases attributable to the period after the Spin-Off date. In April 2010, Abbott Laboratories acquired Facet and later renamed the entity AbbVie Biotherapeutics, Inc. (&#8220;AbbVie&#8221;). If AbbVie were to default under its lease obligations, the Company could be held liable by the landlord as a co-tenant and, thus, the Company has in substance guaranteed the payments under the lease agreements for the Redwood City facilities. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the total lease payments for the duration of the guarantee, which runs through December 2021, are approximately </font><font style="font-family:inherit;font-size:10pt;">$28.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company prepared a discounted, probability weighted cash flow analysis to calculate the estimated fair value of the lease guarantee as of the Spin-Off. The Company was required to make assumptions regarding the probability of Facet&#8217;s default on the lease payment, the likelihood of a sublease being executed and the times at which these events could occur. These assumptions are based on information that the Company received from real estate brokers and the then-current economic conditions, as well as expectations of future economic conditions. The fair value of this lease guarantee was charged to additional paid-in capital upon the Spin-Off and any future adjustments to the carrying value of the obligation will also be recorded in additional paid-in capital.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has recorded a liability of </font><font style="font-family:inherit;font-size:10pt;">$10.7 million</font><font style="font-family:inherit;font-size:10pt;"> on its Condensed Consolidated Balance Sheets as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, related to this guarantee. In future periods, the Company may adjust this liability for any changes in the ultimate outcome of this matter that are both probable and estimable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Obligations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noden DAC and Novartis entered into a supply agreement pursuant to which Novartis will manufacture and supply to Noden DAC a bulk tableted form of the Noden Products and active pharmaceutical ingredient (&#8220;API&#8221;). In May 2019, Noden DAC and Novartis entered into an amended supply agreement pursuant to which Novartis will supply to Noden DAC a bulk tableted form of the Noden Products through 2020 and API through June 2021. The supply agreement may be terminated by either party for material breach that remains uncured for a specified time period. Under the terms of the amended supply agreement, Noden DAC is committed to purchase certain quantities of bulk product and API that would amount to approximately </font><font style="font-family:inherit;font-size:10pt;">$90.9 million</font><font style="font-family:inherit;font-size:10pt;"> through June 2021, of which </font><font style="font-family:inherit;font-size:10pt;">$53.1 million</font><font style="font-family:inherit;font-size:10pt;"> is committed over the next twelve months, which are guaranteed by the Company. While the supply agreement provides that the parties will agree to reasonable accommodations with respect to changes in firm orders, the Company expects that Noden DAC will meet the requirements of the supply agreement, unless otherwise negotiated.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LENSAR entered into various supply agreements for the manufacture and supply of certain components. The supply agreements commit LENSAR to a minimum purchase obligation of approximately </font><font style="font-family:inherit;font-size:10pt;">$6.3 million</font><font style="font-family:inherit;font-size:10pt;"> over the next twenty-four months, of which </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;"> is due in the next twelve months. LENSAR expects to meet these requirements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Escrow Receivable</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 1, 2014, the Company entered into a note purchase agreement with Accel 300, LLC (&#8220;Accel 300&#8221;), a wholly-owned subsidiary of kal&#233;o, Inc. (&#8220;kal&#233;o&#8221;), pursuant to which the Company acquired </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> of secured notes due 2029 (the &#8220;kal&#233;o Note&#8221;). The kal&#233;o Note was issued pursuant to an indenture between Accel 300 and U.S. Bank, National Association, as trustee, and was secured by 20% of net sales of its first approved product, Auvi-Q</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (epinephrine auto-injection, USP) (known as Allerject</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> in Canada) and 10% of net sales of kal&#233;o&#8217;s second proprietary auto-injector based product, EVZIO (naloxone hydrochloride injection) (the &#8220;kal&#233;o Revenue Interests&#8221;), and a pledge of kal&#233;o&#8217;s equity ownership in Accel 300. On September 21, 2017, the Company entered into an agreement (the &#8220;kal&#233;o Note Sale Agreement&#8221;) with MAMKangaroo Lender, LLC, a Delaware limited liability company (the kal&#233;o Purchaser&#8221;), pursuant to which the Company sold its entire interest in the kal&#233;o Note for an aggregate cash purchase price of </font><font style="font-family:inherit;font-size:10pt;">$141.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the terms of the kal&#233;o Note Sale Agreement, </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> of the aggregate purchase price was deposited into an escrow account as a potential payment against certain contingencies. The escrow period ended on March 20, 2019 and the escrow agent released the entire </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> to the Company.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">17. Concentration of Credit Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Line Concentration</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The percentage of total revenue recognized, which individually accounted for 10% or more of the Company&#8217;s total revenues in one or more of the periods presented below, was as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:60%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noden</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assertio</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LENSAR</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">___________________</sup>&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three and six months ended June 30, 2019, the AcelRx royalty asset decrease in fair value of </font><font style="font-family:inherit;font-size:10pt;">$60.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$57.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, are excluded from total revenue when calculating product line concentration.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides information about receivables, contract assets and contract liabilities from contracts with customers:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Receivables, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,872</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,214</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,595</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,938</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Receivables, Net</font><font style="font-family:inherit;font-size:10pt;">&#8212;Receivables, net, include amounts billed and due from customers. The amounts due are stated at their net estimated realizable value and are classified as current or noncurrent based on the timing of when the Company expects to receive payment. The Company maintains an allowance for doubtful accounts to provide for the estimated amount of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and collateral to the extent applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contract assets</font><font style="font-family:inherit;font-size:10pt;">&#8212;The Company&#8217;s contract assets represent revenue recognized for performance obligations completed before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. The Company classifies contract assets in Prepaid and other current assets in the Company&#8217;s Condensed Consolidated Balance Sheets based on the timing of when it expects to receive payment.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,638</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,638</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments received</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets at June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,214</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,214</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contract Liabilities</font><font style="font-family:inherit;font-size:10pt;">&#8212;The Company&#8217;s contract liabilities consist of deferred revenue for products sold to customers for which the performance obligation has not been completed by the Company. The Company classifies deferred revenue as current or noncurrent based on the timing of when it expects to recognize revenue. The noncurrent portion of deferred revenue is included in Other long-term liabilities in the Company&#8217;s Condensed Consolidated Balance Sheets.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,938</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">537</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,855</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,392</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts recognized into revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(645</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,829</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,474</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities at June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,059</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,797</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,856</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> disaggregates its revenue from contracts with customers by segment and geographic location as the Company believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. In the following table, revenue is disaggregated by segment and primary geographical market for the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Primary geographical markets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">North America</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,203</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,038</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,776</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Europe</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">705</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,093</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,923</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,643</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,732</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue from contracts with customers</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,067</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,415</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,044</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,879</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Primary geographical markets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">North America</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,287</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,176</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,319</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,707</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Europe</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,036</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,362</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,163</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,757</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,152</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue from contracts with customers</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,556</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,375</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,590</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,221</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_______________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The tables above do not include lease revenue from the Company&#8217;s Medical Devices segment. For the three-month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, revenue accounted for under Topic 842 and 840, Leases, was </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively and for the six-month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14. Stock-Based Compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company grants restricted stock awards and stock options pursuant to a stockholder approved stock-based incentive plan. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the Company&#8217;s stock option and restricted stock award activity during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six months ended June 30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Stock Awards</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(in thousands, except per share amounts)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Grant-date Fair Value Per Share</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,666</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">851</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised or vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited or canceled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.52</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,535</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">. Net (Loss) Income per Share</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net (Loss) Income per Basic and Diluted Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands, except per share amounts)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Numerator</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Loss) income attributable to PDL&#8217;s shareholders used to compute net (loss) income per basic and diluted share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,419</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,261</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,694</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Denominator</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total weighted-average shares used to compute net (loss) income attributable to PDL&#8217;s shareholders, per basic share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,285</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,484</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149,186</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">507</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used to compute net (loss) income attributable to PDL&#8217;s shareholders, per diluted share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,285</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,923</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,040</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149,186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net (loss) income attributable to PDL&#8217;s shareholders per share - basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.76</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.74</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net (loss) income attributable to PDL&#8217;s shareholders per share - diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company computes net (loss) income per diluted share using the sum of the weighted-average number of common and common equivalent shares outstanding. Common equivalent shares used in the computation of net (loss) income per diluted share include shares that may be issued pursuant to outstanding stock options and restricted stock awards, the </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;"> Convertible Senior Notes due February 1, 2018 (the &#8220;February 2018 Notes&#8221;) that were repaid on February 1, 2018, and the </font><font style="font-family:inherit;font-size:10pt;">2.75%</font><font style="font-family:inherit;font-size:10pt;"> Convertible Senior Notes due December 1, 2021 (the &#8220;December 2021 Notes&#8221;), in each case, on a weighted-average basis for the period that the notes were outstanding, including, if applicable, the underlying shares using the treasury stock method.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">December 2021 Notes Capped Call Potential Dilution</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the Company issued </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal of the December 2021 Notes, which provide in certain situations for the conversion of the outstanding principal amount of the December 2021 Notes into shares of the Company&#8217;s common stock at a predefined conversion rate. In conjunction with the issuance of the December 2021 Notes, the Company entered into a capped call transaction with a hedge counterparty. The capped call transaction is expected generally to reduce the potential dilution, and/or offset, to an extent, the cash payments the Company may choose to make in excess of the principal amount, upon conversion of the December 2021 Notes. The Company has excluded the capped call transaction from the net (loss) income per diluted share computation as such securities would have an anti-dilutive effect and those securities should be considered separately rather than in the aggregate in determining whether their effect on net (loss) income per diluted share would be dilutive or anti-dilutive. For additional information regarding the conversion rates and the capped call transaction related to the Company&#8217;s December 2021 Notes, see Note 10, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Senior Notes</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Anti-Dilutive Effect of Restricted Stock Awards and Stock Options</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company excluded approximately </font><font style="font-family:inherit;font-size:10pt;">1.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">1.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares underlying restricted stock awards, respectively, and for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company excluded approximately </font><font style="font-family:inherit;font-size:10pt;">0.8</font><font style="font-family:inherit;font-size:10pt;"> million and </font><font style="font-family:inherit;font-size:10pt;">1.1 million</font><font style="font-family:inherit;font-size:10pt;"> shares underlying restricted stock awards, respectively, in each case calculated on a weighted-average basis, from its net (loss) income per diluted share calculations because their effect was anti-dilutive.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company excluded approximately </font><font style="font-family:inherit;font-size:10pt;">12.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">4.9 million</font><font style="font-family:inherit;font-size:10pt;"> shares underlying outstanding stock options, respectively, and for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company excluded approximately </font><font style="font-family:inherit;font-size:10pt;">10.4</font><font style="font-family:inherit;font-size:10pt;"> million and </font><font style="font-family:inherit;font-size:10pt;">4.9 million</font><font style="font-family:inherit;font-size:10pt;"> shares underlying outstanding stock options, respectively, in each case calculated on a weighted-average basis, from its net (loss) income per diluted share calculations because their effect was anti-dilutive.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table represents significant unobservable inputs used in determining the estimated fair value of impaired notes receivable investments:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Asset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation</font></div><div style="padding-bottom:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Technique</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable</font></div><div style="padding-bottom:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Input</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Wellstat Diagnostics</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Wellstat Guarantors intellectual property</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Approach</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$21 million</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$21 million</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Settlement Amount</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Approach</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Settlement amount</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$34 million</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$34 million</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Real Estate Property</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Market Approach</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Annual appreciation rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated realtor fee</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated disposal date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/30/2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/30/2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">CareView</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note receivable cash flows</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Approach</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables summarize the changes in Level 3 Royalty Right Assets and the gains and losses included in earnings for the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Royalty Rights - </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">At Fair Value</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value as of December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">376,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total net change in fair value for the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of royalty rights - at fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(28,142</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Proceeds from royalty rights - at fair value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(32,726</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total net change in fair value for the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(60,868</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value as of June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">315,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value as of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Royalty Rights -</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value as of</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Change in Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Assertio (formerly Depomed)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">264,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(459</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">263,912</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">VB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">265</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,373</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U-M</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,316</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">AcelRx</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">70,380</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(57,886</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,494</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">KYBELLA</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,472</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">584</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">376,510</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(60,868</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">315,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the changes in Level 3 Liabilities and the gains and losses included in earnings for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:286px;" rowspan="1" colspan="1"></td><td style="width:286px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Liabilities</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Contingent Consideration</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value as of December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Settlement of financial instrument</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value as of June 30, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> Fair Value Measurements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the Company&#8217;s financial instruments are estimates of the amounts that would be received if the Company were to sell an asset or pay to transfer a liability in an orderly transaction between market participants at the measurement date or exit price. The assets and liabilities are categorized and disclosed in one of the following three categories:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; based on quoted market prices in active markets for identical assets and liabilities;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; based on observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; based on unobservable inputs using management&#8217;s best estimate and assumptions when inputs are unavailable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the fair value of the Company&#8217;s financial instruments measured at fair value on a recurring basis by level within the valuation hierarchy:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="33" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,954</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,954</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,719</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,719</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate securities</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,013</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,013</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty rights - at fair value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">315,642</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">315,642</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">376,510</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">376,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317,487</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">315,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">650,142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,719</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">376,510</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">603,291</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial liabilities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration, current</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,071</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,071</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">___________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate securities are classified as &#8220;Investment in equity affiliate&#8221; on the Condensed Consolidated Balance Sheet.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants are included in &#8220;Other assets&#8221; on the Condensed Consolidated Balance Sheets.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration, current is classified as &#8220;Accrued liabilities&#8221; on the Condensed Consolidated Balance Sheet.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> transfers between levels during the periods presented in the table above. The Company recognizes transfers between levels on the date of the event or change in circumstances that caused the transfer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Money Market Funds - </font><font style="font-family:inherit;font-size:10pt;">The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Corporate Securities -</font><font style="font-family:inherit;font-size:10pt;"> Corporate securities consists of common stock shares of Evofem, a clinical-stage biopharmaceutical company listed on Nasdaq. For additional information on the Evofem investment, see Note 2, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investment in Evofem</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warrants - </font><font style="font-family:inherit;font-size:10pt;">Warrants consist of rights to purchase shares of common stock in Evofem and CareView Communications, Inc. (&#8220;CareView&#8221;), see Note 2, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investment in Evofem</font><font style="font-family:inherit;font-size:10pt;">, and Note 6, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Notes and Other Long-Term Receivables.</font><font style="font-family:inherit;font-size:10pt;"> The fair value of the warrants is estimated using recently quoted market prices of the underlying equity security and the Black-Scholes option pricing model.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Royalty Rights - At Fair Value</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assertio (Depomed) Royalty Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October&#160;18, 2013, the Company entered into the Royalty Purchase and Sale Agreement (the &#8220;Assertio Royalty Agreement&#8221;) with Assertio Therapeutics, Inc. (formerly known as Depomed, Inc.), and Depo DR Sub, LLC (together, &#8220;Assertio&#8221;), whereby the Company acquired the rights to receive royalties and milestones payable on sales of five Type 2 diabetes products licensed by Assertio in exchange for a </font><font style="font-family:inherit;font-size:10pt;">$240.5 million</font><font style="font-family:inherit;font-size:10pt;"> cash payment. Total consideration was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$241.3 million</font><font style="font-family:inherit;font-size:10pt;">, which was comprised of the </font><font style="font-family:inherit;font-size:10pt;">$240.5 million</font><font style="font-family:inherit;font-size:10pt;"> cash payment to Assertio and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> in transaction costs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rights acquired include Assertio&#8217;s royalty and milestone payments accruing from and after October 1, 2013: (a) from Santarus, Inc. (&#8220;Santarus&#8221;), which was subsequently acquired by Salix Pharmaceuticals, Inc. (&#8220;Salix&#8221;), which itself was acquired by Valeant Pharmaceuticals International, Inc. (&#8220;Valeant&#8221;), which, in July 2018, changed its name to Bausch Health Companies Inc. (&#8220;Bausch Health&#8221;) with respect to sales of Glumetza (metformin HCL extended-release tablets) in the United States; (b) from Merck &amp; Co., Inc. with respect to sales of Janumet</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> XR (sitagliptin and metformin HCL extended-release tablets); (c) from Janssen Pharmaceutica N.V. with respect to potential future development milestones and sales of its approved fixed-dose combination of Invokana</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (canagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor) and extended-release metformin tablets, marketed as Invokamet XR</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">; (d) from Boehringer Ingelheim and Eli Lilly and Company with respect to potential future development milestones and sales of the investigational fixed-dose combinations of drugs and extended-release metformin subject to Assertio&#8217;s license agreement with Boehringer Ingelheim, including its approved products, Jentadueto XR</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> and Synjardy XR</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">; and (e) from LG Life Sciences and Bausch Health for sales of extended-release metformin tablets in Korea and Canada, respectively.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2013, a generic equivalent to Glumetza was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and in August 2016, two additional generic equivalents to Glumetza were approved by the FDA. In February 2016, Lupin Pharmaceuticals, Inc., in August 2017, Teva Pharmaceutical Industries Ltd., and in July 2018, Sun Pharmaceutical, Inc. (&#8220;Sun&#8221;) each launched a generic equivalent approved product. In May 2017, the Company received notification that a subsidiary of Valeant had launched an authorized generic equivalent product in February 2017, and the Company received royalties on such authorized generic equivalent product under the same terms as the branded Glumetza product, retroactive to February 2017. The Company continues to monitor whether the generic competition further affects sales of Glumetza and thus royalties on such sales paid to the Company, and the impact of the launched authorized generic equivalent. Due to the uncertainty around Bausch Health&#8217;s marketing and pricing strategy, as well as Sun&#8217;s recently launched generic product and limited historical demand data after generic market entrance, the Company may need to further evaluate future cash flows in the event of more rapid reduction or increase in market share of Glumetza and its authorized generic equivalent product and/or a further erosion in net pricing.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that its royalty purchase interest in Depo DR Sub, LLC represented a variable interest in a variable interest entity. However, the Company did not have the power to direct the activities of Depo DR Sub, LLC that most significantly impact Depo DR Sub, LLC&#8217;s economic performance and was not the primary beneficiary of Depo DR Sub, LLC; therefore, Depo DR Sub, LLC was not subject to consolidation by the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 2, 2018, PDL Investment Holding, LLC (&#8220;PDLIH&#8221;), a wholly-owned subsidiary of the Company and assignee from the Company under the Assertio Royalty Agreement, entered into an amendment to the Assertio Royalty Agreement with Assertio. Pursuant to the amendment, PDLIH purchased all of Assertio&#8217;s remaining interests in royalty and milestone payments payable on sales of Type 2 diabetes products licensed by Assertio for </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">. Prior to the amendment, the Assertio Royalty Agreement provided that the Company would have received all royalty and milestone payments due under license agreements between Assertio and its licensees until the Company received payments equal to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> times the cash payment it made to Assertio, or approximately </font><font style="font-family:inherit;font-size:10pt;">$481.0 million</font><font style="font-family:inherit;font-size:10pt;">, after which all net payments received by Assertio would have been shared equally between the Company and Assertio. Following the amendment, the Assertio Royalty Agreement provides that the Company will receive all royalty and milestone payments due under the license agreements between Assertio and its licensees. The Company has elected to continue to follow the fair value option and carry the financial asset at fair value.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Assertio Royalty Agreement terminates on the third anniversary following the date upon which the later of the following occurs: (a) October 25, 2021, or (b) at such time as no royalty payments remain payable under any license agreement and each of the license agreements has expired by its terms.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2018, in conjunction with the amendment described above, the Company was provided the power to direct the activities of Depo DR Sub, LLC and is the primary beneficiary of Depo DR Sub, LLC; therefore, Depo DR Sub, LLC is subject to consolidation by the Company. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, Depo DR Sub, LLC did not have any assets or liabilities of value for consolidation with the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, PDL submitted notice of its intent to exercise its audit right under the Assertio Royalty Agreement with respect to Glumetza royalties for the period beginning January 1, 2016 and ending December 31, 2018. No material adjustments were identified in connection with this audit.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial asset acquired represents a single unit of accounting. This financial asset is classified as a Level 3 asset within the fair value hierarchy, as the Company&#8217;s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future commercialization for products not yet approved by regulatory agencies outside of the United States. The estimated fair value of the financial asset acquired was determined by using a discounted cash flow analysis related to the expected future cash flows to be generated by each licensed product. The discounted cash flows are based upon expected royalties from sales of licensed products over approximately an </font><font style="font-family:inherit;font-size:10pt;">eight</font><font style="font-family:inherit;font-size:10pt;">-year period. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from the Company&#8217;s estimates. The Company periodically assesses the expected future cash flows and to the extent such payments are greater or less than its initial estimates, or the timing of such payments is materially different than the original estimates, the Company will adjust the estimated fair value of the asset. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. Should the expected royalties increase or decrease by </font><font style="font-family:inherit;font-size:10pt;">2.5%</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the asset could increase or decrease by </font><font style="font-family:inherit;font-size:10pt;">$6.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Significant judgment is required in selecting appropriate discount rates. The discount rates utilized range from </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">24%</font><font style="font-family:inherit;font-size:10pt;">. Should these discount rates increase or decrease by </font><font style="font-family:inherit;font-size:10pt;">2.5%</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the asset could decrease by </font><font style="font-family:inherit;font-size:10pt;">$22.2 million</font><font style="font-family:inherit;font-size:10pt;"> or increase by </font><font style="font-family:inherit;font-size:10pt;">$26.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date for the above described royalty streams.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the asset acquired as reported in the Company&#8217;s Condensed Consolidated Balance Sheet was </font><font style="font-family:inherit;font-size:10pt;">$263.9 million</font><font style="font-family:inherit;font-size:10pt;"> and the maximum loss exposure was </font><font style="font-family:inherit;font-size:10pt;">$263.9 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Viscogliosi Brothers Royalty Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 26, 2014, the Company entered into a Royalty Purchase and Sale Agreement (the &#8220;VB Royalty Agreement&#8221;) with Viscogliosi Brothers, LLC (&#8220;VB&#8221;), whereby VB conveyed to the Company the right to receive royalties payable on sales of a spinal implant that has received pre-market approval from the FDA held by VB and commercialized by Paradigm Spine, LLC (&#8220;Paradigm Spine&#8221;), in exchange for a </font><font style="font-family:inherit;font-size:10pt;">$15.5 million</font><font style="font-family:inherit;font-size:10pt;"> cash payment, less fees. Paradigm Spine was acquired in March 2019 by RTI Surgical Holdings, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The royalty rights acquired include royalties accruing from and after April 1, 2014. Under the terms of the VB Royalty Agreement, the Company receives all royalty payments due to VB pursuant to certain technology transfer agreements between VB and Paradigm Spine until the Company has received payments equal to </font><font style="font-family:inherit;font-size:10pt;">2.3</font><font style="font-family:inherit;font-size:10pt;"> times the cash payment made to VB, after which all rights to receive royalties will be returned to VB. VB&#8217;s ability to repurchase the royalty right for a specified amount expired on June 26, 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of the royalty rights at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company&#8217;s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over approximately a </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">-year period. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from the Company&#8217;s estimates. The Company periodically assesses the expected future cash flows and to the extent such payments are greater or less than its initial estimates, or the timing of such payments is materially different than the original estimates, the Company will adjust the estimated fair value of the asset. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. Should the expected royalties increase or decrease by </font><font style="font-family:inherit;font-size:10pt;">2.5%</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the asset could increase or decrease by </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Significant judgment is required in selecting the appropriate discount rate. The discount rate utilized was </font><font style="font-family:inherit;font-size:10pt;">15.0%</font><font style="font-family:inherit;font-size:10pt;">. Should this discount rate increase or decrease by </font><font style="font-family:inherit;font-size:10pt;">2.5%</font><font style="font-family:inherit;font-size:10pt;">, the fair value of this asset could decrease by </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> or increase by </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of June&#160;30, 2019, the Company&#8217;s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the asset acquired as reported in the Company&#8217;s Condensed Consolidated Balance Sheet was </font><font style="font-family:inherit;font-size:10pt;">$14.4 million</font><font style="font-family:inherit;font-size:10pt;"> and the maximum loss exposure was </font><font style="font-family:inherit;font-size:10pt;">$14.4 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">University of Michigan Royalty Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 6, 2014, the Company acquired a portion of all royalty payments of the Regents of the University of Michigan&#8217;s (&#8220;U-M&#8221;) worldwide royalty interest in Cerdelga</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (eliglustat) for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$65.6 million</font><font style="font-family:inherit;font-size:10pt;"> pursuant to the Royalty Purchase and Sale Agreement with U-M (the &#8220;U-M Royalty Agreement&#8221;). Under the terms of the U-M Royalty Agreement, the Company receives </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">75%</font><font style="font-family:inherit;font-size:10pt;"> of all royalty payments due under U-M&#8217;s license agreement with Genzyme Corporation, a Sanofi company (&#8220;Genzyme&#8221;) until expiration of the licensed patents, excluding any patent term extension. Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme. Cerdelga was approved in the United States in August 2014, in the European Union in January 2015, and in Japan in March 2015. In addition, marketing applications for Cerdelga are under review by other regulatory authorities. While marketing applications have been approved in the United States, the European Union and Japan, national pricing and reimbursement decisions are delayed in some countries.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of the royalty right at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company&#8217;s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over approximately a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year period. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from the Company&#8217;s estimates. An evaluation of those estimates, discount rate utilized and general market conditions affecting fair market value is performed in each reporting period. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. Should the expected royalties increase or decrease by </font><font style="font-family:inherit;font-size:10pt;">2.5%</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the asset could increase or decrease by </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Significant judgment is required in selecting the appropriate discount rate. The discount rate utilized was approximately </font><font style="font-family:inherit;font-size:10pt;">12.8%</font><font style="font-family:inherit;font-size:10pt;">. Should this discount rate increase or decrease by </font><font style="font-family:inherit;font-size:10pt;">2.5%</font><font style="font-family:inherit;font-size:10pt;">, the fair value of this asset could decrease by </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> or increase by </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the asset acquired as reported in the Company&#8217;s Condensed Consolidated Balance Sheet was </font><font style="font-family:inherit;font-size:10pt;">$24.3 million</font><font style="font-family:inherit;font-size:10pt;"> and the maximum loss exposure was </font><font style="font-family:inherit;font-size:10pt;">$24.3 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">AcelRx Royalty Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 18, 2015, the Company entered into a royalty interest assignment agreement (the &#8220;AcelRx Royalty Agreement&#8221;) with ARPI LLC, a wholly-owned subsidiary of AcelRx Pharmaceuticals, Inc. (&#8220;AcelRx&#8221;), whereby the Company acquired the rights to receive a portion of the royalties and certain milestone payments on sales of Zalviso</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (sufentanil sublingual tablet system) in the European Union, Switzerland and Australia by AcelRx&#8217;s commercial partner, Gr&#252;nenthal, in exchange for a </font><font style="font-family:inherit;font-size:10pt;">$65.0 million</font><font style="font-family:inherit;font-size:10pt;"> cash payment. Under the terms of the AcelRx Royalty Agreement, the Company receives </font><font style="font-family:inherit;font-size:10pt;">75%</font><font style="font-family:inherit;font-size:10pt;"> of all royalty payments and </font><font style="font-family:inherit;font-size:10pt;">80%</font><font style="font-family:inherit;font-size:10pt;"> of the first </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> commercial milestone payments due under AcelRx&#8217;s license agreement with Gr&#252;nenthal until the earlier to occur of (i) receipt by the Company of payments equal to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> times the cash payments made to AcelRx and (ii) the expiration of the licensed patents. Zalviso received marketing approval by the European Commission in September 2015. Gr&#252;nenthal launched Zalviso in the second quarter of 2016 and the Company started to receive royalties in the third quarter of 2016.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, and December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that its royalty rights under the AcelRx Royalty Agreement represented a variable interest in a variable interest entity. However, the Company does not have the power to direct the activities of ARPI LLC that most significantly impact ARPI LLC&#8217;s economic performance and is not the primary beneficiary of ARPI LLC; therefore, ARPI LLC is not subject to consolidation by the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to the slower than expected adoption of the product since its initial launch relative to the Company&#8217;s estimates and the increased variance noted between the Company&#8217;s forecast model and actual results in the three months ended June 30, 2019, the Company utilized a third-party expert in the second quarter of 2019 to reassess the market and expectations for the Zalviso product. Key findings from the third-party study included: the post-surgical PCA (Patient-Controlled Analgesia) market being smaller than previously forecasted; the higher price of the product relative to alternative therapies, the product not being used as a replacement for systemic opioids and the design of the delivery device, which is pre-filled for up to three days of treatment, which restricts its use for shorter recovery time procedures. Based on this analysis and the impact to the projected sales-based royalties and milestones, the Company wrote down the fair value of the royalty asset by </font><font style="font-family:inherit;font-size:10pt;">$60.0 million</font><font style="font-family:inherit;font-size:10pt;"> in the second quarter of 2019. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of the royalty right at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company&#8217;s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over approximately a </font><font style="font-family:inherit;font-size:10pt;">fourteen</font><font style="font-family:inherit;font-size:10pt;">-year period. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from the Company&#8217;s estimates. An evaluation of those estimates, discount rate utilized and general market conditions affecting fair market valuation is performed for each reporting period. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. Should the expected royalties increase or decrease by </font><font style="font-family:inherit;font-size:10pt;">2.5%</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the asset could increase or decrease by less than </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Significant judgment is required in selecting the appropriate discount rate. The discount rate utilized was approximately </font><font style="font-family:inherit;font-size:10pt;">13.4%</font><font style="font-family:inherit;font-size:10pt;">. Should this discount rate increase or decrease by </font><font style="font-family:inherit;font-size:10pt;">2.5%</font><font style="font-family:inherit;font-size:10pt;">, the fair value of this asset could decrease by </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> or increase by </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the asset acquired as reported in the Company&#8217;s Condensed Consolidated Balance Sheet was </font><font style="font-family:inherit;font-size:10pt;">$12.5 million</font><font style="font-family:inherit;font-size:10pt;"> and the maximum loss exposure was </font><font style="font-family:inherit;font-size:10pt;">$12.5 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Kybella Royalty Agreement</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 8, 2016, the Company entered into a royalty purchase and sales agreement with an individual, whereby the Company acquired that individual&#8217;s rights to receive certain royalties on sales of KYBELLA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> by Allergan plc in exchange for a </font><font style="font-family:inherit;font-size:10pt;">$9.5 million</font><font style="font-family:inherit;font-size:10pt;"> cash payment and up to </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> in future milestone payments based upon product sales targets. The Company started to receive royalty payments during the third quarter of 2016.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of the royalty right at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company&#8217;s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of a licensed product over approximately a </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">-year period. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from the Company&#8217;s estimates. An evaluation of those estimates, discount rate utilized and general market conditions affecting fair market value is performed in each reporting period. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. Should the expected royalties increase or decrease by </font><font style="font-family:inherit;font-size:10pt;">2.5%</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the asset could increase or decrease by less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Significant judgment is required in selecting the appropriate discount rate. The discount rate utilized was approximately </font><font style="font-family:inherit;font-size:10pt;">14.4%</font><font style="font-family:inherit;font-size:10pt;">. Should this discount rate increase or decrease by </font><font style="font-family:inherit;font-size:10pt;">2.5%</font><font style="font-family:inherit;font-size:10pt;">, the fair value of this asset could decrease or increase by less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of June&#160;30, 2019, the Company&#8217;s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the asset acquired as reported in the Company&#8217;s Condensed Consolidated Balance Sheet was </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> and the maximum loss exposure was </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables summarize the changes in Level 3 Royalty Right Assets and the gains and losses included in earnings for the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Royalty Rights - </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">At Fair Value</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value as of December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">376,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total net change in fair value for the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of royalty rights - at fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(28,142</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Proceeds from royalty rights - at fair value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(32,726</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total net change in fair value for the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(60,868</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value as of June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">315,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value as of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Royalty Rights -</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value as of</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Change in Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Assertio (formerly Depomed)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">264,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(459</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">263,912</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">VB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">265</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,373</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U-M</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,316</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">AcelRx</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">70,380</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(57,886</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,494</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">KYBELLA</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,472</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">584</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">376,510</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(60,868</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">315,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the changes in Level 3 Liabilities and the gains and losses included in earnings for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:286px;" rowspan="1" colspan="1"></td><td style="width:286px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Liabilities</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Contingent Consideration</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value as of December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Settlement of financial instrument</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value as of June 30, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">______________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Represents the final conversion consideration and earn out liability for the LENSAR acquisition of assets from Precision Eye Services.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gains and losses from changes in Level 3 assets included in earnings for each period are presented in &#8220;Royalty rights - change in fair value&#8221; and gains and losses from changes in Level 3 liabilities included in earnings for each period are presented in &#8220;Change in fair value of anniversary payment and contingent consideration&#8221; as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:679px;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:342px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total change in fair value for the period included in earnings for royalty right assets held at the end of the reporting period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,399</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total change in fair value for the period included in earnings for liabilities held at the end of the reporting period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Assets/Liabilities Measured and Recorded at Fair Value on a Nonrecurring Basis</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets consist of long-lived assets, including property and equipment and intangible assets and the shares of Alphaeon Class A common stock, received in connection with loans made to LENSAR by the Company prior to its acquisition of LENSAR. During the three months ended June 30, 2018, the Company recorded an impairment charge of </font><font style="font-family:inherit;font-size:10pt;">$152.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the Noden intangible assets related to the increased probability of a generic form of aliskiren being launched in the United States. As a result of this impairment charge, which was based on the estimated fair value of the assets, the remaining carrying value of these intangible assets was determined to be </font><font style="font-family:inherit;font-size:10pt;">$40.1 million</font><font style="font-family:inherit;font-size:10pt;">. The fair value calculation included level 3 inputs. The Company&#8217;s carrying value of the investment in Alphaeon as of both </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> is </font><font style="font-family:inherit;font-size:10pt;">$6.6 million</font><font style="font-family:inherit;font-size:10pt;"> based on an estimated per share value of </font><font style="font-family:inherit;font-size:10pt;">$3.84</font><font style="font-family:inherit;font-size:10pt;">, which was established by a valuation performed when the </font><font style="font-family:inherit;font-size:10pt;">1.7 million</font><font style="font-family:inherit;font-size:10pt;"> shares were acquired. The value of&#160;the Company&#8217;s investment in Alphaeon is not readily determinable as Alphaeon&#8217;s shares are not publicly traded. The Company evaluates the fair value of this investment by performing a qualitative assessment each reporting period. If the results of this qualitative assessment indicate that the fair value is less than the carrying value, the investment is written down to its fair value. There have been no such write downs since the Company acquired these shares. This investment is included in Other long-term assets. For additional information on the Alphaeon investment, see Note 6, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Notes and Other Long-Term Receivables</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Assets/Liabilities Not Subject to Fair Value Recognition</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present the fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Carrying Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Carrying Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wellstat Diagnostics note receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,191</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,240</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,191</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,322</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hyperion note receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CareView note receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,458</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,458</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,458</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,458</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,849</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,898</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,849</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,980</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2021 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,520</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,017</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,644</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,356</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,520</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,644</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,356</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2018 the Company recorded an impairment loss of </font><font style="font-family:inherit;font-size:10pt;">$8.2 million</font><font style="font-family:inherit;font-size:10pt;"> to the note receivable with CareView Communications, Inc. (&#8220;CareView&#8221;). There were no impairment losses on notes receivable in the three and </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the estimated fair values of the Hyperion Catalysis International, Inc. (&#8220;Hyperion&#8221;) note receivable, and CareView note receivable were determined using discounted cash flow models, incorporating expected principal and interest payments. In addition, during the year ended December 31, 2018, the fair value of the CareView note receivable also considered the recoverability of the note receivable balance utilizing third-party revenue multiples for small cap healthcare technology companies. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the estimated fair value of the Wellstat Diagnostics note receivable was determined by using an asset approach and discounted cash flow model related to the underlying collateral and adjusted to consider estimated costs to sell the assets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined its notes receivable assets are Level 3 assets as the Company&#8217;s valuations utilized significant unobservable inputs, including estimates of future revenues, discount rates, expectations about settlement, terminal values, required yield and the value of underlying collateral. The Company engages a third-party valuation expert when deemed necessary to assist in evaluating its investments and the related inputs needed to estimate the fair value of certain investments. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The CareView note receivable is secured by substantially all assets of, and equity interests in CareView. The Wellstat Diagnostics note receivable is secured by substantially all assets of Wellstat Diagnostics and is supported by a guaranty from the Wellstat Diagnostics Guarantors (as defined in Note 6, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Notes and Other Long-Term Receivables</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the carrying value of one of the Company&#8217;s notes receivable assets differed from its estimated fair value. This is the result of inputs used in estimating the fair value of the collateral, including appraisals, projected cash flows of collateral assets and discount rates used when performing a discounted cash flow analysis.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair values of the Company&#8217;s convertible senior notes were determined using quoted market pricing.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table represents significant unobservable inputs used in determining the estimated fair value of impaired notes receivable investments:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Asset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation</font></div><div style="padding-bottom:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Technique</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable</font></div><div style="padding-bottom:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Input</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Wellstat Diagnostics</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Wellstat Guarantors intellectual property</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Approach</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$21 million</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$21 million</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Settlement Amount</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Approach</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Settlement amount</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$34 million</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$34 million</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Real Estate Property</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Market Approach</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Annual appreciation rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated realtor fee</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated disposal date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/30/2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/30/2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">CareView</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note receivable cash flows</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Approach</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">. Intangible Assets</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets, Net</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 8, 2018, Noden DAC entered into a Settlement Agreement (the &#8220;Settlement Agreement&#8221;) with Anchen Pharmaceuticals, Inc. and its affiliates (&#8220;Anchen&#8221;) to resolve the patent litigation relating to infringement of U.S. Patent No. 8,617,595 (the &#8220;&#8216;595 Patent&#8221;) based on their submission of an Abbreviated New Drug Application (&#8220;ANDA&#8221;) seeking authorization from the FDA to market a generic version of aliskiren, the active ingredient in the Tekturna and Tekturna HCT drug. Under the Settlement Agreement, Anchen, the sole ANDA filer of which the Company is aware, agreed to not commercialize its generic version of aliskiren prior to March 1, 2019. Per the Settlement Agreement, Anchen may commercialize their formulation of aliskiren, but is not permitted to commercialize a copy of Tekturna.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accordingly, management evaluated the ongoing value of the Noden DAC asset group based upon the probability of Anchen&#8217;s market entry of a generic version of aliskiren in the United States and the associated cash flows and conducted a test for impairment.&#160;Due to the increased probability of a generic version of aliskiren being launched in the United States, the Company revised its estimates of future cash flows and as a result of this analysis, determined that the sum of undiscounted cash flows was not greater than the carrying value of the assets. Therefore, the Company performed a discounted cash flow analysis to estimate the fair value of the asset group in accordance with ASC Topic 360, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment or Disposal of Long-lived Assets</font><font style="font-family:inherit;font-size:10pt;">. The cash flows used in this analysis are those expected to be generated by market participants, discounted to reflect an appropriate amount of risk, which was determined to be </font><font style="font-family:inherit;font-size:10pt;">21%</font><font style="font-family:inherit;font-size:10pt;">. The Company concluded that the Noden DAC acquired product rights and customer relationship long-lived assets, with a carrying amount of </font><font style="font-family:inherit;font-size:10pt;">$192.5 million</font><font style="font-family:inherit;font-size:10pt;">, were no longer recoverable and wrote them down to their estimated fair value of </font><font style="font-family:inherit;font-size:10pt;">$40.1 million</font><font style="font-family:inherit;font-size:10pt;">, resulting in an impairment charge of </font><font style="font-family:inherit;font-size:10pt;">$152.3 million</font><font style="font-family:inherit;font-size:10pt;"> in the second quarter of 2018. This write-down is included in &#8220;Impairment of intangible assets&#8221; in the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 4, 2019, the Company announced the U.S. commercial launch of an authorized generic form of Tekturna, with the same drug formulation as Tekturna. The Company performed an impairment assessment of the Noden asset group at this time by estimating the undiscounted future cash flows with respect to the asset against its carrying value and concluded a further impairment was not required.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 22, 2019, the FDA approved Anchen&#8217;s generic form of aliskiren. The Company performed an impairment assessment of the Noden asset group at this time and concluded no further impairment was required.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future events, such as FDA approval of additional generic forms of aliskiren, or pricing or market share pressure resulting from existing generic competition, may be further indicators of impairment which may require the Company to perform additional impairment testing.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2019, LENSAR acquired certain intellectual property from a third-party for </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and obligations to pay a </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> milestone payment and royalties upon the completion of certain events.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of intangible assets as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Carrying Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finite-lived intangible assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired products rights</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,143</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,517</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,626</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,143</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,258</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,885</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) (2) (4)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,028</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,209</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,819</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,028</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired technology</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2) (3) (5)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,311</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,630</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,681</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,011</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,203</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,808</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired trademarks</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">570</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">323</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,052</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,603</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,449</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,752</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,433</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company acquired certain intangible assets as part of the Noden transaction. They are being amortized on a straight-line basis over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">eight years</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company acquired certain intangible assets as part of its acquisition of LENSAR in May 2017. They are being amortized on a straight-line basis over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">15 years</font><font style="font-family:inherit;font-size:10pt;">. The intangible assets for customer relationships are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company acquired certain intangible assets as part of the foreclosure on certain of Direct Flow Medical assets. They are being amortized on a straight-line basis over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">10 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LENSAR acquired certain intangible assets for customer relationships from Precision Eye Services, which are being amortized using a double-declining method over a period of </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LENSAR acquired certain intangible assets from a third-party, which are being amortized on a straight-line basis over a period of </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> amortization expense was </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, and for the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> amortization expense was </font><font style="font-family:inherit;font-size:10pt;">$6.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the intangible assets recorded at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, and assuming no subsequent additions to or impairment of the underlying assets, the remaining amortization expense is expected to be as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019 (Remaining six months)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,394</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,257</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,030</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total remaining amortization expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,449</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18. Income Taxes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax (benefit) expense for the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, was </font><font style="font-family:inherit;font-size:10pt;">$(1.2) million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$(14.3) million</font><font style="font-family:inherit;font-size:10pt;">, respectively, and for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, was </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$(13.2) million</font><font style="font-family:inherit;font-size:10pt;">, respectively, which resulted primarily from applying the federal statutory income tax rate to income before income taxes. The Company&#8217;s effective tax rate for the current period differs from the U.S. federal statutory rate of </font><font style="font-family:inherit;font-size:10pt;">21%</font><font style="font-family:inherit;font-size:10pt;"> due primarily to the effect of state income taxes and non-deductible executive compensation, less the foreign tax rate differential associated with the Company&#8217;s Noden DAC operations in Ireland.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The uncertain tax positions did not change during the three or </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s income tax returns are subject to examination by U.S. federal, foreign, state and local tax authorities for tax years 2000 forward. The Company is currently under audit by the California Franchise Tax Board (the &#8220;CFTB&#8221;) for the tax years 2009 through 2015 and the Internal Revenue Service (the &#8220;IRS&#8221;) for the tax year 2016. The timing of the resolutions to these audits and the amount to be ultimately paid, if any, is uncertain. The outcome of these audits could result in the payment of tax amounts that differ from the amounts the Company has reserved for uncertain tax positions for the periods under audit resulting in incremental expense or a reversal of the Company&#8217;s reserves in a future period. At this time, the Company does not anticipate a material change in the unrecognized tax benefits related to the CFTB or IRS audits that would affect the effective tax rate or deferred tax assets over the next 12 months.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4. Inventories</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,629</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company deferred approximately </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of costs associated with inventory transfers made under the Company&#8217;s third party logistic provider service arrangement. These costs have been recorded as Prepaid and other current assets on the Company&#8217;s Condensed Consolidated Balance Sheets as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. The Company will recognize the cost of product sold as inventory is transferred from its third-party logistics provider to the Company&#8217;s customers.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of lease expense are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:60%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease cost</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">609</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term lease cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total lease cost</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">336</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">511</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">633</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to leases is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:60%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Right-of-use-assets obtained in exchange for lease obligations:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,111</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">N/A</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_______________</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">N/A&#160;&#160;&#160;&#160;Not applicable</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the lease balances within the Condensed Consolidated Balance Sheet, weighted-average remaining lease term, and weighted-average discount rates related to the Company&#8217;s operating leases (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease ROU assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,661</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease liabilities, current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">807</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease liabilities, long-term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">891</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.00 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average discount rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maturities of operating lease liabilities as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019 (Remaining six months)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">472</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">837</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">473</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating lease payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: imputed interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum operating lease payments as of December 31, 2018 were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,003</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,702</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had no additional significant operating or finance leases that had not yet commenced.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7. Leases</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Lessee arrangements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has operating leases for corporate offices and certain equipment. The Company&#8217;s operating leases have remaining lease terms ranging from </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">eight</font><font style="font-family:inherit;font-size:10pt;"> years, some of which include options to extend the leases for up to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years, and some of which include options to terminate the leases within </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of lease expense are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:60%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease cost</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">609</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term lease cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total lease cost</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">336</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">511</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">633</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to leases is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:60%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Right-of-use-assets obtained in exchange for lease obligations:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,111</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">N/A</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_______________</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">N/A&#160;&#160;&#160;&#160;Not applicable</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the lease balances within the Condensed Consolidated Balance Sheet, weighted-average remaining lease term, and weighted-average discount rates related to the Company&#8217;s operating leases (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease ROU assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,661</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease liabilities, current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">807</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease liabilities, long-term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">891</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.00 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average discount rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maturities of operating lease liabilities as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019 (Remaining six months)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">472</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">837</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">473</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating lease payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: imputed interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum operating lease payments as of December 31, 2018 were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,003</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,702</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had no additional significant operating or finance leases that had not yet commenced.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Lessor arrangements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has operating and sales-type leases for medical device equipment generated from its medical devices segment. The Company&#8217;s leases have remaining lease terms of less than one year to five years, some of which include options to extend the leases on a month-to-month basis if the customer does not notify the Company of the intention to return the equipment at the end of the lease term. The Company typically does not offer options to terminate the leases before the end of the lease term. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of lease income are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales-type lease selling price </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product revenue, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of underlying asset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating profit</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income on the lease receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest and other income, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Initial direct costs incurred</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease Income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product revenue, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net investment in sales-type leases are as follows: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease payment receivable, current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net and Notes receivable, current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease payment receivable, long-term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes receivable, long-term and Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">475</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total lease payment receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">978</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equipment under lease is stated at cost less accumulated depreciation and is classified as &#8220;Property and equipment, net&#8221; on the Condensed Consolidated Balance Sheets. Depreciation is computed using the straight-line method over an estimated useful life of the greater of the lease term or </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">. Equipment under lease is as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equipment under lease</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,758</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,698</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,665</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equipment under lease, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,864</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maturities of sales-type lease receivables as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019 (Remaining six months)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">394</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total undiscounted cash flows</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,039</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Present value of lease payments (recognized as lease receivables)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Difference between undiscounted and discounted cash flows</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maturities of operating lease receivables as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019 (Remaining six months)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,587</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total undiscounted cash flows</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,557</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">. Notes and Other Long-Term Receivables</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes and other long-term receivables included the following significant agreements:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Wellstat Diagnostics Note Receivable and Credit Agreement and Related Litigation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 2, 2012, the Company and Wellstat Diagnostics entered into a </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> credit agreement pursuant to which the Company was to accrue quarterly interest payments at the rate of </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> per annum (payable in cash or in kind). In addition, the Company was to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics&#8217; net revenues, generated by the sale, distribution or other use of Wellstat Diagnostics&#8217; products, if any, commencing upon the commercialization of its products. A portion of the proceeds of the </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> credit agreement were used to repay certain notes receivable which Wellstat Diagnostics entered into in March 2012.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2013, the Company was informed that, as of December 31, 2012, Wellstat Diagnostics had used funds contrary to the terms of the credit agreement and breached Sections 2.1.2 and 7 of the credit agreement. The Company sent Wellstat Diagnostics a notice of default on January 22, 2013, and accelerated the amounts owed under the credit agreement. In connection with the notice of default, the Company exercised one of its available remedies and transferred approximately </font><font style="font-family:inherit;font-size:10pt;">$8.1 million</font><font style="font-family:inherit;font-size:10pt;"> of available cash from a bank account of Wellstat Diagnostics to the Company and applied the funds to amounts due under the credit agreement. On February 28, 2013, the parties entered into a forbearance agreement whereby the Company agreed to refrain from exercising additional remedies for </font><font style="font-family:inherit;font-size:10pt;">120</font><font style="font-family:inherit;font-size:10pt;"> days. During such forbearance period, the Company provided approximately </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> to Wellstat Diagnostics to fund ongoing operations of the business. During the year ended December 31, 2013, approximately </font><font style="font-family:inherit;font-size:10pt;">$8.7 million</font><font style="font-family:inherit;font-size:10pt;"> was advanced pursuant to the forbearance agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 15, 2013, the Company entered into an amended and restated credit agreement with Wellstat Diagnostics. The Company determined that the new agreement should be accounted for as a modification of the existing agreement. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except as otherwise described herein, the material terms of the amended and restated credit agreement are substantially the same as those of the original credit agreement, including quarterly interest payments at the rate of </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> per annum (payable in cash or in kind). In addition, the Company was to continue to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics&#8217; net revenues. However, pursuant to the amended and restated credit agreement: (i) the principal amount was reset to approximately </font><font style="font-family:inherit;font-size:10pt;">$44.1 million</font><font style="font-family:inherit;font-size:10pt;">, which was comprised of approximately </font><font style="font-family:inherit;font-size:10pt;">$33.7 million</font><font style="font-family:inherit;font-size:10pt;"> original loan principal and interest, </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> term loan principal and interest and </font><font style="font-family:inherit;font-size:10pt;">$9.1 million</font><font style="font-family:inherit;font-size:10pt;"> forbearance principal and interest; (ii) the specified internal rates of return increased; (iii) the default interest rate was increased; (iv) Wellstat Diagnostics&#8217; obligation to provide certain financial information increased in frequency to monthly; (v) internal financial controls were strengthened by requiring Wellstat Diagnostics to maintain an independent, third-party financial professional with control over fund disbursements; (vi) the Company waived the existing events of default; and (vii) the owners and affiliates of Wellstat Diagnostics were required to contribute additional capital to Wellstat Diagnostics upon the sale of an affiliate entity. The amended and restated credit agreement had an ultimate maturity date of December 31, 2021 (but has subsequently been accelerated as described below).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, the Company received information from Wellstat Diagnostics showing that it was generally unable to pay its debts as they became due, constituting an event of default under the amended and restated credit agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 5, 2014, the Company delivered a notice of default (the &#8220;Wellstat Diagnostics Borrower Notice&#8221;) to Wellstat Diagnostics, which accelerated all obligations under the amended and restated credit agreement and demanded immediate payment in full in an amount equal to approximately </font><font style="font-family:inherit;font-size:10pt;">$53.9 million</font><font style="font-family:inherit;font-size:10pt;">, (which amount, in accordance with the terms of the amended and restated credit agreement, included an amount that, together with interest and royalty payments already made to the Company, would generate a specified internal rate of return to the Company), plus accruing fees, costs and interest, and demanded that Wellstat Diagnostics protect and preserve all collateral securing its obligations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 7, 2014, the Company delivered a notice (the &#8220;Wellstat Diagnostics Guarantor Notice&#8221;) to each of the guarantors of Wellstat Diagnostics&#8217; obligations to the Company (collectively, the &#8220;Wellstat Diagnostics Guarantors&#8221;) under the credit agreement, which included a demand that the guarantors remit payment to the Company in the amount of the outstanding obligations. The guarantors include certain affiliates and related companies of Wellstat Diagnostics, including Wellstat Therapeutics and Wellstat Diagnostics&#8217; stockholders.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 24, 2014, the Company filed an ex-parte petition for appointment of receiver with the Circuit Court of Montgomery County, Maryland (the &#8220;Wellstat Diagnostics Petition&#8221;), which was granted on the same day. Wellstat Diagnostics remained in operation during the period of the receivership with incremental additional funding from the Company. On May 24, 2017, Wellstat Diagnostics transferred substantially all of its assets to the Company pursuant to a credit bid. The credit bid reduced the outstanding balance of the loan by an immaterial amount.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 4, 2015, the Company filed in the Supreme Court of New York a motion for summary judgment in lieu of complaint which requested that the court enter judgment against certain of the Wellstat Diagnostics Guarantors for the total amount due on the Wellstat Diagnostics debt, plus all costs and expenses including lawyers&#8217; fees incurred by the Company in enforcement of the related guarantees. On September 23, 2015, the Company filed in the same court an ex parte application for a temporary restraining order and order of attachment of the Wellstat Diagnostics Guarantor defendants&#8217; assets. Although the court denied the Company&#8217;s request for a temporary restraining order at a hearing on September 24, 2015, it ordered that assets of the Wellstat Diagnostics Guarantor defendants should be held in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">status quo ante</font><font style="font-family:inherit;font-size:10pt;"> and only used in the normal course of business.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 29, 2016, the Supreme Court of New York granted the Company&#8217;s motion for summary judgment and held that the Wellstat Diagnostics Guarantor defendants are liable for all &#8220;Obligations&#8221; owed by Wellstat Diagnostics to the Company.&#160;After appeal by the Wellstat Diagnostics Guarantor defendants on February 14, 2017, the Appellate Division of the Supreme Court of New York reversed on procedural grounds a portion of the Memorandum of Decision granting the Company summary judgment in lieu of complaint, but affirmed the portion of the Memorandum of Decision denying the Wellstat Diagnostics Guarantor defendants&#8217; motion for summary judgment in which they sought a determination that the guarantees had been released. As a result, the litigation has been remanded to the Supreme Court of New York to proceed on the Company&#8217;s claims as a plenary action. On June 21, 2017, the Supreme Court of New York ordered the Company to file a Complaint, which was filed by the Company on July 20, 2017. The Wellstat Diagnostics Guarantors filed their answer on August 9, 2017, including counterclaims against the Company alleging breach of contract, breach of fiduciary duty, and tortious interference with prospective economic advantage. This case is currently pending and in the pre-trial phase.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 14, 2016, the Company sent a notice of default and reference to foreclosure proceedings to certain of the Wellstat Diagnostics Guarantors which are not defendants in the New York action, but which are owners of real estate assets over which a deed of trust in favor of the Company securing the guarantee of the loan to Wellstat Diagnostics had been executed. On March 2, 2017, the Company sent a second notice to foreclose on the real estate assets, and noticed the sale for March 29, 2017. The sale was taken off the calendar by the trustee under the deed of trust and has not been re-scheduled yet. On March 6, 2017, the Company sent a letter to the Wellstat Diagnostics Guarantors seeking information in preparation for a UCC Article 9 sale of some or all of the intellectual property-related collateral of the Wellstat Diagnostics Guarantors. The Wellstat Diagnostics Guarantors did not respond to the Company&#8217;s letter, but on March 17, 2017, filed an order to show cause with the Supreme Court of New York to enjoin the Company&#8217;s sale of the real estate or enforcing its security interests in the Wellstat Diagnostics Guarantors&#8217; intellectual property during the pendency of any action involving the guarantees at issue. On February 6, 2018, the Supreme Court of New York issued an order from the bench which enjoins the Wellstat Diagnostics Guarantors from selling, encumbering, removing, transferring or altering the collateral pending the outcome of the proceedings before it. The Supreme Court of New York also issued an order precluding the Company from foreclosing on certain of the Wellstat Diagnostics Guarantors&#8217; collateral pending the outcome of the proceedings before it. In September of 2018, discovery in the New York action was completed. Summary judgment motions were filed by Wellstat Diagnostics and the Company in 2018 and a hearing was held on May 22, 2019. The court has not yet issued a decision on the motions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In an unrelated litigation, Wellstat Therapeutics filed a lawsuit against BTG International, Inc. for breach of contract (the &#8220;BTG Litigation&#8221;). In September 2017, the Delaware Chancery Court found in favor of Wellstat Therapeutics and awarded a judgment of </font><font style="font-family:inherit;font-size:10pt;">$55.8 million</font><font style="font-family:inherit;font-size:10pt;"> in damages, plus interest. In October 2017, the Company filed a motion with the Supreme Court of New York requesting a pre-judgement attachment of the award. In June 2018, the Delaware Supreme Court largely affirmed the September 2017 decision of the Delaware Chancery Court, including the </font><font style="font-family:inherit;font-size:10pt;">$55.8 million</font><font style="font-family:inherit;font-size:10pt;"> awarded in judgment. In August of 2018, in a letter to the Company&#8217;s counsel, Wellstat Guarantors&#8217; counsel confirmed that the Wellstat Guarantors are preserving the BTG Litigation judgment award proceeds consistent with the New York Court&#8217;s prior directions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 22, 2015, certain of the Wellstat Diagnostics Guarantors filed a separate complaint against the Company in the Supreme Court of New York seeking a declaratory judgment that certain contractual arrangements entered into between the parties subsequent to Wellstat Diagnostics&#8217; default, and which relate to a split of proceeds in the event that the Wellstat Diagnostics Guarantors voluntarily monetize any assets that are the Company&#8217;s collateral, is of no force or effect. This case has been joined for all purposes, including discovery and trial, and consolidated with the pending case filed by the Company. The Wellstat Diagnostic Guarantors filed a summary judgment motion with regard to this case, which was also heard by the court at the hearing on May 22, 2019. The court has not yet issued a decision on this motion.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective April 1, 2014, and as a result of the event of default, the Company determined the loan to be impaired and it ceased to accrue interest revenue. At that time and as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, it has been determined that an allowance on the carrying value of the note was not necessary, as the Company believes the value of the collateral securing Wellstat Diagnostics&#8217; obligations exceeds the carrying value of the asset and is sufficient to enable the Company to recover the current carrying value of </font><font style="font-family:inherit;font-size:10pt;">$50.2 million</font><font style="font-family:inherit;font-size:10pt;">. The Company continues to closely monitor the timing and expected recovery of amounts due, including litigation and other matters related to Wellstat Diagnostics Guarantors&#8217; assets. There can be no assurance that an allowance on the carrying value of the notes receivable investment will not be necessary in a future period depending on future developments.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hyperion Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 27, 2012, the Company and Hyperion (which is also a Wellstat Diagnostics Guarantor) entered into an agreement whereby Hyperion sold to the Company the royalty streams accruing from January 1, 2012 through December 31, 2013 due from Showa Denko K.K. (&#8220;SDK&#8221;) related to a certain patent license agreement between Hyperion and SDK dated December 31, 2008. In exchange for the lump sum payment to Hyperion of </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">, in addition to any royalties from SDK, the Company was to receive </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> equal payments of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> on March 5, 2013 and March 5, 2014. The first payment of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> was paid on March 5, 2013, but the second payment that was due on March 5, 2014 has not been made by Hyperion. Effective as of such date and as a result of the event of default, the Company ceased to accrue interest revenue. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the estimated fair value of the collateral was determined to be in excess of the carrying value. There can be no assurance of realizing value from such collateral in the event of the Company&#8217;s foreclosure on the collateral.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Avinger Credit and Royalty Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 18, 2013, the Company entered into a credit agreement with Avinger, Inc. (the &#8220;Avinger Credit and Royalty Agreement&#8221;). Under the terms of the Avinger Credit and Royalty Agreement, the Company received a low, single-digit royalty on Avinger&#8217;s net revenues until April 2018. Commencing in October 2015, after Avinger repaid </font><font style="font-family:inherit;font-size:10pt;">$21.4 million</font><font style="font-family:inherit;font-size:10pt;"> pursuant to its note payable to the Company prior to its maturity date, the royalty on Avinger&#8217;s net revenues was reduced by </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">, subject to certain minimum payments from the prepayment date until April 18, 2018. The Company accounted for the royalty rights in accordance with the fair value option. As of April 18, 2018, there were no further obligations owed to the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">CareView Credit Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 26, 2015, the Company entered into a credit agreement with CareView, under which the Company made available to CareView up to </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> in loans comprised of two tranches of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> each, subject to CareView&#8217;s attainment of specified milestones relating to the placement of CareView Systems. On October 7, 2015, the Company and CareView entered into an amendment of the credit agreement to modify certain definitions related to the first and second tranche milestones and the Company funded the first tranche of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">, net of fees, based on CareView&#8217;s attainment of the first milestone, as amended. The second </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> tranche was not funded due to CareView&#8217;s failure to achieve the related funding milestones and there is no additional funding obligation due from the Company. Outstanding borrowings under the credit agreement bear interest at the rate of </font><font style="font-family:inherit;font-size:10pt;">13.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum and are payable quarterly in arrears.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the original credit agreement, the Company received a warrant to purchase approximately </font><font style="font-family:inherit;font-size:10pt;">4.4 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock of CareView at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.45</font><font style="font-family:inherit;font-size:10pt;"> per share. The Company has accounted for the warrant as derivative asset with an offsetting credit as debt discount. At each reporting period the warrant is marked to market for changes in fair value.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the October 2015 amendment of the credit agreement, the Company and CareView also agreed to amend the warrant to purchase common stock agreement by reducing the warrant&#8217;s exercise price from </font><font style="font-family:inherit;font-size:10pt;">$0.45</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$0.40</font><font style="font-family:inherit;font-size:10pt;"> per share. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the Company entered into a modification agreement with CareView (the &#8220;February 2018 Modification Agreement&#8221;) whereby the Company agreed, effective December 28, 2017, to modify the credit agreement before remedies could otherwise have become available to the Company under the credit agreement in relation to certain obligations of CareView that would potentially not be met, including the requirement to make principal payments. Under the February 2018 Modification Agreement, the Company agreed that (i) a lower liquidity covenant would be applicable and (ii) principal repayment would be delayed until December 31, 2018. In exchange for agreeing to these modifications, among other things, the exercise price of the Company&#8217;s warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">4.4 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock of CareView was repriced from </font><font style="font-family:inherit;font-size:10pt;">$0.40</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$0.03</font><font style="font-family:inherit;font-size:10pt;"> per share and, subject to the occurrence of certain events, CareView agreed to grant the Company additional equity interests. As a result of the February 2018 Modification Agreement, the Company determined the loan to be impaired and it ceased to accrue interest revenue effective October 1, 2017. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2018, the Company entered into an amendment to the February 2018 Modification Agreement with CareView whereby the Company agreed, effective as of September 28, 2018, that a lower liquidity covenant would be applicable. In December 2018, the Company further modified the loan by agreeing that (i) a lower liquidity covenant would be applicable, (ii) the first principal payment would be deferred until January 31, 2019, and (iii) the scheduled interest payment due December 31, 2018 would be deferred until January 31, 2019. In December 2018, and in consideration of the further modification to the credit agreement, the Company completed an impairment analysis and determined that the note was impaired and recorded an impairment loss of </font><font style="font-family:inherit;font-size:10pt;">$8.2 million</font><font style="font-family:inherit;font-size:10pt;">. For additional information see Note 5, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:inherit;font-size:10pt;">. As of March 31, 2019, the principal repayment and interest payments were deferred until April 30, 2019. The principal repayment and interest payment were subsequently deferred until May 15, 2019. In May 2019, and in consideration of additional capital raised by CareView, the Company further modified the loan by agreeing that (i) the first principal and interest payments would be deferred until September 30, 2019 and (ii) the remaining liquidity covenant would be removed. As of June 30, 2019, the Company performed an analysis and determined that no additional impairment was required and estimated the fair value of the warrants to be less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">. Convertible Senior Notes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal Balance Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Carrying Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturity Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible Senior Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2021 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 1, 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,520</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,644</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,520</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,644</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">February 2018 Notes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 12, 2014, the Company issued </font><font style="font-family:inherit;font-size:10pt;">$300.0 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount, at par, of the February 2018 Notes in an underwritten public offering, for net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$290.2 million</font><font style="font-family:inherit;font-size:10pt;">. The February 2018 Notes were due February 1, 2018. In November 2015, </font><font style="font-family:inherit;font-size:10pt;">$53.6 million</font><font style="font-family:inherit;font-size:10pt;">&#160;in aggregate principal amount of the February 2018 Notes were repurchased and in November 2016 an additional </font><font style="font-family:inherit;font-size:10pt;">$120.0 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of the February 2018 Notes were repurchased in open market transactions.&#160;In connection with these repurchases, the Company unwound a corresponding portion of the purchased call options and warrants related to the notes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 1, 2018, upon maturity of the February 2018 Notes, the Company repaid a total cash amount of </font><font style="font-family:inherit;font-size:10pt;">$129.0 million</font><font style="font-family:inherit;font-size:10pt;"> to the custodian, The Bank of New York Mellon Trust Company, N.A., which was comprised of </font><font style="font-family:inherit;font-size:10pt;">$126.4 million</font><font style="font-family:inherit;font-size:10pt;"> in principal amount and </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;"> in accrued interest, to retire the February 2018 Notes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense for the February 2018 Notes on the Company&#8217;s Condensed Consolidated Statements of Operations was as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual coupon interest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">421</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">293</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">802</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">December 2021 Notes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 22, 2016, the Company issued </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount, at par, of the December 2021 Notes in an underwritten public offering, for net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$145.7 million</font><font style="font-family:inherit;font-size:10pt;">. The December 2021 Notes are due December 1, 2021, and the Company pays interest at </font><font style="font-family:inherit;font-size:10pt;">2.75%</font><font style="font-family:inherit;font-size:10pt;"> on the December 2021 Notes semiannually in arrears on June 1 and December 1 of each year, beginning June 1, 2017. A portion of the proceeds from the December 2021 Notes, net of amounts used for the capped call transaction described below, was used to extinguish </font><font style="font-family:inherit;font-size:10pt;">$120.0 million</font><font style="font-family:inherit;font-size:10pt;"> of the February 2018 Notes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the occurrence of a fundamental change, as defined in the indenture entered into in connection with the December 2021 Notes (the &#8220;December 2021 Notes Indenture&#8221;), holders have the option to require the Company to repurchase their December 2021 Notes at a purchase price equal to </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the principal, plus accrued interest.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The December 2021 Notes are convertible under any of the following circumstances:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During any fiscal quarter (and only during such fiscal quarter) commencing after the fiscal quarter ended June 30, 2017, if the last reported sale price of Company common stock for at least </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive), in the period of </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days, ending on, and including, the last trading day of the immediately preceding fiscal quarter, exceeds </font><font style="font-family:inherit;font-size:10pt;">130%</font><font style="font-family:inherit;font-size:10pt;"> of the conversion price for the notes on each applicable trading day;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the five business-day period immediately after any five consecutive trading-day period, which the Company refers to as the measurement period, in which the trading price per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount of notes for each trading day of that measurement period was less than </font><font style="font-family:inherit;font-size:10pt;">98%</font><font style="font-family:inherit;font-size:10pt;"> of the product of the last reported sale price of Company common stock and the conversion rate for the notes for each such trading day; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the occurrence of specified corporate events as described in the December 2021 Notes Indenture.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The initial conversion rate for the December 2021 Notes is </font><font style="font-family:inherit;font-size:10pt;">262.2951</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount of December 2021 Notes, which is equivalent to an initial conversion price of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.81</font><font style="font-family:inherit;font-size:10pt;"> per share of common stock, subject to adjustments upon the occurrence of certain specified events as set forth in the December 2021 Notes Indenture.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion, the Company was required to separately account for the liability component of the instrument in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. As a result, the Company separated the principal balance of the December 2021 Notes between the fair value of the debt component and the fair value of the common stock conversion feature. Using an assumed borrowing rate of </font><font style="font-family:inherit;font-size:10pt;">9.5%</font><font style="font-family:inherit;font-size:10pt;">, which represented the estimated market interest rate for a similar nonconvertible instrument available to the Company on the date of issuance, the Company recorded a total debt discount of </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;">, allocated </font><font style="font-family:inherit;font-size:10pt;">$23.8 million</font><font style="font-family:inherit;font-size:10pt;"> to additional paid-in capital and allocated </font><font style="font-family:inherit;font-size:10pt;">$12.8 million</font><font style="font-family:inherit;font-size:10pt;"> to deferred tax liability. The discount is being amortized to interest expense over the term of the December 2021 Notes and increases interest expense during the term of the December 2021 Notes from the </font><font style="font-family:inherit;font-size:10pt;">2.75%</font><font style="font-family:inherit;font-size:10pt;"> cash coupon interest rate to an effective interest rate of </font><font style="font-family:inherit;font-size:10pt;">3.4%</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the remaining discount amortization period is </font><font style="font-family:inherit;font-size:10pt;">2.4 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying value and unamortized discount of the December 2021 Notes were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount of the December 2021 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized discount of liability component</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,480</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,356</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net carrying value of the December 2021 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,520</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,644</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense for the December 2021 Notes on the Company&#8217;s Condensed Consolidated Statements of Operations was as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual coupon interest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,032</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,062</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of conversion feature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,794</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,626</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,984</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,811</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,939</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,594</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the December 2021 Notes are not convertible.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Capped Call Transaction</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">In connection with the offering of the December 2021 Notes, the Company entered into a privately-negotiated capped call transaction with an affiliate of the underwriter of such issuance.&#160;The aggregate cost of the&#160;capped call&#160;transaction was&#160;</font><font style="font-family:inherit;font-size:10pt;">$14.4 million</font><font style="font-family:inherit;font-size:10pt;">. The&#160;capped call&#160;transaction is generally expected to reduce the potential dilution upon conversion of the December 2021 Notes and/or partially offset any cash payments the Company is required to make in excess of the principal amount of converted December 2021 Notes in the event that the market price per share of the Company&#8217;s common stock, as measured under the terms of the&#160;capped call&#160;transaction, is greater than the strike price of the&#160;capped call&#160;transaction. This initially corresponds to the approximate&#160;</font><font style="font-family:inherit;font-size:10pt;">$3.81</font><font style="font-family:inherit;font-size:10pt;"> per share conversion price of the December 2021 Notes and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of the December 2021 Notes. The cap price of the&#160;capped call&#160;transaction was initially&#160;</font><font style="font-family:inherit;font-size:10pt;">$4.88</font><font style="font-family:inherit;font-size:10pt;"> per share, and is subject to certain adjustments under the terms of the&#160;capped call&#160;transaction. The Company will not be required to make any cash payments to the option counterparty upon the exercise of the options that are a part of the capped call transaction, but the Company will be entitled to receive from it an aggregate amount of cash and/or number of shares of the Company&#8217;s common stock, based on the settlement method election chosen for the related convertible senior notes, with a value equal to the amount by which the market price per share of the Company&#8217;s common stock, as measured under the terms of the capped call transaction, is greater than the strike price of the capped call transaction during the relevant valuation period under the capped call transaction, with such number of shares of the Company&#8217;s common stock and/or amount of cash subject to the cap price.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the&#160;capped call&#160;transaction under authoritative accounting guidance and determined that it should be accounted for as separate transaction and classified as a net reduction to additional paid-in capital within stockholders&#8217; equity with no recurring fair value measurement recorded.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adopted Accounting Pronouncements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Leases,</font><font style="font-family:inherit;font-size:10pt;"> that supersedes Accounting Standards Codification (&#8220;ASC&#8221;) 840, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">. Subsequently, the FASB issued several updates to ASU No. 2016-02, codified in ASC Topic 842 (&#8220;ASC 842&#8221;). The Company adopted ASC 842, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases, </font><font style="font-family:inherit;font-size:10pt;">on January 1, 2019 using the modified retrospective method for all leases not substantially completed as of the date of adoption. The reported results for the three and </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> reflect the application of ASC 842 guidance while the reported results for the three and </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> were prepared under the guidance of ASC 840, which is also referred to herein as &#8220;legacy GAAP&#8221; or the &#8220;previous guidance&#8221;. The cumulative impact of the adoption of ASC 842 was not material, therefore, the Company did not record any adjustments to retained earnings. As a result of adopting ASC 842, the Company recorded operating lease right-of-use (&#8220;ROU&#8221;) assets of </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;"> and operating lease liabilities of </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">, primarily related to corporate office leases, based on the present value of the future lease payments on the date of adoption. Changes to lessor accounting focused on conforming with certain changes made to lessee accounting and the recently adopted revenue recognition guidance. The adoption of ASC 842 did not materially change how the Company accounts for lessor arrangements.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Policy Elections and Practical Expedients Taken</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For leases that commenced before the effective date of ASC 842, the Company elected the practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted a policy of expensing short-term leases, defined as </font><font style="font-family:inherit;font-size:10pt;">12 months</font><font style="font-family:inherit;font-size:10pt;"> or less, as incurred.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has a policy to exclude from the consideration in a lessor contract all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific lease revenue-producing transaction and collected by the Company from a lessee.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determines if an arrangement is a lease or contains an embedded lease at inception. The Company has lease arrangements with lease and non-lease components, which are accounted for separately. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Lessee arrangements</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lessee operating leases are included in Other assets, Accrued liabilities, and Other long-term liabilities in the Company&#8217;s Condensed Consolidated Balance Sheet. The Company does not have lessee financing leases.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses the implicit rate when readily determinable at lease inception. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company&#8217;s remaining lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis as operating expense in the Condensed Consolidated Statements of Operations over the lease term. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Lessor arrangements</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leases medical device equipment to customers in both operating lease and sales-type lease arrangements generated from its Medical Devices segment. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For sales-type leases, the Company derecognizes the carrying amount of the underlying asset and capitalizes the net investment in the lease, which consists of the total minimum lease payments receivable from the lessee, at lease inception. The Company does not estimate an unguaranteed residual value of the equipment at lease termination because the equipment transfers to the lessee upon completion of the lease. Selling profit or loss is recognized at lease inception. Initial direct costs are recognized as an expense, unless there is no selling profit or loss. If there is no selling profit or loss, initial direct costs are deferred and recognized over the lease term. The Company recognizes interest income from the lease receivable over the lease term in Interest and other income, net in the Condensed Consolidated Statements of Operations. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For operating leases, rental income is recognized on a straight-line basis over the lease term. The cost of customer-leased equipment is recorded within Property and equipment, net in the accompanying Condensed Consolidated Balance Sheets and depreciated over the equipment&#8217;s estimated useful life. Depreciation expense associated with the leased equipment under operating lease arrangements is reflected in Cost of product revenue in the accompanying Condensed Consolidated Statements of Operations. Some of the Company&#8217;s operating leases include a purchase option for the customer to purchase the leased asset at the end of the lease arrangement. The Company manages its risk on its investment in the equipment through pricing and the term of the leases. Lessees do not provide residual value guarantees on leased equipment. Equipment returned to the Company may be leased or sold to other customers. Initial direct costs are deferred and recognized over the lease term. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leases are generally not cancellable until after an initial term and may or may not require the customer to purchase a minimum number of procedures and consumables throughout the contract term.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For lease arrangements with lease and non-lease components where the Company is the&#160;lessor, the Company allocates the contract&#8217;s transaction price to the lease and non-lease components on a relative standalone selling price basis using the Company&#8217;s best estimate of the standalone selling price of each distinct product or service in the contract. Allocation of the transaction price is determined at the inception of the lease arrangement. The Company&#8217;s leases primarily consist of leases with fixed lease payments. For those leases with variable lease payments, the variable lease payment is typically based upon use of the leased equipment or the purchase of procedure licenses and consumables used with the leased equipment. Non-lease components are accounted for under ASC 606, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers. </font><font style="font-family:inherit;font-size:10pt;">For additional information regarding ASC 606, see Note 15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangibles-Goodwill and Other</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other: Simplifying the Test for Goodwill Impairment</font><font style="font-family:inherit;font-size:10pt;">, to simplify the subsequent measurement of goodwill by eliminating step two from the goodwill impairment test. Under the amendments, an entity will recognize an impairment charge for the amount by which the carrying value exceeds the fair value. The amendments are effective for fiscal years and interim periods within those years beginning after December 15, 2019 on a prospective basis and early adoption is permitted. The Company adopted the requirements of ASU No. 2017-04 on January 1, 2019. The adoption did not have an effect on the Company&#8217;s Consolidated Financial Statements on the adoption date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments</font><font style="font-family:inherit;font-size:10pt;">. The new guidance amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses. ASU No. 2016-13 has an effective date of the fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is currently evaluating the impact of this guidance on its Consolidated Financial Statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU No. 2018-13,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">.&#160;The new guidance modifies disclosure requirements related to fair value measurement.&#160;The amendments in ASU No. 2018-13 are effective for fiscal years, and interim periods within those fiscal years,&#160;beginning after December 15, 2019.&#160;Implementation on a prospective or retrospective basis varies by specific disclosure requirement.&#160;Early adoption is permitted. The standard also allows for early adoption of any removed or modified disclosures upon issuance of ASU No. 2018-13 while delaying adoption of the additional disclosures until their effective date. The Company is currently evaluating the impact of this guidance on the its Consolidated Financial Statement disclosures. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU No. 2018-15,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software</font><font style="font-family:inherit;font-size:10pt;">.&#160;The new guidance reduces complexity for the accounting for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license).&#160;For public companies, the amendments in ASU No. 2018-15 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted.&#160;Implementation should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption.&#160;The Company is currently evaluating the impact of this guidance on the Company&#8217;s Consolidated Financial Statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11. Other Long-Term Liabilities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Uncertain tax positions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,402</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,706</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,803</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,847</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued lease guarantee</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term incentive accrual</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,130</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">465</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,181</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,843</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15. Revenue from Contracts with Customers</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Nature of Goods and Services</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a description of principal activities - separated by reportable segments - from which the Company generates its revenue. For more detailed information about reportable segments, see Note 16, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Segment Information</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pharmaceutical</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Pharmaceutical segment consists of revenue derived from the branded prescription Noden Products and the authorized generic launched in March 2019.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The agreement between Novartis and Noden DAC provides for various transition periods for development and commercialization activities relating to the Noden Products. Initially, Novartis distributed the Noden Products on behalf of Noden DAC worldwide and Noden DAC received a profit transfer on such sales. Generally, the profit transfer to Noden DAC was defined as gross revenues less product cost and a low single-digit percentage fee to Novartis. The profit transfer terminated upon the transfer of the marketing authorization from Novartis to Noden DAC in each country. In the United States, the duration of the profit transfer ran from July 1, 2016 through October 4, 2016. Outside the United States, the profit transfer ended in the first quarter of 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the transfer of the marketing authorization, revenue was presented on a &#8220;net&#8221; basis; after the transfer of the marketing authorization, revenue is presented on a &#8220;gross&#8221; basis, meaning product costs are reported separately and there is no fee to Novartis. Except for the sales outside of the United States preceding the final profit transfer that occurred in the first quarter of 2018, revenues of the Noden Products for the periods herein are presented on a gross basis.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noden USA launched an authorized generic of Tekturna in the United States in March 2019.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Pharmaceutical segment principally generates revenue from products sold to wholesalers and distributors. Customer orders are generally fulfilled within a few days of receipt resulting in minimal order backlog. Contractual performance obligations are usually limited to transfer of the product to the customer. The transfer occurs either upon shipment or upon receipt of the product in certain countries outside the United States after considering when the customer obtains control of the product. In addition, for some non-U.S. countries, the Company sells product on a consignment basis where control is not transferred until the customer resells the product to an end user. At these points, customers are able to direct the use of and obtain substantially all of the remaining benefits of the product.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales to customers are initially invoiced at contractual list prices. Payment terms are typically </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days based on customary practice in each country. Revenue is reduced from the list price at the time of recognition for expected chargebacks, discounts, rebates, sales allowances and product returns, which are collectively referred to as gross-to-net adjustments. These reductions are attributed to various commercial agreements, managed healthcare organizations and government programs such as Medicare, Medicaid, and the 340B Drug Pricing Program containing various pricing implications such as mandatory discounts, pricing protection below wholesaler list price and other discounts when Medicare Part D beneficiaries are in the coverage gap. These various reductions in the transaction price have been estimated using either a most likely amount, in the case of prompt pay discounts, or expected value method for all other variable consideration and have been reflected as liabilities and are settled through cash payments, typically within time periods ranging from a few months to one year. Significant judgment is required in estimating gross-to-net adjustments considering legal interpretations of applicable laws and regulations, historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, processing time lags and inventory levels in the distribution channel.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front license fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Medical Devices</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Medical Devices segment principally generates revenue from the sale and lease of the LENSAR</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">Laser System, which may include equipment, PIDs or consumables, procedure licenses, training, installation, warranty and maintenance agreements. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For bundled packages, the Company accounts for individual products and services separately if they are distinct - i.e. if a product or service is separately identifiable from other items in the bundled package and if the customer can benefit from it on its own or with other resources that are readily available to the customer. The LENSAR</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Laser System, standard warranty training and installation services are one performance obligation. All other elements are separate performance obligations. PIDs, procedure licenses, warranty and maintenance services are also sold on a stand-alone basis.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As the Company both sells and leases the LENSAR</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">Laser System, the consideration (including any discounts) is first allocated between lease and non-lease components and then allocated between the separate products and services based on their stand-alone selling prices. The stand-alone selling prices for the PIDs and procedure licenses are determined based on the prices at which the Company separately sells the PIDs and procedure licenses. The LENSAR</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">Laser System and warranty stand-alone selling prices are determined using the expected cost plus a margin approach. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For LENSAR</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">Laser System sales, the Company recognizes Product revenue when a customer takes possession of the system. This usually occurs after the customer signs a contract, LENSAR installs the system, and LENSAR performs the requisite training for use of the system. For LENSAR</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">Laser System leases, the Company recognized Product revenue over the length of the lease in accordance with ASC Topic 840, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">, through December 31, 2018 and recognized Product revenue in accordance with ASC Topic 842, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">, after January 1, 2019. For additional information regarding accounting for leases, see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7, Leases</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The LENSAR</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">Laser System requires both a consumable and a procedure license to perform each procedure. The Company recognizes Product revenue for PIDs when the customer takes possession of the PID. PIDs are sold by the case. The Company recognizes Product revenue for procedure licenses when a customer purchases a procedure license from the web portal. Typically, consideration for PIDs and procedure licenses is considered fixed consideration except for certain customer agreements that provide for tiered volume discount pricing which is considered variable consideration.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company offers an extended warranty that provides additional services beyond the standard warranty. The Company recognizes Product revenue from the sale of extended warranties over the warranty period. Customers have the option of renewing the warranty period, which is considered a new and separate contract.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Generating Assets</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For licenses of intellectual property, if the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2018, DFM, LLC, a wholly-owned subsidiary of the Company, granted an exclusive license related to certain Direct Flow Medical, Inc. assets in exchange for </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and up to </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> in royalty payments. The </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> payment was accounted for in accordance with ASC 606 under which the full cash payment was recognized as revenue in the first quarter of 2018 as DFM, LLC had fulfilled its performance obligation under the agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disaggregation of Revenue</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company disaggregates its revenue from contracts with customers by segment and geographic location as the Company believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. In the following table, revenue is disaggregated by segment and primary geographical market for the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Primary geographical markets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">North America</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,203</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,038</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,776</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Europe</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">705</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,093</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,923</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,643</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,732</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue from contracts with customers</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,067</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,415</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,044</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,879</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Primary geographical markets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">North America</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,287</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,176</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,319</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,707</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Europe</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,036</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,362</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,163</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,757</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,152</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue from contracts with customers</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,556</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,375</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,590</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,221</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_______________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The tables above do not include lease revenue from the Company&#8217;s Medical Devices segment. For the three-month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, revenue accounted for under Topic 842 and 840, Leases, was </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively and for the six-month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. For additional information, see Note 7, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contract Balances</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides information about receivables, contract assets and contract liabilities from contracts with customers:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Receivables, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,872</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,214</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,595</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,938</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Receivables, Net</font><font style="font-family:inherit;font-size:10pt;">&#8212;Receivables, net, include amounts billed and due from customers. The amounts due are stated at their net estimated realizable value and are classified as current or noncurrent based on the timing of when the Company expects to receive payment. The Company maintains an allowance for doubtful accounts to provide for the estimated amount of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and collateral to the extent applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contract assets</font><font style="font-family:inherit;font-size:10pt;">&#8212;The Company&#8217;s contract assets represent revenue recognized for performance obligations completed before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. The Company classifies contract assets in Prepaid and other current assets in the Company&#8217;s Condensed Consolidated Balance Sheets based on the timing of when it expects to receive payment.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,638</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,638</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments received</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets at June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,214</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,214</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contract Liabilities</font><font style="font-family:inherit;font-size:10pt;">&#8212;The Company&#8217;s contract liabilities consist of deferred revenue for products sold to customers for which the performance obligation has not been completed by the Company. The Company classifies deferred revenue as current or noncurrent based on the timing of when it expects to recognize revenue. The noncurrent portion of deferred revenue is included in Other long-term liabilities in the Company&#8217;s Condensed Consolidated Balance Sheets.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,938</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">537</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,855</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,392</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts recognized into revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(645</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,829</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,474</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities at June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,059</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,797</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,856</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Transaction Price Allocated to Future Performance Obligations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical product sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,326</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,442</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical device sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,347</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,986</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,333</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with original expected lengths of one year or less or (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for the products delivered or services performed.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical product sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,326</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,442</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical device sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,347</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,986</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,333</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of intangible assets as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Carrying Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finite-lived intangible assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired products rights</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,143</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,517</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,626</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,143</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,258</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,885</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) (2) (4)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,028</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,209</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,819</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,028</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired technology</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2) (3) (5)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,311</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,630</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,681</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,011</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,203</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,808</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired trademarks</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">570</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">323</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,052</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,603</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,449</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,752</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,433</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company acquired certain intangible assets as part of the Noden transaction. They are being amortized on a straight-line basis over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">eight years</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company acquired certain intangible assets as part of its acquisition of LENSAR in May 2017. They are being amortized on a straight-line basis over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">15 years</font><font style="font-family:inherit;font-size:10pt;">. The intangible assets for customer relationships are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company acquired certain intangible assets as part of the foreclosure on certain of Direct Flow Medical assets. They are being amortized on a straight-line basis over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">10 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,987</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,954</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,719</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">284,941</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">394,590</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal Balance Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Carrying Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturity Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible Senior Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2021 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 1, 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,520</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,644</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,520</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,644</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net (Loss) Income per Basic and Diluted Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands, except per share amounts)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Numerator</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Loss) income attributable to PDL&#8217;s shareholders used to compute net (loss) income per basic and diluted share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,419</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,261</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,694</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Denominator</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total weighted-average shares used to compute net (loss) income attributable to PDL&#8217;s shareholders, per basic share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,285</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,484</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149,186</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">507</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used to compute net (loss) income attributable to PDL&#8217;s shareholders, per diluted share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,285</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,923</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,040</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149,186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net (loss) income attributable to PDL&#8217;s shareholders per share - basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.76</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.74</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net (loss) income attributable to PDL&#8217;s shareholders per share - diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="33" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,954</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,954</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,719</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,719</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate securities</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,013</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,013</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty rights - at fair value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">315,642</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">315,642</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">376,510</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">376,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317,487</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">315,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">650,142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,719</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">376,510</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">603,291</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial liabilities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration, current</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,071</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,071</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,629</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Uncertain tax positions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,402</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,706</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,803</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,847</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued lease guarantee</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term incentive accrual</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,130</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">465</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,181</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,843</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The percentage of total revenue recognized, which individually accounted for 10% or more of the Company&#8217;s total revenues in one or more of the periods presented below, was as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:60%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noden</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assertio</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LENSAR</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">___________________</sup>&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three and six months ended June 30, 2019, the AcelRx royalty asset decrease in fair value of </font><font style="font-family:inherit;font-size:10pt;">$60.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$57.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, are excluded from total revenue when calculating product line concentration.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information regarding the Company&#8217;s segments for the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#160;is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues by segment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,422</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,882</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,148</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,864</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Strategic Positions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income Generating Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,363</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,814</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,136</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,526</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,575</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,387</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,093</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Loss) income by segment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(111,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(113,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,678</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,904</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,893</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,491</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Strategic Positions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,044</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,044</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income Generating Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,440</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">943</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,190</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,845</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net (loss) income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,419</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,261</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,694</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information regarding the Company&#8217;s segments as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Long-lived assets by segment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,681</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,545</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Strategic Positions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income Generating Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-lived assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,914</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,387</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the intangible assets recorded at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, and assuming no subsequent additions to or impairment of the underlying assets, the remaining amortization expense is expected to be as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019 (Remaining six months)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,394</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,257</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,030</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total remaining amortization expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,449</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16. Segment Information</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with its investment in Evofem in the second quarter of 2019, the Company added a fourth reportable segment, &#8220;Strategic Positions.&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information regarding the Company&#8217;s segments for the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#160;is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues by segment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,422</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,882</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,148</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,864</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Strategic Positions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income Generating Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,363</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,814</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,136</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,526</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,575</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,387</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,093</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Loss) income by segment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(111,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(113,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,678</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,904</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,893</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,491</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Strategic Positions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,044</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,044</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income Generating Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,440</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">943</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,190</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,845</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net (loss) income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,419</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,261</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,694</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information regarding the Company&#8217;s segments as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Long-lived assets by segment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,681</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,545</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Strategic Positions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income Generating Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-lived assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,914</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,387</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The operations for the Pharmaceutical and Medical Devices segments are primarily located in Italy, Ireland and the United States, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1. Summary of Significant Accounting Policies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited Condensed Consolidated Financial Statements of PDL Biopharma, Inc. and its subsidiaries (collectively, the &#8220;Company&#8221; or &#8220;PDL&#8221;) have been prepared in accordance with Generally Accepted Accounting Principles (United States) (&#8220;GAAP&#8221;) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments), that management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited Condensed Consolidated Financial Statements and related financial information should be read in conjunction with the Company&#8217;s audited Consolidated Financial Statements and the related notes thereto for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 15, 2019. The Condensed Consolidated Balance Sheet at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, included herein, has been derived from the audited Consolidated Financial Statements at that date, but does not include all disclosures required by GAAP.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying Notes to the Condensed Consolidated Financial Statements. The accounting estimates that require management&#8217;s most significant, difficult and subjective judgments include the valuation of royalty rights - at fair value, product revenue recognition and allowance for customer rebates and allowances, the valuation of notes receivable and inventory, the assessment of recoverability of intangible assets and their estimated useful lives, the valuation and recognition of stock-based compensation, the recognition and measurement of current and deferred income tax assets and liabilities, and the valuation of warrants to acquire shares of common stock. Actual results could differ from those estimates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Condensed Consolidated Financial Statements included herein include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the nature of the Company&#8217;s existing investments and how they are managed, the Company structured its operations in </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> segments designated as Pharmaceutical, Medical Devices, Strategic Positions and Income Generating Assets. During the second quarter of 2019 the Company made an investment in Evofem Biosciences, Inc. (&#8220;Evofem&#8221;) and added a new segment designated as Strategic Positions. This had no impact on its prior segment reporting structure. </font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> and Tekturna HCT</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> in the United States and Rasilez</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> and Rasilez HCT</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> in the rest of the world and an authorized generic form of Tekturna sold in the United States (collectively, the &#8220;Noden Products&#8221;). The branded prescription Noden Products were acquired from Novartis in July 2016 (the &#8220;Noden Transaction&#8221;) by the Company&#8217;s wholly-owned subsidiary, Noden Pharma DAC (&#8220;Noden DAC&#8221;). The Company, through its wholly-owned subsidiary, Noden Pharma USA Inc. (&#8220;Noden USA&#8221;) launched its authorized generic form of Tekturna in the United States in March 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Medical Devices segment consists of revenue derived from the LENSAR</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Laser System sales made by the Company&#8217;s subsidiary, LENSAR, Inc. (&#8220;LENSAR&#8221;), which may include equipment, Patient Interface Devices (&#8220;PIDs&#8221; or &#8220;consumables&#8221;), procedure licenses, training, installation, warranty and maintenance agreements. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Strategic Positions segment consists of an investment in Evofem. The Company&#8217;s investment includes shares of common stock and warrants to purchase additional shares of common stock. Evofem is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Evofem is leveraging its proprietary Multipurpose Vaginal pH Regulator (MVP-R&#8482;) platform to develop Amphora&#174; (L-lactic acid, citric acid and potassium bitartrate) for hormone-free birth control.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Income Generating Assets segment consists of revenue derived from (i) royalty rights - at fair value, (ii) notes and other long-term receivables, (iii) equity investments and (iv) royalties from issued patents in the United States and elsewhere covering the humanization of antibodies (&#8220;Queen et al. patents&#8221;).</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Accounting Policies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s significant accounting policies are described in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended&#160;December&#160;31, 2018. Summarized below and in Note 2, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investment in Evofem Biosciences, Inc.,</font><font style="font-family:inherit;font-size:10pt;"> are the accounting pronouncements and policies adopted subsequent to December 31, 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adopted Accounting Pronouncements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Leases,</font><font style="font-family:inherit;font-size:10pt;"> that supersedes Accounting Standards Codification (&#8220;ASC&#8221;) 840, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">. Subsequently, the FASB issued several updates to ASU No. 2016-02, codified in ASC Topic 842 (&#8220;ASC 842&#8221;). The Company adopted ASC 842, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases, </font><font style="font-family:inherit;font-size:10pt;">on January 1, 2019 using the modified retrospective method for all leases not substantially completed as of the date of adoption. The reported results for the three and </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> reflect the application of ASC 842 guidance while the reported results for the three and </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> were prepared under the guidance of ASC 840, which is also referred to herein as &#8220;legacy GAAP&#8221; or the &#8220;previous guidance&#8221;. The cumulative impact of the adoption of ASC 842 was not material, therefore, the Company did not record any adjustments to retained earnings. As a result of adopting ASC 842, the Company recorded operating lease right-of-use (&#8220;ROU&#8221;) assets of </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;"> and operating lease liabilities of </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">, primarily related to corporate office leases, based on the present value of the future lease payments on the date of adoption. Changes to lessor accounting focused on conforming with certain changes made to lessee accounting and the recently adopted revenue recognition guidance. The adoption of ASC 842 did not materially change how the Company accounts for lessor arrangements.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Policy Elections and Practical Expedients Taken</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For leases that commenced before the effective date of ASC 842, the Company elected the practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted a policy of expensing short-term leases, defined as </font><font style="font-family:inherit;font-size:10pt;">12 months</font><font style="font-family:inherit;font-size:10pt;"> or less, as incurred.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has a policy to exclude from the consideration in a lessor contract all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific lease revenue-producing transaction and collected by the Company from a lessee.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determines if an arrangement is a lease or contains an embedded lease at inception. The Company has lease arrangements with lease and non-lease components, which are accounted for separately. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Lessee arrangements</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lessee operating leases are included in Other assets, Accrued liabilities, and Other long-term liabilities in the Company&#8217;s Condensed Consolidated Balance Sheet. The Company does not have lessee financing leases.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses the implicit rate when readily determinable at lease inception. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company&#8217;s remaining lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis as operating expense in the Condensed Consolidated Statements of Operations over the lease term. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Lessor arrangements</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leases medical device equipment to customers in both operating lease and sales-type lease arrangements generated from its Medical Devices segment. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For sales-type leases, the Company derecognizes the carrying amount of the underlying asset and capitalizes the net investment in the lease, which consists of the total minimum lease payments receivable from the lessee, at lease inception. The Company does not estimate an unguaranteed residual value of the equipment at lease termination because the equipment transfers to the lessee upon completion of the lease. Selling profit or loss is recognized at lease inception. Initial direct costs are recognized as an expense, unless there is no selling profit or loss. If there is no selling profit or loss, initial direct costs are deferred and recognized over the lease term. The Company recognizes interest income from the lease receivable over the lease term in Interest and other income, net in the Condensed Consolidated Statements of Operations. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For operating leases, rental income is recognized on a straight-line basis over the lease term. The cost of customer-leased equipment is recorded within Property and equipment, net in the accompanying Condensed Consolidated Balance Sheets and depreciated over the equipment&#8217;s estimated useful life. Depreciation expense associated with the leased equipment under operating lease arrangements is reflected in Cost of product revenue in the accompanying Condensed Consolidated Statements of Operations. Some of the Company&#8217;s operating leases include a purchase option for the customer to purchase the leased asset at the end of the lease arrangement. The Company manages its risk on its investment in the equipment through pricing and the term of the leases. Lessees do not provide residual value guarantees on leased equipment. Equipment returned to the Company may be leased or sold to other customers. Initial direct costs are deferred and recognized over the lease term. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leases are generally not cancellable until after an initial term and may or may not require the customer to purchase a minimum number of procedures and consumables throughout the contract term.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For lease arrangements with lease and non-lease components where the Company is the&#160;lessor, the Company allocates the contract&#8217;s transaction price to the lease and non-lease components on a relative standalone selling price basis using the Company&#8217;s best estimate of the standalone selling price of each distinct product or service in the contract. Allocation of the transaction price is determined at the inception of the lease arrangement. The Company&#8217;s leases primarily consist of leases with fixed lease payments. For those leases with variable lease payments, the variable lease payment is typically based upon use of the leased equipment or the purchase of procedure licenses and consumables used with the leased equipment. Non-lease components are accounted for under ASC 606, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers. </font><font style="font-family:inherit;font-size:10pt;">For additional information regarding ASC 606, see Note 15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangibles-Goodwill and Other</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other: Simplifying the Test for Goodwill Impairment</font><font style="font-family:inherit;font-size:10pt;">, to simplify the subsequent measurement of goodwill by eliminating step two from the goodwill impairment test. Under the amendments, an entity will recognize an impairment charge for the amount by which the carrying value exceeds the fair value. The amendments are effective for fiscal years and interim periods within those years beginning after December 15, 2019 on a prospective basis and early adoption is permitted. The Company adopted the requirements of ASU No. 2017-04 on January 1, 2019. The adoption did not have an effect on the Company&#8217;s Consolidated Financial Statements on the adoption date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments</font><font style="font-family:inherit;font-size:10pt;">. The new guidance amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses. ASU No. 2016-13 has an effective date of the fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is currently evaluating the impact of this guidance on its Consolidated Financial Statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU No. 2018-13,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">.&#160;The new guidance modifies disclosure requirements related to fair value measurement.&#160;The amendments in ASU No. 2018-13 are effective for fiscal years, and interim periods within those fiscal years,&#160;beginning after December 15, 2019.&#160;Implementation on a prospective or retrospective basis varies by specific disclosure requirement.&#160;Early adoption is permitted. The standard also allows for early adoption of any removed or modified disclosures upon issuance of ASU No. 2018-13 while delaying adoption of the additional disclosures until their effective date. The Company is currently evaluating the impact of this guidance on the its Consolidated Financial Statement disclosures. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU No. 2018-15,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software</font><font style="font-family:inherit;font-size:10pt;">.&#160;The new guidance reduces complexity for the accounting for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license).&#160;For public companies, the amendments in ASU No. 2018-15 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted.&#160;Implementation should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption.&#160;The Company is currently evaluating the impact of this guidance on the Company&#8217;s Consolidated Financial Statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13. Stockholders&#8217; Equity</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Repurchase Program</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 25, 2017, the Company announced that its board of directors authorized the repurchase of issued and outstanding shares of the Company&#8217;s common stock having an aggregate value of up to </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;"> pursuant to a share repurchase program. The repurchases under the share repurchase program were made from time to time in the open market or in privately negotiated transactions and were funded from the Company&#8217;s working capital. All shares of common stock repurchased under this share repurchase&#160;program were retired and restored to authorized but unissued shares of common stock. The Company repurchased </font><font style="font-family:inherit;font-size:10pt;">8.7 million</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock under the share repurchase program during the fiscal year ended December 31, 2018, for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">, or an average cost of </font><font style="font-family:inherit;font-size:10pt;">$2.86</font><font style="font-family:inherit;font-size:10pt;"> per share, including trading commissions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 24, 2018, the Company announced that its board of directors authorized the repurchase of issued and outstanding shares of the Company&#8217;s common stock having an aggregate value of up to </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> pursuant to a share repurchase program. The Company repurchased </font><font style="font-family:inherit;font-size:10pt;">21.1 million</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock under this share repurchase program during the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$70.4 million</font><font style="font-family:inherit;font-size:10pt;">, or an average cost of </font><font style="font-family:inherit;font-size:10pt;">$3.34</font><font style="font-family:inherit;font-size:10pt;"> per share, including trading commissions. Since the inception of this share repurchase program through </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company has repurchased </font><font style="font-family:inherit;font-size:10pt;">29.7 million</font><font style="font-family:inherit;font-size:10pt;"> shares for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$95.9 million</font><font style="font-family:inherit;font-size:10pt;">, or an average cost of </font><font style="font-family:inherit;font-size:10pt;">$3.22</font><font style="font-family:inherit;font-size:10pt;"> per share, including trading commissions. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">178,700</font><font style="font-family:inherit;font-size:10pt;"> shares held in treasury stock at a total cost of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">. Those shares were settled and retired on July 5, 2019. All shares of common stock repurchased under this share repurchase&#160;program were retired and restored to authorized but unissued shares of common stock. This program was completed in July 2019 as further discussed in Note 20, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Subsequent Events.</font></div></div> unaudited Note 1 Net of tax of unaudited EX-101.SCH 7 pdli-20190630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2111100 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - Accrued Liabilities Accrued Liabilities, Current (Tables) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Accrued Liabilities (Accrued Liabilities) (Detail) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Accrued Liabilities (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2420403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Schedule of Balances of Accumulated Other Comprehensive Income (Loss)) (Detail) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2431403 - Disclosure - Asset Acquisitions Asset Acquisition Details (Details) link:presentationLink link:calculationLink link:definitionLink 2431402 - Disclosure - Asset Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2131100 - Disclosure - Asset Acquisitions (Notes) link:presentationLink link:calculationLink link:definitionLink 2331301 - Disclosure - Asset Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 2425405 - Disclosure - Business Combinations Asset and Liabilities Acquired (Details) link:presentationLink link:calculationLink link:definitionLink 2425403 - Disclosure - Business Combinations (Details) link:presentationLink link:calculationLink link:definitionLink 2325302 - Disclosure - Business Combinations Fair Value of Intangible Assets Acquired and Liabilities Assumed (Tables) link:presentationLink link:calculationLink link:definitionLink 2125100 - Disclosure - Business Combinations (Notes) link:presentationLink link:calculationLink link:definitionLink 2425404 - Disclosure - Business Combinations Proforma (Details) link:presentationLink link:calculationLink link:definitionLink 2325301 - Disclosure - Business Combinations (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Cash Dividends link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Cash Dividends (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2417403 - Disclosure - Cash Dividends (Summary of Conversion Rates for Convertible Notes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Cash Dividends (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Cash Equivalents and Investments link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Cash Equivalents and Investments (Available-For-Sale Securities Balance Sheet Classification) (Detail) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Cash Equivalents and Investments (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Cash Equivalents and Investments (Summary of Cash and Available-For-Sale Securities) (Detail) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Cash Equivalents and Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Commitments and Contingencies (Future Minimum Operating Lease Payments) (Detail) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Commitments and Contingencies (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement link:presentationLink link:calculationLink link:definitionLink 2414400 - Disclosure - Convertible and Non-Recourse Notes (Future Minimum Principal Payments) (Detail) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Convertible Notes link:presentationLink link:calculationLink link:definitionLink 2413411 - Disclosure - Convertible Notes Convertible Notes (Interest Expense for December 2021 Notes) (Details) link:presentationLink link:calculationLink link:definitionLink 2413409 - Disclosure - Convertible Notes Convertible Notes (Interest Expense for February 2018 Notes) (Detail) (Details) link:presentationLink link:calculationLink link:definitionLink 2413410 - Disclosure - Convertible Notes Convertible Notes (Summary of December 2021 Notes) (Details) link:presentationLink link:calculationLink link:definitionLink 2413408 - Disclosure - Convertible Notes Convertible Notes (Summary of February 2018 Notes) (Detail) (Details) link:presentationLink link:calculationLink link:definitionLink 2413407 - Disclosure - Convertible Notes (Interest Expense for the May 2015 Notes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - Convertible Notes (Interest Expense for the Series 2012 Notes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Convertible Notes (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - Convertible Notes (Summary of Convertible Notes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2413406 - Disclosure - Convertible Notes (Summary of May 2015 Notes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2413404 - Disclosure - Convertible Notes (Summary of Series 2012 Notes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Convertible Notes (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Customer Concentration link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - Customer Concentration (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2418403 - Disclosure - Customer Concentration (Percentage of Total Revenue From Licenses Over 10% of Revenue) (Detail) link:presentationLink link:calculationLink link:definitionLink 2318301 - Disclosure - Customer Concentration (Tables) link:presentationLink link:calculationLink link:definitionLink 2418404 - Disclosure - Customer Concentration (Total Revenues by Geographic Area) (Detail) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Fair Value Measurements (Financial Instruments Measured at Fair Value on a Recurring Basis) (Detail) link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - Fair Value Measurements Level 3 Unobservable Input Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Fair Value Measurements (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Fair Value Measurements (Schedule of Fair Value of Assets and Liabilities not Subject to Fair Value Recognition) (Detail) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Foreign Currency Hedging link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Foreign Currency Hedging (Fair Value of Foreign Currency Exchange Contracts on Condensed Consolidated Balance Sheet) (Detail) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Foreign Currency Hedging (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Foreign Currency Hedging (Schedule of Effect of Derivative Instruments in Consolidated Statements of Income and Consolidated Statements of Comprehensive Income) (Detail) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Foreign Currency Hedging (Schedule of Foreign Currency Exchange Contracts Designated as Cash Flow Hedges) (Detail) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Foreign Currency Hedging (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Income Taxes (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2419403 - Disclosure - Income Taxes (Provision for Income Taxes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2419404 - Disclosure - Income Taxes (Reconciliation of the Income Tax Provision Computed Using the U.S. Statutory Federal Income Tax Rate) (Detail) link:presentationLink link:calculationLink link:definitionLink 2419406 - Disclosure - Income Taxes (Reconciliation of Unrecognized Tax Benefits) (Detail) link:presentationLink link:calculationLink link:definitionLink 2419405 - Disclosure - Income Taxes (Significant Components of Deferred Tax Assets and Liabilities) (Detail) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2426403 - Disclosure - Intangibles and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2126100 - Disclosure - Intangibles and Goodwill (Notes) link:presentationLink link:calculationLink link:definitionLink 2326302 - Disclosure - Intangibles and Goodwill Remaining Amortization Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 2426404 - Disclosure - Intangibles and Goodwill Schedule of Finite-Lived Intangible Asset Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2326301 - Disclosure - Intangibles and Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 2428402 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 2128100 - Disclosure - Inventory (Notes) link:presentationLink link:calculationLink link:definitionLink 2328301 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 2433402 - Disclosure - Investment in Evofem (Details) link:presentationLink link:calculationLink link:definitionLink 2433403 - Disclosure - Investment in Evofem Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2133100 - Disclosure - Investment in Evofem (Notes) link:presentationLink link:calculationLink link:definitionLink 2333301 - Disclosure - Investment in Evofem (Tables) link:presentationLink link:calculationLink link:definitionLink 2432402 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2432403 - Disclosure - Leases Lease expense (Details) link:presentationLink link:calculationLink link:definitionLink 2132100 - Disclosure - Leases (Notes) link:presentationLink link:calculationLink link:definitionLink 2332301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 2421401 - Disclosure - Legal Proceedings (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Net Income per Share link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Net Income per Share (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Net Income per Share (Net Income Per Basic and Diluted Share) (Detail) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Net Income per Share (Net Income Per Basic and Diluted Share) (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Net Income per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Notes Receivable and Other Long-term Receivables link:presentationLink link:calculationLink link:definitionLink 2407401 - Disclosure - Notes Receivable and Other Long-term Receivables (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Organization and Business (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2124100 - Disclosure - Other Assets link:presentationLink link:calculationLink link:definitionLink 2424402 - Disclosure - Other Assets (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2424403 - Disclosure - Other Assets (Other Assets) (Detail) link:presentationLink link:calculationLink link:definitionLink 2324301 - Disclosure - Other Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Other Long-Term Liabilities link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Other Long-Term Liabilities (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Other Long-Term Liabilities (Other Long-Term Liabilities) (Detail) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Other Long-Term Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Prepaid and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Prepaid and Other Current Assets (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Prepaid and Other Current Assets (Prepaid and Other Current Assets) (Detail) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Prepaid and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Property and Equipment (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Property and Equipment (Property and Equipment) (Detail) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2123100 - Disclosure - Quarterly Financial Data (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2423402 - Disclosure - Quarterly Financial Data (Unaudited) (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2423403 - Disclosure - Quarterly Financial Data (Unaudited) (Quarterly Financial Data (Unaudited)) (Detail) link:presentationLink link:calculationLink link:definitionLink 2323301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 2430403 - Disclosure - Revenue from Contracts with Customers Contract Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2430402 - Disclosure - Revenue from Contracts with Customers (Details) link:presentationLink link:calculationLink link:definitionLink 2130100 - Disclosure - Revenue from Contracts with Customers (Notes) link:presentationLink link:calculationLink link:definitionLink 2330301 - Disclosure - Revenue from Contracts with Customers (Tables) link:presentationLink link:calculationLink link:definitionLink 2430404 - Disclosure - Revenue from Contracts with Customers Transaction Price Allocated to the Remaining Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2427402 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 2127100 - Disclosure - Segment Information (Notes) link:presentationLink link:calculationLink link:definitionLink 2327301 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2416406 - Disclosure - Stock-Based Compensation (Additional Information Regarding Our Options Exercised) (Detail) link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Stock-Based Compensation (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2416407 - Disclosure - Stock-Based Compensation (Restricted Stock Activity) (Detail) link:presentationLink link:calculationLink link:definitionLink 2416404 - Disclosure - Stock-Based Compensation (Shares of Company Common Stock Available Under Share-Based Plans) (Detail) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Stock-Based Compensation (Stock-Based Compensation Expense for Employees and Directors and Non-Employees) (Detail) link:presentationLink link:calculationLink link:definitionLink 2416405 - Disclosure - Stock-Based Compensation (Summary of Stock Option and Restricted Stock Award Activity) (Detail) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2429402 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2129100 - Disclosure - Stockholders' Equity (Notes) link:presentationLink link:calculationLink link:definitionLink 2329301 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2422401 - Disclosure - Subsequent Events (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - Summary of Significant Accounting Policies Correction of immaterial error table (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Summary of Significant Accounting Policies (Schedule of Property and Equipment of Estimated Useful Lives) (Detail) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Summary of Significant Accounting Policies (Schedule of Revenue by Major Customers) (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 pdli-20190630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 pdli-20190630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 pdli-20190630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Investments, Equity Securities [Abstract] Investments, Equity Securities [Abstract] Affiliate financial statements [Table] Affiliate financial statements [Table] Affiliate financial statements [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Revenue from Contract with Customer [Member] Revenue from Contract with Customer [Member] Operating Income (Loss) [Member] Operating Income (Loss) [Member] Income (Loss) [Member] Income (Loss) [Member] Income (Loss) [Member] Investment [Axis] Investment [Axis] Investment [Domain] Investment [Domain] Evofem [Member] Evofem [Member] Evofem [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other Current Assets [Member] Other Current Assets [Member] Other Assets [Member] Other Noncurrent Assets [Member] Other Current Liabilities [Member] Other Current Liabilities [Member] Other Noncurrent Liabilities [Member] Other Noncurrent Liabilities [Member] Affiliate financial statements [Line Items] Affiliate financial statements [Line Items] [Line Items] for Affiliate financial statements [Table] Evofem financial statements [Table Text Block] Affiliate financial statements [Table Text Block] [Table Text Block] for Affiliate financial statements [Table] Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Receivable Type [Axis] Receivable Type [Axis] Receivable Type [Domain] Receivable [Domain] Subsequent Event [Line Items] Subsequent Event [Line Items] Treasury Stock Acquired, Average Cost Per Share Treasury Stock Acquired, Average Cost Per Share Stock Repurchased During Period, Shares Stock Repurchased During Period, Shares Stock Repurchased During Period, Value Stock Repurchased During Period, Value Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Authorized Amount Other Long-Term Liabilities [Abstract] Other Long-Term Liabilities [Abstract] Schedule of Other Liabilities [Table] Schedule of Other Liabilities [Table] Schedule of Other Liabilities [Table] Schedule of Other Liabilities [Line Items] Schedule of Other Liabilities [Line Items] [Line Items] for Schedule of Other Liabilities [Table] Accrued lease liability Accrued Rent, Noncurrent Segment Reporting [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Income generating assets [Member] Income generating assets [Member] Income generating assets [Member] Pharmaceutical [Member] Pharmaceutical [Member] Pharmaceutical [Member] Medical devices [Member] Medical devices [Member] Medical devices [Member] Strategic positions [Member] Strategic positions [Member] Strategic positions [Member] Subsegments [Axis] Subsegments [Axis] Subsegments [Domain] Subsegments [Domain] Subsegments Consolidation Items [Axis] Subsegments Consolidation Items [Axis] Subsegments Consolidation Items [Domain] Subsegments Consolidation Items [Domain] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Long-Lived Assets Long-Lived Assets Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Parent Revenues Revenues Inventory [Abstract] Inventory [Abstract] Inventory Disclosure [Text Block] Inventory Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Measurement Input Type [Axis] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input Type [Domain] Measurement Input, Discount Rate [Member] Measurement Input, Discount Rate [Member] Collateral [Axis] Collateral [Axis] Collateral [Domain] Collateral [Domain] Other [Member] Other [Member] Other [Member] Intellectual Property [Member] Intellectual Property [Member] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] CareView [Member] CareView [Member] CareView [Member] Wellstat Diagnostics [Member] Wellstat Diagnostics [Member] Wellstat Diagnostics [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Depomed [Member] Depomed [Member] Depomed [Member] VB [Member] VB [Member] VB [Member] University of Michigan [Member] University of Michigan [Member] University of Michigan [Member] AcelRx [Member] AcelRx [Member] AcelRx [Member] Kybella [Member] Kybella [Member] Kybella [Member] Level 3 Rollforward Disclosure Classification [Axis] Level 3 Rollforward Disclosure Classification [Axis] Level 3 Rollforward Disclosure Classification [Axis] Level 3 Rollforward Disclosure Classification [Domain] Level 3 Rollforward Disclosure Classification [Domain] [Domain] for Level 3 Rollforward Disclosure Classification [Axis] Contingent Consideration [Member] Contingent Consideration [Member] Contingent Consideration [Member] Royalty right [Member] Royalty right [Member] Royalty right [Member] Fair Value by Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Note receivable cash flows [Member] Note receivable cash flows [Member] Note receivable cash flows [Member] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Change in fair value of acquired royalty rights Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Beginning balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Change in fair value of acquired royalty rights, Level 3 Rollforward Change in fair value of acquired royalty rights, Level 3 Rollforward Change in fair value of acquired royalty rights, Level 3 Rollforward Ending balance Payments for (Proceeds from) Productive Assets Payments for (Proceeds from) Productive Assets Change in fair value included in earnings for liabilities Change in fair value included in earnings for liabilities Change in fair value included in earnings for liabilities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Investment in Evofem [Text Block] Investment in Evofem [Text Block] Investment in Evofem [Text Block] Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] Schedule of Business Acquisitions, by Acquisition [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table Text Block] Customer Concentration [Abstract] Customer Concentration [Abstract] Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Payables and Accruals [Abstract] Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Schedule of Segment Reporting Information, by Segment [Table Text Block] Segment Reporting Disclosure [Text Block] Stockholders' Equity Note [Abstract] Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of fair value of financial instruments measured on recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy Schedule of fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy Schedule of fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Equity Securities [Member] Equity Securities [Member] Money Market Funds [Member] Money Market Funds [Member] Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Investments in and Advances to Affiliates, at Fair Value Investments in and Advances to Affiliates, at Fair Value Business Combination, Contingent Consideration, Liability, Current Business Combination, Contingent Consideration, Liability, Current Financial and Nonfinancial Liabilities, Fair Value Disclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure Royalty rights Royalty rights Royalty rights Financial assets: Financial assets: Financial assets: Cash and Cash Equivalents, Fair Value Cash and Cash Equivalents, Fair Value Disclosure Assets, Fair Value Assets, Fair Value Disclosure Warrants and Rights Outstanding Warrants and Rights Outstanding Financial liabilites: Financial liabilites: Financial liabilites: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Statement of Cash Flows [Abstract] Statement [Table] Statement [Table] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Statement [Line Items] Statement [Line Items] Payments to Acquire Interest in Subsidiaries and Affiliates Payments to Acquire Interest in Subsidiaries and Affiliates Payment for Contingent Consideration Liability, Financing Activities Payment for Contingent Consideration Liability, Financing Activities Noncash or Part Noncash Acquisition, Other Assets Acquired Noncash or Part Noncash Acquisition, Other Assets Acquired Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Assets held for sale reclassified from other assets to intangibles Assets held for sale reclassified from other assets to intangibles Assets held for sale reclassified from other assets to intangibles Payments to Acquire Intangible Assets Payments to Acquire Intangible Assets Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Amortization of convertible notes Amortization of Debt Issuance Costs Amortization of Intangible Assets Amortization of Intangible Assets Amortization Of Right of Use Assets Amortization Of Right of Use Assets Amortization Of Right of Use Assets Impairment of Intangible Assets, Finite-lived Impairment of Intangible Assets, Finite-lived Change in fair value of acquired royalty rights Change in fair value of acquired royalty rights Change in fair value of acquired royalty rights Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Change in Unrealized Gain (Loss) Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Change in Unrealized Gain (Loss) Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Depreciation, Amortization and Accretion, Net Depreciation, Amortization and Accretion, Net Gain (Loss) on Sale of Investments Gain (Loss) on Sale of Investments Gain (Loss) on Disposition of Property Plant Equipment Gain (Loss) on Disposition of Property Plant Equipment Inventory Write-down Inventory Write-down Provision for Doubtful Accounts Provision for Doubtful Accounts Stock-based compensation expense Share-based Compensation Deferred income taxes Deferred Income Taxes and Tax Credits Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Receivables from licensees and other Increase (Decrease) in Accounts Receivable Increase (Decrease) in Accounts and Other Receivables Increase (Decrease) in Accounts and Other Receivables Prepaid and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accrued interest on notes receivable Increase (Decrease) in Notes Receivable, Current Increase (Decrease) in Inventories Increase (Decrease) in Inventories Other assets Increase (Decrease) in Other Operating Assets Accounts payable Increase (Decrease) in Accounts Payable, Trade Accrued liabilities Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Deferred Revenue Increase (Decrease) in Deferred Revenue Increase (Decrease) in Income Taxes Payable Increase (Decrease) in Income Taxes Payable Other long-term liabilities Increase (Decrease) in Other Noncurrent Liabilities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Payments to Acquire Investments Payments to Acquire Investments Proceeds from Sale and Maturity of Other Investments Proceeds from Sale and Maturity of Other Investments Proceeds from Sale of Available-for-sale Securities, Equity Proceeds from Sale of Available-for-sale Securities, Equity Proceeds from Sale of Notes Receivable Proceeds from Sale of Notes Receivable Payments for (Proceeds from) Productive Assets Proceeds from Sale of Productive Assets Proceeds from Sale of Productive Assets Purchase of royalty rights Purchase of royalty rights Purchase of royalty rights Proceeds from Collection of Notes Receivable Proceeds from Collection of Notes Receivable Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Repayments of Secured Debt Repayments of Secured Debt Repayments of Other Debt Repayments of Other Debt Cash paid for purchase of noncontrolling interest Cash paid for purchase of noncontrolling interest Cash paid for purchase of noncontrolling interest Cash dividends paid Payments of Dividends Payments for Repurchase of Common Stock Payments for Repurchase of Common Stock Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Net decrease in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of the period Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Supplemental cash flow information Supplemental Cash Flow Information [Abstract] Cash (refunded) paid for income taxes Income Taxes Paid, Net Cash paid for interest Interest Paid, Including Capitalized Interest, Operating and Investing Activities Assets held for sale reclassified from notes receivable to other assets Assets held for sale reclassified from notes receivable to other assets Assets held for sale reclassified from notes receivable to other assets Extinguishment of Debt, Amount Extinguishment of Debt, Amount Supplemental disclosures of non-cash financing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Other Liabilities Disclosure [Abstract] Accrued Bonuses Accrued Bonuses Uncertain tax position Liability for Uncertainty in Income Taxes, Noncurrent Deferred Tax Liabilities, Net, Noncurrent Deferred Tax Liabilities, Net, Noncurrent Liabilities, Other than Long-term Debt, Noncurrent Liabilities, Other than Long-term Debt, Noncurrent Total Other Liabilities, Noncurrent DocumentAndEntityInformation [Abstract] DocumentAndEntityInformation [Abstract] Entities [Table] Entities [Table] Entity Information [Line Items] Entity Information [Line Items] Entity Emerging Growth Company Entity Emerging Growth Company Entity Small Business Entity Small Business Entity Shell Company Entity Shell Company Entity Registrant Name Entity Registrant Name Document Type Document Type Current Fiscal Year End Date Current Fiscal Year End Date Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity Current Reporting Status Entity Current Reporting Status Entity Filer Category Entity Filer Category Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Business Acquisition, Pro Forma Revenue Business Acquisition, Pro Forma Revenue Business Acquisition, Pro Forma Net Income (Loss) Business Acquisition, Pro Forma Net Income (Loss) Business Acquisition, Pro Forma Earnings Per Share, Basic Business Acquisition, Pro Forma Earnings Per Share, Basic Business Acquisition, Pro Forma Earnings Per Share, Diluted Business Acquisition, Pro Forma Earnings Per Share, Diluted Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Business Acquisition, Pro Forma Information [Table Text Block] Business Acquisition, Pro Forma Information [Table Text Block] Debt Disclosure [Abstract] Debt Instrument [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument [Domain] Debt Instrument, Name [Domain] Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Face Amount Debt Instrument, Face Amount Unamortized discount of liability component Debt Instrument, Unamortized Discount Convertible Notes Payable, Carrying Value Notes Payable Revenue from Contracts with Customers [Abstract] Revenue from Contracts with Customers [Abstract] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Duration [Axis] Duration [Axis] Duration [Axis] Duration [Domain] Duration [Domain] [Domain] for Duration [Axis] Less than one year [Member] Less than one year [Member] Less than one year [Member] Greater than one year [Member] Greater than one year [Member] Greater than one year [Member] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Amount Revenue, Remaining Performance Obligation, Amount Inventory, Current [Table] Inventory, Current [Table] Inventory [Axis] Inventory [Axis] Inventory [Domain] Inventory [Domain] Inventory [Line Items] Inventory [Line Items] Inventory, Raw Materials, Gross Inventory, Raw Materials, Gross Inventory, Work in Process, Gross Inventory, Work in Process, Gross Inventory, Finished Goods, Gross Inventory, Finished Goods, Gross Inventory, Net Inventory, Net Deferred Costs and Other Assets Deferred Costs and Other Assets Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Finite-Lived Intangible Assets, Amortization Expense, Year Two Finite-Lived Intangible Assets, Amortization Expense, Year Two Finite-Lived Intangible Assets, Amortization Expense, Year Three Finite-Lived Intangible Assets, Amortization Expense, Year Three Finite-Lived Intangible Assets, Amortization Expense, Year Four Finite-Lived Intangible Assets, Amortization Expense, Year Four Finite-Lived Intangible Assets, Amortization Expense, Year Five Finite-Lived Intangible Assets, Amortization Expense, Year Five Finite-Lived Intangible Assets, Amortization Expense, after Year Five Finite-Lived Intangible Assets, Amortization Expense, after Year Five Finite-Lived Intangible Assets, Net Finite-Lived Intangible Assets, Net Cash and Cash Equivalents [Abstract] Schedule of Available-For-Sale Securities [Table] Schedule of Available-for-sale Securities [Table] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Cash [Member] Cash and Cash Equivalents [Member] Schedule of Available-For-Sale Securities [Line Items] Debt Securities, Available-for-sale [Line Items] Adjusted Cost Available-for-sale Securities, Amortized Cost Basis Cash and cash equivalents Stockholders' Equity Attributable to Parent [Abstract] Compensation Employee-related Liabilities, Current Interest Interest Payable, Current Legal Accrued Professional Fees, Current Accrued liabilities, amounts received in advance of revenue recognition Accrued liabilities, amounts received in advance of revenue recognition Accrued liabilities, amounts received in advance of revenue recognition Other Other Accrued Liabilities, Current Total Accrued Liabilities, Current Deferred Revenue, Current Deferred Revenue, Current Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Noden [Member] Noden [Member] Noden [Member] Alphaeon [Member] Alphaeon [Member] Alphaeon [Member] Intangible Assets, Net (Excluding Goodwill) Intangible Assets, Net (Excluding Goodwill) Investment Owned, Balance, Shares Investment Owned, Balance, Shares Investment Owned, at Cost Investment Owned, at Cost Investment estimated fair value, per share Investment estimated fair value, per share Investment estimated fair value, per share Goodwill and Intangible Asset Impairment Goodwill and Intangible Asset Impairment Cash payment for purchase of royalty right Cash payment for purchase of royalty right Cash payment for purchase of royalty right Purchase of royalty rights Purchase of royalty right Purchase of royalty right Royalty right purchase transaction costs Royalty right purchase transaction costs Royalty right purchase transaction costs Reversionary interest period Reversionary interest period Reversionary interest period Cash flow model expected royalty sales term Cash flow model expected royalty sales term Cash flow model expected royalty sales term Sensitivity range for royalty disclosures Sensitivity range for royalty disclosures Sensitivity range for royalty disclosures Sensitivity - decrease in fair value from increase in discount rate Sensitivity - decrease in fair value from increase in discount rate Sensitivity - decrease in fair value from increase in discount rate Sensitivity - increase in fair value from decrease in discount rate Sensitivity - increase in fair value from decrease in discount rate Sensitivity - increase in fair value from decrease in discount rate Sensitivity to increase or decrease in expected royalty Sensitivity to increase or decrease in expected royalty Sensitivity to increase or decrease in expected royalty Fair Value Measurements, Sensitivity Analysis, Description Fair Value Measurements, Sensitivity Analysis, Description Litigation Settlement, Amount Awarded from Other Party Litigation Settlement, Amount Awarded from Other Party Revenue Recognition, Milestone Method, Revenue Recognized Revenue Recognition, Milestone Method, Revenue Recognized Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount Transfers from level 1 to level 2, amount Fair Value, Equity, Level 1 to Level 2 Transfers, Amount Transfers from level 2 to level 1, amount Fair Value, Equity, Level 2 to Level 1 Transfers, Amount Percentage of royalty acquired Percentage of royalty acquired Percentage of royalty acquired Percentage of first four milestone payments acquired Percentage of first four milestone payments acquired Percentage of first four milestone payments acquired Number of potential milestone royalties Number of potential milestone royalties Number of potential milestone royalties Contractual cap on potential royalty asset multiple Contractual cap on potential royalty asset multiple Contractual cap on potential royalty asset multiple Maximum amount of additional funds, upon attainment of milestones Maximum amount of additional funds, upon attainment of milestones Maximum amount of additional funds, upon attainment of milestones. Notes Receivable, Fair Value Disclosure Notes Receivable, Fair Value Disclosure Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Asset Impairment Charges Asset Impairment Charges Leases [Abstract] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Equipment Leased to Other Party [Member] Equipment Leased to Other Party [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Property, Plant and Equipment, Gross Property, Plant and Equipment, Gross Capital Leases, Lessee Balance Sheet, Assets by Major Class, Property, Plant, and Equipment Other, Accumulated Depreciation Capital Leases, Lessee Balance Sheet, Assets by Major Class, Property, Plant, and Equipment Other, Accumulated Depreciation Property, Plant and Equipment, Net Property, Plant and Equipment, Net Operating Leases, Future Minimum Payments Due, Next Twelve Months Operating Leases, Future Minimum Payments Due, Next Twelve Months Operating Lease, Payments Operating Lease, Payments Operating Lease, Expense Operating Lease, Expense Short-term Lease, Cost Short-term Lease, Cost Lease, Cost Lease, Cost Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments, Due in Three Years Operating Leases, Future Minimum Payments, Due in Three Years Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases, Future Minimum Payments, Due Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Operating Leases, Future Minimum Payments Due Operating Leases, Future Minimum Payments Due Accounting Policies [Abstract] Basis of Presentation, Policy Basis of Accounting [Text Block] New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Asset Acquisitions [Abstract] Asset Acquisitions [Abstract] Ownership [Axis] Ownership [Axis] Ownership [Domain] Ownership [Domain] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Business Combination, Consideration Transferred Business Combination, Consideration Transferred Business Combination, Contingent Consideration, Liability, Noncurrent Business Combination, Contingent Consideration, Liability, Noncurrent Income Tax Disclosure [Abstract] Federal Income Tax Note [Table] Federal Income Tax Note [Table] Investments, Owned, Federal Income Tax Note [Line Items] Investments, Owned, Federal Income Tax Note [Line Items] Change in Uncertain Tax Positions Change in Uncertain Tax Positions Change in Uncertain Tax Positions Income Tax Expense Income Tax Expense (Benefit) Federal income tax rate Federal income tax rate Federal income tax rate Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Abstract] CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Abstract] Restatement [Axis] Restatement [Axis] Restatement [Domain] Restatement [Domain] Report Date [Axis] Report Date [Axis] Financial Statement Filing Date [Domain] Financial Statement Filing Date [Domain] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock [Member] Treasury Stock [Member] Treasury Stock [Member] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] AOCI Attributable to Parent [Member] Noncontrolling Interest [Member] Noncontrolling Interest [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Adjustments for Change in Accounting Principle [Axis] Adjustments for Change in Accounting Principle [Axis] Adjustments for Change in Accounting Principle [Domain] Adjustments for Change in Accounting Principle [Domain] Adjustments for Error Corrections [Axis] Adjustments for Error Corrections [Axis] Adjustments for Error Correction [Domain] Adjustments for Error Correction [Domain] Shares, Issued Shares, Issued Stockholders' Equity Attributable to Parent Stockholders' Equity Attributable to Parent Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Other Noncontrolling Interests Other Noncontrolling Interests Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Restricted Stock Award, Forfeitures, Dividends Restricted Stock Award, Forfeitures, Dividends Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock Repurchased During Period, Shares Stock Repurchased and Retired During Period, Shares Treasury Stock, Retired, Par Value Method, Amount Treasury Stock, Retired, Par Value Method, Amount Reduction in Treasury stock held Reduction in Treasury stock held Reduction in Treasury stock held Treasury Stock, Value, Acquired, Cost Method Treasury Stock, Value, Acquired, Cost Method Treasury Stock, Retired, Cost Method, Amount Treasury Stock, Retired, Cost Method, Amount Adjustments to Additional Paid in Capital, Other Adjustments to Additional Paid in Capital, Other Noncontrolling Interest, Period Increase (Decrease) Noncontrolling Interest, Period Increase (Decrease) Stock Repurchased and Retired During Period, Value Stock Repurchased and Retired During Period, Value Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive Income (Loss), Net of Tax, Attributable to Parent Noncontrolling Interest, Increase from Subsidiary Equity Issuance Noncontrolling Interest, Increase from Subsidiary Equity Issuance Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss) Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Shares, Issued Other Noncontrolling Interests Stockholders' Equity Attributable to Parent Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Series 2012 Notes [Member] Series 2012 Notes [Member] Series 2012 Notes [Member] Contractual coupon interest Interest Expense, Debt, Excluding Amortization Amortization of debt issuance costs Amortization of debt issuance costs Amortization of debt issuance costs Amortization of debt discount Amortization of Debt Discount (Premium) Total Interest Expense, Debt Lease, Cost [Table Text Block] Lease, Cost [Table Text Block] Supplemental cash flow related to leases [Table Text Block] Supplemental cash flow related to leases [Table Text Block] Supplemental cash flow related to leases [Table Text Block] Receivables [Abstract] Schedule Of Accounts Notes Loans And Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] DirectFlow [Member] DirectFlow [Member] DirectFlow [Member] License and other [Member] License and other [Member] License and other [Member] Credit Agreement [Member] Credit Agreement [Member] Credit Agreement [Member] Initial Loan [Member] Initial Loan [Member] Initial Loan [Member] Additional Loan [Member] Additional Loan [Member] Additional Loan [Member] Royalty Agreement [Member] Royalty Agreement [Member] Royalty Agreement [Member] Term loan and interest [Member] Term loan and interest [Member] Term loan and interest [Member] Forbearance principal and interest [Member] Forbearance principal and interest [Member] Forbearance principal and interest [Member] Avinger [Member] Avinger [Member] Avinger [Member] Hyperion [Member] Hyperion [Member] Hyperion [Member] kaleo Note Receivable [Member] kaleo Note Receivable [Member] kaleo Note Receivable [Member] Accounts Notes And Loans Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Financing Receivable, Gross Financing Receivable, Gross SEC Schedule, 12-17, Insurance Companies, Reinsurance, Premium, Percentage Assumed to Net SEC Schedule, 12-17, Insurance Companies, Reinsurance, Premium, Percentage Assumed to Net Gain Contingency, Unrecorded Amount Gain Contingency, Unrecorded Amount Financing Receivables, Impaired, Troubled Debt Restructuring, Write-down Financing Receivables, Impaired, Troubled Debt Restructuring, Write-down Proceeds from Sale of Other Assets Proceeds from Sale of Other Assets Investment Warrants, Exercise Price Investment Warrants, Exercise Price Number of payments to be received Number of payments to be received Number of payments to be received Periodic contractual payments Periodic contractual payments Periodic contractual payments Financing Receivable, Net Financing Receivable, Net Interest rate of note receivable (in Percent) Interest rate of note receivable (in Percent) Interest rate of note receivable (in Percent) Reduction in royalty rate (in percent) Reduction in royalty rate (in percent) Reduction in royalty rate (in percent) Repayment of notes receivable Accounts Receivable, Net, Noncurrent Accounts Receivable, Net, Noncurrent Credit agreement, stated interest rate (in Percent) Credit agreement, stated interest rate (in Percent) Stated interest rate of credit agreement. Proceeds received under remedies available for borrower's breach of terms credit agreement Proceeds received under remedies available for borrower's breach of terms credit agreement Proceeds received under remedies available for borrower's breach of terms credit agreement and applied to amounts due under the credit agreement. Forbearance number of days under terms of credit agreement (in Duration) Forbearance number of days under terms of credit agreement (in Duration) Forbearance number of days, under terms of credit agreement whereby PDL has agreed to refrain from exercising additional remedies. Amount company has agreed to advance under agreement Amount company has agreed to advance under credit agreement Amount company has agreed to advance under credit agreement. Financing Receivable, Modifications, Post-Modification Recorded Investment Financing Receivable, Modifications, Post-Modification Recorded Investment Commitments and Contingencies Commitments and Contingencies Tranche 1 of note receivable Tranche 1 of note receivable Tranche 1 of note receivable Tranche 2 of note receivable Tranche 2 of note receivable Tranche 2 of note receivable Class of Warrant or Right, Number of Securities Called by Warrants or Rights Class of Warrant or Right, Number of Securities Called by Warrants or Rights Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Warrant or Right, Exercise Price of Warrants or Rights Financial Instruments, Owned, Other, at Fair Value Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share Based Compensation Arrangements by Share Based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Domain] Equity Award [Domain] Employee Stock Option [Member] Employee Stock Option [Member] Restricted Stock [Member] Restricted Stock [Member] Share Based Compensation Arrangment By Share Based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Shares Available for Grant, Balance beginning of period (in Shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Restricted Stock Award, Number of Shares, Balance at beginning of period (in Shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Restricted Stock Awards, Number of Shares Granted (in Shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted Stock Awards, Number of Shares, Balance at end of period (in Shares) Restricted Stock Awards, Weighted Average Grant-date Fair Value, Balance at beginning of period (in Dollars per Share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Restricted Stock Awards, Weighted Average Grant-date Fair Value, Granted (in Dollars per Share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Restricted Stock Awards, Weighted Average Grant-date Fair Value, Balance at end of period (in Dollars per Share) Shares Available for Grant, Balance end of period (in Shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations Convertible and Non-Recourse Notes Long-term Debt [Text Block] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] December 2021 Notes [Member] December 2021 Notes [Member] December 2021 Notes [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Convertible, Beneficial Conversion Feature Debt Instrument, Convertible, Beneficial Conversion Feature Interest Expense, Debt Schedule of carrying value and unamortized discount on December 2021 Notes [Table Text Block] Schedule of carrying value and unamortized discount on December 2021 Notes [Table Text Block] [Table Text Block] for Schedule of carrying value and unamortized discount on December 2021 Notes [Table] Schedule of convertible and non-recourse notes activity Schedule of Debt [Table Text Block] Schedule of carrying value and unamortized discount on February 2018 Notes [Table Text Block] Schedule of carrying value and unamortized discount on February 2018 Notes [Table Text Block] Schedule of carrying value and unamortized discount on February 2018 Notes [Table Text Block] Schedule of interest expense for February 2018 Notes [Table Text Block] Schedule of interest expense for February 2018 Notes [Table Text Block] Schedule of interest expense for February 2018 Notes [Table Text Block] Schedule of interest expense for December 2021 Notes [Table Text Block] Schedule of interest expense for December 2021 Notes [Table Text Block] Schedule of interest expense for December 2021 Notes [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Gains (losses) on sales of available-for-sale securities Available-for-sale Securities, Gross Realized Gain (Loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax Fair Value Measurements Fair Value Disclosures [Text Block] Schedule of Revenue by Major Customers, by Reporting Segment [Table] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Major Customers [Axis] Name of Major Customer [Domain] LENSAR [Member] LENSAR [Member] LENSAR [Member] Interest revenues [Member] Interest revenues [Member] Interest revenues [Member] Tysabri [Member] Tysabri [Member] Tysabri [Member] Revenue, Major Customer [Line Items] Revenue, Major Customer [Line Items] Concentration Risk, Percentage Concentration Risk, Percentage Dividends payable quarterly (in Dollars per Share) Dividends Payable, Amount Per Share Payments of Dividends Statement of Financial Position [Abstract] Other Noncontrolling Interests Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Short-term investments Debt Securities, Available-for-sale, Current Accounts receivable, net Accounts and Other Receivables, Net, Current Notes receivable Notes, Loans and Financing Receivable, Net, Current Prepaid and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Inventory, Net Investments Investments Notes receivables, long-term Notes, Loans and Financing Receivable, Net, Noncurrent Other assets Other Assets, Noncurrent Total assets Assets Liabilities and Stockholders' Deficit Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued liabilities Accrued Income Taxes, Current Accrued Income Taxes, Current Convertible Notes Payable, Current Convertible Notes Payable, Current Total current liabilities Liabilities, Current Convertible notes payable Convertible Notes Payable, Noncurrent Other long-term liabilities Total liabilities Liabilities Liabilities, Other than Long-term Debt, Noncurrent Commitments and contingencies (Note 12) Stockholders' deficit: Preferred stock, par value $0.01 per share, 10,000 shares authorized; no shares issued and outstanding Preferred Stock, Value, Issued Common stock, par value $0.01 per share, 350,000 shares authorized; 145,976 and 153,775 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Treasury Stock, Value Treasury Stock, Value Accumulated other comprehensive income Retained earnings Retained Earnings (Accumulated Deficit) Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total liabilities and stockholders’ equity Liabilities and Equity Total PDL’s stockholders’ equity February 2018 Notes [Member] February 2018 Notes [Member] February 2018 Notes [Member] Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Convertible, Conversion Ratio Debt Instrument, Convertible, Conversion Ratio Convertible notes, conversion price (in Dollars per Share) Debt Instrument, Convertible, Conversion Price Principal amount a $5 incentive cash payment per each to convert debt Principal amount a $5 incentive cash payment per each to convert debt The amount of principal tendered which a $5.00 cash payment is made per each to convert the Series 2012 notes to February 2015 notes. Convertible Notes, Maturity Date (Date) Debt Instrument, Maturity Date Convertible Notes, Principal Balance Outstanding Convertible Notes Payable, Carrying Value Goodwill and Intangible Assets Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Text Block] Preferred stock par value (in Dollars per Share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in Shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in Shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in Shares) Preferred Stock, Shares Outstanding Common stock par value (in Dollars per Share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in Shares) Common Stock, Shares Authorized Common stock, shares issued (in Shares) Common Stock, Shares, Issued Common stock, shares outstanding (in Shares) Common Stock, Shares, Outstanding Accumulated Other Comprehensive Income (Loss) [Abstract] Accumulated Other Comprehensive Income (Loss) [Abstract] Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Unrealized gains (losses) on available-for-sale securities Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax Business Combination Disclosure [Text Block] Business Combination Disclosure [Text Block] Earnings Per Share [Abstract] Numerator Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Income used to compute net income per diluted share Net Income (Loss) Available to Common Stockholders, Diluted Denominator Weighted Average Number of Shares Outstanding, Diluted [Abstract] Total weighted-average shares used to compute net income per basic share (in Shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in Shares) Weighted Average Number of Shares Outstanding, Diluted Basic (in Dollars per Share) Earnings Per Share, Basic Net income per diluted share (in Dollars per Share) Earnings Per Share, Diluted Award Type [Domain] Additional shares included in the calculation of diluted EPS (in Shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Stockholders' Equity, Total [Member] Stockholders' Equity, Total [Member] Other Noncurrent Assets [Member] Affiliate financial statements - balance sheet Affiliate financial statements - balance sheet Affiliate financial statements - balance sheet Affiliate financial statements - income statements Affiliate financial statements - income statements Affiliate financial statements - income statements Schedule of Inventory, Current [Table Text Block] Schedule of Inventory, Current [Table Text Block] Disaggregation of Revenue [Table Text Block] Disaggregation of Revenue [Table Text Block] Contract with Customer, Asset and Liability [Table Text Block] Contract with Customer, Asset and Liability [Table Text Block] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] Schedule of Guarantor Obligations [Table] Schedule of Guarantor Obligations [Table] Bulk product [Member] Bulk product [Member] Bulk product [Member] Next twelve months [Member] Next twelve months [Member] Next twelve months [Member] Next twenty-four months [Member] [Member] Next twenty-four months [Member] [Member] Next twenty-four months [Member] [Member] Guarantor Obligations [Line Items] Guarantor Obligations [Line Items] Debt Instrument, Unamortized Discount Purchase Obligation Purchase Obligation Total lease payments for the duration of the guarantee Guarantor Obligations, Maximum Exposure, Undiscounted Property, Plant and Equipment, Useful Life Property, Plant and Equipment, Useful Life Lessor, Operating Lease, Term of Contract Lessor, Operating Lease, Term of Contract Lease termination option Lease termination option Lease termination option Sales-type Lease, Revenue Sales-type Lease, Revenue Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Next Rolling Twelve Months Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Next Rolling Twelve Months Capital Leases, Lessor Balance Sheet, Net Investment in Direct Financing and Sales Type Leases, Noncurrent Capital Leases, Lessor Balance Sheet, Net Investment in Direct Financing and Sales Type Leases, Noncurrent Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Remainder of Fiscal Year Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Remainder of Fiscal Year Lessor, Operating Lease, Payments to be Received, Remainder of Fiscal Year Lessor, Operating Lease, Payments to be Received, Remainder of Fiscal Year Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Operating Lease, Right-of-Use Asset Operating Lease, Right-of-Use Asset Operating Lease, Liability, Current Operating Lease, Liability, Current Operating Lease, Liability, Noncurrent Operating Lease, Liability, Noncurrent Operating Lease, Liability Operating Lease, Liability Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two Lessee, Operating Lease, Liability, Payments, Due Year Three Lessee, Operating Lease, Liability, Payments, Due Year Three Lessee, Operating Lease, Liability, Payments, Due Year Four Lessee, Operating Lease, Liability, Payments, Due Year Four Lessee, Operating Lease, Liability, Payments, Due Year Five Lessee, Operating Lease, Liability, Payments, Due Year Five Lessee, Operating Lease, Liability, Payments, Due after Year Five Lessee, Operating Lease, Liability, Payments, Due after Year Five Lessee, Operating Lease, Liability, Payments, Due Lessee, Operating Lease, Liability, Payments, Due Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lessor, Operating Lease, Payments to be Received, Two Years Lessor, Operating Lease, Payments to be Received, Two Years Lessor, Operating Lease, Payments to be Received, Three Years Lessor, Operating Lease, Payments to be Received, Three Years Lessor, Operating Lease, Payments to be Received, Four Years Lessor, Operating Lease, Payments to be Received, Four Years Lessor, Operating Lease, Payments to be Received, Rolling Year Five Lessor, Operating Lease, Payments to be Received, Rolling Year Five Lessor, Operating Lease, Payments to be Received, Thereafter Lessor, Operating Lease, Payments to be Received, Thereafter Lessor, Operating Lease, Payments to be Received Lessor, Operating Lease, Payments to be Received Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Two Years Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Two Years Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Three Years Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Three Years Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Four Years Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Four Years Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Five Years Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Five Years Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Thereafter Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Thereafter Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received Sales-type and Direct Financing Leases, Lease Receivable Sales-type and Direct Financing Leases, Lease Receivable Sales-type and Direct Financing Leases, Lease Receivable, Undiscounted Excess Amount Sales-type and Direct Financing Leases, Lease Receivable, Undiscounted Excess Amount Cost of Goods Sold, Sales-type Lease Cost of Goods Sold, Sales-type Lease Sales-type Lease, Selling Profit (Loss) Sales-type Lease, Selling Profit (Loss) Sales-type Lease, Interest Income, Lease Receivable Sales-type Lease, Interest Income, Lease Receivable Operating Leases, Income Statement, Initial Direct Costs Operating Leases, Income Statement, Initial Direct Costs Operating Lease, Lease Income Operating Lease, Lease Income Lessee, Operating Lease, Renewal Term Lessee, Operating Lease, Renewal Term Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Investment Secondary Categorization [Axis] Investment Secondary Categorization [Axis] Investments by Secondary Categorization [Domain] Investments by Secondary Categorization [Domain] Warrant [Member] Warrant [Member] Debt and Equity Securities, FV-NI [Line Items] Debt and Equity Securities, FV-NI [Line Items] Tranche 1 of investment Tranche 1 of investment Tranche 1 of investment Gain (Loss) on Investments Gain (Loss) on Investments Warrants acquired Warrants acquired Warrants acquired Board member appointed Board member appointed Board member appointed Board observer appointed Board observer appointed Board observer appointed Warrants and Rights Outstanding, Term Warrants and Rights Outstanding, Term Shares acquired Shares acquired Shares acquired Tranche 2 of investment Tranche 2 of investment Tranche 2 of investment Cost of tranche two investment option, per share Cost of investment, per share Cost of investment, per share Investment ownership percentage Investment ownership percentage Investment ownership percentage Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Segment Reporting Information, by Segment [Table Text Block] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized Business Combination, Bargain Purchase, Gain Recognized, Amount Business Combination, Bargain Purchase, Gain Recognized, Amount Summary of Significant Accounting Policies (Narrative) [Abstract] Summary of Significant Accounting Policies (Narrative) [Abstract] Number of Reportable Segments Number of Reportable Segments Maximum term of short-term lease expensed via exemption Maximum term of short-term lease expensed via exemption Maximum term of short-term lease expensed via exemption Cash Equivalents and Investments Cash, Cash Equivalents, and Marketable Securities [Text Block] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Other Long-Term Liabilities Other Liabilities Disclosure [Text Block] Net Income per Share Earnings Per Share [Text Block] Revenue from Contract with Customers [Abstract] Revenue from Contract with Customers [Abstract] Revenue from Contract with Customer [Text Block] Revenue from Contract with Customer [Text Block] Lessee, Operating Leases [Text Block] Lessee, Operating Leases [Text Block] Derivative Instruments and Hedging Activities Disclosure [Abstract] Foreign Currency Hedging Derivative Instruments and Hedging Activities Disclosure [Text Block] Accounts Receivable, Net Accounts Receivable, Net Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Contract with Customer, Basis of Pricing [Axis] Contract with Customer, Basis of Pricing [Axis] Contract with Customer, Basis of Pricing [Domain] Contract with Customer, Basis of Pricing [Domain] Contract with Customer, Duration [Axis] Contract with Customer, Duration [Axis] Contract with Customer, Duration [Domain] Contract with Customer, Duration [Domain] Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Domain] Timing of Transfer of Good or Service [Domain] Contract with Customer, Sales Channel [Axis] Contract with Customer, Sales Channel [Axis] Contract with Customer, Sales Channel [Domain] Contract with Customer, Sales Channel [Domain] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Contract with Customer, Asset, Net Contract with Customer, Asset, Net Contract asset payments received Contract asset payments received Contract asset payments received Contract assets recognized Contract assets recognized Contract assets recognized Contract with Customer, Liability Contract with Customer, Liability Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price Contract with Customer, Liability, Revenue Recognized Contract with Customer, Liability, Revenue Recognized Fair Value By Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Real estate appreciation [Member] Real estate appreciation [Member] Real estate appreciation [Member] Estimated realtor fee [Member] Estimated realtor fee [Member] Estimated realtor fee [Member] Wellstat Note Receivable [Member] Wellstat Note Receivable [Member] Wellstat Note Receivable [Member] Fair Value by Balance Sheet Grouping [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Loans Held-for-sale, Measurement Input Loans Held-for-sale, Measurement Input Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Notes receivable, Carrying Value Notes, Loans and Financing Receivable, Gross, Noncurrent Notes receivable, Fair Value Liabilities: Liabilities [Abstract] Notes payable, Fair Value Long-term Debt, Fair Value Accounting Changes and Error Corrections [Abstract] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Error Corrections and Prior Period Adjustments Restatement [Line Items] Error Corrections and Prior Period Adjustments Restatement [Line Items] Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment by Type [Axis] Property, Plant and Equipment by Type [Domain] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Sales Allowances and Accruals [Abstract] Sales Allowances and Accruals [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Discount and Distribution Fees [Member] Discount and Distribution Fees [Member] Discount and Distribution Fees [Member] Government Rebates and Chargebacks [Member] Government Rebates and Chargebacks [Member] Government Rebates and Chargebacks [Member] Assistance and Other Discounts [Member] Assistance and Other Discounts [Member] Assistance and Other Discounts [Member] Product Returns [Member] Product Returns [Member] Product Returns [Member] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Discount and Distribution Fees Discount and Distribution Fees Discount and Distribution Fees Government rebates and chargebacks Government rebates and chargebacks Government rebates and chargebacks Assistance and Other Discounts Assistance and Other Discounts Assistance and Other Discounts Product return Product return Product return Allowances for current period sales Allowances for current period sales Allowances for current period sales Allowances for prior period sales Allowances for prior period sales Allowances for prior period sales Payments for current period sales Payments for current period sales Payments for current period sales Payments for prior period sales Payments for prior period sales Payments for prior period sales Income Statement [Abstract] Queen et al. patents [Member] Queen et al. patents [Member] Queen et al. patents [Member] Acquired rights [Member] Acquired rights [Member] Acquired rights [Member] Product Revenue [Member] Product Revenue [Member] Product Revenue [Member] Revenues Revenues [Abstract] Interest revenue Interest revenue Interest revenue Revenue from Contract with Customer, Including Assessed Tax Revenue from Contract with Customer, Including Assessed Tax Operating expenses Operating Expenses [Abstract] Cost of Revenue Cost of Revenue General and administrative General and Administrative Expense Selling and Marketing Expense Selling and Marketing Expense Research and Development Expense Research and Development Expense Change in fair value of contingent consideration Change in fair value of contingent consideration Change in fair value of contingent consideration Total operating expenses Operating Expenses Operating loss Operating Income (Loss) Non-operating expense, net Nonoperating Income (Expense) [Abstract] Interest and other income, net Investment Income, Net Interest expense Interest Expense Total non-operating income (expense), net Nonoperating Income (Expense) (Loss) income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income tax (benefit) expense Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net (loss) income Net income per share Weighted average shares outstanding Basic (in Shares) Derivative [Table] Derivative [Table] Derivative, by Nature [Axis] Derivative Instrument [Axis] Derivative Contract Type [Domain] Derivative Contract [Domain] Derivative [Line Items] Derivative [Line Items] Income Taxes Income Tax Disclosure [Text Block] Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Option on Securities [Member] Option on Securities [Member] Convertible notes Convertible Debt Antidilutive securities excluded from computation of earnings per share (in Shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Notes and Other Long-term Receivables Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Mergers, Acquisitions and Dispositions Disclosures [Text Block] Mergers, Acquisitions and Dispositions Disclosures [Text Block] Statement of Comprehensive Income [Abstract] Unrealized gains (losses) on available-for-sale securities, tax Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax Statement Business Segments [Axis] Products [Domain] Indefinite-lived Intangible Assets Acquired as Part of Business Combination [Table] Indefinite-lived Intangible Assets Acquired as Part of Business Combination [Table] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Acquired Indefinite-lived Intangible Assets [Line Items] Acquired Indefinite-lived Intangible Assets [Line Items] Business Combination, Consideration Transferred Contractual Obligation Contractual Obligation Accounts and Notes Receivable, Net Accounts and Notes Receivable, Net Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax [Abstract] Change in fair value of investments in available-for-sale securities, net of tax Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Total change in unrealized gains (losses) on investments in available-for-sale securities, net of tax Total other comprehensive income (loss), net of tax Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Comprehensive income Schedule of other liabilities Schedule of Other Assets and Other Liabilities [Table Text Block] Sales Allowances and Accruals [Table Text Block] Sales Allowances and Accruals [Table Text Block] [Table Text Block] for Sales Allowances and Accruals [Table] Comprehensive Income (Loss) Note [Text Block] Comprehensive Income (Loss) Note [Text Block] Concentration Risk Disclosure [Text Block] Concentration Risk Disclosure [Text Block] Schedule of calculation of numerator and denominator in earnings per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Treasury Stock, Shares, Acquired Treasury Stock, Common, Shares Debt Instrument, Unamortized Discount North America [Member] North America [Member] Europe [Member] Europe [Member] Asia [Member] Asia [Member] Non-US [Member] Non-US [Member] Term of receivable (in Duration) Term of receivable (in Duration) The term of the note receivable. Non ASC 606 revenue Non ASC 606 revenue Non ASC 606 revenue Revenue from Contract with Customer, Excluding Assessed Tax Revenue from Contract with Customer, Excluding Assessed Tax Future potential royalty payments Future potential royalty payments Future potential royalty payments Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Schedule of the effect of derivative instruments in the Consolidated Statements of Income and Consolidated Statements of Comprehensive Income Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block] Payment Type [Axis] Payment Type [Axis] Payment Type [Axis] Payment Type [Domain] Payment Type [Domain] [Domain] for Payment Type [Axis] Cash paid [Member] Cash paid [Member] Cash paid [Member] Milestone [Member] Milestone [Member] Milestone [Member] Original acquisition [Member] Original acquisition [Member] Original acquisition [Member] Precision Eye Services [Member] Precision Eye Services [Member] Precision Eye Services [Member] third-party [Member] third-party [Member] third-party [Member] Contractual Rights [Member] Contractual Rights [Member] Customer Relationships [Member] Customer Relationships [Member] Patented Technology [Member] Patented Technology [Member] Trademarks [Member] Trademarks [Member] Fair Value Inputs, Discount Rate (Deprecated 2018-01-31) Finite-Lived Intangible Asset, Useful Life Finite-Lived Intangible Asset, Useful Life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Net Derivative Name [Domain] Gain (loss) reclassified from accumulated OCI into royalty revenue, net of tax Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net February 2018 Note Warrant [Member] February 2018 Note Warrant [Member] February 2018 Note Warrant [Member] February 2018 Note Purchase Call Option [Member] February 2018 Note Purchase Call Option [Member] February 2018 Note Purchase Call Option [Member] Purchased Call Options [Member] Purchased Call Options [Member] Purchased Call Options [Member] Deferred issuance costs Deferred issuance costs Deferred issuance costs Purchase call option unwind Purchase call option unwind Purchase call option unwind Warrant unwind Warrant unwind Warrant unwind Convertible note rate conversion trading days (in days) Convertible note rate conversion trading days (in days) Convertible note rate conversion trading days (in days) Convertible Notes rate conversion consecutive trading days (in days) Convertible Notes rate conversion consecutive trading days (in days) Convertible Notes rate conversion consecutive trading days (in days) Fees and Commissions, Transfer Agent (Deprecated 2018-01-31) Noninterest Expense Transfer Agent and Custodian Fees Debt discount recorded to additional paid in capital Debt discount recorded to additional paid in capital Debt discount recorded to additional paid in capital Debt discount recorded to deferred tax liability Debt discount recorded to deferred tax liability Debt discount recorded to deferred tax liability Minimum conversion price percent for note conversion (in Percent) Minimum conversion price percent for note conversion (in Percent) The minimum conversion price of convertible notes in order for holders to convert their notes. Maximum percent of common stock closing price and conversion rate to convert note (in Percent) Maximum percent of common stock closing price and conversion rate to convert note (in Percent) Maximum percent of common stock closing price and conversion rate to convert note. Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Interest Rate, Effective Percentage Estimated market interest rate for similar nonconvertible instrument Estimated market interest rate for similar nonconvertible instrument Estimated market interest rate for similar nonconvertible instrument Debt instrument, convertible, remaining amortization period (in Duration) Debt Instrument, Convertible, Remaining Discount Amortization Period Net proceeds from the issuance of convertible notes Proceeds from Convertible Debt Debt Instrument, Repurchase Amount Debt Instrument, Repurchase Amount Repurchase price upon fundamental change as described in 2021 Notes indenture Repurchase price upon fundamental change as described in 2021 Notes indenture Repurchase price upon fundamental change as described in 2021 Notes indenture Debt instrument, repurchase amount paid Debt instrument, repurchase amount paid Debt instrument, repurchase amount paid Interest Paid, Including Capitalized Interest, Operating and Investing Activities Conversion Rate per $1,000 Principal Amount (in Ratio) Purchased call options cost Purchased call options cost Cost of the purchased call options. Number of shares of common stock covered by the purchased call options purchased (in Shares) Number of shares of common stock covered by the purchased call options purchased (in Shares) The number of shares of common stock covered by the purchased call option. Proceeds from Issuance of Warrants Proceeds from Issuance of Warrants Deferred taxes included in purchased call options cost Deferred taxes included in purchased call options cost The deferred taxes on purchased call options cost. Gain on conversion of convertible notes Gain (Loss) on Extinguishment of Debt Share Price Share Price Repayments of Debt Repayments of Debt Debt Instrument, Periodic Payment, Principal Debt Instrument, Periodic Payment, Principal Debt Instrument, Periodic Payment, Interest Debt Instrument, Periodic Payment, Interest Derivative Instruments Gain Loss By Hedging Relationship By Income Statement Location By Derivative Instrument Risk [Table] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) by Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Derivative Instrument Gain Loss [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Subsequent Events [Text Block] Subsequent Events [Text Block] Summary of cash and available-for-sale securities Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] EX-101.PRE 11 pdli-20190630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 pdllogoa22.jpg begin 644 pdllogoa22.jpg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end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.19.2
Document And Entity Information - shares
 6 Months Ended
Jun. 30, 2019
Jul. 30, 2019
Entity Information [Line Items]    
Entity Emerging Growth Company false  
Entity Small Business false  
Entity Shell Company false  
Entity Registrant Name PDL BIOPHARMA, INC.  
Document Type 10-Q  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding   114,202,671
Amendment Flag false  
Entity Central Index Key 0000882104  
Entity Current Reporting Status Yes  
Entity Filer Category Accelerated Filer  
Document Period End Date Jun. 30, 2019  
Document Fiscal Year Focus 2019  
Document Fiscal Period Focus Q2  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.19.2
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Revenues        
Interest revenue $ 0 $ 751 $ 0 $ 1,500
Revenues (22,526) 46,575 16,387 85,093
Operating expenses        
Cost of Revenue 12,348 14,524 25,158 25,090
Amortization of Intangible Assets 1,598 6,384 3,170 12,677
General and administrative 10,483 14,529 20,945 26,190
Selling and Marketing Expense 2,073 5,385 4,803 10,898
Research and Development Expense 886 684 1,755 1,477
Impairment of Intangible Assets, Finite-lived 0 152,330 0 152,330
Change in fair value of contingent consideration 0 (22,135) 0 (22,735)
Total operating expenses 27,388 171,701 55,831 205,927
Operating loss (49,914) (125,126) (39,444) (120,834)
Non-operating expense, net        
Interest and other income, net 1,650 1,376 3,524 3,290
Interest expense (2,984) (2,811) (5,939) (6,396)
Gain (Loss) on Investments 45,487 0 45,487 0
Total non-operating income (expense), net 44,153 (1,435) 43,072 (3,106)
(Loss) income before income taxes (5,761) (126,561) 3,628 (123,940)
Income tax (benefit) expense (1,247) (14,265) 1,525 (13,246)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest (4,514) (112,296) 2,103 (110,694)
Net Income (Loss) Attributable to Noncontrolling Interest (95) 0 (158) 0
Net (loss) income $ (4,419) $ (112,296) $ 2,261 $ (110,694)
Net income per share        
Basic (in Dollars per Share) $ (0.04) $ (0.76) $ 0.02 $ (0.74)
Net income per diluted share (in Dollars per Share) $ (0.04) $ (0.76) $ 0.02 $ (0.74)
Weighted average shares outstanding        
Basic (in Shares) 118,285 146,923 123,484 149,186
Diluted (in Shares) 118,285 146,923 124,040 149,186
Queen et al. patents [Member]        
Revenues        
Revenues $ 6 $ 1,218 $ 9 $ 4,001
Acquired rights [Member]        
Revenues        
Revenues (40,399) 12,842 (28,142) 23,933
Product Revenue [Member]        
Revenues        
Revenue from Contract with Customer, Including Assessed Tax 17,837 31,761 44,523 55,085
License and other [Member]        
Revenues        
Revenues $ 30 $ 3 $ (3) $ 574
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.19.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $ (4,514) $ (112,296) $ 2,103 $ (110,694)
Other comprehensive income (loss), net of tax        
Change in fair value of investments in available-for-sale securities, net of tax 0 0 0 (578)
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax 0 0 0 603
Total change in unrealized gains (losses) on investments in available-for-sale securities, net of tax [1] 0 0 0 (1,181)
Total other comprehensive income (loss), net of tax 0 0 0 (1,181)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest (4,514) (112,296) 2,103 (111,875)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest (95) 0 (158) 0
Comprehensive income $ (4,419) $ (112,296) $ 2,261 $ (111,875)
[1] Net of tax of
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.19.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parentheticals) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Unrealized gains (losses) on available-for-sale securities, tax $ 0 $ 0 $ 0
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.19.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Other Noncontrolling Interests $ 198 $ 0
Current assets:    
Cash and cash equivalents 284,941 [1],[2] 394,590 [3]
Accounts receivable, net 17,872 [1] 21,648 [3]
Notes receivable 63,280 [1] 63,042 [3]
Prepaid and other current assets 17,347 [1] 18,995 [3]
Total current assets 399,703 [1] 517,217 [3]
Property and equipment, net 6,914 [1] 7,387 [3]
Inventory, Net [1] 16,263 18,942
Royalty rights 315,642 [1] 376,510 [3]
Investments 88,533 0
Notes receivables, long-term 547 [1] 771 [3]
Intangible Assets, Net (Excluding Goodwill) [1] 50,449 51,319
Other assets 28,673 [1] 10,532 [3]
Total assets 890,461 [1] 963,736 [3]
Current liabilities:    
Accounts payable 14,812 [1] 13,142 [3]
Accrued liabilities 23,499 [1] 39,312 [3]
Accrued Income Taxes, Current 25 [1] 16 [3]
Total current liabilities 38,336 [1] 52,470 [3]
Convertible notes payable 128,520 [1] 124,644 [3]
Other long-term liabilities 1,130 465
Total liabilities 225,037 [1] 233,957 [3]
Liabilities, Other than Long-term Debt, Noncurrent 58,181 [1] 56,843 [3]
Commitments and contingencies (Note 12) [1] [3]
Stockholders' deficit:    
Preferred stock, par value $0.01 per share, 10,000 shares authorized; no shares issued and outstanding 0 [1] 0 [3]
Common stock, par value $0.01 per share, 350,000 shares authorized; 145,976 and 153,775 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively 1,157 [1] 1,365 [3]
Additional paid-in capital (94,465) [1] (98,030) [3]
Treasury Stock, Value 546 2,103
Retained earnings 759,080 [1] 828,547 [3]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 665,424 729,779
Total liabilities and stockholders’ equity 890,461 [1] 963,736 [3]
Total PDL’s stockholders’ equity $ 665,226 [1] $ 729,779 [3]
[1] unaudited
[2] unaudited
[3] Note 1
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.19.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares
shares in Thousands
Jun. 30, 2019
 [1]
Dec. 31, 2018
 [2]
Preferred stock par value (in Dollars per Share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in Shares) 10,000 10,000
Preferred stock, shares issued (in Shares) 0 0
Preferred stock, shares outstanding (in Shares) 0 0
Common stock par value (in Dollars per Share) $ 0.01 $ 0.01
Common stock, shares authorized (in Shares) 350,000 350,000
Common stock, shares issued (in Shares) 123,817 136,513
Common stock, shares outstanding (in Shares) 123,817 136,513
[1] unaudited
[2] Note 1
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.19.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Payments to Acquire Interest in Subsidiaries and Affiliates $ (60,000)  
Payment for Contingent Consideration Liability, Financing Activities 1,071 $ 0
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 2,103 (110,694)
Assets held for sale reclassified from other assets to intangibles 0 1,811
Payments to Acquire Intangible Assets 1,700 0
Adjustments to reconcile net income to net cash provided by operating activities:    
Amortization of convertible notes 3,876 3,911
Amortization of Intangible Assets 3,170 12,677
Amortization Of Right of Use Assets 441  
Impairment of Intangible Assets, Finite-lived 0 152,330
Change in fair value of acquired royalty rights 28,142 (23,933)
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount (37,907)  
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Change in Unrealized Gain (Loss) (7,577) (74)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability 0 (22,735)
Depreciation, Amortization and Accretion, Net 1,649 2,028
Gain (Loss) on Sale of Investments 0 (764)
Gain (Loss) on Disposition of Property Plant Equipment 0 66
Provision for Doubtful Accounts (7) 43
Stock-based compensation expense 3,344 2,218
Deferred income taxes (125) (11,276)
Changes in assets and liabilities:    
Receivables from licensees and other 3,546 11,709
Prepaid and other current assets 1,647 (6,816)
Accrued interest on notes receivable 0 (150)
Increase (Decrease) in Inventories 1,857 (5,834)
Other assets 476 (1,531)
Accounts payable 1,670 (8,679)
Accrued liabilities (14,656) (11,759)
Increase (Decrease) in Income Taxes Payable 9 (1,159)
Other long-term liabilities 167 666
Net cash used in operating activities (8,175) (19,756)
Cash flows from investing activities    
Proceeds from Sale of Available-for-sale Securities, Equity 0 4,116
Payments for (Proceeds from) Productive Assets 32,726 37,993
Payments to Acquire Property, Plant, and Equipment 163 3,915
Net cash (used in) provided by investing activities (29,137) 38,194
Cash flows from financing activities    
Repayments of Secured Debt 0 126,447
Payments for Repurchase of Common Stock (71,266) (23,604)
Net cash used in financing activities (72,337) (150,051)
Net decrease in cash and cash equivalents (109,649) (131,613)
Cash and cash equivalents at beginning of the period [1] 394,590 527,266
Cash and cash equivalents at end of period [3] 284,941 [2] 395,653
Supplemental cash flow information    
Cash (refunded) paid for income taxes (2,693) 3,980
Cash paid for interest $ 2,063 $ 4,591
[1] Note 1
[2] unaudited
[3] unaudited
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.19.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement - USD ($)
$ in Thousands
Total
Common Stock [Member]
Treasury Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Noncontrolling Interest [Member]
Shares, Issued at Dec. 31, 2017 153,774,756            
Stockholders' Equity Attributable to Parent at Dec. 31, 2017 $ 845,890 $ 1,538 $ 0 $ (102,443) $ 945,614 $ 1,181  
Other Noncontrolling Interests at Dec. 31, 2017 $ 0            
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures 37,500            
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition $ 957            
Stock Repurchased During Period, Shares (1,000,000)            
Treasury Stock, Retired, Par Value Method, Amount $ (10)            
Treasury Stock, Value, Acquired, Cost Method 1,188            
Treasury Stock, Retired, Cost Method, Amount 2,961            
Stock Repurchased and Retired During Period, Value (4,159)            
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax (1,181)         (1,181)  
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 421            
Net Income (Loss) Attributable to Parent $ 1,602       1,602    
Shares, Issued at Mar. 31, 2018 152,812,256            
Other Noncontrolling Interests at Mar. 31, 2018 $ 0            
Stockholders' Equity Attributable to Parent at Mar. 31, 2018 $ 843,109 1,528 (1,188) (101,486) 944,255 0  
Shares, Issued at Dec. 31, 2017 153,774,756            
Stockholders' Equity Attributable to Parent at Dec. 31, 2017 $ 845,890 1,538 0 (102,443) 945,614 1,181  
Other Noncontrolling Interests at Dec. 31, 2017 0            
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax [1] (1,181)            
Comprehensive Income (Loss), Net of Tax, Attributable to Parent (111,875)            
Net Income (Loss) Attributable to Parent (110,694)            
Net Income (Loss) Attributable to Noncontrolling Interest 0            
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest (110,694)            
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest $ (111,875)            
Shares, Issued at Jun. 30, 2018 145,971,432            
Other Noncontrolling Interests at Jun. 30, 2018 $ 0            
Stockholders' Equity Attributable to Parent at Jun. 30, 2018 $ 712,628 1,460   (100,229)   0  
Shares, Issued at Mar. 31, 2018 152,812,256            
Stockholders' Equity Attributable to Parent at Mar. 31, 2018 $ 843,109 1,528 (1,188) (101,486) 944,255 0  
Other Noncontrolling Interests at Mar. 31, 2018 $ 0            
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures 324,591            
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures $ (4) (4)   (3)      
Restricted Stock Award, Forfeitures, Dividends 3            
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition $ 1,260            
Stock Repurchased During Period, Shares (7,165,415)            
Treasury Stock, Retired, Par Value Method, Amount $ (72)            
Reduction in Treasury stock held 1,188            
Treasury Stock, Retired, Cost Method, Amount 20,565            
Stock Repurchased and Retired During Period, Value (19,449)            
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax [1] 0            
Comprehensive Income (Loss), Net of Tax, Attributable to Parent (112,296)            
Net Income (Loss) Attributable to Parent (112,296)       (112,296)    
Net Income (Loss) Attributable to Noncontrolling Interest 0            
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest (112,296)            
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest $ (112,296)            
Shares, Issued at Jun. 30, 2018 145,971,432            
Other Noncontrolling Interests at Jun. 30, 2018 $ 0            
Stockholders' Equity Attributable to Parent at Jun. 30, 2018 $ 712,628 1,460   (100,229)   0  
Shares, Issued at Dec. 31, 2018 136,512,522            
Stockholders' Equity Attributable to Parent at Dec. 31, 2018 $ 729,779 [2] 1,365 (2,103) (98,030) 828,547 0  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Dec. 31, 2018 729,779            
Other Noncontrolling Interests at Dec. 31, 2018 $ 0            
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures 764,785            
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures   (8)   (8)      
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition $ 1,169            
Stock Repurchased During Period, Shares (13,460,164)            
Treasury Stock, Retired, Par Value Method, Amount $ (135)            
Reduction in Treasury stock held 613            
Treasury Stock, Retired, Cost Method, Amount 44,831            
Stock Repurchased and Retired During Period, Value (44,353)            
Noncontrolling Interest, Increase from Subsidiary Equity Issuance 572            
Net Income (Loss) Attributable to Parent         6,680    
Net Income (Loss) Attributable to Noncontrolling Interest (63)            
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6,617            
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest $ 6,617            
Shares, Issued at Mar. 31, 2019 123,817,143            
Other Noncontrolling Interests at Mar. 31, 2019 $ 509            
Stockholders' Equity Attributable to Parent at Mar. 31, 2019   1,238 (1,490) (96,869) 790,396 0  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Mar. 31, 2019 $ 693,784            
Shares, Issued at Dec. 31, 2018 136,512,522            
Stockholders' Equity Attributable to Parent at Dec. 31, 2018 $ 729,779 [2] 1,365 (2,103) (98,030) 828,547 0  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Dec. 31, 2018 729,779            
Other Noncontrolling Interests at Dec. 31, 2018 0            
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax [1] 0            
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 2,261            
Net Income (Loss) Attributable to Parent 2,261            
Net Income (Loss) Attributable to Noncontrolling Interest (158)            
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 2,103            
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest $ 2,103            
Shares, Issued at Jun. 30, 2019 115,669,169            
Other Noncontrolling Interests at Jun. 30, 2019 $ 198            
Stockholders' Equity Attributable to Parent at Jun. 30, 2019 665,226 [3] 1,157 (546) (94,465) 759,080 0  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Jun. 30, 2019 $ 665,424            
Shares, Issued at Mar. 31, 2019 123,817,143            
Stockholders' Equity Attributable to Parent at Mar. 31, 2019   1,238 (1,490) (96,869) 790,396 0  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Mar. 31, 2019 $ 693,784            
Other Noncontrolling Interests at Mar. 31, 2019 $ 509            
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures 37,996            
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition $ 2,175            
Stock Repurchased During Period, Shares (8,185,970)            
Treasury Stock, Retired, Par Value Method, Amount $ (81)            
Reduction in Treasury stock held 944            
Treasury Stock, Retired, Cost Method, Amount 26,897            
Adjustments to Additional Paid in Capital, Other             $ 229
Noncontrolling Interest, Period Increase (Decrease) (216)            
Stock Repurchased and Retired During Period, Value (26,034)            
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax [1] 0            
Comprehensive Income (Loss), Net of Tax, Attributable to Parent (4,419)            
Noncontrolling Interest, Increase from Subsidiary Equity Issuance 13            
Net Income (Loss) Attributable to Parent (4,419)       (4,419)    
Net Income (Loss) Attributable to Noncontrolling Interest (95)            
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest (4,514)            
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest $ (4,514)            
Shares, Issued at Jun. 30, 2019 115,669,169            
Other Noncontrolling Interests at Jun. 30, 2019 $ 198            
Stockholders' Equity Attributable to Parent at Jun. 30, 2019 665,226 [3] $ 1,157 $ (546) $ (94,465) $ 759,080 $ 0  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Jun. 30, 2019 $ 665,424            
[1] Net of tax of
[2] Note 1
[3] unaudited
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.19.2
Summary of Significant Accounting Policies
 6 Months Ended
Jun. 30, 2019
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
1. Summary of Significant Accounting Policies
 
Basis of Presentation
 
The accompanying unaudited Condensed Consolidated Financial Statements of PDL Biopharma, Inc. and its subsidiaries (collectively, the “Company” or “PDL”) have been prepared in accordance with Generally Accepted Accounting Principles (United States) (“GAAP”) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments), that management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year.
 
The accompanying unaudited Condensed Consolidated Financial Statements and related financial information should be read in conjunction with the Company’s audited Consolidated Financial Statements and the related notes thereto for the year ended December 31, 2018, included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the Securities and Exchange Commission (“SEC”) on March 15, 2019. The Condensed Consolidated Balance Sheet at December 31, 2018, included herein, has been derived from the audited Consolidated Financial Statements at that date, but does not include all disclosures required by GAAP.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying Notes to the Condensed Consolidated Financial Statements. The accounting estimates that require management’s most significant, difficult and subjective judgments include the valuation of royalty rights - at fair value, product revenue recognition and allowance for customer rebates and allowances, the valuation of notes receivable and inventory, the assessment of recoverability of intangible assets and their estimated useful lives, the valuation and recognition of stock-based compensation, the recognition and measurement of current and deferred income tax assets and liabilities, and the valuation of warrants to acquire shares of common stock. Actual results could differ from those estimates.

The Condensed Consolidated Financial Statements included herein include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Based on the nature of the Company’s existing investments and how they are managed, the Company structured its operations in four segments designated as Pharmaceutical, Medical Devices, Strategic Positions and Income Generating Assets. During the second quarter of 2019 the Company made an investment in Evofem Biosciences, Inc. (“Evofem”) and added a new segment designated as Strategic Positions. This had no impact on its prior segment reporting structure.
•
The Company’s Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna® and Tekturna HCT® in the United States and Rasilez® and Rasilez HCT® in the rest of the world and an authorized generic form of Tekturna sold in the United States (collectively, the “Noden Products”). The branded prescription Noden Products were acquired from Novartis in July 2016 (the “Noden Transaction”) by the Company’s wholly-owned subsidiary, Noden Pharma DAC (“Noden DAC”). The Company, through its wholly-owned subsidiary, Noden Pharma USA Inc. (“Noden USA”) launched its authorized generic form of Tekturna in the United States in March 2019.
•
The Company’s Medical Devices segment consists of revenue derived from the LENSAR® Laser System sales made by the Company’s subsidiary, LENSAR, Inc. (“LENSAR”), which may include equipment, Patient Interface Devices (“PIDs” or “consumables”), procedure licenses, training, installation, warranty and maintenance agreements.
•
The Company’s Strategic Positions segment consists of an investment in Evofem. The Company’s investment includes shares of common stock and warrants to purchase additional shares of common stock. Evofem is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Evofem is leveraging its proprietary Multipurpose Vaginal pH Regulator (MVP-R™) platform to develop Amphora® (L-lactic acid, citric acid and potassium bitartrate) for hormone-free birth control.
•
The Company’s Income Generating Assets segment consists of revenue derived from (i) royalty rights - at fair value, (ii) notes and other long-term receivables, (iii) equity investments and (iv) royalties from issued patents in the United States and elsewhere covering the humanization of antibodies (“Queen et al. patents”).

Significant Accounting Policies

The Company’s significant accounting policies are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018. Summarized below and in Note 2, Investment in Evofem Biosciences, Inc., are the accounting pronouncements and policies adopted subsequent to December 31, 2018.

Adopted Accounting Pronouncements

Leases

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases, that supersedes Accounting Standards Codification (“ASC”) 840, Leases. Subsequently, the FASB issued several updates to ASU No. 2016-02, codified in ASC Topic 842 (“ASC 842”). The Company adopted ASC 842, Leases, on January 1, 2019 using the modified retrospective method for all leases not substantially completed as of the date of adoption. The reported results for the three and six month periods ended June 30, 2019 reflect the application of ASC 842 guidance while the reported results for the three and six month periods ended June 30, 2018 were prepared under the guidance of ASC 840, which is also referred to herein as “legacy GAAP” or the “previous guidance”. The cumulative impact of the adoption of ASC 842 was not material, therefore, the Company did not record any adjustments to retained earnings. As a result of adopting ASC 842, the Company recorded operating lease right-of-use (“ROU”) assets of $2.1 million and operating lease liabilities of $2.1 million, primarily related to corporate office leases, based on the present value of the future lease payments on the date of adoption. Changes to lessor accounting focused on conforming with certain changes made to lessee accounting and the recently adopted revenue recognition guidance. The adoption of ASC 842 did not materially change how the Company accounts for lessor arrangements.
Policy Elections and Practical Expedients Taken
For leases that commenced before the effective date of ASC 842, the Company elected the practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases.
The Company adopted a policy of expensing short-term leases, defined as 12 months or less, as incurred.
The Company has a policy to exclude from the consideration in a lessor contract all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific lease revenue-producing transaction and collected by the Company from a lessee.
General
The Company determines if an arrangement is a lease or contains an embedded lease at inception. The Company has lease arrangements with lease and non-lease components, which are accounted for separately.
Lessee arrangements
Lessee operating leases are included in Other assets, Accrued liabilities, and Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheet. The Company does not have lessee financing leases.
Operating lease ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses the implicit rate when readily determinable at lease inception. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company’s remaining lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis as operating expense in the Condensed Consolidated Statements of Operations over the lease term.
Lessor arrangements
The Company leases medical device equipment to customers in both operating lease and sales-type lease arrangements generated from its Medical Devices segment.
For sales-type leases, the Company derecognizes the carrying amount of the underlying asset and capitalizes the net investment in the lease, which consists of the total minimum lease payments receivable from the lessee, at lease inception. The Company does not estimate an unguaranteed residual value of the equipment at lease termination because the equipment transfers to the lessee upon completion of the lease. Selling profit or loss is recognized at lease inception. Initial direct costs are recognized as an expense, unless there is no selling profit or loss. If there is no selling profit or loss, initial direct costs are deferred and recognized over the lease term. The Company recognizes interest income from the lease receivable over the lease term in Interest and other income, net in the Condensed Consolidated Statements of Operations.
 
For operating leases, rental income is recognized on a straight-line basis over the lease term. The cost of customer-leased equipment is recorded within Property and equipment, net in the accompanying Condensed Consolidated Balance Sheets and depreciated over the equipment’s estimated useful life. Depreciation expense associated with the leased equipment under operating lease arrangements is reflected in Cost of product revenue in the accompanying Condensed Consolidated Statements of Operations. Some of the Company’s operating leases include a purchase option for the customer to purchase the leased asset at the end of the lease arrangement. The Company manages its risk on its investment in the equipment through pricing and the term of the leases. Lessees do not provide residual value guarantees on leased equipment. Equipment returned to the Company may be leased or sold to other customers. Initial direct costs are deferred and recognized over the lease term.

Leases are generally not cancellable until after an initial term and may or may not require the customer to purchase a minimum number of procedures and consumables throughout the contract term.

For lease arrangements with lease and non-lease components where the Company is the lessor, the Company allocates the contract’s transaction price to the lease and non-lease components on a relative standalone selling price basis using the Company’s best estimate of the standalone selling price of each distinct product or service in the contract. Allocation of the transaction price is determined at the inception of the lease arrangement. The Company’s leases primarily consist of leases with fixed lease payments. For those leases with variable lease payments, the variable lease payment is typically based upon use of the leased equipment or the purchase of procedure licenses and consumables used with the leased equipment. Non-lease components are accounted for under ASC 606, Revenue from Contracts with Customers. For additional information regarding ASC 606, see Note 15, Revenue from Contracts with Customers.
Intangibles-Goodwill and Other
In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other: Simplifying the Test for Goodwill Impairment, to simplify the subsequent measurement of goodwill by eliminating step two from the goodwill impairment test. Under the amendments, an entity will recognize an impairment charge for the amount by which the carrying value exceeds the fair value. The amendments are effective for fiscal years and interim periods within those years beginning after December 15, 2019 on a prospective basis and early adoption is permitted. The Company adopted the requirements of ASU No. 2017-04 on January 1, 2019. The adoption did not have an effect on the Company’s Consolidated Financial Statements on the adoption date.

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. The new guidance amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses. ASU No. 2016-13 has an effective date of the fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is currently evaluating the impact of this guidance on its Consolidated Financial Statements.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement. The new guidance modifies disclosure requirements related to fair value measurement. The amendments in ASU No. 2018-13 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Implementation on a prospective or retrospective basis varies by specific disclosure requirement. Early adoption is permitted. The standard also allows for early adoption of any removed or modified disclosures upon issuance of ASU No. 2018-13 while delaying adoption of the additional disclosures until their effective date. The Company is currently evaluating the impact of this guidance on the its Consolidated Financial Statement disclosures.

In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software. The new guidance reduces complexity for the accounting for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). For public companies, the amendments in ASU No. 2018-15 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. Implementation should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The Company is currently evaluating the impact of this guidance on the Company’s Consolidated Financial Statements.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.19.2
Net Income per Share
 6 Months Ended
Jun. 30, 2019
Earnings Per Share [Abstract]  
Net Income per Share
. Net (Loss) Income per Share
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
Net (Loss) Income per Basic and Diluted Share
 
2019
 
2018
 
2019
 
2018
 (in thousands, except per share amounts)
 
 
 
 
 
 
 
 
Numerator
 
 
 
 
 
 
 
 
(Loss) income attributable to PDL’s shareholders used to compute net (loss) income per basic and diluted share
 
$
(4,419
)
 
$
(112,296
)
 
$
2,261

 
$
(110,694
)
 
 
 
 
 
 
 
 
 
Denominator
 
 

 
 

 
 
 
 
Total weighted-average shares used to compute net (loss) income attributable to PDL’s shareholders, per basic share
 
118,285

 
146,923

 
123,484

 
149,186

Restricted stock
 
—

 
—

 
507

 
—

Stock options
 
—

 
—

 
49

 
—

Shares used to compute net (loss) income attributable to PDL’s shareholders, per diluted share
 
118,285

 
146,923

 
124,040

 
149,186

 
 
 
 
 
 
 
 
 
Net (loss) income attributable to PDL’s shareholders per share - basic
 
$
(0.04
)
 
$
(0.76
)
 
$
0.02

 
$
(0.74
)
Net (loss) income attributable to PDL’s shareholders per share - diluted
 
$
(0.04
)
 
$
(0.76
)
 
$
0.02

 
$
(0.74
)


The Company computes net (loss) income per diluted share using the sum of the weighted-average number of common and common equivalent shares outstanding. Common equivalent shares used in the computation of net (loss) income per diluted share include shares that may be issued pursuant to outstanding stock options and restricted stock awards, the 4.0% Convertible Senior Notes due February 1, 2018 (the “February 2018 Notes”) that were repaid on February 1, 2018, and the 2.75% Convertible Senior Notes due December 1, 2021 (the “December 2021 Notes”), in each case, on a weighted-average basis for the period that the notes were outstanding, including, if applicable, the underlying shares using the treasury stock method.

December 2021 Notes Capped Call Potential Dilution

In November 2016, the Company issued $150.0 million in aggregate principal of the December 2021 Notes, which provide in certain situations for the conversion of the outstanding principal amount of the December 2021 Notes into shares of the Company’s common stock at a predefined conversion rate. In conjunction with the issuance of the December 2021 Notes, the Company entered into a capped call transaction with a hedge counterparty. The capped call transaction is expected generally to reduce the potential dilution, and/or offset, to an extent, the cash payments the Company may choose to make in excess of the principal amount, upon conversion of the December 2021 Notes. The Company has excluded the capped call transaction from the net (loss) income per diluted share computation as such securities would have an anti-dilutive effect and those securities should be considered separately rather than in the aggregate in determining whether their effect on net (loss) income per diluted share would be dilutive or anti-dilutive. For additional information regarding the conversion rates and the capped call transaction related to the Company’s December 2021 Notes, see Note 10, Convertible Senior Notes.

Anti-Dilutive Effect of Restricted Stock Awards and Stock Options

For the three months ended June 30, 2019 and 2018, the Company excluded approximately 1.1 million and 1.0 million shares underlying restricted stock awards, respectively, and for the six months ended June 30, 2019 and 2018, the Company excluded approximately 0.8 million and 1.1 million shares underlying restricted stock awards, respectively, in each case calculated on a weighted-average basis, from its net (loss) income per diluted share calculations because their effect was anti-dilutive.

For the three months ended June 30, 2019 and 2018, the Company excluded approximately 12.7 million and 4.9 million shares underlying outstanding stock options, respectively, and for the six months ended June 30, 2019 and 2018, the Company excluded approximately 10.4 million and 4.9 million shares underlying outstanding stock options, respectively, in each case calculated on a weighted-average basis, from its net (loss) income per diluted share calculations because their effect was anti-dilutive.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.19.2
Fair Value Measurements
 6 Months Ended
Jun. 30, 2019
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Fair Value Measurements

The fair value of the Company’s financial instruments are estimates of the amounts that would be received if the Company were to sell an asset or pay to transfer a liability in an orderly transaction between market participants at the measurement date or exit price. The assets and liabilities are categorized and disclosed in one of the following three categories:

Level 1 – based on quoted market prices in active markets for identical assets and liabilities;
 
Level 2 – based on observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
 
Level 3 – based on unobservable inputs using management’s best estimate and assumptions when inputs are unavailable.

Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis

The following table presents the fair value of the Company’s financial instruments measured at fair value on a recurring basis by level within the valuation hierarchy:
 
 
June 30, 2019
 
December 31, 2018
(in thousands)
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market funds
 
$
228,954

 
$
—

 
$
—

 
$
228,954

 
$
226,719

 
$
—

 
$
—

 
$
226,719

Corporate securities(1)
 
88,533

 
—

 
—

 
88,533

 
—

 
—

 
—

 
—

Warrants(2)
 
—

 
17,013

 
—

 
17,013

 
—

 
62

 
—

 
62

Royalty rights - at fair value
 
—

 
—

 
315,642

 
315,642

 
—

 
—

 
376,510

 
376,510

Total
 
$
317,487

 
$
17,013

 
$
315,642

 
$
650,142

 
$
226,719

 
$
62

 
$
376,510

 
$
603,291

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial liabilities:
 
 

 
 

 
 
 
 

 
 

 
 

 
 
 
 

Contingent consideration, current(3)
 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
1,071

 
$
1,071

Total
 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
1,071

 
$
1,071


___________________
(1) 
Corporate securities are classified as “Investment in equity affiliate” on the Condensed Consolidated Balance Sheet.
(2) 
Warrants are included in “Other assets” on the Condensed Consolidated Balance Sheets.
(3) 
Contingent consideration, current is classified as “Accrued liabilities” on the Condensed Consolidated Balance Sheet.

There have been no transfers between levels during the periods presented in the table above. The Company recognizes transfers between levels on the date of the event or change in circumstances that caused the transfer.

Money Market Funds - The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.

Corporate Securities - Corporate securities consists of common stock shares of Evofem, a clinical-stage biopharmaceutical company listed on Nasdaq. For additional information on the Evofem investment, see Note 2, Investment in Evofem.

Warrants - Warrants consist of rights to purchase shares of common stock in Evofem and CareView Communications, Inc. (“CareView”), see Note 2, Investment in Evofem, and Note 6, Notes and Other Long-Term Receivables. The fair value of the warrants is estimated using recently quoted market prices of the underlying equity security and the Black-Scholes option pricing model.

Royalty Rights - At Fair Value

Assertio (Depomed) Royalty Agreement

On October 18, 2013, the Company entered into the Royalty Purchase and Sale Agreement (the “Assertio Royalty Agreement”) with Assertio Therapeutics, Inc. (formerly known as Depomed, Inc.), and Depo DR Sub, LLC (together, “Assertio”), whereby the Company acquired the rights to receive royalties and milestones payable on sales of five Type 2 diabetes products licensed by Assertio in exchange for a $240.5 million cash payment. Total consideration was $241.3 million, which was comprised of the $240.5 million cash payment to Assertio and $0.8 million in transaction costs.

The rights acquired include Assertio’s royalty and milestone payments accruing from and after October 1, 2013: (a) from Santarus, Inc. (“Santarus”), which was subsequently acquired by Salix Pharmaceuticals, Inc. (“Salix”), which itself was acquired by Valeant Pharmaceuticals International, Inc. (“Valeant”), which, in July 2018, changed its name to Bausch Health Companies Inc. (“Bausch Health”) with respect to sales of Glumetza (metformin HCL extended-release tablets) in the United States; (b) from Merck & Co., Inc. with respect to sales of Janumet® XR (sitagliptin and metformin HCL extended-release tablets); (c) from Janssen Pharmaceutica N.V. with respect to potential future development milestones and sales of its approved fixed-dose combination of Invokana® (canagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor) and extended-release metformin tablets, marketed as Invokamet XR®; (d) from Boehringer Ingelheim and Eli Lilly and Company with respect to potential future development milestones and sales of the investigational fixed-dose combinations of drugs and extended-release metformin subject to Assertio’s license agreement with Boehringer Ingelheim, including its approved products, Jentadueto XR® and Synjardy XR®; and (e) from LG Life Sciences and Bausch Health for sales of extended-release metformin tablets in Korea and Canada, respectively.

In February 2013, a generic equivalent to Glumetza was approved by the U.S. Food and Drug Administration (“FDA”) and in August 2016, two additional generic equivalents to Glumetza were approved by the FDA. In February 2016, Lupin Pharmaceuticals, Inc., in August 2017, Teva Pharmaceutical Industries Ltd., and in July 2018, Sun Pharmaceutical, Inc. (“Sun”) each launched a generic equivalent approved product. In May 2017, the Company received notification that a subsidiary of Valeant had launched an authorized generic equivalent product in February 2017, and the Company received royalties on such authorized generic equivalent product under the same terms as the branded Glumetza product, retroactive to February 2017. The Company continues to monitor whether the generic competition further affects sales of Glumetza and thus royalties on such sales paid to the Company, and the impact of the launched authorized generic equivalent. Due to the uncertainty around Bausch Health’s marketing and pricing strategy, as well as Sun’s recently launched generic product and limited historical demand data after generic market entrance, the Company may need to further evaluate future cash flows in the event of more rapid reduction or increase in market share of Glumetza and its authorized generic equivalent product and/or a further erosion in net pricing.

The Company determined that its royalty purchase interest in Depo DR Sub, LLC represented a variable interest in a variable interest entity. However, the Company did not have the power to direct the activities of Depo DR Sub, LLC that most significantly impact Depo DR Sub, LLC’s economic performance and was not the primary beneficiary of Depo DR Sub, LLC; therefore, Depo DR Sub, LLC was not subject to consolidation by the Company.

On August 2, 2018, PDL Investment Holding, LLC (“PDLIH”), a wholly-owned subsidiary of the Company and assignee from the Company under the Assertio Royalty Agreement, entered into an amendment to the Assertio Royalty Agreement with Assertio. Pursuant to the amendment, PDLIH purchased all of Assertio’s remaining interests in royalty and milestone payments payable on sales of Type 2 diabetes products licensed by Assertio for $20.0 million. Prior to the amendment, the Assertio Royalty Agreement provided that the Company would have received all royalty and milestone payments due under license agreements between Assertio and its licensees until the Company received payments equal to two times the cash payment it made to Assertio, or approximately $481.0 million, after which all net payments received by Assertio would have been shared equally between the Company and Assertio. Following the amendment, the Assertio Royalty Agreement provides that the Company will receive all royalty and milestone payments due under the license agreements between Assertio and its licensees. The Company has elected to continue to follow the fair value option and carry the financial asset at fair value.

The Assertio Royalty Agreement terminates on the third anniversary following the date upon which the later of the following occurs: (a) October 25, 2021, or (b) at such time as no royalty payments remain payable under any license agreement and each of the license agreements has expired by its terms.

As of December 31, 2018, in conjunction with the amendment described above, the Company was provided the power to direct the activities of Depo DR Sub, LLC and is the primary beneficiary of Depo DR Sub, LLC; therefore, Depo DR Sub, LLC is subject to consolidation by the Company. As of June 30, 2019, Depo DR Sub, LLC did not have any assets or liabilities of value for consolidation with the Company.

In October 2018, PDL submitted notice of its intent to exercise its audit right under the Assertio Royalty Agreement with respect to Glumetza royalties for the period beginning January 1, 2016 and ending December 31, 2018. No material adjustments were identified in connection with this audit.

The financial asset acquired represents a single unit of accounting. This financial asset is classified as a Level 3 asset within the fair value hierarchy, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future commercialization for products not yet approved by regulatory agencies outside of the United States. The estimated fair value of the financial asset acquired was determined by using a discounted cash flow analysis related to the expected future cash flows to be generated by each licensed product. The discounted cash flows are based upon expected royalties from sales of licensed products over approximately an eight-year period. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. The Company periodically assesses the expected future cash flows and to the extent such payments are greater or less than its initial estimates, or the timing of such payments is materially different than the original estimates, the Company will adjust the estimated fair value of the asset. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $6.6 million, respectively. Significant judgment is required in selecting appropriate discount rates. The discount rates utilized range from 10% to 24%. Should these discount rates increase or decrease by 2.5%, the fair value of the asset could decrease by $22.2 million or increase by $26.3 million, respectively.

As of June 30, 2019, the Company’s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date for the above described royalty streams.

As of June 30, 2019, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was $263.9 million and the maximum loss exposure was $263.9 million.

Viscogliosi Brothers Royalty Agreement

On June 26, 2014, the Company entered into a Royalty Purchase and Sale Agreement (the “VB Royalty Agreement”) with Viscogliosi Brothers, LLC (“VB”), whereby VB conveyed to the Company the right to receive royalties payable on sales of a spinal implant that has received pre-market approval from the FDA held by VB and commercialized by Paradigm Spine, LLC (“Paradigm Spine”), in exchange for a $15.5 million cash payment, less fees. Paradigm Spine was acquired in March 2019 by RTI Surgical Holdings, Inc.

The royalty rights acquired include royalties accruing from and after April 1, 2014. Under the terms of the VB Royalty Agreement, the Company receives all royalty payments due to VB pursuant to certain technology transfer agreements between VB and Paradigm Spine until the Company has received payments equal to 2.3 times the cash payment made to VB, after which all rights to receive royalties will be returned to VB. VB’s ability to repurchase the royalty right for a specified amount expired on June 26, 2018.

The estimated fair value of the royalty rights at June 30, 2019, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over approximately a nine-year period. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. The Company periodically assesses the expected future cash flows and to the extent such payments are greater or less than its initial estimates, or the timing of such payments is materially different than the original estimates, the Company will adjust the estimated fair value of the asset. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.4 million, respectively. Significant judgment is required in selecting the appropriate discount rate. The discount rate utilized was 15.0%. Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $1.3 million or increase by $1.5 million, respectively.

As of June 30, 2019, the Company’s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date.

As of June 30, 2019, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was $14.4 million and the maximum loss exposure was $14.4 million.

University of Michigan Royalty Agreement

On November 6, 2014, the Company acquired a portion of all royalty payments of the Regents of the University of Michigan’s (“U-M”) worldwide royalty interest in Cerdelga® (eliglustat) for $65.6 million pursuant to the Royalty Purchase and Sale Agreement with U-M (the “U-M Royalty Agreement”). Under the terms of the U-M Royalty Agreement, the Company receives 75% of all royalty payments due under U-M’s license agreement with Genzyme Corporation, a Sanofi company (“Genzyme”) until expiration of the licensed patents, excluding any patent term extension. Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme. Cerdelga was approved in the United States in August 2014, in the European Union in January 2015, and in Japan in March 2015. In addition, marketing applications for Cerdelga are under review by other regulatory authorities. While marketing applications have been approved in the United States, the European Union and Japan, national pricing and reimbursement decisions are delayed in some countries.

The estimated fair value of the royalty right at June 30, 2019 was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over approximately a three-year period. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. An evaluation of those estimates, discount rate utilized and general market conditions affecting fair market value is performed in each reporting period. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.6 million, respectively. Significant judgment is required in selecting the appropriate discount rate. The discount rate utilized was approximately 12.8%. Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $0.9 million or increase by $1.0 million, respectively.

As of June 30, 2019, the Company’s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows.

As of June 30, 2019, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was $24.3 million and the maximum loss exposure was $24.3 million.

AcelRx Royalty Agreement

On September 18, 2015, the Company entered into a royalty interest assignment agreement (the “AcelRx Royalty Agreement”) with ARPI LLC, a wholly-owned subsidiary of AcelRx Pharmaceuticals, Inc. (“AcelRx”), whereby the Company acquired the rights to receive a portion of the royalties and certain milestone payments on sales of Zalviso® (sufentanil sublingual tablet system) in the European Union, Switzerland and Australia by AcelRx’s commercial partner, Grünenthal, in exchange for a $65.0 million cash payment. Under the terms of the AcelRx Royalty Agreement, the Company receives 75% of all royalty payments and 80% of the first four commercial milestone payments due under AcelRx’s license agreement with Grünenthal until the earlier to occur of (i) receipt by the Company of payments equal to three times the cash payments made to AcelRx and (ii) the expiration of the licensed patents. Zalviso received marketing approval by the European Commission in September 2015. Grünenthal launched Zalviso in the second quarter of 2016 and the Company started to receive royalties in the third quarter of 2016.

As of June 30, 2019, and December 31, 2018, the Company determined that its royalty rights under the AcelRx Royalty Agreement represented a variable interest in a variable interest entity. However, the Company does not have the power to direct the activities of ARPI LLC that most significantly impact ARPI LLC’s economic performance and is not the primary beneficiary of ARPI LLC; therefore, ARPI LLC is not subject to consolidation by the Company.

Due to the slower than expected adoption of the product since its initial launch relative to the Company’s estimates and the increased variance noted between the Company’s forecast model and actual results in the three months ended June 30, 2019, the Company utilized a third-party expert in the second quarter of 2019 to reassess the market and expectations for the Zalviso product. Key findings from the third-party study included: the post-surgical PCA (Patient-Controlled Analgesia) market being smaller than previously forecasted; the higher price of the product relative to alternative therapies, the product not being used as a replacement for systemic opioids and the design of the delivery device, which is pre-filled for up to three days of treatment, which restricts its use for shorter recovery time procedures. Based on this analysis and the impact to the projected sales-based royalties and milestones, the Company wrote down the fair value of the royalty asset by $60.0 million in the second quarter of 2019.

The estimated fair value of the royalty right at June 30, 2019 was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over approximately a fourteen-year period. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. An evaluation of those estimates, discount rate utilized and general market conditions affecting fair market valuation is performed for each reporting period. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by less than $0.3 million, respectively. Significant judgment is required in selecting the appropriate discount rate. The discount rate utilized was approximately 13.4%. Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $1.2 million or increase by $1.5 million, respectively.

As of June 30, 2019, the Company’s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date.

As of June 30, 2019, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was $12.5 million and the maximum loss exposure was $12.5 million.

Kybella Royalty Agreement

On July 8, 2016, the Company entered into a royalty purchase and sales agreement with an individual, whereby the Company acquired that individual’s rights to receive certain royalties on sales of KYBELLA® by Allergan plc in exchange for a $9.5 million cash payment and up to $1.0 million in future milestone payments based upon product sales targets. The Company started to receive royalty payments during the third quarter of 2016.

The estimated fair value of the royalty right at June 30, 2019, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of a licensed product over approximately a six-year period. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. An evaluation of those estimates, discount rate utilized and general market conditions affecting fair market value is performed in each reporting period. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by less than $0.1 million, respectively. Significant judgment is required in selecting the appropriate discount rate. The discount rate utilized was approximately 14.4%. Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease or increase by less than $0.1 million, respectively.

As of June 30, 2019, the Company’s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date.

As of June 30, 2019, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was $0.6 million and the maximum loss exposure was $0.6 million.

The following tables summarize the changes in Level 3 Royalty Right Assets and the gains and losses included in earnings for the six months ended June 30, 2019:
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets
 
 
 
 
 
 
 
(in thousands)
 
Royalty Rights -
At Fair Value
Fair value as of December 31, 2018
 
 
 
$
376,510

 
 
 
 
 
 
 
 
Total net change in fair value for the period
 
 
 
 
 
 
Change in fair value of royalty rights - at fair value
 
$
(28,142
)
 
 
 
 
Proceeds from royalty rights - at fair value
 
$
(32,726
)
 
 
 
 
Total net change in fair value for the period
 
 
 
(60,868
)
 
 
 
 
 
 
 
Fair value as of June 30, 2019
 


 
$
315,642


Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets
 
 
 
 
 
 
 
 
 
Fair Value as of
 
Royalty Rights -
 
Fair Value as of
(in thousands)
 
December 31, 2018
 
Change in Fair Value
 
June 30, 2019
 
 
 
 
 
 
 
Assertio (formerly Depomed)
 
$
264,371

 
$
(459
)
 
$
263,912

VB
 
14,108

 
265

 
14,373

U-M
 
25,595

 
(1,316
)
 
24,279

AcelRx
 
70,380

 
(57,886
)
 
12,494

KYBELLA
 
2,056

 
(1,472
)
 
584

 
 
$
376,510

 
$
(60,868
)
 
$
315,642


The following table summarizes the changes in Level 3 Liabilities and the gains and losses included in earnings for the six months ended June 30, 2019:
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Liabilities
 
 
 
(in thousands)
 
Contingent Consideration
Fair value as of December 31, 2018
 
$
(1,071
)
 
 
 
 
 
 
Settlement of financial instrument(1)
 
1,071

 
 
 
 
 
Fair value as of June 30, 2019
 
$
—


______________
(1) 
Represents the final conversion consideration and earn out liability for the LENSAR acquisition of assets from Precision Eye Services.

Gains and losses from changes in Level 3 assets included in earnings for each period are presented in “Royalty rights - change in fair value” and gains and losses from changes in Level 3 liabilities included in earnings for each period are presented in “Change in fair value of anniversary payment and contingent consideration” as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
Total change in fair value for the period included in earnings for royalty right assets held at the end of the reporting period
 
$
(40,399
)
 
$
12,842

 
$
(28,142
)
 
$
23,933

 
 
 
 
 
 
 
 
 
Total change in fair value for the period included in earnings for liabilities held at the end of the reporting period
 
$
—

 
$
22,135

 
$
—

 
$
22,735


Assets/Liabilities Measured and Recorded at Fair Value on a Nonrecurring Basis

The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets consist of long-lived assets, including property and equipment and intangible assets and the shares of Alphaeon Class A common stock, received in connection with loans made to LENSAR by the Company prior to its acquisition of LENSAR. During the three months ended June 30, 2018, the Company recorded an impairment charge of $152.3 million for the Noden intangible assets related to the increased probability of a generic form of aliskiren being launched in the United States. As a result of this impairment charge, which was based on the estimated fair value of the assets, the remaining carrying value of these intangible assets was determined to be $40.1 million. The fair value calculation included level 3 inputs. The Company’s carrying value of the investment in Alphaeon as of both June 30, 2019 and December 31, 2018 is $6.6 million based on an estimated per share value of $3.84, which was established by a valuation performed when the 1.7 million shares were acquired. The value of the Company’s investment in Alphaeon is not readily determinable as Alphaeon’s shares are not publicly traded. The Company evaluates the fair value of this investment by performing a qualitative assessment each reporting period. If the results of this qualitative assessment indicate that the fair value is less than the carrying value, the investment is written down to its fair value. There have been no such write downs since the Company acquired these shares. This investment is included in Other long-term assets. For additional information on the Alphaeon investment, see Note 6, Notes and Other Long-Term Receivables.

Assets/Liabilities Not Subject to Fair Value Recognition

The following tables present the fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy:
 
 
June 30, 2019
 
December 31, 2018
(in thousands)
 
Carrying Value
 
Fair Value
Level 2
 
Fair Value
Level 3
 
Carrying Value
 
Fair Value
Level 2
 
Fair Value
Level 3
 
 
 
 
 
 
 
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
Wellstat Diagnostics note receivable
 
$
50,191

 
$
—

 
$
59,240

 
$
50,191

 
$
—

 
$
57,322

Hyperion note receivable
 
1,200

 
—

 
1,200

 
1,200

 
—

 
1,200

CareView note receivable
 
11,458

 
—

 
11,458

 
11,458

 
—

 
11,458

Total
 
$
62,849

 
$
—

 
$
71,898

 
$
62,849

 
$
—

 
$
69,980

 
 
 
 
 
 
 
 
 
 
 
 
 
Liabilities:
 
 

 
 

 
 

 
 

 
 

 
 

December 2021 Notes
 
$
128,520

 
$
157,017

 
$
—

 
$
124,644

 
$
151,356

 
$
—

Total
 
$
128,520

 
$
157,017

 
$
—

 
$
124,644

 
$
151,356

 
$
—



During the year ended December 31, 2018 the Company recorded an impairment loss of $8.2 million to the note receivable with CareView Communications, Inc. (“CareView”). There were no impairment losses on notes receivable in the three and six month periods ended June 30, 2019.

As of June 30, 2019 and December 31, 2018, the estimated fair values of the Hyperion Catalysis International, Inc. (“Hyperion”) note receivable, and CareView note receivable were determined using discounted cash flow models, incorporating expected principal and interest payments. In addition, during the year ended December 31, 2018, the fair value of the CareView note receivable also considered the recoverability of the note receivable balance utilizing third-party revenue multiples for small cap healthcare technology companies. As of June 30, 2019 and December 31, 2018, the estimated fair value of the Wellstat Diagnostics note receivable was determined by using an asset approach and discounted cash flow model related to the underlying collateral and adjusted to consider estimated costs to sell the assets.

The Company determined its notes receivable assets are Level 3 assets as the Company’s valuations utilized significant unobservable inputs, including estimates of future revenues, discount rates, expectations about settlement, terminal values, required yield and the value of underlying collateral. The Company engages a third-party valuation expert when deemed necessary to assist in evaluating its investments and the related inputs needed to estimate the fair value of certain investments.

The CareView note receivable is secured by substantially all assets of, and equity interests in CareView. The Wellstat Diagnostics note receivable is secured by substantially all assets of Wellstat Diagnostics and is supported by a guaranty from the Wellstat Diagnostics Guarantors (as defined in Note 6, Notes and Other Long-Term Receivables).

On June 30, 2019, the carrying value of one of the Company’s notes receivable assets differed from its estimated fair value. This is the result of inputs used in estimating the fair value of the collateral, including appraisals, projected cash flows of collateral assets and discount rates used when performing a discounted cash flow analysis.

The fair values of the Company’s convertible senior notes were determined using quoted market pricing.

The following table represents significant unobservable inputs used in determining the estimated fair value of impaired notes receivable investments:
Asset
 
Valuation
Technique
 
Unobservable
Input
 
June 30, 2019
 
December 31, 2018
 
 
 
 
 
 
 
 
 
Wellstat Diagnostics
 
 
 
 
 
 
 
 
Wellstat Guarantors intellectual property
 
Income Approach
 
 
 
 
 
 
 
 
 
 
Discount rate
 
12%
 
12%
 
 
 
 
Royalty amount
 
$21 million
 
$21 million
Settlement Amount
 
Income Approach
 
 
 
 
 
 
 
 
 
 
Discount rate
 
15%
 
15%
 
 
 
 
Settlement amount
 
$34 million
 
$34 million
 
 
 
 
 
 
 
 
 
Real Estate Property
 
Market Approach
 
 
 
 
 
 
 
 
 
 
Annual appreciation rate
 
4%
 
4%
 
 
 
 
Estimated realtor fee
 
6%
 
6%
 
 
 
 
Estimated disposal date
 
9/30/2019
 
9/30/2019
 
 
 
 
 
 
 
 
 
CareView
 
 
 
 
 
 
 
 
Note receivable cash flows
 
Income Approach
 
 
 
 
 
 
 
 
 
 
Discount rate
 
30%
 
30%
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.19.2
Cash Equivalents and Investments
 6 Months Ended
Jun. 30, 2019
Cash and Cash Equivalents [Abstract]  
Cash Equivalents and Investments
3. Cash and Cash Equivalents
 
As of June 30, 2019 and December 31, 2018 the Company had invested its excess cash balances primarily in money market funds. The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.

The following table summarizes the Company’s cash and cash equivalents by significant investment category as of June 30, 2019 and December 31, 2018:
(in thousands)
 
June 30, 2019
 
December 31, 2018
 
 
 
 
 
Cash
 
$
55,987

 
$
167,871

Money market funds
 
228,954

 
226,719

Total
 
$
284,941

 
$
394,590



The Company recognized zero and $0.8 million of gains on sales of available-for-sale securities in the three and six months ended June 30, 2018, respectively. As of June 30, 2019 and December 31, 2018 the Company had no available-for-sale securities.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.19.2
Notes Receivable and Other Long-term Receivables
 6 Months Ended
Jun. 30, 2019
Receivables [Abstract]  
Notes and Other Long-term Receivables
. Notes and Other Long-Term Receivables

Notes and other long-term receivables included the following significant agreements:

Wellstat Diagnostics Note Receivable and Credit Agreement and Related Litigation

On November 2, 2012, the Company and Wellstat Diagnostics entered into a $40.0 million credit agreement pursuant to which the Company was to accrue quarterly interest payments at the rate of 5% per annum (payable in cash or in kind). In addition, the Company was to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics’ net revenues, generated by the sale, distribution or other use of Wellstat Diagnostics’ products, if any, commencing upon the commercialization of its products. A portion of the proceeds of the $40.0 million credit agreement were used to repay certain notes receivable which Wellstat Diagnostics entered into in March 2012.

In January 2013, the Company was informed that, as of December 31, 2012, Wellstat Diagnostics had used funds contrary to the terms of the credit agreement and breached Sections 2.1.2 and 7 of the credit agreement. The Company sent Wellstat Diagnostics a notice of default on January 22, 2013, and accelerated the amounts owed under the credit agreement. In connection with the notice of default, the Company exercised one of its available remedies and transferred approximately $8.1 million of available cash from a bank account of Wellstat Diagnostics to the Company and applied the funds to amounts due under the credit agreement. On February 28, 2013, the parties entered into a forbearance agreement whereby the Company agreed to refrain from exercising additional remedies for 120 days. During such forbearance period, the Company provided approximately $1.3 million to Wellstat Diagnostics to fund ongoing operations of the business. During the year ended December 31, 2013, approximately $8.7 million was advanced pursuant to the forbearance agreement.

On August 15, 2013, the Company entered into an amended and restated credit agreement with Wellstat Diagnostics. The Company determined that the new agreement should be accounted for as a modification of the existing agreement.

Except as otherwise described herein, the material terms of the amended and restated credit agreement are substantially the same as those of the original credit agreement, including quarterly interest payments at the rate of 5% per annum (payable in cash or in kind). In addition, the Company was to continue to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics’ net revenues. However, pursuant to the amended and restated credit agreement: (i) the principal amount was reset to approximately $44.1 million, which was comprised of approximately $33.7 million original loan principal and interest, $1.3 million term loan principal and interest and $9.1 million forbearance principal and interest; (ii) the specified internal rates of return increased; (iii) the default interest rate was increased; (iv) Wellstat Diagnostics’ obligation to provide certain financial information increased in frequency to monthly; (v) internal financial controls were strengthened by requiring Wellstat Diagnostics to maintain an independent, third-party financial professional with control over fund disbursements; (vi) the Company waived the existing events of default; and (vii) the owners and affiliates of Wellstat Diagnostics were required to contribute additional capital to Wellstat Diagnostics upon the sale of an affiliate entity. The amended and restated credit agreement had an ultimate maturity date of December 31, 2021 (but has subsequently been accelerated as described below).

In June 2014, the Company received information from Wellstat Diagnostics showing that it was generally unable to pay its debts as they became due, constituting an event of default under the amended and restated credit agreement.

On August 5, 2014, the Company delivered a notice of default (the “Wellstat Diagnostics Borrower Notice”) to Wellstat Diagnostics, which accelerated all obligations under the amended and restated credit agreement and demanded immediate payment in full in an amount equal to approximately $53.9 million, (which amount, in accordance with the terms of the amended and restated credit agreement, included an amount that, together with interest and royalty payments already made to the Company, would generate a specified internal rate of return to the Company), plus accruing fees, costs and interest, and demanded that Wellstat Diagnostics protect and preserve all collateral securing its obligations.

On August 7, 2014, the Company delivered a notice (the “Wellstat Diagnostics Guarantor Notice”) to each of the guarantors of Wellstat Diagnostics’ obligations to the Company (collectively, the “Wellstat Diagnostics Guarantors”) under the credit agreement, which included a demand that the guarantors remit payment to the Company in the amount of the outstanding obligations. The guarantors include certain affiliates and related companies of Wellstat Diagnostics, including Wellstat Therapeutics and Wellstat Diagnostics’ stockholders.

On September 24, 2014, the Company filed an ex-parte petition for appointment of receiver with the Circuit Court of Montgomery County, Maryland (the “Wellstat Diagnostics Petition”), which was granted on the same day. Wellstat Diagnostics remained in operation during the period of the receivership with incremental additional funding from the Company. On May 24, 2017, Wellstat Diagnostics transferred substantially all of its assets to the Company pursuant to a credit bid. The credit bid reduced the outstanding balance of the loan by an immaterial amount.

On September 4, 2015, the Company filed in the Supreme Court of New York a motion for summary judgment in lieu of complaint which requested that the court enter judgment against certain of the Wellstat Diagnostics Guarantors for the total amount due on the Wellstat Diagnostics debt, plus all costs and expenses including lawyers’ fees incurred by the Company in enforcement of the related guarantees. On September 23, 2015, the Company filed in the same court an ex parte application for a temporary restraining order and order of attachment of the Wellstat Diagnostics Guarantor defendants’ assets. Although the court denied the Company’s request for a temporary restraining order at a hearing on September 24, 2015, it ordered that assets of the Wellstat Diagnostics Guarantor defendants should be held in status quo ante and only used in the normal course of business.

On July 29, 2016, the Supreme Court of New York granted the Company’s motion for summary judgment and held that the Wellstat Diagnostics Guarantor defendants are liable for all “Obligations” owed by Wellstat Diagnostics to the Company. After appeal by the Wellstat Diagnostics Guarantor defendants on February 14, 2017, the Appellate Division of the Supreme Court of New York reversed on procedural grounds a portion of the Memorandum of Decision granting the Company summary judgment in lieu of complaint, but affirmed the portion of the Memorandum of Decision denying the Wellstat Diagnostics Guarantor defendants’ motion for summary judgment in which they sought a determination that the guarantees had been released. As a result, the litigation has been remanded to the Supreme Court of New York to proceed on the Company’s claims as a plenary action. On June 21, 2017, the Supreme Court of New York ordered the Company to file a Complaint, which was filed by the Company on July 20, 2017. The Wellstat Diagnostics Guarantors filed their answer on August 9, 2017, including counterclaims against the Company alleging breach of contract, breach of fiduciary duty, and tortious interference with prospective economic advantage. This case is currently pending and in the pre-trial phase.

On October 14, 2016, the Company sent a notice of default and reference to foreclosure proceedings to certain of the Wellstat Diagnostics Guarantors which are not defendants in the New York action, but which are owners of real estate assets over which a deed of trust in favor of the Company securing the guarantee of the loan to Wellstat Diagnostics had been executed. On March 2, 2017, the Company sent a second notice to foreclose on the real estate assets, and noticed the sale for March 29, 2017. The sale was taken off the calendar by the trustee under the deed of trust and has not been re-scheduled yet. On March 6, 2017, the Company sent a letter to the Wellstat Diagnostics Guarantors seeking information in preparation for a UCC Article 9 sale of some or all of the intellectual property-related collateral of the Wellstat Diagnostics Guarantors. The Wellstat Diagnostics Guarantors did not respond to the Company’s letter, but on March 17, 2017, filed an order to show cause with the Supreme Court of New York to enjoin the Company’s sale of the real estate or enforcing its security interests in the Wellstat Diagnostics Guarantors’ intellectual property during the pendency of any action involving the guarantees at issue. On February 6, 2018, the Supreme Court of New York issued an order from the bench which enjoins the Wellstat Diagnostics Guarantors from selling, encumbering, removing, transferring or altering the collateral pending the outcome of the proceedings before it. The Supreme Court of New York also issued an order precluding the Company from foreclosing on certain of the Wellstat Diagnostics Guarantors’ collateral pending the outcome of the proceedings before it. In September of 2018, discovery in the New York action was completed. Summary judgment motions were filed by Wellstat Diagnostics and the Company in 2018 and a hearing was held on May 22, 2019. The court has not yet issued a decision on the motions.

In an unrelated litigation, Wellstat Therapeutics filed a lawsuit against BTG International, Inc. for breach of contract (the “BTG Litigation”). In September 2017, the Delaware Chancery Court found in favor of Wellstat Therapeutics and awarded a judgment of $55.8 million in damages, plus interest. In October 2017, the Company filed a motion with the Supreme Court of New York requesting a pre-judgement attachment of the award. In June 2018, the Delaware Supreme Court largely affirmed the September 2017 decision of the Delaware Chancery Court, including the $55.8 million awarded in judgment. In August of 2018, in a letter to the Company’s counsel, Wellstat Guarantors’ counsel confirmed that the Wellstat Guarantors are preserving the BTG Litigation judgment award proceeds consistent with the New York Court’s prior directions.

On October 22, 2015, certain of the Wellstat Diagnostics Guarantors filed a separate complaint against the Company in the Supreme Court of New York seeking a declaratory judgment that certain contractual arrangements entered into between the parties subsequent to Wellstat Diagnostics’ default, and which relate to a split of proceeds in the event that the Wellstat Diagnostics Guarantors voluntarily monetize any assets that are the Company’s collateral, is of no force or effect. This case has been joined for all purposes, including discovery and trial, and consolidated with the pending case filed by the Company. The Wellstat Diagnostic Guarantors filed a summary judgment motion with regard to this case, which was also heard by the court at the hearing on May 22, 2019. The court has not yet issued a decision on this motion.

Effective April 1, 2014, and as a result of the event of default, the Company determined the loan to be impaired and it ceased to accrue interest revenue. At that time and as of June 30, 2019, it has been determined that an allowance on the carrying value of the note was not necessary, as the Company believes the value of the collateral securing Wellstat Diagnostics’ obligations exceeds the carrying value of the asset and is sufficient to enable the Company to recover the current carrying value of $50.2 million. The Company continues to closely monitor the timing and expected recovery of amounts due, including litigation and other matters related to Wellstat Diagnostics Guarantors’ assets. There can be no assurance that an allowance on the carrying value of the notes receivable investment will not be necessary in a future period depending on future developments.

Hyperion Agreement

On January 27, 2012, the Company and Hyperion (which is also a Wellstat Diagnostics Guarantor) entered into an agreement whereby Hyperion sold to the Company the royalty streams accruing from January 1, 2012 through December 31, 2013 due from Showa Denko K.K. (“SDK”) related to a certain patent license agreement between Hyperion and SDK dated December 31, 2008. In exchange for the lump sum payment to Hyperion of $2.3 million, in addition to any royalties from SDK, the Company was to receive two equal payments of $1.2 million on March 5, 2013 and March 5, 2014. The first payment of $1.2 million was paid on March 5, 2013, but the second payment that was due on March 5, 2014 has not been made by Hyperion. Effective as of such date and as a result of the event of default, the Company ceased to accrue interest revenue. As of June 30, 2019, the estimated fair value of the collateral was determined to be in excess of the carrying value. There can be no assurance of realizing value from such collateral in the event of the Company’s foreclosure on the collateral.

Avinger Credit and Royalty Agreement

On April 18, 2013, the Company entered into a credit agreement with Avinger, Inc. (the “Avinger Credit and Royalty Agreement”). Under the terms of the Avinger Credit and Royalty Agreement, the Company received a low, single-digit royalty on Avinger’s net revenues until April 2018. Commencing in October 2015, after Avinger repaid $21.4 million pursuant to its note payable to the Company prior to its maturity date, the royalty on Avinger’s net revenues was reduced by 50%, subject to certain minimum payments from the prepayment date until April 18, 2018. The Company accounted for the royalty rights in accordance with the fair value option. As of April 18, 2018, there were no further obligations owed to the Company.

CareView Credit Agreement

On June 26, 2015, the Company entered into a credit agreement with CareView, under which the Company made available to CareView up to $40.0 million in loans comprised of two tranches of $20.0 million each, subject to CareView’s attainment of specified milestones relating to the placement of CareView Systems. On October 7, 2015, the Company and CareView entered into an amendment of the credit agreement to modify certain definitions related to the first and second tranche milestones and the Company funded the first tranche of $20.0 million, net of fees, based on CareView’s attainment of the first milestone, as amended. The second $20.0 million tranche was not funded due to CareView’s failure to achieve the related funding milestones and there is no additional funding obligation due from the Company. Outstanding borrowings under the credit agreement bear interest at the rate of 13.5% per annum and are payable quarterly in arrears.

As part of the original credit agreement, the Company received a warrant to purchase approximately 4.4 million shares of common stock of CareView at an exercise price of $0.45 per share. The Company has accounted for the warrant as derivative asset with an offsetting credit as debt discount. At each reporting period the warrant is marked to market for changes in fair value.

In connection with the October 2015 amendment of the credit agreement, the Company and CareView also agreed to amend the warrant to purchase common stock agreement by reducing the warrant’s exercise price from $0.45 to $0.40 per share.

In February 2018, the Company entered into a modification agreement with CareView (the “February 2018 Modification Agreement”) whereby the Company agreed, effective December 28, 2017, to modify the credit agreement before remedies could otherwise have become available to the Company under the credit agreement in relation to certain obligations of CareView that would potentially not be met, including the requirement to make principal payments. Under the February 2018 Modification Agreement, the Company agreed that (i) a lower liquidity covenant would be applicable and (ii) principal repayment would be delayed until December 31, 2018. In exchange for agreeing to these modifications, among other things, the exercise price of the Company’s warrants to purchase 4.4 million shares of common stock of CareView was repriced from $0.40 to $0.03 per share and, subject to the occurrence of certain events, CareView agreed to grant the Company additional equity interests. As a result of the February 2018 Modification Agreement, the Company determined the loan to be impaired and it ceased to accrue interest revenue effective October 1, 2017.

In September 2018, the Company entered into an amendment to the February 2018 Modification Agreement with CareView whereby the Company agreed, effective as of September 28, 2018, that a lower liquidity covenant would be applicable. In December 2018, the Company further modified the loan by agreeing that (i) a lower liquidity covenant would be applicable, (ii) the first principal payment would be deferred until January 31, 2019, and (iii) the scheduled interest payment due December 31, 2018 would be deferred until January 31, 2019. In December 2018, and in consideration of the further modification to the credit agreement, the Company completed an impairment analysis and determined that the note was impaired and recorded an impairment loss of $8.2 million. For additional information see Note 5, Fair Value Measurements. As of March 31, 2019, the principal repayment and interest payments were deferred until April 30, 2019. The principal repayment and interest payment were subsequently deferred until May 15, 2019. In May 2019, and in consideration of additional capital raised by CareView, the Company further modified the loan by agreeing that (i) the first principal and interest payments would be deferred until September 30, 2019 and (ii) the remaining liquidity covenant would be removed. As of June 30, 2019, the Company performed an analysis and determined that no additional impairment was required and estimated the fair value of the warrants to be less than $0.1 million.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.19.2
Accrued Liabilities
 6 Months Ended
Jun. 30, 2019
Payables and Accruals [Abstract]  
Accrued Liabilities
. Accrued Liabilities

Accrued liabilities consist of the following:
(in thousands)
 
June 30,
2019
 
December 31,
2018
 
 
 
 
 
Accrued rebates, chargebacks and other revenue reserves
 
$
8,248

 
$
20,133

Deferred revenue
 
4,800

 
8,811

Compensation
 
5,017

 
4,468

Interest
 
344

 
344

Legal
 
314

 
623

Other
 
4,776

 
4,933

Total
 
$
23,499

 
$
39,312


The following table provides a summary of activity with respect to the Company’s sales allowances and accruals for the six months ended June 30, 2019:
(in thousands)
 
Discount and Distribution Fees
 
Government Rebates and Chargebacks
 
Assistance and Other Discounts
 
Product Returns
 
Total
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2018
 
$
3,094

 
$
8,901

 
$
3,457

 
$
4,681

 
$
20,133

Allowances for current period sales
 
3,069

 
6,455

 
2,962

 
951

 
13,437

Allowances for prior period sales
 
—

 
1,841

 
120

 
—

 
1,961

Credits/payments for current period sales
 
(1,544
)
 
(4,929
)
 
(2,401
)
 
(232
)
 
(9,106
)
Credits/payments for prior period sales
 
(3,044
)
 
(9,910
)
 
(3,005
)
 
(2,218
)
 
(18,177
)
Balance at June 30, 2019
 
$
1,575

 
$
2,358

 
$
1,133

 
$
3,182

 
$
8,248
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.19.2
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
12. Commitments and Contingencies

Lease Guarantee

In connection with the spin-off (the “Spin-Off”) by the Company of Facet Biotech Corporation (“Facet”), the Company entered into amendments to the leases for the Company’s former facilities in Redwood City, California, under which Facet was added as a co-tenant, and a Co-Tenancy Agreement, under which Facet agreed to indemnify the Company for all matters related to the leases attributable to the period after the Spin-Off date. In April 2010, Abbott Laboratories acquired Facet and later renamed the entity AbbVie Biotherapeutics, Inc. (“AbbVie”). If AbbVie were to default under its lease obligations, the Company could be held liable by the landlord as a co-tenant and, thus, the Company has in substance guaranteed the payments under the lease agreements for the Redwood City facilities. As of June 30, 2019, the total lease payments for the duration of the guarantee, which runs through December 2021, are approximately $28.2 million.

The Company prepared a discounted, probability weighted cash flow analysis to calculate the estimated fair value of the lease guarantee as of the Spin-Off. The Company was required to make assumptions regarding the probability of Facet’s default on the lease payment, the likelihood of a sublease being executed and the times at which these events could occur. These assumptions are based on information that the Company received from real estate brokers and the then-current economic conditions, as well as expectations of future economic conditions. The fair value of this lease guarantee was charged to additional paid-in capital upon the Spin-Off and any future adjustments to the carrying value of the obligation will also be recorded in additional paid-in capital.

The Company has recorded a liability of $10.7 million on its Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018, related to this guarantee. In future periods, the Company may adjust this liability for any changes in the ultimate outcome of this matter that are both probable and estimable.

Purchase Obligations

Noden DAC and Novartis entered into a supply agreement pursuant to which Novartis will manufacture and supply to Noden DAC a bulk tableted form of the Noden Products and active pharmaceutical ingredient (“API”). In May 2019, Noden DAC and Novartis entered into an amended supply agreement pursuant to which Novartis will supply to Noden DAC a bulk tableted form of the Noden Products through 2020 and API through June 2021. The supply agreement may be terminated by either party for material breach that remains uncured for a specified time period. Under the terms of the amended supply agreement, Noden DAC is committed to purchase certain quantities of bulk product and API that would amount to approximately $90.9 million through June 2021, of which $53.1 million is committed over the next twelve months, which are guaranteed by the Company. While the supply agreement provides that the parties will agree to reasonable accommodations with respect to changes in firm orders, the Company expects that Noden DAC will meet the requirements of the supply agreement, unless otherwise negotiated.

LENSAR entered into various supply agreements for the manufacture and supply of certain components. The supply agreements commit LENSAR to a minimum purchase obligation of approximately $6.3 million over the next twenty-four months, of which $4.9 million is due in the next twelve months. LENSAR expects to meet these requirements.

Escrow Receivable

On April 1, 2014, the Company entered into a note purchase agreement with Accel 300, LLC (“Accel 300”), a wholly-owned subsidiary of kaléo, Inc. (“kaléo”), pursuant to which the Company acquired $150.0 million of secured notes due 2029 (the “kaléo Note”). The kaléo Note was issued pursuant to an indenture between Accel 300 and U.S. Bank, National Association, as trustee, and was secured by 20% of net sales of its first approved product, Auvi-Q® (epinephrine auto-injection, USP) (known as Allerject® in Canada) and 10% of net sales of kaléo’s second proprietary auto-injector based product, EVZIO (naloxone hydrochloride injection) (the “kaléo Revenue Interests”), and a pledge of kaléo’s equity ownership in Accel 300. On September 21, 2017, the Company entered into an agreement (the “kaléo Note Sale Agreement”) with MAMKangaroo Lender, LLC, a Delaware limited liability company (the kaléo Purchaser”), pursuant to which the Company sold its entire interest in the kaléo Note for an aggregate cash purchase price of $141.7 million.

Pursuant to the terms of the kaléo Note Sale Agreement, $1.4 million of the aggregate purchase price was deposited into an escrow account as a potential payment against certain contingencies. The escrow period ended on March 20, 2019 and the escrow agent released the entire $1.4 million to the Company.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.19.2
Convertible Notes
 6 Months Ended
Jun. 30, 2019
Debt Disclosure [Abstract]  
Convertible and Non-Recourse Notes
. Convertible Senior Notes
  
 
 
 
 
Principal Balance Outstanding
 
Carrying Value
 
 
 
 
June 30,
 
June 30,
 
December 31,
Description
 
Maturity Date
 
2019
 
2019
 
2018
(in thousands)
 
 
 
 
 
 
 
 
Convertible Senior Notes
 
 
 
 
 
 
 
 
December 2021 Notes
 
December 1, 2021
 
$
150,000

 
$
128,520

 
$
124,644

Total
 
 
 
 

 
$
128,520

 
$
124,644



February 2018 Notes

On February 12, 2014, the Company issued $300.0 million in aggregate principal amount, at par, of the February 2018 Notes in an underwritten public offering, for net proceeds of $290.2 million. The February 2018 Notes were due February 1, 2018. In November 2015, $53.6 million in aggregate principal amount of the February 2018 Notes were repurchased and in November 2016 an additional $120.0 million in aggregate principal amount of the February 2018 Notes were repurchased in open market transactions. In connection with these repurchases, the Company unwound a corresponding portion of the purchased call options and warrants related to the notes.

On February 1, 2018, upon maturity of the February 2018 Notes, the Company repaid a total cash amount of $129.0 million to the custodian, The Bank of New York Mellon Trust Company, N.A., which was comprised of $126.4 million in principal amount and $2.6 million in accrued interest, to retire the February 2018 Notes.

Interest expense for the February 2018 Notes on the Company’s Condensed Consolidated Statements of Operations was as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2018
 
2018
 
 
 
 
 
Contractual coupon interest
 
$
—

 
$
421

Amortization of debt issuance costs
 
—

 
88

Amortization of debt discount
 
—

 
293

Total
 
$
—

 
$
802



December 2021 Notes

On November 22, 2016, the Company issued $150.0 million in aggregate principal amount, at par, of the December 2021 Notes in an underwritten public offering, for net proceeds of $145.7 million. The December 2021 Notes are due December 1, 2021, and the Company pays interest at 2.75% on the December 2021 Notes semiannually in arrears on June 1 and December 1 of each year, beginning June 1, 2017. A portion of the proceeds from the December 2021 Notes, net of amounts used for the capped call transaction described below, was used to extinguish $120.0 million of the February 2018 Notes.

Upon the occurrence of a fundamental change, as defined in the indenture entered into in connection with the December 2021 Notes (the “December 2021 Notes Indenture”), holders have the option to require the Company to repurchase their December 2021 Notes at a purchase price equal to 100% of the principal, plus accrued interest.

The December 2021 Notes are convertible under any of the following circumstances:
•
During any fiscal quarter (and only during such fiscal quarter) commencing after the fiscal quarter ended June 30, 2017, if the last reported sale price of Company common stock for at least 20 trading days (whether or not consecutive), in the period of 30 consecutive trading days, ending on, and including, the last trading day of the immediately preceding fiscal quarter, exceeds 130% of the conversion price for the notes on each applicable trading day;
•
During the five business-day period immediately after any five consecutive trading-day period, which the Company refers to as the measurement period, in which the trading price per $1,000 principal amount of notes for each trading day of that measurement period was less than 98% of the product of the last reported sale price of Company common stock and the conversion rate for the notes for each such trading day; or
•
Upon the occurrence of specified corporate events as described in the December 2021 Notes Indenture.

The initial conversion rate for the December 2021 Notes is 262.2951 shares of the Company’s common stock per $1,000 principal amount of December 2021 Notes, which is equivalent to an initial conversion price of approximately $3.81 per share of common stock, subject to adjustments upon the occurrence of certain specified events as set forth in the December 2021 Notes Indenture.

In accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion, the Company was required to separately account for the liability component of the instrument in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. As a result, the Company separated the principal balance of the December 2021 Notes between the fair value of the debt component and the fair value of the common stock conversion feature. Using an assumed borrowing rate of 9.5%, which represented the estimated market interest rate for a similar nonconvertible instrument available to the Company on the date of issuance, the Company recorded a total debt discount of $4.3 million, allocated $23.8 million to additional paid-in capital and allocated $12.8 million to deferred tax liability. The discount is being amortized to interest expense over the term of the December 2021 Notes and increases interest expense during the term of the December 2021 Notes from the 2.75% cash coupon interest rate to an effective interest rate of 3.4%. As of June 30, 2019, the remaining discount amortization period is 2.4 years.

The carrying value and unamortized discount of the December 2021 Notes were as follows:
(in thousands)
 
June 30, 2019
 
December 31, 2018
 
 
 
 
 
Principal amount of the December 2021 Notes
 
$
150,000

 
$
150,000

Unamortized discount of liability component
 
(21,480
)
 
(25,356
)
Net carrying value of the December 2021 Notes
 
$
128,520

 
$
124,644



Interest expense for the December 2021 Notes on the Company’s Condensed Consolidated Statements of Operations was as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
Contractual coupon interest
 
$
1,032

 
$
1,031

 
$
2,063

 
$
2,062

Amortization of debt issuance costs
 
20

 
19

 
40

 
38

Amortization of debt discount
 
138

 
135

 
276

 
269

Amortization of conversion feature
 
1,794

 
1,626

 
3,560

 
3,225

Total
 
$
2,984

 
$
2,811

 
$
5,939

 
$
5,594



As of June 30, 2019, the December 2021 Notes are not convertible.

Capped Call Transaction

In connection with the offering of the December 2021 Notes, the Company entered into a privately-negotiated capped call transaction with an affiliate of the underwriter of such issuance. The aggregate cost of the capped call transaction was $14.4 million. The capped call transaction is generally expected to reduce the potential dilution upon conversion of the December 2021 Notes and/or partially offset any cash payments the Company is required to make in excess of the principal amount of converted December 2021 Notes in the event that the market price per share of the Company’s common stock, as measured under the terms of the capped call transaction, is greater than the strike price of the capped call transaction. This initially corresponds to the approximate $3.81 per share conversion price of the December 2021 Notes and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of the December 2021 Notes. The cap price of the capped call transaction was initially $4.88 per share, and is subject to certain adjustments under the terms of the capped call transaction. The Company will not be required to make any cash payments to the option counterparty upon the exercise of the options that are a part of the capped call transaction, but the Company will be entitled to receive from it an aggregate amount of cash and/or number of shares of the Company’s common stock, based on the settlement method election chosen for the related convertible senior notes, with a value equal to the amount by which the market price per share of the Company’s common stock, as measured under the terms of the capped call transaction, is greater than the strike price of the capped call transaction during the relevant valuation period under the capped call transaction, with such number of shares of the Company’s common stock and/or amount of cash subject to the cap price.

The Company evaluated the capped call transaction under authoritative accounting guidance and determined that it should be accounted for as separate transaction and classified as a net reduction to additional paid-in capital within stockholders’ equity with no recurring fair value measurement recorded.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.19.2
Other Long-Term Liabilities
 6 Months Ended
Jun. 30, 2019
Other Liabilities Disclosure [Abstract]  
Other Long-Term Liabilities
11. Other Long-Term Liabilities

Other long-term liabilities consist of the following:
 
 
June 30,
 
December 31,
(in thousands)
 
2019
 
2018
 
 
 
 
 
Uncertain tax positions
 
$
32,402

 
$
31,706

Deferred tax liabilities
 
13,803

 
13,847

Accrued lease guarantee
 
10,700

 
10,700

Long-term incentive accrual
 
146

 
125

Other
 
1,130

 
465

Total
 
$
58,181

 
$
56,843
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.19.2
Stock-Based Compensation
 6 Months Ended
Jun. 30, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation
14. Stock-Based Compensation

The Company grants restricted stock awards and stock options pursuant to a stockholder approved stock-based incentive plan.

The following table summarizes the Company’s stock option and restricted stock award activity during the six months ended June 30, 2019:
 
 
Stock Options
 
Restricted Stock Awards
(in thousands, except per share amounts)
 
Number of Shares Outstanding
 
Weighted Average Exercise Price
 
Number of Shares Outstanding
 
Weighted Average Grant-date Fair Value Per Share
 
 
 
 
 
 
 
 
 
Balance at December 31, 2018
 
7,869

 
$
2.82

 
883

 
$
2.87

Granted
 
5,666

 
$
3.61

 
851

 
$
3.66

Exercised or vested
 
—

 
$
—

 
(335
)
 
$
2.69

Forfeited or canceled
 
—

 
$
—

 
(49
)
 
$
2.52

Balance at June 30, 2019
 
13,535

 
$
3.15

 
1,350

 
$
3.43
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.19.2
Cash Dividends
 6 Months Ended
Jun. 30, 2019
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Note Disclosure [Text Block]
13. Stockholders’ Equity

Stock Repurchase Program

On September 25, 2017, the Company announced that its board of directors authorized the repurchase of issued and outstanding shares of the Company’s common stock having an aggregate value of up to $25.0 million pursuant to a share repurchase program. The repurchases under the share repurchase program were made from time to time in the open market or in privately negotiated transactions and were funded from the Company’s working capital. All shares of common stock repurchased under this share repurchase program were retired and restored to authorized but unissued shares of common stock. The Company repurchased 8.7 million shares of its common stock under the share repurchase program during the fiscal year ended December 31, 2018, for an aggregate purchase price of $25.0 million, or an average cost of $2.86 per share, including trading commissions.

On September 24, 2018, the Company announced that its board of directors authorized the repurchase of issued and outstanding shares of the Company’s common stock having an aggregate value of up to $100.0 million pursuant to a share repurchase program. The Company repurchased 21.1 million shares of its common stock under this share repurchase program during the six months ended June 30, 2019, for an aggregate purchase price of $70.4 million, or an average cost of $3.34 per share, including trading commissions. Since the inception of this share repurchase program through June 30, 2019, the Company has repurchased 29.7 million shares for an aggregate purchase price of $95.9 million, or an average cost of $3.22 per share, including trading commissions. As of June 30, 2019, the Company had 178,700 shares held in treasury stock at a total cost of $0.5 million. Those shares were settled and retired on July 5, 2019. All shares of common stock repurchased under this share repurchase program were retired and restored to authorized but unissued shares of common stock. This program was completed in July 2019 as further discussed in Note 20, Subsequent Events.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.19.2
Customer Concentration
 6 Months Ended
Jun. 30, 2019
Customer Concentration [Abstract]  
Concentration Risk Disclosure [Text Block]
17. Concentration of Credit Risk

Product Line Concentration

The percentage of total revenue recognized, which individually accounted for 10% or more of the Company’s total revenues in one or more of the periods presented below, was as follows:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
2019(1)
 
2018
 
2019(1)
 
2018
Noden
 
28%
 
56%
 
41%
 
52%
Assertio
 
49%
 
20%
 
39%
 
20%
LENSAR
 
20%
 
13%
 
19%
 
13%
___________________ 
(1)
For the three and six months ended June 30, 2019, the AcelRx royalty asset decrease in fair value of $60.0 million and $57.9 million, respectively, are excluded from total revenue when calculating product line concentration.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.19.2
Income Taxes
 6 Months Ended
Jun. 30, 2019
Income Tax Disclosure [Abstract]  
Income Taxes
18. Income Taxes
 
Income tax (benefit) expense for the three months ended June 30, 2019 and 2018, was $(1.2) million and $(14.3) million, respectively, and for the six months ended June 30, 2019 and 2018, was $1.5 million and $(13.2) million, respectively, which resulted primarily from applying the federal statutory income tax rate to income before income taxes. The Company’s effective tax rate for the current period differs from the U.S. federal statutory rate of 21% due primarily to the effect of state income taxes and non-deductible executive compensation, less the foreign tax rate differential associated with the Company’s Noden DAC operations in Ireland.

The uncertain tax positions did not change during the three or six months ended June 30, 2019 and 2018.

The Company’s income tax returns are subject to examination by U.S. federal, foreign, state and local tax authorities for tax years 2000 forward. The Company is currently under audit by the California Franchise Tax Board (the “CFTB”) for the tax years 2009 through 2015 and the Internal Revenue Service (the “IRS”) for the tax year 2016. The timing of the resolutions to these audits and the amount to be ultimately paid, if any, is uncertain. The outcome of these audits could result in the payment of tax amounts that differ from the amounts the Company has reserved for uncertain tax positions for the periods under audit resulting in incremental expense or a reversal of the Company’s reserves in a future period. At this time, the Company does not anticipate a material change in the unrecognized tax benefits related to the CFTB or IRS audits that would affect the effective tax rate or deferred tax assets over the next 12 months.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.19.2
Intangibles and Goodwill (Notes)
 6 Months Ended
Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Disclosure [Text Block]
. Intangible Assets

Intangible Assets, Net

On June 8, 2018, Noden DAC entered into a Settlement Agreement (the “Settlement Agreement”) with Anchen Pharmaceuticals, Inc. and its affiliates (“Anchen”) to resolve the patent litigation relating to infringement of U.S. Patent No. 8,617,595 (the “‘595 Patent”) based on their submission of an Abbreviated New Drug Application (“ANDA”) seeking authorization from the FDA to market a generic version of aliskiren, the active ingredient in the Tekturna and Tekturna HCT drug. Under the Settlement Agreement, Anchen, the sole ANDA filer of which the Company is aware, agreed to not commercialize its generic version of aliskiren prior to March 1, 2019. Per the Settlement Agreement, Anchen may commercialize their formulation of aliskiren, but is not permitted to commercialize a copy of Tekturna.

Accordingly, management evaluated the ongoing value of the Noden DAC asset group based upon the probability of Anchen’s market entry of a generic version of aliskiren in the United States and the associated cash flows and conducted a test for impairment. Due to the increased probability of a generic version of aliskiren being launched in the United States, the Company revised its estimates of future cash flows and as a result of this analysis, determined that the sum of undiscounted cash flows was not greater than the carrying value of the assets. Therefore, the Company performed a discounted cash flow analysis to estimate the fair value of the asset group in accordance with ASC Topic 360, Impairment or Disposal of Long-lived Assets. The cash flows used in this analysis are those expected to be generated by market participants, discounted to reflect an appropriate amount of risk, which was determined to be 21%. The Company concluded that the Noden DAC acquired product rights and customer relationship long-lived assets, with a carrying amount of $192.5 million, were no longer recoverable and wrote them down to their estimated fair value of $40.1 million, resulting in an impairment charge of $152.3 million in the second quarter of 2018. This write-down is included in “Impairment of intangible assets” in the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows.

On March 4, 2019, the Company announced the U.S. commercial launch of an authorized generic form of Tekturna, with the same drug formulation as Tekturna. The Company performed an impairment assessment of the Noden asset group at this time by estimating the undiscounted future cash flows with respect to the asset against its carrying value and concluded a further impairment was not required.

On March 22, 2019, the FDA approved Anchen’s generic form of aliskiren. The Company performed an impairment assessment of the Noden asset group at this time and concluded no further impairment was required.

Future events, such as FDA approval of additional generic forms of aliskiren, or pricing or market share pressure resulting from existing generic competition, may be further indicators of impairment which may require the Company to perform additional impairment testing.

In April 2019, LENSAR acquired certain intellectual property from a third-party for $2.0 million in cash and obligations to pay a $0.3 million milestone payment and royalties upon the completion of certain events.

The components of intangible assets as of June 30, 2019 and December 31, 2018 were as follows:
 
 
June 30, 2019
 
December 31, 2018
(in thousands)
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
 
 
 
 
 
 
 
 
 
 
 
 
Finite-lived intangible assets:
 
 
 
 
 
 
 
 
 
 
 
 
Acquired products rights(1)
 
$
36,143

 
$
(4,517
)
 
$
31,626

 
$
36,143

 
$
(2,258
)
 
$
33,885

Customer relationships(1) (2) (4)
 
8,028

 
(1,209
)
 
6,819

 
8,028

 
(782
)
 
7,246

Acquired technology(2) (3) (5)
 
13,311

 
(1,630
)
 
11,681

 
11,011

 
(1,203
)
 
9,808

Acquired trademarks(2)
 
570

 
(247
)
 
323

 
570

 
(190
)
 
380

 
 
$
58,052

 
$
(7,603
)
 
$
50,449

 
$
55,752

 
$
(4,433
)
 
$
51,319

________________
(1) 
The Company acquired certain intangible assets as part of the Noden transaction. They are being amortized on a straight-line basis over a weighted-average period of eight years.
(2)
The Company acquired certain intangible assets as part of its acquisition of LENSAR in May 2017. They are being amortized on a straight-line basis over a weighted-average period of 15 years. The intangible assets for customer relationships are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained.
(3) 
The Company acquired certain intangible assets as part of the foreclosure on certain of Direct Flow Medical assets. They are being amortized on a straight-line basis over a weighted-average period of 10 years.
(4)
LENSAR acquired certain intangible assets for customer relationships from Precision Eye Services, which are being amortized using a double-declining method over a period of 20 years.
(5)
LENSAR acquired certain intangible assets from a third-party, which are being amortized on a straight-line basis over a period of 15 years.

For the three and six months ended June 30, 2019 amortization expense was $1.6 million and $3.2 million, respectively, and for the three and six months ended June 30, 2018 amortization expense was $6.4 million and $12.7 million, respectively.

Based on the intangible assets recorded at June 30, 2019, and assuming no subsequent additions to or impairment of the underlying assets, the remaining amortization expense is expected to be as follows (in thousands):
Fiscal Year
 
Amount
 
 
 
2019 (Remaining six months)
 
$
3,212

2020
 
6,394

2021
 
6,362

2022
 
6,257

2023
 
6,194

Thereafter
 
22,030

Total remaining amortization expense
 
$
50,449
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.19.2
Segment Information (Notes)
 6 Months Ended
Jun. 30, 2019
Segment Reporting Information [Line Items]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
16. Segment Information

In connection with its investment in Evofem in the second quarter of 2019, the Company added a fourth reportable segment, “Strategic Positions.”

Information regarding the Company’s segments for the three and six months ended June 30, 2019 and 2018 is as follows:
Revenues by segment
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
$
10,415

 
$
25,879

 
$
30,375

 
$
44,221

Medical Devices
 
7,422

 
5,882

 
14,148

 
10,864

Strategic Positions
 
—

 
—

 
—

 
—

Income Generating Assets
 
(40,363
)
 
14,814

 
(28,136
)
 
30,008

Total revenues
 
$
(22,526
)
 
$
46,575

 
$
16,387

 
$
85,093


(Loss) income by segment
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
$
(345
)
 
$
(111,335
)
 
$
5,300

 
$
(113,048
)
Medical Devices
 
(1,678
)
 
(1,904
)
 
(2,893
)
 
(2,491
)
Strategic Positions
 
19,044

 
—

 
19,044

 
—

Income Generating Assets
 
(21,440
)
 
943

 
(19,190
)
 
4,845

Total net (loss) income
 
$
(4,419
)
 
$
(112,296
)
 
$
2,261

 
$
(110,694
)

Information regarding the Company’s segments as of June 30, 2019 and December 31, 2018 is as follows:
Long-lived assets by segment
 
 
 
 
(in thousands)
 
June 30,
2019
 
December 31,
2018
 
 
 
 
 
Pharmaceutical
 
$
4,082

 
$
3,682

Medical Devices
 
2,681

 
3,545

Strategic Positions
 
—

 
—

Income Generating Assets
 
151

 
160

Total long-lived assets
 
$
6,914

 
$
7,387



The operations for the Pharmaceutical and Medical Devices segments are primarily located in Italy, Ireland and the United States, respectively.
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.19.2
Inventory (Notes)
 6 Months Ended
Jun. 30, 2019
Inventory [Abstract]  
Inventory Disclosure [Text Block]
4. Inventories

Inventories consisted of the following:
(in thousands)
 
June 30, 2019
 
December 31, 2018
 
 
 
 
 
Raw materials
 
$
6,023

 
$
6,214

Work in process
 
2,629

 
549

Finished goods
 
7,611

 
12,179

Total inventory
 
$
16,263

 
$
18,942



As of June 30, 2019 and December 31, 2018, the Company deferred approximately $0.1 million and $0.5 million, respectively, of costs associated with inventory transfers made under the Company’s third party logistic provider service arrangement. These costs have been recorded as Prepaid and other current assets on the Company’s Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018. The Company will recognize the cost of product sold as inventory is transferred from its third-party logistics provider to the Company’s customers.
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Equity (Notes)
 6 Months Ended
Jun. 30, 2019
Stockholders' Equity Attributable to Parent [Abstract]  
Stockholders' Equity Note Disclosure [Text Block]
13. Stockholders’ Equity

Stock Repurchase Program

On September 25, 2017, the Company announced that its board of directors authorized the repurchase of issued and outstanding shares of the Company’s common stock having an aggregate value of up to $25.0 million pursuant to a share repurchase program. The repurchases under the share repurchase program were made from time to time in the open market or in privately negotiated transactions and were funded from the Company’s working capital. All shares of common stock repurchased under this share repurchase program were retired and restored to authorized but unissued shares of common stock. The Company repurchased 8.7 million shares of its common stock under the share repurchase program during the fiscal year ended December 31, 2018, for an aggregate purchase price of $25.0 million, or an average cost of $2.86 per share, including trading commissions.

On September 24, 2018, the Company announced that its board of directors authorized the repurchase of issued and outstanding shares of the Company’s common stock having an aggregate value of up to $100.0 million pursuant to a share repurchase program. The Company repurchased 21.1 million shares of its common stock under this share repurchase program during the six months ended June 30, 2019, for an aggregate purchase price of $70.4 million, or an average cost of $3.34 per share, including trading commissions. Since the inception of this share repurchase program through June 30, 2019, the Company has repurchased 29.7 million shares for an aggregate purchase price of $95.9 million, or an average cost of $3.22 per share, including trading commissions. As of June 30, 2019, the Company had 178,700 shares held in treasury stock at a total cost of $0.5 million. Those shares were settled and retired on July 5, 2019. All shares of common stock repurchased under this share repurchase program were retired and restored to authorized but unissued shares of common stock. This program was completed in July 2019 as further discussed in Note 20, Subsequent Events.
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.19.2
Revenue from Contracts with Customers (Notes)
 6 Months Ended
Jun. 30, 2019
Revenue from Contract with Customers [Abstract]  
Revenue from Contract with Customer [Text Block]
 15. Revenue from Contracts with Customers

Revenue

Nature of Goods and Services

The following is a description of principal activities - separated by reportable segments - from which the Company generates its revenue. For more detailed information about reportable segments, see Note 16, Segment Information.

Pharmaceutical

The Company’s Pharmaceutical segment consists of revenue derived from the branded prescription Noden Products and the authorized generic launched in March 2019.

The agreement between Novartis and Noden DAC provides for various transition periods for development and commercialization activities relating to the Noden Products. Initially, Novartis distributed the Noden Products on behalf of Noden DAC worldwide and Noden DAC received a profit transfer on such sales. Generally, the profit transfer to Noden DAC was defined as gross revenues less product cost and a low single-digit percentage fee to Novartis. The profit transfer terminated upon the transfer of the marketing authorization from Novartis to Noden DAC in each country. In the United States, the duration of the profit transfer ran from July 1, 2016 through October 4, 2016. Outside the United States, the profit transfer ended in the first quarter of 2018.

Prior to the transfer of the marketing authorization, revenue was presented on a “net” basis; after the transfer of the marketing authorization, revenue is presented on a “gross” basis, meaning product costs are reported separately and there is no fee to Novartis. Except for the sales outside of the United States preceding the final profit transfer that occurred in the first quarter of 2018, revenues of the Noden Products for the periods herein are presented on a gross basis.

Noden USA launched an authorized generic of Tekturna in the United States in March 2019.

The Pharmaceutical segment principally generates revenue from products sold to wholesalers and distributors. Customer orders are generally fulfilled within a few days of receipt resulting in minimal order backlog. Contractual performance obligations are usually limited to transfer of the product to the customer. The transfer occurs either upon shipment or upon receipt of the product in certain countries outside the United States after considering when the customer obtains control of the product. In addition, for some non-U.S. countries, the Company sells product on a consignment basis where control is not transferred until the customer resells the product to an end user. At these points, customers are able to direct the use of and obtain substantially all of the remaining benefits of the product.

Sales to customers are initially invoiced at contractual list prices. Payment terms are typically 30 to 90 days based on customary practice in each country. Revenue is reduced from the list price at the time of recognition for expected chargebacks, discounts, rebates, sales allowances and product returns, which are collectively referred to as gross-to-net adjustments. These reductions are attributed to various commercial agreements, managed healthcare organizations and government programs such as Medicare, Medicaid, and the 340B Drug Pricing Program containing various pricing implications such as mandatory discounts, pricing protection below wholesaler list price and other discounts when Medicare Part D beneficiaries are in the coverage gap. These various reductions in the transaction price have been estimated using either a most likely amount, in the case of prompt pay discounts, or expected value method for all other variable consideration and have been reflected as liabilities and are settled through cash payments, typically within time periods ranging from a few months to one year. Significant judgment is required in estimating gross-to-net adjustments considering legal interpretations of applicable laws and regulations, historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, processing time lags and inventory levels in the distribution channel.

For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front license fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.

Medical Devices

The Medical Devices segment principally generates revenue from the sale and lease of the LENSAR® Laser System, which may include equipment, PIDs or consumables, procedure licenses, training, installation, warranty and maintenance agreements.

For bundled packages, the Company accounts for individual products and services separately if they are distinct - i.e. if a product or service is separately identifiable from other items in the bundled package and if the customer can benefit from it on its own or with other resources that are readily available to the customer. The LENSAR® Laser System, standard warranty training and installation services are one performance obligation. All other elements are separate performance obligations. PIDs, procedure licenses, warranty and maintenance services are also sold on a stand-alone basis.

As the Company both sells and leases the LENSAR® Laser System, the consideration (including any discounts) is first allocated between lease and non-lease components and then allocated between the separate products and services based on their stand-alone selling prices. The stand-alone selling prices for the PIDs and procedure licenses are determined based on the prices at which the Company separately sells the PIDs and procedure licenses. The LENSAR® Laser System and warranty stand-alone selling prices are determined using the expected cost plus a margin approach.

For LENSAR® Laser System sales, the Company recognizes Product revenue when a customer takes possession of the system. This usually occurs after the customer signs a contract, LENSAR installs the system, and LENSAR performs the requisite training for use of the system. For LENSAR® Laser System leases, the Company recognized Product revenue over the length of the lease in accordance with ASC Topic 840, Leases, through December 31, 2018 and recognized Product revenue in accordance with ASC Topic 842, Leases, after January 1, 2019. For additional information regarding accounting for leases, see Note 7, Leases.

The LENSAR® Laser System requires both a consumable and a procedure license to perform each procedure. The Company recognizes Product revenue for PIDs when the customer takes possession of the PID. PIDs are sold by the case. The Company recognizes Product revenue for procedure licenses when a customer purchases a procedure license from the web portal. Typically, consideration for PIDs and procedure licenses is considered fixed consideration except for certain customer agreements that provide for tiered volume discount pricing which is considered variable consideration.

The Company offers an extended warranty that provides additional services beyond the standard warranty. The Company recognizes Product revenue from the sale of extended warranties over the warranty period. Customers have the option of renewing the warranty period, which is considered a new and separate contract.

Income Generating Assets

For licenses of intellectual property, if the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.

In January 2018, DFM, LLC, a wholly-owned subsidiary of the Company, granted an exclusive license related to certain Direct Flow Medical, Inc. assets in exchange for $0.5 million in cash and up to $2.0 million in royalty payments. The $0.5 million payment was accounted for in accordance with ASC 606 under which the full cash payment was recognized as revenue in the first quarter of 2018 as DFM, LLC had fulfilled its performance obligation under the agreement.

Disaggregation of Revenue

The Company disaggregates its revenue from contracts with customers by segment and geographic location as the Company believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. In the following table, revenue is disaggregated by segment and primary geographical market for the three and six months ended June 30, 2019 and 2018:
 
 
Three Months Ended
 
Three Months Ended
 
 
June 30, 2019
 
June 30, 2018
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Medical Devices
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
Primary geographical markets:
 
 
 
 
 
 
 
 
North America
 
$
2,203

 
$
3,038

 
$
615

 
$
10,776

Europe
 
705

 
5,454

 
679

 
6,371

Asia
 
3,093

 
1,923

 
1,643

 
8,732

Other
 
66

 
—

 
107

 
—

Total revenue from contracts with customers(1)
 
$
6,067

 
$
10,415

 
$
3,044

 
$
25,879


 
 
Six Months Ended
 
Six Months Ended
 
 
June 30, 2019
 
June 30, 2018
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Medical Devices
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
Primary geographical markets:
 
 
 
 
 
 
 
 
North America
 
$
4,287

 
$
15,176

 
$
2,319

 
$
21,707

Europe
 
1,722

 
11,036

 
1,294

 
12,362

Asia
 
5,362

 
4,163

 
2,757

 
10,152

Other
 
185

 
—

 
220

 
—

Total revenue from contracts with customers(1)
 
$
11,556

 
$
30,375

 
$
6,590

 
$
44,221

_______________
(1)
The tables above do not include lease revenue from the Company’s Medical Devices segment. For the three-month periods ended June 30, 2019 and 2018, revenue accounted for under Topic 842 and 840, Leases, was $1.4 million and $2.8 million, respectively and for the six-month periods ended June 30, 2019 and 2018 was $2.6 million and $4.3 million, respectively. For additional information, see Note 7, Leases.

Contract Balances

The following table provides information about receivables, contract assets and contract liabilities from contracts with customers:
(in thousands)
 
June 30, 2019
 
December 31, 2018
 
 
 
 
 
Receivables, net
 
$
17,872

 
$
20,655

Contract assets
 
$
3,214

 
$
2,595

Contract liabilities
 
$
4,856

 
$
8,938


Receivables, Net—Receivables, net, include amounts billed and due from customers. The amounts due are stated at their net estimated realizable value and are classified as current or noncurrent based on the timing of when the Company expects to receive payment. The Company maintains an allowance for doubtful accounts to provide for the estimated amount of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and collateral to the extent applicable.

Contract assets—The Company’s contract assets represent revenue recognized for performance obligations completed before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. The Company classifies contract assets in Prepaid and other current assets in the Company’s Condensed Consolidated Balance Sheets based on the timing of when it expects to receive payment.
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Total
 
 
 
 
 
 
 
Contract assets at December 31, 2018
 
$
—

 
$
2,595

 
$
2,595

Contract assets recognized
 
—

 
4,638

 
4,638

Payments received
 
—

 
(4,019
)
 
(4,019
)
Contract assets at June 30, 2019
 
$
—

 
$
3,214

 
$
3,214


Contract Liabilities—The Company’s contract liabilities consist of deferred revenue for products sold to customers for which the performance obligation has not been completed by the Company. The Company classifies deferred revenue as current or noncurrent based on the timing of when it expects to recognize revenue. The noncurrent portion of deferred revenue is included in Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheets.
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Total
 
 
 
 
 
 
 
Contract liabilities at December 31, 2018
 
$
1,167

 
$
7,771

 
$
8,938

Contract liabilities recognized
 
537

 
2,855

 
3,392

Amounts recognized into revenue
 
(645
)
 
(6,829
)
 
(7,474
)
Contract liabilities at June 30, 2019
 
$
1,059

 
$
3,797

 
$
4,856



Transaction Price Allocated to Future Performance Obligations

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.
 
 
Six Months Ended
 
 
 
 
(in thousands)
 
December 31, 2019
 
Thereafter
 
Total
 
 
 
 
 
 
 
Pharmaceutical product sales
 
$
116

 
$
2,326

 
$
2,442

Medical device sales
 
$
2,347

 
$
3,986

 
$
6,333



The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with original expected lengths of one year or less or (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for the products delivered or services performed.
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.19.2
Leases (Notes)
 6 Months Ended
Jun. 30, 2019
Leases [Abstract]  
Lessee, Operating Leases [Text Block]
7. Leases

Lessee arrangements

The Company has operating leases for corporate offices and certain equipment. The Company’s operating leases have remaining lease terms ranging from one to eight years, some of which include options to extend the leases for up to five years, and some of which include options to terminate the leases within three years.

The components of lease expense are as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
Operating lease cost
 
$
234

 
$
324

 
$
467

 
$
609

Short-term lease cost
 
19

 
12

 
44

 
24

Total lease cost
 
$
253

 
$
336

 
$
511

 
$
633


Supplemental cash flow information related to leases is as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
 
 
 
 
 
Operating cash flows from operating leases
 
$
235

 
$
324

 
$
450

 
$
609

Right-of-use-assets obtained in exchange for lease obligations:
 
 
 
 
 
 
 
 
Operating leases
 
$
—

 
N/A
 
$
2,111

 
N/A
_______________
N/A    Not applicable

The following table presents the lease balances within the Condensed Consolidated Balance Sheet, weighted-average remaining lease term, and weighted-average discount rates related to the Company’s operating leases (in thousands):
Operating Leases
 
Classification
 
June 30, 2019
 
 
 
 
 
Operating lease ROU assets
 
Other assets
 
$
1,661

 
 
 
 
 
Operating lease liabilities, current
 
Accrued liabilities
 
$
807

Operating lease liabilities, long-term
 
Other long-term liabilities
 
891

Total operating lease liabilities
 
Total operating lease liabilities
 
$
1,698

 
 
 
 
 
Weighted-average remaining lease term
 
 
 
2.00 years

Weighted-average discount rate
 
 
 
6
%

Maturities of operating lease liabilities as of June 30, 2019 are as follows (in thousands):
Fiscal Year
 
Amount
 
 
 
2019 (Remaining six months)
 
$
472

2020
 
837

2021
 
473

2022
 
—

2023
 
—

Thereafter
 
—

Total operating lease payments
 
1,782

Less: imputed interest
 
84

Total operating lease liabilities
 
$
1,698


Future minimum operating lease payments as of December 31, 2018 were as follows (in thousands):
Fiscal Year
 
Amount
 
 
 
2019
 
$
1,140

2020
 
1,003

2021
 
559

2022
 
—

2023
 
—

Thereafter
 
—

Total
 
$
2,702


As of June 30, 2019, the Company had no additional significant operating or finance leases that had not yet commenced.

Lessor arrangements

The Company has operating and sales-type leases for medical device equipment generated from its medical devices segment. The Company’s leases have remaining lease terms of less than one year to five years, some of which include options to extend the leases on a month-to-month basis if the customer does not notify the Company of the intention to return the equipment at the end of the lease term. The Company typically does not offer options to terminate the leases before the end of the lease term.

The components of lease income are as follows:
 
 
 
 
Three Months Ended
 
Six Months Ended
 
 
 
 
June 30,
 
June 30,
(in thousands)
 
Classification
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
 
 
Sales-type lease selling price
 
Product revenue, net
 
$
—

 
$
—

 
$
—

 
$
151

Cost of underlying asset
 
 
 
—

 
—

 
—

 
58

Operating profit
 
 
 
$
—

 
$
—

 
$
—

 
$
209

 
 
 
 
 
 
 
 
 
 
 
Interest income on the lease receivable
 
Interest and other income, net
 
$
14

 
$
12

 
$
26

 
$
24

 
 
 
 
 
 
 
 
 
 
 
Initial direct costs incurred
 
Operating expense
 
$
—

 
$
—

 
$
—

 
$
8

 
 
 
 
 
 
 
 
 
 
 
Operating lease Income
 
Product revenue, net
 
$
1,355

 
$
2,840

 
$
2,592

 
$
4,125


Net investment in sales-type leases are as follows:
(in thousands)
 
Classification
 
June 30, 2019
 
December 31, 2018
 
 
 
 
 
 
 
Lease payment receivable, current
 
Accounts receivable, net and Notes receivable, current
 
$
431

 
$
533

Lease payment receivable, long-term
 
Notes receivable, long-term and Other assets
 
547

 
475

Total lease payment receivable
 
 
 
$
978

 
$
1,008


Equipment under lease is stated at cost less accumulated depreciation and is classified as “Property and equipment, net” on the Condensed Consolidated Balance Sheets. Depreciation is computed using the straight-line method over an estimated useful life of the greater of the lease term or five years to ten years. Equipment under lease is as follows:

(in thousands)
 
June 30, 2019
 
December 31, 2018
 
 
 
 
 
Equipment under lease
 
$
6,758

 
$
6,529

Less accumulated depreciation
 
(4,698
)
 
(3,665
)
Equipment under lease, net
 
$
2,060

 
$
2,864


Maturities of sales-type lease receivables as of June 30, 2019 are as follows (in thousands):
Fiscal Year
 
Amount
 
 
 
2019 (Remaining six months)
 
$
245

2020
 
394

2021
 
198

2022
 
150

2023
 
52

Thereafter
 
—

Total undiscounted cash flows
 
1,039

Present value of lease payments (recognized as lease receivables)
 
978

Difference between undiscounted and discounted cash flows
 
$
61


Maturities of operating lease receivables as of June 30, 2019 are as follows (in thousands):
Fiscal Year
 
Amount
 
 
 
2019 (Remaining six months)
 
$
1,274

2020
 
1,587

2021
 
551

2022
 
116

2023
 
29

Thereafter
 
—

Total undiscounted cash flows
 
$
3,557
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.19.2
Investment in Evofem (Notes)
 6 Months Ended
Jun. 30, 2019
Investments, Equity Securities [Abstract]  
Investment in Evofem [Text Block]
2. Investment in Evofem Biosciences, Inc.

Equity Investment in Evofem Biosciences, Inc.

On April 10, 2019, the Company entered into a securities purchase agreement with Evofem and two other purchasers, pursuant to which the Company purchased $60.0 million of Evofem securities in a private placement. The transaction was structured in two tranches.

The first tranche closed on April 11, 2019, pursuant to which the Company invested $30.0 million to purchase 6,666,667 shares of Evofem common stock at $4.50 per share and was also issued warrants to purchase up to 1,666,667 shares of Evofem common stock exercisable for seven years beginning six months after the issuance date at an exercise price of $6.38 per share.

The second tranche closed on June 10, 2019, pursuant to which the Company invested an additional $30.0 million to purchase an additional 6,666,667 shares of Evofem common stock at $4.50 per share and was also issued warrants to purchase up to an additional 1,666,667 shares of Evofem common stock with the same terms as the warrants issued in the first tranche. Following the closing of the second tranche, the Company appointed one member to Evofem’s Board of Directors and has a limited right to have one board observer participate in Evofem board meetings.

The Company has registration rights on customary terms for all Evofem shares issued under the securities purchase agreement, including the shares underlying the warrants.

As of June 30, 2019, the Company owned approximately 29% of Evofem’s common stock. The Company’s investment in Evofem qualifies for equity method accounting given its percentage ownership in Evofem and the ability to exercise significant influence. The Company elected the fair value method to account for its investment in Evofem as it believes it better reflects economic reality, the financial reporting of the investment and the current value of the asset. Changes in fair value of the Evofem equity investment are presented in Non-operating income (expense), net on the Condensed Consolidated Statements of Operations. Because the mark to market valuation will occur at the end of each quarterly reporting period, changes in fair value will vary based upon the volatility of the stock price. The Evofem equity investment is presented on the Condensed Consolidated Balance Sheet as an Investment in equity affiliate and reflects the fair value of the equity investment at the end of the reporting period.

For the three and six months ended June 30, 2019, the Company has recognized an unrealized gain of $45.5 million, of which $37.9 million was related to Evofem common stock and $7.6 million was related to Evofem warrants.

Following are condensed consolidated balance sheet data for Evofem as of June 30, 2019:
(in thousands)
 
June 30, 2019
 
 
(unaudited)
 
 
 
Current assets
 
$
52,849

Non-current assets
 
$
1,566

Current liabilities
 
$
18,623

Non-current liabilities
 
$
—

Total stockholders’ equity
 
$
35,792


Following are condensed consolidated statements of operations data for Evofem for the three and six months ended June 30, 2019:
 
Three months ended
 
Six months ended
(in thousands)
June 30, 2019
 
June 30, 2019
 
(unaudited)
 
(unaudited)
 
 
 
Revenues
$
—

 
$
—

Operating loss
$
(11,941
)
 
$
(25,573
)
Net loss
$
(35,450
)
 
$
(53,518
)
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.19.2
Summary of Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2019
Accounting Policies [Abstract]  
Basis of Presentation, Policy
Basis of Presentation
 
The accompanying unaudited Condensed Consolidated Financial Statements of PDL Biopharma, Inc. and its subsidiaries (collectively, the “Company” or “PDL”) have been prepared in accordance with Generally Accepted Accounting Principles (United States) (“GAAP”) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments), that management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year.
 
The accompanying unaudited Condensed Consolidated Financial Statements and related financial information should be read in conjunction with the Company’s audited Consolidated Financial Statements and the related notes thereto for the year ended December 31, 2018, included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the Securities and Exchange Commission (“SEC”) on March 15, 2019. The Condensed Consolidated Balance Sheet at December 31, 2018, included herein, has been derived from the audited Consolidated Financial Statements at that date, but does not include all disclosures required by GAAP.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying Notes to the Condensed Consolidated Financial Statements. The accounting estimates that require management’s most significant, difficult and subjective judgments include the valuation of royalty rights - at fair value, product revenue recognition and allowance for customer rebates and allowances, the valuation of notes receivable and inventory, the assessment of recoverability of intangible assets and their estimated useful lives, the valuation and recognition of stock-based compensation, the recognition and measurement of current and deferred income tax assets and liabilities, and the valuation of warrants to acquire shares of common stock. Actual results could differ from those estimates.

The Condensed Consolidated Financial Statements included herein include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Based on the nature of the Company’s existing investments and how they are managed, the Company structured its operations in four segments designated as Pharmaceutical, Medical Devices, Strategic Positions and Income Generating Assets. During the second quarter of 2019 the Company made an investment in Evofem Biosciences, Inc. (“Evofem”) and added a new segment designated as Strategic Positions. This had no impact on its prior segment reporting structure.
•
The Company’s Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna® and Tekturna HCT® in the United States and Rasilez® and Rasilez HCT® in the rest of the world and an authorized generic form of Tekturna sold in the United States (collectively, the “Noden Products”). The branded prescription Noden Products were acquired from Novartis in July 2016 (the “Noden Transaction”) by the Company’s wholly-owned subsidiary, Noden Pharma DAC (“Noden DAC”). The Company, through its wholly-owned subsidiary, Noden Pharma USA Inc. (“Noden USA”) launched its authorized generic form of Tekturna in the United States in March 2019.
•
The Company’s Medical Devices segment consists of revenue derived from the LENSAR® Laser System sales made by the Company’s subsidiary, LENSAR, Inc. (“LENSAR”), which may include equipment, Patient Interface Devices (“PIDs” or “consumables”), procedure licenses, training, installation, warranty and maintenance agreements.
•
The Company’s Strategic Positions segment consists of an investment in Evofem. The Company’s investment includes shares of common stock and warrants to purchase additional shares of common stock. Evofem is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Evofem is leveraging its proprietary Multipurpose Vaginal pH Regulator (MVP-R™) platform to develop Amphora® (L-lactic acid, citric acid and potassium bitartrate) for hormone-free birth control.
•
The Company’s Income Generating Assets segment consists of revenue derived from (i) royalty rights - at fair value, (ii) notes and other long-term receivables, (iii) equity investments and (iv) royalties from issued patents in the United States and elsewhere covering the humanization of antibodies (“Queen et al. patents”).

Significant Accounting Policies

The Company’s significant accounting policies are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018. Summarized below and in Note 2, Investment in Evofem Biosciences, Inc., are the accounting pronouncements and policies adopted subsequent to December 31, 2018.
New Accounting Pronouncements, Policy [Policy Text Block]
Adopted Accounting Pronouncements

Leases

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases, that supersedes Accounting Standards Codification (“ASC”) 840, Leases. Subsequently, the FASB issued several updates to ASU No. 2016-02, codified in ASC Topic 842 (“ASC 842”). The Company adopted ASC 842, Leases, on January 1, 2019 using the modified retrospective method for all leases not substantially completed as of the date of adoption. The reported results for the three and six month periods ended June 30, 2019 reflect the application of ASC 842 guidance while the reported results for the three and six month periods ended June 30, 2018 were prepared under the guidance of ASC 840, which is also referred to herein as “legacy GAAP” or the “previous guidance”. The cumulative impact of the adoption of ASC 842 was not material, therefore, the Company did not record any adjustments to retained earnings. As a result of adopting ASC 842, the Company recorded operating lease right-of-use (“ROU”) assets of $2.1 million and operating lease liabilities of $2.1 million, primarily related to corporate office leases, based on the present value of the future lease payments on the date of adoption. Changes to lessor accounting focused on conforming with certain changes made to lessee accounting and the recently adopted revenue recognition guidance. The adoption of ASC 842 did not materially change how the Company accounts for lessor arrangements.
Policy Elections and Practical Expedients Taken
For leases that commenced before the effective date of ASC 842, the Company elected the practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases.
The Company adopted a policy of expensing short-term leases, defined as 12 months or less, as incurred.
The Company has a policy to exclude from the consideration in a lessor contract all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific lease revenue-producing transaction and collected by the Company from a lessee.
General
The Company determines if an arrangement is a lease or contains an embedded lease at inception. The Company has lease arrangements with lease and non-lease components, which are accounted for separately.
Lessee arrangements
Lessee operating leases are included in Other assets, Accrued liabilities, and Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheet. The Company does not have lessee financing leases.
Operating lease ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses the implicit rate when readily determinable at lease inception. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company’s remaining lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis as operating expense in the Condensed Consolidated Statements of Operations over the lease term.
Lessor arrangements
The Company leases medical device equipment to customers in both operating lease and sales-type lease arrangements generated from its Medical Devices segment.
For sales-type leases, the Company derecognizes the carrying amount of the underlying asset and capitalizes the net investment in the lease, which consists of the total minimum lease payments receivable from the lessee, at lease inception. The Company does not estimate an unguaranteed residual value of the equipment at lease termination because the equipment transfers to the lessee upon completion of the lease. Selling profit or loss is recognized at lease inception. Initial direct costs are recognized as an expense, unless there is no selling profit or loss. If there is no selling profit or loss, initial direct costs are deferred and recognized over the lease term. The Company recognizes interest income from the lease receivable over the lease term in Interest and other income, net in the Condensed Consolidated Statements of Operations.
 
For operating leases, rental income is recognized on a straight-line basis over the lease term. The cost of customer-leased equipment is recorded within Property and equipment, net in the accompanying Condensed Consolidated Balance Sheets and depreciated over the equipment’s estimated useful life. Depreciation expense associated with the leased equipment under operating lease arrangements is reflected in Cost of product revenue in the accompanying Condensed Consolidated Statements of Operations. Some of the Company’s operating leases include a purchase option for the customer to purchase the leased asset at the end of the lease arrangement. The Company manages its risk on its investment in the equipment through pricing and the term of the leases. Lessees do not provide residual value guarantees on leased equipment. Equipment returned to the Company may be leased or sold to other customers. Initial direct costs are deferred and recognized over the lease term.

Leases are generally not cancellable until after an initial term and may or may not require the customer to purchase a minimum number of procedures and consumables throughout the contract term.

For lease arrangements with lease and non-lease components where the Company is the lessor, the Company allocates the contract’s transaction price to the lease and non-lease components on a relative standalone selling price basis using the Company’s best estimate of the standalone selling price of each distinct product or service in the contract. Allocation of the transaction price is determined at the inception of the lease arrangement. The Company’s leases primarily consist of leases with fixed lease payments. For those leases with variable lease payments, the variable lease payment is typically based upon use of the leased equipment or the purchase of procedure licenses and consumables used with the leased equipment. Non-lease components are accounted for under ASC 606, Revenue from Contracts with Customers. For additional information regarding ASC 606, see Note 15, Revenue from Contracts with Customers.
Intangibles-Goodwill and Other
In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other: Simplifying the Test for Goodwill Impairment, to simplify the subsequent measurement of goodwill by eliminating step two from the goodwill impairment test. Under the amendments, an entity will recognize an impairment charge for the amount by which the carrying value exceeds the fair value. The amendments are effective for fiscal years and interim periods within those years beginning after December 15, 2019 on a prospective basis and early adoption is permitted. The Company adopted the requirements of ASU No. 2017-04 on January 1, 2019. The adoption did not have an effect on the Company’s Consolidated Financial Statements on the adoption date.

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. The new guidance amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses. ASU No. 2016-13 has an effective date of the fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is currently evaluating the impact of this guidance on its Consolidated Financial Statements.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement. The new guidance modifies disclosure requirements related to fair value measurement. The amendments in ASU No. 2018-13 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Implementation on a prospective or retrospective basis varies by specific disclosure requirement. Early adoption is permitted. The standard also allows for early adoption of any removed or modified disclosures upon issuance of ASU No. 2018-13 while delaying adoption of the additional disclosures until their effective date. The Company is currently evaluating the impact of this guidance on the its Consolidated Financial Statement disclosures.

In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software. The new guidance reduces complexity for the accounting for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). For public companies, the amendments in ASU No. 2018-15 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. Implementation should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The Company is currently evaluating the impact of this guidance on the Company’s Consolidated Financial Statements.
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.19.2
Net Income per Share (Tables)
 6 Months Ended
Jun. 30, 2019
Earnings Per Share [Abstract]  
Schedule of calculation of numerator and denominator in earnings per share
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
Net (Loss) Income per Basic and Diluted Share
 
2019
 
2018
 
2019
 
2018
 (in thousands, except per share amounts)
 
 
 
 
 
 
 
 
Numerator
 
 
 
 
 
 
 
 
(Loss) income attributable to PDL’s shareholders used to compute net (loss) income per basic and diluted share
 
$
(4,419
)
 
$
(112,296
)
 
$
2,261

 
$
(110,694
)
 
 
 
 
 
 
 
 
 
Denominator
 
 

 
 

 
 
 
 
Total weighted-average shares used to compute net (loss) income attributable to PDL’s shareholders, per basic share
 
118,285

 
146,923

 
123,484

 
149,186

Restricted stock
 
—

 
—

 
507

 
—

Stock options
 
—

 
—

 
49

 
—

Shares used to compute net (loss) income attributable to PDL’s shareholders, per diluted share
 
118,285

 
146,923

 
124,040

 
149,186

 
 
 
 
 
 
 
 
 
Net (loss) income attributable to PDL’s shareholders per share - basic
 
$
(0.04
)
 
$
(0.76
)
 
$
0.02

 
$
(0.74
)
Net (loss) income attributable to PDL’s shareholders per share - diluted
 
$
(0.04
)
 
$
(0.76
)
 
$
0.02

 
$
(0.74
)
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.19.2
Fair Value Measurements (Tables)
 6 Months Ended
Jun. 30, 2019
Fair Value Disclosures [Abstract]  
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
The following table represents significant unobservable inputs used in determining the estimated fair value of impaired notes receivable investments:
Asset
 
Valuation
Technique
 
Unobservable
Input
 
June 30, 2019
 
December 31, 2018
 
 
 
 
 
 
 
 
 
Wellstat Diagnostics
 
 
 
 
 
 
 
 
Wellstat Guarantors intellectual property
 
Income Approach
 
 
 
 
 
 
 
 
 
 
Discount rate
 
12%
 
12%
 
 
 
 
Royalty amount
 
$21 million
 
$21 million
Settlement Amount
 
Income Approach
 
 
 
 
 
 
 
 
 
 
Discount rate
 
15%
 
15%
 
 
 
 
Settlement amount
 
$34 million
 
$34 million
 
 
 
 
 
 
 
 
 
Real Estate Property
 
Market Approach
 
 
 
 
 
 
 
 
 
 
Annual appreciation rate
 
4%
 
4%
 
 
 
 
Estimated realtor fee
 
6%
 
6%
 
 
 
 
Estimated disposal date
 
9/30/2019
 
9/30/2019
 
 
 
 
 
 
 
 
 
CareView
 
 
 
 
 
 
 
 
Note receivable cash flows
 
Income Approach
 
 
 
 
 
 
 
 
 
 
Discount rate
 
30%
 
30%
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
The following tables summarize the changes in Level 3 Royalty Right Assets and the gains and losses included in earnings for the six months ended June 30, 2019:
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets
 
 
 
 
 
 
 
(in thousands)
 
Royalty Rights -
At Fair Value
Fair value as of December 31, 2018
 
 
 
$
376,510

 
 
 
 
 
 
 
 
Total net change in fair value for the period
 
 
 
 
 
 
Change in fair value of royalty rights - at fair value
 
$
(28,142
)
 
 
 
 
Proceeds from royalty rights - at fair value
 
$
(32,726
)
 
 
 
 
Total net change in fair value for the period
 
 
 
(60,868
)
 
 
 
 
 
 
 
Fair value as of June 30, 2019
 


 
$
315,642


Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets
 
 
 
 
 
 
 
 
 
Fair Value as of
 
Royalty Rights -
 
Fair Value as of
(in thousands)
 
December 31, 2018
 
Change in Fair Value
 
June 30, 2019
 
 
 
 
 
 
 
Assertio (formerly Depomed)
 
$
264,371

 
$
(459
)
 
$
263,912

VB
 
14,108

 
265

 
14,373

U-M
 
25,595

 
(1,316
)
 
24,279

AcelRx
 
70,380

 
(57,886
)
 
12,494

KYBELLA
 
2,056

 
(1,472
)
 
584

 
 
$
376,510

 
$
(60,868
)
 
$
315,642


The following table summarizes the changes in Level 3 Liabilities and the gains and losses included in earnings for the six months ended June 30, 2019:
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Liabilities
 
 
 
(in thousands)
 
Contingent Consideration
Fair value as of December 31, 2018
 
$
(1,071
)
 
 
 
 
 
 
Settlement of financial instrument(1)
 
1,071

 
 
 
 
 
Fair value as of June 30, 2019
 
$
—
Schedule of fair value of financial instruments measured on recurring basis
 
 
June 30, 2019
 
December 31, 2018
(in thousands)
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market funds
 
$
228,954

 
$
—

 
$
—

 
$
228,954

 
$
226,719

 
$
—

 
$
—

 
$
226,719

Corporate securities(1)
 
88,533

 
—

 
—

 
88,533

 
—

 
—

 
—

 
—

Warrants(2)
 
—

 
17,013

 
—

 
17,013

 
—

 
62

 
—

 
62

Royalty rights - at fair value
 
—

 
—

 
315,642

 
315,642

 
—

 
—

 
376,510

 
376,510

Total
 
$
317,487

 
$
17,013

 
$
315,642

 
$
650,142

 
$
226,719

 
$
62

 
$
376,510

 
$
603,291

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial liabilities:
 
 

 
 

 
 
 
 

 
 

 
 

 
 
 
 

Contingent consideration, current(3)
 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
1,071

 
$
1,071

Total
 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
1,071

 
$
1,071
Schedule of fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy
ollows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
Total change in fair value for the period included in earnings for royalty right assets held at the end of the reporting period
 
$
(40,399
)
 
$
12,842

 
$
(28,142
)
 
$
23,933

 
 
 
 
 
 
 
 
 
Total change in fair value for the period included in earnings for liabilities held at the end of the reporting period
 
$
—

 
$
22,135

 
$
—

 
$
22,735


Assets/Liabilities Measured and Recorded at Fair Value on a Nonrecurring Basis

The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets consist of long-lived assets, including property and equipment and intangible assets and the shares of Alphaeon Class A common stock, received in connection with loans made to LENSAR by the Company prior to its acquisition of LENSAR. During the three months ended June 30, 2018, the Company recorded an impairment charge of $152.3 million for the Noden intangible assets related to the increased probability of a generic form of aliskiren being launched in the United States. As a result of this impairment charge, which was based on the estimated fair value of the assets, the remaining carrying value of these intangible assets was determined to be $40.1 million. The fair value calculation included level 3 inputs. The Company’s carrying value of the investment in Alphaeon as of both June 30, 2019 and December 31, 2018 is $6.6 million based on an estimated per share value of $3.84, which was established by a valuation performed when the 1.7 million shares were acquired. The value of the Company’s investment in Alphaeon is not readily determinable as Alphaeon’s shares are not publicly traded. The Company evaluates the fair value of this investment by performing a qualitative assessment each reporting period. If the results of this qualitative assessment indicate that the fair value is less than the carrying value, the investment is written down to its fair value. There have been no such write downs since the Company acquired these shares. This investment is included in Other long-term assets. For additional information on the Alphaeon investment, see Note 6, Notes and Other Long-Term Receivables.

Assets/Liabilities Not Subject to Fair Value Recognition

The following tables present the fair value of assets and liabilities not subject to fair value recognition by level within the valuation h
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.19.2
Cash Equivalents and Investments (Tables)
 6 Months Ended
Jun. 30, 2019
Cash and Cash Equivalents [Abstract]  
Summary of cash and available-for-sale securities
(in thousands)
 
June 30, 2019
 
December 31, 2018
 
 
 
 
 
Cash
 
$
55,987

 
$
167,871

Money market funds
 
228,954

 
226,719

Total
 
$
284,941

 
$
394,590
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.19.2
Accrued Liabilities (Tables)
 6 Months Ended
Jun. 30, 2019
Sales Allowances and Accruals [Abstract]  
Sales Allowances and Accruals [Table Text Block]
The following table provides a summary of activity with respect to the Company’s sales allowances and accruals for the six months ended June 30, 2019:
(in thousands)
 
Discount and Distribution Fees
 
Government Rebates and Chargebacks
 
Assistance and Other Discounts
 
Product Returns
 
Total
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2018
 
$
3,094

 
$
8,901

 
$
3,457

 
$
4,681

 
$
20,133

Allowances for current period sales
 
3,069

 
6,455

 
2,962

 
951

 
13,437

Allowances for prior period sales
 
—

 
1,841

 
120

 
—

 
1,961

Credits/payments for current period sales
 
(1,544
)
 
(4,929
)
 
(2,401
)
 
(232
)
 
(9,106
)
Credits/payments for prior period sales
 
(3,044
)
 
(9,910
)
 
(3,005
)
 
(2,218
)
 
(18,177
)
Balance at June 30, 2019
 
$
1,575

 
$
2,358

 
$
1,133

 
$
3,182

 
$
8,248
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.19.2
Convertible Notes (Tables)
 6 Months Ended
Jun. 30, 2019
Debt Disclosure [Abstract]  
Schedule of carrying value and unamortized discount on December 2021 Notes [Table Text Block]
The carrying value and unamortized discount of the December 2021 Notes were as follows:
(in thousands)
 
June 30, 2019
 
December 31, 2018
 
 
 
 
 
Principal amount of the December 2021 Notes
 
$
150,000

 
$
150,000

Unamortized discount of liability component
 
(21,480
)
 
(25,356
)
Net carrying value of the December 2021 Notes
 
$
128,520

 
$
124,644
Schedule of convertible and non-recourse notes activity
 
 
 
 
Principal Balance Outstanding
 
Carrying Value
 
 
 
 
June 30,
 
June 30,
 
December 31,
Description
 
Maturity Date
 
2019
 
2019
 
2018
(in thousands)
 
 
 
 
 
 
 
 
Convertible Senior Notes
 
 
 
 
 
 
 
 
December 2021 Notes
 
December 1, 2021
 
$
150,000

 
$
128,520

 
$
124,644

Total
 
 
 
 

 
$
128,520

 
$
124,644
Schedule of carrying value and unamortized discount on February 2018 Notes [Table Text Block]

Schedule of interest expense for February 2018 Notes [Table Text Block]
Interest expense for the February 2018 Notes on the Company’s Condensed Consolidated Statements of Operations was as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2018
 
2018
 
 
 
 
 
Contractual coupon interest
 
$
—

 
$
421

Amortization of debt issuance costs
 
—

 
88

Amortization of debt discount
 
—

 
293

Total
 
$
—

 
$
802
Schedule of interest expense for December 2021 Notes [Table Text Block]
Interest expense for the December 2021 Notes on the Company’s Condensed Consolidated Statements of Operations was as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
Contractual coupon interest
 
$
1,032

 
$
1,031

 
$
2,063

 
$
2,062

Amortization of debt issuance costs
 
20

 
19

 
40

 
38

Amortization of debt discount
 
138

 
135

 
276

 
269

Amortization of conversion feature
 
1,794

 
1,626

 
3,560

 
3,225

Total
 
$
2,984

 
$
2,811

 
$
5,939

 
$
5,594
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.19.2
Other Long-Term Liabilities (Tables)
 6 Months Ended
Jun. 30, 2019
Other Liabilities Disclosure [Abstract]  
Schedule of other liabilities
 
 
June 30,
 
December 31,
(in thousands)
 
2019
 
2018
 
 
 
 
 
Uncertain tax positions
 
$
32,402

 
$
31,706

Deferred tax liabilities
 
13,803

 
13,847

Accrued lease guarantee
 
10,700

 
10,700

Long-term incentive accrual
 
146

 
125

Other
 
1,130

 
465

Total
 
$
58,181

 
$
56,843
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.19.2
Customer Concentration (Tables)
 6 Months Ended
Jun. 30, 2019
Customer Concentration [Abstract]  
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]
The percentage of total revenue recognized, which individually accounted for 10% or more of the Company’s total revenues in one or more of the periods presented below, was as follows:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
2019(1)
 
2018
 
2019(1)
 
2018
Noden
 
28%
 
56%
 
41%
 
52%
Assertio
 
49%
 
20%
 
39%
 
20%
LENSAR
 
20%
 
13%
 
19%
 
13%
___________________ 
(1)
For the three and six months ended June 30, 2019, the AcelRx royalty asset decrease in fair value of $60.0 million and $57.9 million, respectively, are excluded from total revenue when calculating product line concentration.
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.19.2
Intangibles and Goodwill (Tables)
 6 Months Ended
Jun. 30, 2019
Acquired Finite-Lived Intangible Assets [Line Items]  
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]
The components of intangible assets as of June 30, 2019 and December 31, 2018 were as follows:
 
 
June 30, 2019
 
December 31, 2018
(in thousands)
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
 
 
 
 
 
 
 
 
 
 
 
 
Finite-lived intangible assets:
 
 
 
 
 
 
 
 
 
 
 
 
Acquired products rights(1)
 
$
36,143

 
$
(4,517
)
 
$
31,626

 
$
36,143

 
$
(2,258
)
 
$
33,885

Customer relationships(1) (2) (4)
 
8,028

 
(1,209
)
 
6,819

 
8,028

 
(782
)
 
7,246

Acquired technology(2) (3) (5)
 
13,311

 
(1,630
)
 
11,681

 
11,011

 
(1,203
)
 
9,808

Acquired trademarks(2)
 
570

 
(247
)
 
323

 
570

 
(190
)
 
380

 
 
$
58,052

 
$
(7,603
)
 
$
50,449

 
$
55,752

 
$
(4,433
)
 
$
51,319

________________
(1) 
The Company acquired certain intangible assets as part of the Noden transaction. They are being amortized on a straight-line basis over a weighted-average period of eight years.
(2)
The Company acquired certain intangible assets as part of its acquisition of LENSAR in May 2017. They are being amortized on a straight-line basis over a weighted-average period of 15 years. The intangible assets for customer relationships are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained.
(3) 
The Company acquired certain intangible assets as part of the foreclosure on certain of Direct Flow Medical assets. They are being amortized on a straight-line basis over a weighted-average period of 10 years.
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.19.2
Intangibles and Goodwill Remaining Amortization Expense (Tables)
 6 Months Ended
Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
Based on the intangible assets recorded at June 30, 2019, and assuming no subsequent additions to or impairment of the underlying assets, the remaining amortization expense is expected to be as follows (in thousands):
Fiscal Year
 
Amount
 
 
 
2019 (Remaining six months)
 
$
3,212

2020
 
6,394

2021
 
6,362

2022
 
6,257

2023
 
6,194

Thereafter
 
22,030

Total remaining amortization expense
 
$
50,449
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.19.2
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2019
Segment Reporting Information [Line Items]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Information regarding the Company’s segments for the three and six months ended June 30, 2019 and 2018 is as follows:
Revenues by segment
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
$
10,415

 
$
25,879

 
$
30,375

 
$
44,221

Medical Devices
 
7,422

 
5,882

 
14,148

 
10,864

Strategic Positions
 
—

 
—

 
—

 
—

Income Generating Assets
 
(40,363
)
 
14,814

 
(28,136
)
 
30,008

Total revenues
 
$
(22,526
)
 
$
46,575

 
$
16,387

 
$
85,093


(Loss) income by segment
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
$
(345
)
 
$
(111,335
)
 
$
5,300

 
$
(113,048
)
Medical Devices
 
(1,678
)
 
(1,904
)
 
(2,893
)
 
(2,491
)
Strategic Positions
 
19,044

 
—

 
19,044

 
—

Income Generating Assets
 
(21,440
)
 
943

 
(19,190
)
 
4,845

Total net (loss) income
 
$
(4,419
)
 
$
(112,296
)
 
$
2,261

 
$
(110,694
)

Information regarding the Company’s segments as of June 30, 2019 and December 31, 2018 is as follows:
Long-lived assets by segment
 
 
 
 
(in thousands)
 
June 30,
2019
 
December 31,
2018
 
 
 
 
 
Pharmaceutical
 
$
4,082

 
$
3,682

Medical Devices
 
2,681

 
3,545

Strategic Positions
 
—

 
—

Income Generating Assets
 
151

 
160

Total long-lived assets
 
$
6,914

 
$
7,387
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.19.2
Inventory (Tables)
 6 Months Ended
Jun. 30, 2019
Inventory [Line Items]  
Schedule of Inventory, Current [Table Text Block]
Inventories consisted of the following:
(in thousands)
 
June 30, 2019
 
December 31, 2018
 
 
 
 
 
Raw materials
 
$
6,023

 
$
6,214

Work in process
 
2,629

 
549

Finished goods
 
7,611

 
12,179

Total inventory
 
$
16,263

 
$
18,942
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.19.2
Revenue from Contracts with Customers (Tables)
 6 Months Ended
Jun. 30, 2019
Revenue from Contracts with Customers [Abstract]  
Disaggregation of Revenue [Table Text Block]
disaggregates its revenue from contracts with customers by segment and geographic location as the Company believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. In the following table, revenue is disaggregated by segment and primary geographical market for the three and six months ended June 30, 2019 and 2018:
 
 
Three Months Ended
 
Three Months Ended
 
 
June 30, 2019
 
June 30, 2018
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Medical Devices
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
Primary geographical markets:
 
 
 
 
 
 
 
 
North America
 
$
2,203

 
$
3,038

 
$
615

 
$
10,776

Europe
 
705

 
5,454

 
679

 
6,371

Asia
 
3,093

 
1,923

 
1,643

 
8,732

Other
 
66

 
—

 
107

 
—

Total revenue from contracts with customers(1)
 
$
6,067

 
$
10,415

 
$
3,044

 
$
25,879


 
 
Six Months Ended
 
Six Months Ended
 
 
June 30, 2019
 
June 30, 2018
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Medical Devices
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
Primary geographical markets:
 
 
 
 
 
 
 
 
North America
 
$
4,287

 
$
15,176

 
$
2,319

 
$
21,707

Europe
 
1,722

 
11,036

 
1,294

 
12,362

Asia
 
5,362

 
4,163

 
2,757

 
10,152

Other
 
185

 
—

 
220

 
—

Total revenue from contracts with customers(1)
 
$
11,556

 
$
30,375

 
$
6,590

 
$
44,221

_______________
(1)
The tables above do not include lease revenue from the Company’s Medical Devices segment. For the three-month periods ended June 30, 2019 and 2018, revenue accounted for under Topic 842 and 840, Leases, was $1.4 million and $2.8 million, respectively and for the six-month periods ended June 30, 2019 and 2018 was $2.6 million and $4.3 million, respectively.
Contract with Customer, Asset and Liability [Table Text Block]
The following table provides information about receivables, contract assets and contract liabilities from contracts with customers:
(in thousands)
 
June 30, 2019
 
December 31, 2018
 
 
 
 
 
Receivables, net
 
$
17,872

 
$
20,655

Contract assets
 
$
3,214

 
$
2,595

Contract liabilities
 
$
4,856

 
$
8,938


Receivables, Net—Receivables, net, include amounts billed and due from customers. The amounts due are stated at their net estimated realizable value and are classified as current or noncurrent based on the timing of when the Company expects to receive payment. The Company maintains an allowance for doubtful accounts to provide for the estimated amount of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and collateral to the extent applicable.

Contract assets—The Company’s contract assets represent revenue recognized for performance obligations completed before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. The Company classifies contract assets in Prepaid and other current assets in the Company’s Condensed Consolidated Balance Sheets based on the timing of when it expects to receive payment.
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Total
 
 
 
 
 
 
 
Contract assets at December 31, 2018
 
$
—

 
$
2,595

 
$
2,595

Contract assets recognized
 
—

 
4,638

 
4,638

Payments received
 
—

 
(4,019
)
 
(4,019
)
Contract assets at June 30, 2019
 
$
—

 
$
3,214

 
$
3,214


Contract Liabilities—The Company’s contract liabilities consist of deferred revenue for products sold to customers for which the performance obligation has not been completed by the Company. The Company classifies deferred revenue as current or noncurrent based on the timing of when it expects to recognize revenue. The noncurrent portion of deferred revenue is included in Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheets.
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Total
 
 
 
 
 
 
 
Contract liabilities at December 31, 2018
 
$
1,167

 
$
7,771

 
$
8,938

Contract liabilities recognized
 
537

 
2,855

 
3,392

Amounts recognized into revenue
 
(645
)
 
(6,829
)
 
(7,474
)
Contract liabilities at June 30, 2019
 
$
1,059

 
$
3,797

 
$
4,856
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]
The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.
 
 
Six Months Ended
 
 
 
 
(in thousands)
 
December 31, 2019
 
Thereafter
 
Total
 
 
 
 
 
 
 
Pharmaceutical product sales
 
$
116

 
$
2,326

 
$
2,442

Medical device sales
 
$
2,347

 
$
3,986

 
$
6,333
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.19.2
Leases (Tables)
 6 Months Ended
Jun. 30, 2019
Leases [Abstract]  
Lease, Cost [Table Text Block]
The components of lease expense are as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
Operating lease cost
 
$
234

 
$
324

 
$
467

 
$
609

Short-term lease cost
 
19

 
12

 
44

 
24

Total lease cost
 
$
253

 
$
336

 
$
511

 
$
633


Supplemental cash flow information related to leases is as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
 
 
 
 
 
Operating cash flows from operating leases
 
$
235

 
$
324

 
$
450

 
$
609

Right-of-use-assets obtained in exchange for lease obligations:
 
 
 
 
 
 
 
 
Operating leases
 
$
—

 
N/A
 
$
2,111

 
N/A
_______________
N/A    Not applicable

The following table presents the lease balances within the Condensed Consolidated Balance Sheet, weighted-average remaining lease term, and weighted-average discount rates related to the Company’s operating leases (in thousands):
Operating Leases
 
Classification
 
June 30, 2019
 
 
 
 
 
Operating lease ROU assets
 
Other assets
 
$
1,661

 
 
 
 
 
Operating lease liabilities, current
 
Accrued liabilities
 
$
807

Operating lease liabilities, long-term
 
Other long-term liabilities
 
891

Total operating lease liabilities
 
Total operating lease liabilities
 
$
1,698

 
 
 
 
 
Weighted-average remaining lease term
 
 
 
2.00 years

Weighted-average discount rate
 
 
 
6
%

Maturities of operating lease liabilities as of June 30, 2019 are as follows (in thousands):
Fiscal Year
 
Amount
 
 
 
2019 (Remaining six months)
 
$
472

2020
 
837

2021
 
473

2022
 
—

2023
 
—

Thereafter
 
—

Total operating lease payments
 
1,782

Less: imputed interest
 
84

Total operating lease liabilities
 
$
1,698


Future minimum operating lease payments as of December 31, 2018 were as follows (in thousands):
Fiscal Year
 
Amount
 
 
 
2019
 
$
1,140

2020
 
1,003

2021
 
559

2022
 
—

2023
 
—

Thereafter
 
—

Total
 
$
2,702


As of June 30, 2019, the Company had no additional significant operating or finance leases that had not yet commenced.
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.19.2
Investment in Evofem (Tables)
 6 Months Ended
Jun. 30, 2019
Affiliate financial statements [Line Items]  
Evofem financial statements [Table Text Block]
Following are condensed consolidated balance sheet data for Evofem as of June 30, 2019:
(in thousands)
 
June 30, 2019
 
 
(unaudited)
 
 
 
Current assets
 
$
52,849

Non-current assets
 
$
1,566

Current liabilities
 
$
18,623

Non-current liabilities
 
$
—

Total stockholders’ equity
 
$
35,792


Following are condensed consolidated statements of operations data for Evofem for the three and six months ended June 30, 2019:
 
Three months ended
 
Six months ended
(in thousands)
June 30, 2019
 
June 30, 2019
 
(unaudited)
 
(unaudited)
 
 
 
Revenues
$
—

 
$
—

Operating loss
$
(11,941
)
 
$
(25,573
)
Net loss
$
(35,450
)
 
$
(53,518
)
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.19.2
Summary of Significant Accounting Policies (Narrative) (Detail)
$ in Millions
 6 Months Ended
Jun. 30, 2019
Jan. 02, 2019
USD ($)
Number of Reportable Segments 4  
Operating Lease, Right-of-Use Asset   $ 2.1
Operating Lease, Liability   $ 2.1
Maximum term of short-term lease expensed via exemption 12 months  
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.19.2
Net Income per Share (Narrative) (Detail) - USD ($)
$ in Thousands, shares in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Mar. 31, 2018
Nov. 22, 2016
Nov. 20, 2015
Feb. 12, 2014
Restricted Stock [Member]                  
Debt Instrument [Line Items]                  
Antidilutive securities excluded from computation of earnings per share (in Shares) 1.1 1.0 0.0 1.1          
Option on Securities [Member]                  
Debt Instrument [Line Items]                  
Antidilutive securities excluded from computation of earnings per share (in Shares) 12.7 4.9 0.0 4.9          
February 2018 Notes [Member]                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage           4.00%      
Convertible notes                 $ 300,000
December 2021 Notes [Member]                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage 2.75%   2.75%       2.75%    
Convertible notes $ 128,520   $ 128,520   $ 124,644   $ 150,000 $ 150,000  
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.19.2
Net Income per Share (Net Income Per Basic and Diluted Share) (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Numerator        
Income used to compute net income per diluted share $ (4,419) $ (112,296) $ 2,261 $ (110,694)
Denominator        
Total weighted-average shares used to compute net income per basic share (in Shares) 118,285 146,923 123,484 149,186
Diluted (in Shares) 118,285 146,923 124,040 149,186
Basic (in Dollars per Share) $ (0.04) $ (0.76) $ 0.02 $ (0.74)
Net income per diluted share (in Dollars per Share) $ (0.04) $ (0.76) $ 0.02 $ (0.74)
Restricted Stock [Member]        
Debt Instrument [Line Items]        
Additional shares included in the calculation of diluted EPS (in Shares) 0 0 507 0
Employee Stock Option [Member]        
Debt Instrument [Line Items]        
Additional shares included in the calculation of diluted EPS (in Shares) 0 0 49 0
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.19.2
Fair Value Measurements (Narrative) (Detail)
$ / shares in Units, shares in Millions
 3 Months Ended 6 Months Ended 12 Months Ended
Aug. 02, 2018
USD ($)
Jul. 08, 2016
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Aug. 03, 2018
USD ($)
Jun. 29, 2018
USD ($)
Jul. 09, 2016
USD ($)
Dec. 31, 2015
$ / shares
Dec. 15, 2015
shares
Sep. 18, 2015
USD ($)
Nov. 06, 2014
USD ($)
Jun. 26, 2014
USD ($)
Oct. 18, 2013
USD ($)
Intangible Assets, Net (Excluding Goodwill) [1]     $ 50,449,000   $ 50,449,000   $ 51,319,000                  
Impairment of Intangible Assets, Finite-lived     0 $ 152,330,000 0 $ 152,330,000 152,300,000                  
Investment Owned, at Cost     $ 6,600,000   6,600,000                      
Goodwill and Intangible Asset Impairment         $ 152,300,000                      
Cash payment for purchase of royalty right                           $ 65,600,000    
Purchase of royalty rights $ 20,000,000                              
Reversionary interest period               $ 481,000,000                
Sensitivity range for royalty disclosures     2.50%   2.50%                      
Royalty rights     $ 315,642,000 [1]   $ 315,642,000 [1]   376,510,000 [2]                  
Transfers from level 1 to level 2, amount     0   0   0                  
Transfers from level 2 to level 1, amount     0   0   0                  
Percentage of royalty acquired                           75.00%    
Revenues     (22,526,000) 46,575,000 16,387,000 85,093,000                    
Finite-Lived Intangible Assets, Gross     58,052,000   58,052,000   55,752,000                  
Asset Impairment Charges     $ 0   0   $ 8,200,000                  
Depomed [Member]                                
Cash payment for purchase of royalty right                               $ 240,500,000
Purchase of royalty rights                               241,300,000
Royalty right purchase transaction costs                               $ 800,000
Cash flow model expected royalty sales term     8 years                          
Sensitivity - decrease in fair value from increase in discount rate     $ 22,200,000   22,200,000                      
Sensitivity - increase in fair value from decrease in discount rate     26,300,000   26,300,000                      
Sensitivity to increase or decrease in expected royalty     6,600,000   6,600,000                      
Royalty rights     263,900,000   263,900,000                      
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount     $ 263,900,000   $ 263,900,000                      
Contractual cap on potential royalty asset multiple         2                      
VB [Member]                                
Purchase of royalty rights                             $ 15,500,000  
Cash flow model expected royalty sales term     9 years                          
Sensitivity - decrease in fair value from increase in discount rate     $ 1,300,000   $ 1,300,000                      
Sensitivity - increase in fair value from decrease in discount rate     1,500,000   1,500,000                      
Sensitivity to increase or decrease in expected royalty     $ 400,000   $ 400,000                      
Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate     15.00%   15.00%                      
Royalty rights     $ 14,400,000   $ 14,400,000                      
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount     $ 14,400,000   $ 14,400,000                      
Contractual cap on potential royalty asset multiple         2.3                      
University of Michigan [Member]                                
Cash flow model expected royalty sales term     3 years                          
Sensitivity - decrease in fair value from increase in discount rate     $ 900,000   $ 900,000                      
Sensitivity - increase in fair value from decrease in discount rate     1,000,000   1,000,000                      
Sensitivity to increase or decrease in expected royalty     $ 600,000   $ 600,000                      
Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate     12.80%   12.80%                      
Royalty rights     $ 24,300,000   $ 24,300,000                      
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount     $ 24,300,000   24,300,000                      
AcelRx [Member]                                
Purchase of royalty rights                         $ 65,000,000      
Cash flow model expected royalty sales term     14 years                          
Sensitivity - decrease in fair value from increase in discount rate     $ 1,200,000   1,200,000                      
Sensitivity - increase in fair value from decrease in discount rate     1,500,000   1,500,000                      
Sensitivity to increase or decrease in expected royalty     $ 300,000   $ 300,000                      
Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate     13.40%   13.40%                      
Royalty rights     $ 12,500,000   $ 12,500,000                      
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount     12,500,000   $ 12,500,000                      
Percentage of royalty acquired                         75.00%      
Percentage of first four milestone payments acquired                         80.00%      
Number of potential milestone royalties                         4      
Contractual cap on potential royalty asset multiple         3                      
Revenues     $ 60,000,000                          
Kybella [Member]                                
Purchase of royalty rights                   $ 9,500,000            
Cash flow model expected royalty sales term     6 years                          
Sensitivity - increase in fair value from decrease in discount rate     $ 100,000   $ 100,000                      
Sensitivity to increase or decrease in expected royalty     $ 100,000   $ 100,000                      
Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate     14.40%   14.40%                      
Royalty rights     $ 600,000   $ 600,000                      
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount     $ 600,000   $ 600,000                      
Maximum amount of additional funds, upon attainment of milestones   $ 1,000,000                            
Alphaeon [Member]                                
Investment Owned, Balance, Shares | shares                       1.7        
Investment estimated fair value, per share | $ / shares                     $ 3.84          
Noden [Member]                                
Intangible Assets, Net (Excluding Goodwill)       40,100,000   40,100,000                    
Finite-Lived Intangible Assets, Gross       $ 40,100,000   $ 40,100,000     $ 192,500,000              
Minimum [Member] | Depomed [Member]                                
Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate     10.00%   10.00%                      
Maximum [Member] | Depomed [Member]                                
Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate     24.00%   24.00%                      
[1] unaudited
[2] Note 1
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.19.2
Fair Value Measurements (Financial Instruments Measured at Fair Value on a Recurring Basis) (Detail) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2019
Dec. 31, 2018
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability, Current $ 0  
Royalty rights 315,642 [1] $ 376,510 [2]
Financial assets:    
Assets, Fair Value 650,142 603,291
Warrants and Rights Outstanding 17,013 62
Equity Securities [Member]    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments in and Advances to Affiliates, at Fair Value 88,533 0
Money Market Funds [Member]    
Financial assets:    
Cash and Cash Equivalents, Fair Value 228,954 226,719
Fair Value Level 1 [Member]    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial and Nonfinancial Liabilities, Fair Value Disclosure 0 0
Financial assets:    
Assets, Fair Value 317,487 226,719
Fair Value Level 1 [Member] | Equity Securities [Member]    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments in and Advances to Affiliates, at Fair Value 88,533 0
Fair Value Level 1 [Member] | Money Market Funds [Member]    
Financial assets:    
Cash and Cash Equivalents, Fair Value 228,954 226,719
Fair Value Level 2 [Member]    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial and Nonfinancial Liabilities, Fair Value Disclosure 0 0
Financial assets:    
Assets, Fair Value 17,013 62
Warrants and Rights Outstanding 17,013 62
Fair Value Level 2 [Member] | Equity Securities [Member]    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments in and Advances to Affiliates, at Fair Value 0 0
Fair Value Level 2 [Member] | Money Market Funds [Member]    
Financial assets:    
Cash and Cash Equivalents, Fair Value 0 0
Fair Value Level 3 [Member]    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability, Current 0  
Financial and Nonfinancial Liabilities, Fair Value Disclosure 0 1,071
Royalty rights 315,642 376,510
Financial assets:    
Assets, Fair Value 315,642 376,510
Warrants and Rights Outstanding 0  
Royalty right [Member]    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings (60,868)  
Contingent Consideration [Member]    
Financial liabilites:    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 0 $ 1,071
VB [Member]    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Royalty rights 14,400  
VB [Member] | Royalty right [Member]    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings $ 265  
[1] unaudited
[2] Note 1
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.19.2
Fair Value Measurements (Schedule of Fair Value of Assets and Liabilities not Subject to Fair Value Recognition) (Detail)
$ in Thousands
Jun. 30, 2019
USD ($)
Dec. 31, 2018
USD ($)
Assets    
Notes receivable, Carrying Value $ 62,849 $ 62,849
Liabilities:    
Convertible Notes Payable, Carrying Value 128,520 124,644
December 2021 Notes [Member]    
Liabilities:    
Convertible Notes Payable, Carrying Value 128,520 124,644
Wellstat Note Receivable [Member]    
Assets    
Notes receivable, Carrying Value 50,191 50,191
Hyperion [Member]    
Assets    
Notes receivable, Carrying Value 1,200 1,200
CareView [Member]    
Assets    
Notes receivable, Carrying Value 11,458 11,458
Fair Value Level 2 [Member]    
Liabilities:    
Notes payable, Fair Value 157,017 151,356
Fair Value Level 2 [Member] | December 2021 Notes [Member]    
Liabilities:    
Notes payable, Fair Value 157,017 151,356
Fair Value Level 2 [Member] | Hyperion [Member]    
Assets    
Notes receivable, Fair Value 0 0
Fair Value Level 2 [Member] | CareView [Member]    
Assets    
Notes receivable, Fair Value 0 0
Fair Value Level 3 [Member]    
Assets    
Notes receivable, Fair Value 71,898 69,980
Fair Value Level 3 [Member] | Wellstat Note Receivable [Member]    
Assets    
Notes receivable, Fair Value 59,240 57,322
Fair Value Level 3 [Member] | Hyperion [Member]    
Assets    
Notes receivable, Fair Value 1,200 1,200
Fair Value Level 3 [Member] | CareView [Member]    
Assets    
Notes receivable, Fair Value $ 11,458 $ 11,458
Real estate appreciation [Member] | Wellstat Diagnostics [Member]    
Fair Value by Balance Sheet Grouping [Line Items]    
Loans Held-for-sale, Measurement Input 0.04 0.04
Estimated realtor fee [Member] | Wellstat Diagnostics [Member]    
Fair Value by Balance Sheet Grouping [Line Items]    
Loans Held-for-sale, Measurement Input 0.06 0.06
Minimum [Member] | Measurement Input, Discount Rate [Member] | Wellstat Diagnostics [Member]    
Fair Value by Balance Sheet Grouping [Line Items]    
Loans Held-for-sale, Measurement Input 0.12 0.12
Maximum [Member] | Measurement Input, Discount Rate [Member] | Wellstat Diagnostics [Member]    
Fair Value by Balance Sheet Grouping [Line Items]    
Loans Held-for-sale, Measurement Input 0.15 0.15
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.19.2
Fair Value Measurements Level 3 Unobservable Input Reconciliation (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements     $ 1,071    
Change in fair value of acquired royalty rights, Level 3 Rollforward $ (40,399) $ 12,842 (28,142) $ 23,933  
Payments for (Proceeds from) Productive Assets     (32,726) (37,993)  
Change in fair value included in earnings for liabilities 0 $ 22,135 0 $ 22,735  
Contingent Consideration [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 0   0   $ (1,071)
Royalty right [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Beginning balance     376,510    
Change in fair value of acquired royalty rights, Level 3 Rollforward     (28,142)    
Ending balance 315,642   315,642    
Payments for (Proceeds from) Productive Assets     (32,726)    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings     (60,868)    
Depomed [Member] | Royalty right [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Beginning balance     264,371    
Ending balance $ 263,912   263,912    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings     $ (459)    
VB [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate 15.00%   15.00%    
VB [Member] | Royalty right [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Beginning balance     $ 14,108    
Ending balance $ 14,373   14,373    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings     $ 265    
University of Michigan [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate 12.80%   12.80%    
University of Michigan [Member] | Royalty right [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Beginning balance     $ 25,595    
Ending balance $ 24,279   24,279    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings     $ (1,316)    
AcelRx [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate 13.40%   13.40%    
AcelRx [Member] | Royalty right [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Beginning balance     $ 70,380    
Ending balance $ 12,494   12,494    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings $ (59,974)   $ (57,886)    
Kybella [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate 14.40%   14.40%    
Kybella [Member] | Royalty right [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Beginning balance     $ 2,056    
Ending balance $ 584   584    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings     $ (1,472)    
CareView [Member] | Note receivable cash flows [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate 30.00%   30.00%   30.00%
Measurement Input, Discount Rate [Member] | Other [Member] | Wellstat Diagnostics [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Beginning balance     $ 34,000    
Ending balance $ 34,000   34,000    
Measurement Input, Discount Rate [Member] | Intellectual Property [Member] | Wellstat Diagnostics [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Beginning balance     21,000    
Ending balance $ 21,000   $ 21,000    
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.19.2
Cash Equivalents and Investments (Narrative) (Detail) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Cash and Cash Equivalents [Abstract]        
Gains (losses) on sales of available-for-sale securities $ 0.0 $ 0.0 $ 0.0 $ 0.8
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.19.2
Cash Equivalents and Investments (Summary of Cash and Available-For-Sale Securities) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Jun. 30, 2018
 [2]
Dec. 31, 2017
 [3]
Schedule of Available-For-Sale Securities [Line Items]        
Cash and cash equivalents $ 284,941 [1],[2] $ 394,590 [3] $ 395,653 $ 527,266
Cash [Member]        
Schedule of Available-For-Sale Securities [Line Items]        
Cash and cash equivalents 55,987 167,871    
Money Market Funds [Member]        
Schedule of Available-For-Sale Securities [Line Items]        
Cash and cash equivalents $ 228,954 $ 226,719    
[1] unaudited
[2] unaudited
[3] Note 1
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.19.2
Notes Receivable and Other Long-term Receivables (Narrative) (Detail)
$ / shares in Units, $ in Thousands, shares in Millions
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 58 Months Ended
Jan. 08, 2018
USD ($)
Sep. 21, 2017
USD ($)
Sep. 22, 2015
USD ($)
Jun. 26, 2015
USD ($)
$ / shares
shares
Aug. 15, 2013
USD ($)
Feb. 28, 2013
Jan. 31, 2013
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2013
USD ($)
Apr. 30, 2018
Feb. 02, 2018
$ / shares
Oct. 07, 2015
$ / shares
Sep. 30, 2014
USD ($)
Apr. 01, 2014
USD ($)
Jun. 28, 2013
USD ($)
Mar. 05, 2013
USD ($)
Nov. 02, 2012
USD ($)
Jan. 27, 2012
USD ($)
Accounts Notes And Loans Receivable [Line Items]                                            
Revenues               $ (22,526) $ 46,575 $ 16,387 $ 85,093                      
Accounts Receivable, Net, Noncurrent [1]                       $ 1,400                    
Investment Owned, at Cost               6,600   6,600                        
Commitments and Contingencies               [1]   [1]   [2]                    
Financial Instruments, Owned, Other, at Fair Value               17,013   17,013   62                    
Asset Impairment Charges               0   0   $ 8,200                    
Wellstat Diagnostics [Member]                                            
Accounts Notes And Loans Receivable [Line Items]                                            
Financing Receivable, Gross                                 $ 53,900          
Gain Contingency, Unrecorded Amount               55,800   55,800                        
Financing Receivable, Net               50,200   50,200                        
Interest rate of note receivable (in Percent)         5.00%                                  
Avinger [Member]                                            
Accounts Notes And Loans Receivable [Line Items]                                            
Repayment of notes receivable     $ 21,400                                      
Hyperion [Member]                                            
Accounts Notes And Loans Receivable [Line Items]                                            
Financing Receivable, Gross                                           $ 2,300
Number of payments to be received                                           2
Periodic contractual payments                                       $ 1,200    
kaleo Note Receivable [Member]                                            
Accounts Notes And Loans Receivable [Line Items]                                            
Financing Receivable, Gross                                   $ 150,000        
Repayment of notes receivable   $ 141,700                                        
CareView [Member]                                            
Accounts Notes And Loans Receivable [Line Items]                                            
Interest rate of note receivable (in Percent)       13.50%                                    
Amount company has agreed to advance under agreement       $ 40,000                                    
Tranche 1 of note receivable       20,000                                    
Tranche 2 of note receivable       $ 20,000                                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares       4.4                                    
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares       $ 0.45                     $ 0.03 $ 0.40            
Financial Instruments, Owned, Other, at Fair Value               100   100                        
Credit Agreement [Member] | Wellstat Diagnostics [Member]                                            
Accounts Notes And Loans Receivable [Line Items]                                            
Financing Receivable, Gross                                         $ 40,000  
Credit agreement, stated interest rate (in Percent)                                         5.00%  
Proceeds received under remedies available for borrower's breach of terms credit agreement             $ 8,100                              
Forbearance number of days under terms of credit agreement (in Duration)           120 days                                
Amount company has agreed to advance under agreement                         $ 8,700                  
Financing Receivable, Modifications, Post-Modification Recorded Investment         $ 44,100                                  
Initial Loan [Member] | Wellstat Diagnostics [Member]                                            
Accounts Notes And Loans Receivable [Line Items]                                            
Financing Receivable, Modifications, Post-Modification Recorded Investment         33,700                                  
Additional Loan [Member] | Wellstat Diagnostics [Member]                                            
Accounts Notes And Loans Receivable [Line Items]                                            
Financing Receivable, Gross                                     $ 1,300      
Royalty Agreement [Member] | Avinger [Member]                                            
Accounts Notes And Loans Receivable [Line Items]                                            
Reduction in royalty rate (in percent)                           50.00%                
Term loan and interest [Member] | Wellstat Diagnostics [Member]                                            
Accounts Notes And Loans Receivable [Line Items]                                            
Financing Receivable, Modifications, Post-Modification Recorded Investment         1,300                                  
Forbearance principal and interest [Member] | Wellstat Diagnostics [Member]                                            
Accounts Notes And Loans Receivable [Line Items]                                            
Financing Receivable, Modifications, Post-Modification Recorded Investment         $ 9,100                                  
License and other [Member]                                            
Accounts Notes And Loans Receivable [Line Items]                                            
Revenues $ 500             $ 30 $ 3 $ (3) $ 574                      
[1] unaudited
[2] Note 1
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.19.2
Accrued Liabilities (Narrative) (Detail) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2019
Dec. 31, 2018
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]    
Discount and Distribution Fees $ 1,575 $ 3,094
Government rebates and chargebacks 2,358 8,901
Assistance and Other Discounts 1,133 3,457
Product return 3,182 4,681
Accrued liabilities, amounts received in advance of revenue recognition 8,248 $ 20,133
Allowances for current period sales 13,437  
Allowances for prior period sales 1,961  
Payments for current period sales (9,106)  
Payments for prior period sales (18,177)  
Discount and Distribution Fees [Member]    
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]    
Allowances for current period sales 3,069  
Allowances for prior period sales 0  
Payments for current period sales (1,544)  
Payments for prior period sales (3,044)  
Government Rebates and Chargebacks [Member]    
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]    
Allowances for current period sales 6,455  
Allowances for prior period sales 1,841  
Payments for current period sales (4,929)  
Payments for prior period sales (9,910)  
Assistance and Other Discounts [Member]    
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]    
Allowances for current period sales 2,962  
Allowances for prior period sales 120  
Payments for current period sales (2,401)  
Payments for prior period sales (3,005)  
Product Returns [Member]    
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]    
Allowances for current period sales 951  
Allowances for prior period sales 0  
Payments for current period sales (232)  
Payments for prior period sales $ (2,218)  
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.19.2
Accrued Liabilities (Accrued Liabilities) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Payables and Accruals [Abstract]    
Compensation $ 5,017 $ 4,468
Interest 344 344
Legal 314 623
Accrued liabilities, amounts received in advance of revenue recognition 8,248 20,133
Other 4,776 4,933
Total 23,499 [1] 39,312 [2]
Deferred Revenue, Current $ 4,800 $ 8,811
[1] unaudited
[2] Note 1
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.19.2
Commitments and Contingencies (Narrative) (Detail) - USD ($)
$ in Thousands
Sep. 21, 2017
Jun. 30, 2019
Dec. 31, 2018
Apr. 01, 2014
Guarantor Obligations [Line Items]        
Accounts Receivable, Net, Noncurrent [1]     $ 1,400  
Total lease payments for the duration of the guarantee   $ 28,200    
Accrued lease liability   10,700 $ 10,700  
kaleo Note Receivable [Member]        
Guarantor Obligations [Line Items]        
Financing Receivable, Gross       $ 150,000
Proceeds from Collection of Notes Receivable $ 141,700      
Noden [Member] | Next twelve months [Member]        
Guarantor Obligations [Line Items]        
Purchase Obligation   53,100    
Noden [Member] | Next twenty-four months [Member] [Member]        
Guarantor Obligations [Line Items]        
Purchase Obligation   90,900    
LENSAR [Member] | Next twelve months [Member]        
Guarantor Obligations [Line Items]        
Purchase Obligation   4,900    
LENSAR [Member] | Next twenty-four months [Member] [Member]        
Guarantor Obligations [Line Items]        
Purchase Obligation   $ 6,300    
[1] unaudited
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.19.2
Convertible Notes (Narrative) (Detail)
 6 Months Ended
Feb. 02, 2018
USD ($)
Nov. 21, 2016
USD ($)
Feb. 11, 2014
USD ($)
Jun. 30, 2019
USD ($)
$ / shares
Jun. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Mar. 31, 2018
Nov. 22, 2016
USD ($)
$ / shares
Nov. 20, 2015
USD ($)
Feb. 12, 2014
USD ($)
Debt Instrument [Line Items]                    
Principal amount a $5 incentive cash payment per each to convert debt       $ 1,000            
Convertible note rate conversion trading days (in days)       0            
Convertible Notes rate conversion consecutive trading days (in days)       $ 30            
Minimum conversion price percent for note conversion (in Percent)       130.00%            
Repurchase price upon fundamental change as described in 2021 Notes indenture       100.00%            
Interest Paid, Including Capitalized Interest, Operating and Investing Activities       $ 2,063,000 $ 4,591,000          
February 2018 Notes [Member]                    
Debt Instrument [Line Items]                    
Convertible notes                   $ 300,000,000
Debt Instrument, Interest Rate, Stated Percentage             4.00%      
Net proceeds from the issuance of convertible notes     $ 290,200,000              
Debt Instrument, Repurchase Amount               $ 120,000,000 $ 53,600,000  
Repayments of Debt $ 129,000,000                  
Debt Instrument, Periodic Payment, Principal 126,400,000                  
Debt Instrument, Periodic Payment, Interest $ 2,600,000                  
December 2021 Notes [Member]                    
Debt Instrument [Line Items]                    
Convertible notes       $ 128,520,000   $ 124,644,000   $ 150,000,000 $ 150,000,000  
Debt Instrument, Interest Rate, Stated Percentage       2.75%       2.75%    
Unamortized discount of liability component       $ (21,480,000)   (25,356,000)   $ (4,300,000)    
Debt discount recorded to additional paid in capital               23,800,000    
Debt discount recorded to deferred tax liability               $ 12,800,000    
Maximum percent of common stock closing price and conversion rate to convert note (in Percent)       98.00%            
Debt Instrument, Interest Rate, Effective Percentage               3.40%    
Convertible notes, conversion price (in Dollars per Share) | $ / shares               $ 3.81    
Estimated market interest rate for similar nonconvertible instrument               9.50%    
Debt instrument, convertible, remaining amortization period (in Duration)       2 years 5 months 5 days            
Net proceeds from the issuance of convertible notes   $ 145,700,000                
Debt Instrument, Face Amount       $ 150,000,000   $ 150,000,000        
Conversion Rate per $1,000 Principal Amount (in Ratio)   262.2951                
Proceeds from Issuance of Warrants   $ 14,400,000                
Purchased Call Options [Member]                    
Debt Instrument [Line Items]                    
Convertible notes, conversion price (in Dollars per Share) | $ / shares       $ 4.88            
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.19.2
Convertible Notes (Summary of Convertible Notes) (Detail)
 6 Months Ended
Nov. 21, 2016
Jun. 30, 2019
USD ($)
Dec. 31, 2018
USD ($)
Mar. 31, 2018
Nov. 22, 2016
$ / shares
Debt Instrument [Line Items]          
Principal amount a $5 incentive cash payment per each to convert debt   $ 1,000      
Convertible Notes Payable, Carrying Value   $ 128,520,000 $ 124,644,000    
February 2018 Notes [Member]          
Debt Instrument [Line Items]          
Debt Instrument, Interest Rate, Stated Percentage       4.00%  
December 2021 Notes [Member]          
Debt Instrument [Line Items]          
Debt Instrument, Interest Rate, Stated Percentage   2.75%     2.75%
Debt Instrument, Convertible, Conversion Ratio 262.2951        
Convertible notes, conversion price (in Dollars per Share) | $ / shares         $ 3.81
Convertible Notes, Maturity Date (Date)   Dec. 01, 2021      
Convertible Notes, Principal Balance Outstanding   $ 150,000,000 150,000,000    
Convertible Notes Payable, Carrying Value   $ 128,520,000 $ 124,644,000    
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.19.2
Convertible Notes (Summary of Series 2012 Notes) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Debt Instrument [Line Items]    
Convertible Notes Payable, Carrying Value $ 128,520 $ 124,644
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.19.2
Convertible Notes (Summary of May 2015 Notes) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Debt Instrument [Line Items]    
Convertible Notes Payable, Carrying Value $ 128,520 $ 124,644
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.19.2
Convertible Notes Convertible Notes (Summary of February 2018 Notes) (Detail) (Details)
$ in Millions
Feb. 12, 2014
USD ($)
February 2018 Notes [Member]  
Debt Instrument [Line Items]  
Convertible notes $ 300.0
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.19.2
Convertible Notes Convertible Notes (Interest Expense for February 2018 Notes) (Detail) (Details) - February 2018 Notes [Member] - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2018
Debt Instrument [Line Items]    
Contractual coupon interest $ 0 $ 421
Amortization of debt issuance costs 0 88
Amortization of debt discount 0 293
Total $ 0 $ 802
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.19.2
Convertible Notes Convertible Notes (Summary of December 2021 Notes) (Details) - December 2021 Notes [Member] - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Nov. 22, 2016
Nov. 20, 2015
Debt Instrument [Line Items]        
Debt Instrument, Face Amount $ 150,000 $ 150,000    
Debt Instrument, Unamortized Discount (21,480) (25,356) $ (4,300)  
Convertible notes $ 128,520 $ 124,644 $ 150,000 $ 150,000
XML 76 R64.htm IDEA: XBRL DOCUMENT v3.19.2
Convertible Notes Convertible Notes (Interest Expense for December 2021 Notes) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Debt Instrument [Line Items]        
Debt Instrument, Convertible, Beneficial Conversion Feature $ 1,794 $ 1,626 $ 3,560 $ 3,225
December 2021 Notes [Member]        
Debt Instrument [Line Items]        
Contractual coupon interest 1,032 1,031 2,063 2,062
Amortization of debt issuance costs 20 19 40 38
Amortization of debt discount 138 135 276 269
Interest Expense, Debt $ 2,984 $ 2,811 $ 5,939 $ 5,594
XML 77 R65.htm IDEA: XBRL DOCUMENT v3.19.2
Other Long-Term Liabilities (Narrative) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Schedule of Other Liabilities [Line Items]    
Accrued lease liability $ 10,700 $ 10,700
XML 78 R66.htm IDEA: XBRL DOCUMENT v3.19.2
Other Long-Term Liabilities (Other Long-Term Liabilities) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Schedule of Other Liabilities [Line Items]    
Accrued lease liability $ 10,700 $ 10,700
Accrued Bonuses 146 125
Uncertain tax position 32,402 31,706
Deferred Tax Liabilities, Net, Noncurrent 13,803 13,847
Liabilities, Other than Long-term Debt, Noncurrent 58,181 [1] 56,843 [2]
Total $ 1,130 $ 465
[1] unaudited
[2] Note 1
XML 79 R67.htm IDEA: XBRL DOCUMENT v3.19.2
Stock-Based Compensation (Summary of Stock Option and Restricted Stock Award Activity) (Detail) - $ / shares
shares in Thousands
 6 Months Ended
Jun. 30, 2019
Dec. 31, 2018
Share Based Compensation Arrangment By Share Based Payment Award [Line Items]    
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price $ 0  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 335  
Employee Stock Option [Member]    
Share Based Compensation Arrangment By Share Based Payment Award [Line Items]    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 13,535 7,869
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 5,666  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 3.61  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 0  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $ 3.15 $ 2.82
Restricted Stock [Member]    
Share Based Compensation Arrangment By Share Based Payment Award [Line Items]    
Restricted Stock Award, Number of Shares, Balance at beginning of period (in Shares) 883  
Restricted Stock Awards, Number of Shares Granted (in Shares) 851  
Restricted Stock Awards, Number of Shares, Balance at end of period (in Shares) 1,350  
Restricted Stock Awards, Weighted Average Grant-date Fair Value, Balance at beginning of period (in Dollars per Share) $ 2.87  
Restricted Stock Awards, Weighted Average Grant-date Fair Value, Granted (in Dollars per Share) 3.66  
Restricted Stock Awards, Weighted Average Grant-date Fair Value, Balance at end of period (in Dollars per Share) 3.43  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value 2.69  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value $ 2.52  
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations (49)  
XML 80 R68.htm IDEA: XBRL DOCUMENT v3.19.2
Customer Concentration (Percentage of Total Revenue From Licenses Over 10% of Revenue) (Detail) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Depomed [Member]        
Revenue, Major Customer [Line Items]        
Concentration Risk, Percentage 49.00% 20.00% 39.00% 20.00%
Noden [Member]        
Revenue, Major Customer [Line Items]        
Concentration Risk, Percentage 28.00% 56.00% 41.00% 52.00%
LENSAR [Member]        
Revenue, Major Customer [Line Items]        
Concentration Risk, Percentage 20.00% 13.00% 19.00% 13.00%
Royalty right [Member]        
Revenue, Major Customer [Line Items]        
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings     $ (60,868)  
AcelRx [Member] | Royalty right [Member]        
Revenue, Major Customer [Line Items]        
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings $ (59,974)   $ (57,886)  
XML 81 R69.htm IDEA: XBRL DOCUMENT v3.19.2
Income Taxes (Narrative) (Detail) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Investments, Owned, Federal Income Tax Note [Line Items]        
Change in Uncertain Tax Positions $ 0 $ 0 $ 0 $ 0
Income Tax Expense $ (1,247,000) $ (14,265,000) $ 1,525,000 $ (13,246,000)
Federal income tax rate     21.00%  
XML 82 R70.htm IDEA: XBRL DOCUMENT v3.19.2
Accumulated Other Comprehensive Income (Loss) (Schedule of Balances of Accumulated Other Comprehensive Income (Loss)) (Detail) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Mar. 31, 2018
Jun. 30, 2019
Jun. 30, 2018
Unrealized gains (losses) on available-for-sale securities $ 0 [1] $ 0 [1] $ (1,181) $ 0 [1] $ (1,181) [1]
Other Comprehensive Income (Loss), Net of Tax $ 0 $ 0   $ 0 $ (1,181)
AOCI Attributable to Parent [Member]          
Unrealized gains (losses) on available-for-sale securities     $ (1,181)    
[1] Net of tax of
XML 83 R71.htm IDEA: XBRL DOCUMENT v3.19.2
Subsequent Events (Narrative) (Detail) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 1 Months Ended 4 Months Ended 6 Months Ended 9 Months Ended 10 Months Ended
Aug. 07, 2019
Jul. 05, 2018
Jun. 30, 2019
Jun. 30, 2019
Aug. 07, 2019
Sep. 21, 2018
Sep. 25, 2017
Subsequent Event [Line Items]              
Treasury Stock Acquired, Average Cost Per Share   $ 2.86 $ 3.34 $ 3.22      
Stock Repurchased During Period, Shares   8.7 21.1 29.7      
Stock Repurchased During Period, Value   $ 25.0 $ 70.4 $ 95.9      
Stock Repurchase Program, Authorized Amount           $ 100.0 $ 25.0
Subsequent Event [Member]              
Subsequent Event [Line Items]              
Treasury Stock Acquired, Average Cost Per Share $ 3.17       $ 3.22    
Stock Repurchased During Period, Shares 1.3       31.0    
Stock Repurchased During Period, Value $ 4.1       $ 100.0    
XML 84 R72.htm IDEA: XBRL DOCUMENT v3.19.2
Business Combinations (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Acquired Indefinite-lived Intangible Assets [Line Items]        
Gain (Loss) on Investments $ 45,487 $ 0 $ 45,487 $ 0
XML 85 R73.htm IDEA: XBRL DOCUMENT v3.19.2
Intangibles and Goodwill (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Apr. 22, 2019
Dec. 31, 2018
Jun. 29, 2018
Acquired Finite-Lived Intangible Assets [Line Items]              
Goodwill and Intangible Asset Impairment     $ 152,300        
Finite-Lived Intangible Assets, Gross $ 58,052   58,052     $ 55,752  
Finite-Lived Intangible Assets, Accumulated Amortization (7,603)   (7,603)     (4,433)  
Finite-Lived Intangible Assets, Net 50,449   50,449     51,319  
Amortization of Intangible Assets 1,598 $ 6,384 3,170 $ 12,677      
Contractual Rights [Member]              
Acquired Finite-Lived Intangible Assets [Line Items]              
Finite-Lived Intangible Assets, Gross 36,143   36,143     36,143  
Finite-Lived Intangible Assets, Accumulated Amortization (4,517)   (4,517)     (2,258)  
Finite-Lived Intangible Assets, Net 31,626   31,626     33,885  
Customer Relationships [Member]              
Acquired Finite-Lived Intangible Assets [Line Items]              
Finite-Lived Intangible Assets, Gross 8,028   8,028     8,028  
Finite-Lived Intangible Assets, Accumulated Amortization (1,209)   (1,209)     (782)  
Finite-Lived Intangible Assets, Net 6,819   6,819     7,246  
Patented Technology [Member]              
Acquired Finite-Lived Intangible Assets [Line Items]              
Finite-Lived Intangible Assets, Gross 13,311   13,311     11,011  
Finite-Lived Intangible Assets, Accumulated Amortization (1,630)   (1,630)     (1,203)  
Finite-Lived Intangible Assets, Net 11,681   11,681     9,808  
Trademarks [Member]              
Acquired Finite-Lived Intangible Assets [Line Items]              
Finite-Lived Intangible Assets, Gross 570   570     570  
Finite-Lived Intangible Assets, Accumulated Amortization (247)   (247)     (190)  
Finite-Lived Intangible Assets, Net $ 323   $ 323     $ 380  
DirectFlow [Member]              
Acquired Finite-Lived Intangible Assets [Line Items]              
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life     10 years        
Noden [Member]              
Acquired Finite-Lived Intangible Assets [Line Items]              
Finite-Lived Intangible Asset, Useful Life     8 years        
Finite-Lived Intangible Assets, Gross   $ 40,100   $ 40,100     $ 192,500
Noden [Member]              
Acquired Finite-Lived Intangible Assets [Line Items]              
Fair Value Inputs, Discount Rate (Deprecated 2018-01-31)   21.00%   21.00%      
Original acquisition [Member] | LENSAR [Member]              
Acquired Finite-Lived Intangible Assets [Line Items]              
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life     15 years        
Precision Eye Services [Member] | LENSAR [Member]              
Acquired Finite-Lived Intangible Assets [Line Items]              
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life     20 years        
third-party [Member] | LENSAR [Member]              
Acquired Finite-Lived Intangible Assets [Line Items]              
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life     15 years        
Cash paid [Member] | third-party [Member] | LENSAR [Member]              
Acquired Finite-Lived Intangible Assets [Line Items]              
Finite-Lived Intangible Assets, Gross         $ 2,000    
Milestone [Member] | third-party [Member] | LENSAR [Member]              
Acquired Finite-Lived Intangible Assets [Line Items]              
Finite-Lived Intangible Assets, Gross         $ 300    
XML 86 R74.htm IDEA: XBRL DOCUMENT v3.19.2
Intangibles and Goodwill Schedule of Finite-Lived Intangible Asset Amortization Expense (Details) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year $ 3,212  
Finite-Lived Intangible Assets, Amortization Expense, Year Two 6,394  
Finite-Lived Intangible Assets, Amortization Expense, Year Three 6,362  
Finite-Lived Intangible Assets, Amortization Expense, Year Four 6,257  
Finite-Lived Intangible Assets, Amortization Expense, Year Five 6,194  
Finite-Lived Intangible Assets, Amortization Expense, after Year Five 22,030  
Finite-Lived Intangible Assets, Net $ 50,449 $ 51,319
XML 87 R75.htm IDEA: XBRL DOCUMENT v3.19.2
Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Mar. 31, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Segment Reporting Information [Line Items]            
Long-Lived Assets $ 6,914     $ 6,914   $ 7,387
Net Income (Loss) Attributable to Parent (4,419) $ (112,296) $ 1,602 2,261 $ (110,694)  
Revenues (22,526) 46,575   16,387 85,093  
Income generating assets [Member]            
Segment Reporting Information [Line Items]            
Long-Lived Assets 151     151   160
Net Income (Loss) Attributable to Parent (21,440) 943   (19,190) 4,845  
Revenues (40,363) 14,814   (28,136) 30,008  
Pharmaceutical [Member]            
Segment Reporting Information [Line Items]            
Long-Lived Assets 4,082     4,082   3,682
Net Income (Loss) Attributable to Parent (345) (111,335)   5,300 (113,048)  
Revenues 10,415 25,879   30,375 44,221  
Medical devices [Member]            
Segment Reporting Information [Line Items]            
Long-Lived Assets 2,681     2,681   3,545
Net Income (Loss) Attributable to Parent (1,678) (1,904)   (2,893) (2,491)  
Revenues 7,422 5,882   14,148 10,864  
Strategic positions [Member]            
Segment Reporting Information [Line Items]            
Long-Lived Assets 0     0   $ 0
Net Income (Loss) Attributable to Parent 19,044 0   19,044 0  
Revenues $ 0 $ 0   $ 0 $ 0  
XML 88 R76.htm IDEA: XBRL DOCUMENT v3.19.2
Inventory (Details) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Inventory [Line Items]    
Inventory, Raw Materials, Gross $ 6,023 $ 6,214
Inventory, Work in Process, Gross 2,629 549
Inventory, Finished Goods, Gross 7,611 12,179
Inventory, Net [1] 16,263 18,942
Deferred Costs and Other Assets $ 100 $ 500
[1] unaudited
XML 89 R77.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Equity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 4 Months Ended 6 Months Ended 9 Months Ended
Jul. 05, 2018
Jun. 30, 2019
Jun. 30, 2019
Dec. 31, 2018
Sep. 21, 2018
Sep. 25, 2017
Stockholders' Equity Attributable to Parent [Abstract]            
Stock Repurchase Program, Authorized Amount         $ 100,000 $ 25,000
Stock Repurchased During Period, Shares 8,700,000 21,100,000 29,700,000      
Stock Repurchased During Period, Value $ 25,000 $ 70,400 $ 95,900      
Treasury Stock Acquired, Average Cost Per Share $ 2.86 $ 3.34 $ 3.22      
Treasury Stock, Shares, Acquired   178,700 178,700      
Treasury Stock, Value   $ 546 $ 546 $ 2,103    
XML 90 R78.htm IDEA: XBRL DOCUMENT v3.19.2
Revenue from Contracts with Customers (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jan. 08, 2018
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Jan. 06, 2018
Disaggregation of Revenue [Line Items]            
Revenues   $ (22,526) $ 46,575 $ 16,387 $ 85,093  
Future potential royalty payments           $ 2,000
License and other [Member]            
Disaggregation of Revenue [Line Items]            
Revenues $ 500 30 3 (3) 574  
Medical devices [Member]            
Disaggregation of Revenue [Line Items]            
Revenues   7,422 5,882 14,148 10,864  
Non ASC 606 revenue   1,400 2,800 2,600 4,300  
Revenue from Contract with Customer, Excluding Assessed Tax   6,067 3,044 11,556 6,590  
Medical devices [Member] | North America [Member]            
Disaggregation of Revenue [Line Items]            
Revenue from Contract with Customer, Excluding Assessed Tax     615   2,319  
Medical devices [Member] | Europe [Member]            
Disaggregation of Revenue [Line Items]            
Revenue from Contract with Customer, Excluding Assessed Tax     679   1,294  
Medical devices [Member] | Asia [Member]            
Disaggregation of Revenue [Line Items]            
Revenue from Contract with Customer, Excluding Assessed Tax     1,643   2,757  
Medical devices [Member] | Non-US [Member]            
Disaggregation of Revenue [Line Items]            
Revenue from Contract with Customer, Excluding Assessed Tax     107   220  
Pharmaceutical [Member]            
Disaggregation of Revenue [Line Items]            
Revenues   10,415 25,879 30,375 44,221  
Revenue from Contract with Customer, Excluding Assessed Tax   $ 10,415 25,879 $ 30,375 44,221  
Pharmaceutical [Member] | North America [Member]            
Disaggregation of Revenue [Line Items]            
Revenue from Contract with Customer, Excluding Assessed Tax     10,776   21,707  
Pharmaceutical [Member] | Europe [Member]            
Disaggregation of Revenue [Line Items]            
Revenue from Contract with Customer, Excluding Assessed Tax     6,371   12,362  
Pharmaceutical [Member] | Asia [Member]            
Disaggregation of Revenue [Line Items]            
Revenue from Contract with Customer, Excluding Assessed Tax     8,732   10,152  
Pharmaceutical [Member] | Non-US [Member]            
Disaggregation of Revenue [Line Items]            
Revenue from Contract with Customer, Excluding Assessed Tax     $ 0   $ 0  
Minimum [Member]            
Disaggregation of Revenue [Line Items]            
Term of receivable (in Duration)       30 days    
Maximum [Member]            
Disaggregation of Revenue [Line Items]            
Term of receivable (in Duration)       90 days    
XML 91 R79.htm IDEA: XBRL DOCUMENT v3.19.2
Revenue from Contracts with Customers Contract Assets and Liabilities (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2019
Dec. 31, 2018
Revenue from Contracts with Customers [Abstract]    
Accounts Receivable, Net $ 17,872 $ 20,655
Disaggregation of Revenue [Line Items]    
Contract with Customer, Asset, Net 3,214 2,595
Contract asset payments received (4,019)  
Contract assets recognized 4,638  
Contract with Customer, Liability 4,856 8,938
Medical devices [Member]    
Disaggregation of Revenue [Line Items]    
Contract with Customer, Asset, Net 0 0
Contract asset payments received 0  
Contract assets recognized 0  
Contract with Customer, Liability 1,059  
Pharmaceutical [Member]    
Disaggregation of Revenue [Line Items]    
Contract with Customer, Asset, Net 3,214 $ 2,595
Contract asset payments received (4,019)  
Contract assets recognized 4,638  
Contract with Customer, Liability $ 3,797  
XML 92 R80.htm IDEA: XBRL DOCUMENT v3.19.2
Revenue from Contracts with Customers Transaction Price Allocated to the Remaining Performance Obligations (Details)
$ in Thousands
Jun. 30, 2019
USD ($)
Pharmaceutical [Member]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, Remaining Performance Obligation, Amount $ 2,442
Medical devices [Member]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, Remaining Performance Obligation, Amount $ 6,333
XML 93 R81.htm IDEA: XBRL DOCUMENT v3.19.2
Asset Acquisitions Asset Acquisition Details (Details)
$ in Thousands
Jun. 30, 2019
USD ($)
Business Acquisition [Line Items]  
Business Combination, Contingent Consideration, Liability, Current $ 0
XML 94 R82.htm IDEA: XBRL DOCUMENT v3.19.2
Leases (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Jan. 02, 2019
Dec. 31, 2018
Lessee, Lease, Description [Line Items]            
Lease termination option 3 years          
Sales-type Lease, Revenue $ 0 $ 0 $ 0 $ 151    
Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Next Rolling Twelve Months 431   431     $ 533
Capital Leases, Lessor Balance Sheet, Net Investment in Direct Financing and Sales Type Leases, Noncurrent 547   547     475
Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Remainder of Fiscal Year 245   245      
Lessor, Operating Lease, Payments to be Received, Remainder of Fiscal Year 1,274   1,274      
Operating Lease, Right-of-Use Asset         $ 2,100  
Operating Lease, Liability         $ 2,100  
Lessor, Operating Lease, Payments to be Received, Two Years 1,587   1,587      
Lessor, Operating Lease, Payments to be Received, Three Years 551   551      
Lessor, Operating Lease, Payments to be Received, Four Years 116   116      
Lessor, Operating Lease, Payments to be Received, Rolling Year Five 29   29      
Lessor, Operating Lease, Payments to be Received, Thereafter 0   0      
Lessor, Operating Lease, Payments to be Received 3,557   3,557      
Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Two Years 394   394      
Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Three Years 198   198      
Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Four Years 150   150      
Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Five Years 52   52      
Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received, Thereafter 0   0      
Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received 1,039   1,039      
Sales-type and Direct Financing Leases, Lease Receivable 978   978     $ 1,008
Sales-type and Direct Financing Leases, Lease Receivable, Undiscounted Excess Amount 61   61      
Cost of Goods Sold, Sales-type Lease 0 0 0 58    
Sales-type Lease, Selling Profit (Loss) 0 0 0 209    
Sales-type Lease, Interest Income, Lease Receivable 14 12 26 24    
Operating Leases, Income Statement, Initial Direct Costs 0 0 0 (8)    
Operating Lease, Lease Income $ 1,355 $ 2,840 $ 2,592 $ 4,125    
Lessee, Operating Lease, Renewal Term 5 years   5 years      
Minimum [Member]            
Lessee, Lease, Description [Line Items]            
Lessor, Operating Lease, Term of Contract 1 year   1 year      
Maximum [Member]            
Lessee, Lease, Description [Line Items]            
Lessor, Operating Lease, Term of Contract 8 years   8 years      
Equipment Leased to Other Party [Member] | Minimum [Member]            
Lessee, Lease, Description [Line Items]            
Property, Plant and Equipment, Useful Life     5 years      
Equipment Leased to Other Party [Member] | Maximum [Member]            
Lessee, Lease, Description [Line Items]            
Property, Plant and Equipment, Useful Life     10 years      
XML 95 R83.htm IDEA: XBRL DOCUMENT v3.19.2
Leases Lease expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Lessee, Lease, Description [Line Items]          
Property, Plant and Equipment, Net $ 6,914 [1]   $ 6,914 [1]   $ 7,387 [2]
Operating Leases, Future Minimum Payments Due, Next Twelve Months         1,140
Lease, Cost 253 $ 336 511 $ 633  
Operating Leases, Future Minimum Payments, Due in Two Years         1,003
Operating Leases, Future Minimum Payments, Due in Three Years         559
Operating Leases, Future Minimum Payments, Due in Four Years         0
Operating Leases, Future Minimum Payments, Due in Five Years         0
Operating Leases, Future Minimum Payments, Due Thereafter         0
Operating Leases, Future Minimum Payments Due         2,702
Equipment Leased to Other Party [Member]          
Lessee, Lease, Description [Line Items]          
Property, Plant and Equipment, Gross 6,758   6,758   6,529
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Property, Plant, and Equipment Other, Accumulated Depreciation (4,698)   (4,698)   (3,665)
Property, Plant and Equipment, Net $ 2,060   $ 2,060   $ 2,864
[1] unaudited
[2] Note 1
XML 96 R84.htm IDEA: XBRL DOCUMENT v3.19.2
Investment in Evofem (Details) - Evofem [Member]
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Revenue from Contract with Customer [Member]    
Affiliate financial statements [Line Items]    
Affiliate financial statements - income statements $ 0 $ 0
Operating Income (Loss) [Member]    
Affiliate financial statements [Line Items]    
Affiliate financial statements - income statements (11,941) (25,573)
Income (Loss) [Member]    
Affiliate financial statements [Line Items]    
Affiliate financial statements - income statements (35,450) (53,518)
Stockholders' Equity, Total [Member]    
Affiliate financial statements [Line Items]    
Affiliate financial statements - balance sheet 35,792 35,792
Other Noncurrent Liabilities [Member]    
Affiliate financial statements [Line Items]    
Affiliate financial statements - balance sheet 0 0
Other Current Liabilities [Member]    
Affiliate financial statements [Line Items]    
Affiliate financial statements - balance sheet 18,623 18,623
Other Noncurrent Assets [Member]    
Affiliate financial statements [Line Items]    
Affiliate financial statements - balance sheet 1,566 1,566
Other Current Assets [Member]    
Affiliate financial statements [Line Items]    
Affiliate financial statements - balance sheet $ 52,849 $ 52,849
XML 97 R85.htm IDEA: XBRL DOCUMENT v3.19.2
Investment in Evofem Narrative (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
$ / shares
Jun. 30, 2018
USD ($)
Jun. 10, 2019
USD ($)
$ / shares
shares
Apr. 11, 2019
USD ($)
$ / shares
shares
Debt and Equity Securities, FV-NI [Line Items]            
Investment Owned, at Cost $ 6,600   $ 6,600      
Gain (Loss) on Investments 45,487 $ 0 45,487 $ 0    
Evofem [Member]            
Debt and Equity Securities, FV-NI [Line Items]            
Investment Owned, at Cost 60,000   60,000      
Tranche 1 of investment           $ 30,000
Gain (Loss) on Investments $ 45,487   $ 45,487      
Investment Owned, Balance, Shares | shares           6,666,667
Warrants acquired | shares         1,666,667 1,666,667
Board member appointed         1  
Board observer appointed         1  
Warrants and Rights Outstanding, Term           7 years
Shares acquired | shares         6,666,667  
Investment Warrants, Exercise Price | $ / shares     $ 6.38      
Tranche 2 of investment         $ 30,000  
Cost of tranche two investment option, per share | $ / shares         $ 4.50 $ 4.50
Investment ownership percentage 29.00%   29.00%      
Common Stock [Member] | Evofem [Member]            
Debt and Equity Securities, FV-NI [Line Items]            
Gain (Loss) on Investments $ 37,900   $ 37,900      
Warrant [Member] | Evofem [Member]            
Debt and Equity Securities, FV-NI [Line Items]            
Gain (Loss) on Investments $ 7,600   $ 7,600      
EXCEL 98 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 100 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 101 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 344 462 1 true 100 0 false 4 false false R1.htm 0001000 - Document - Document And Entity Information Sheet http://www.pdl.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) Sheet http://www.pdl.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) Statements 2 false false R3.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) Sheet http://www.pdl.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) Statements 3 false false R4.htm 1002501 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parentheticals) Sheet http://www.pdl.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParentheticals CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parentheticals) Statements 4 false false R5.htm 1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.pdl.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 5 false false R6.htm 1003501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.pdl.com/role/CondensedConsolidatedBalanceSheetsParentheticals CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 6 false false R7.htm 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.pdl.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 7 false false R8.htm 1005000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement Sheet http://www.pdl.com/role/CondensedConsolidatedStatementsOfStockholdersEquityStatement CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement Statements 8 false false R9.htm 2102100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.pdl.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2103100 - Disclosure - Net Income per Share Sheet http://www.pdl.com/role/NetIncomePerShare Net Income per Share Notes 10 false false R11.htm 2104100 - Disclosure - Fair Value Measurements Sheet http://www.pdl.com/role/FairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 2105100 - Disclosure - Cash Equivalents and Investments Sheet http://www.pdl.com/role/CashEquivalentsAndInvestments Cash Equivalents and Investments Notes 12 false false R13.htm 2107100 - Disclosure - Notes Receivable and Other Long-term Receivables Notes http://www.pdl.com/role/NotesReceivableAndOtherLongTermReceivables Notes Receivable and Other Long-term Receivables Notes 13 false false R14.htm 2111100 - Disclosure - Accrued Liabilities Sheet http://www.pdl.com/role/AccruedLiabilities Accrued Liabilities Notes 14 false false R15.htm 2112100 - Disclosure - Commitments and Contingencies Sheet http://www.pdl.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 2113100 - Disclosure - Convertible Notes Notes http://www.pdl.com/role/ConvertibleNotes Convertible Notes Notes 16 false false R17.htm 2115100 - Disclosure - Other Long-Term Liabilities Sheet http://www.pdl.com/role/OtherLongTermLiabilities Other Long-Term Liabilities Notes 17 false false R18.htm 2116100 - Disclosure - Stock-Based Compensation Sheet http://www.pdl.com/role/StockBasedCompensation Stock-Based Compensation Notes 18 false false R19.htm 2117100 - Disclosure - Cash Dividends Sheet http://www.pdl.com/role/CashDividends Cash Dividends Notes 19 false false R20.htm 2118100 - Disclosure - Customer Concentration Sheet http://www.pdl.com/role/CustomerConcentration Customer Concentration Notes 20 false false R21.htm 2119100 - Disclosure - Income Taxes Sheet http://www.pdl.com/role/IncomeTaxes Income Taxes Notes 21 false false R22.htm 2126100 - Disclosure - Intangibles and Goodwill (Notes) Notes http://www.pdl.com/role/IntangiblesAndGoodwillNotes Intangibles and Goodwill (Notes) Notes 22 false false R23.htm 2127100 - Disclosure - Segment Information (Notes) Notes http://www.pdl.com/role/SegmentInformationNotes Segment Information (Notes) Notes 23 false false R24.htm 2128100 - Disclosure - Inventory (Notes) Notes http://www.pdl.com/role/InventoryNotes Inventory (Notes) Notes 24 false false R25.htm 2129100 - Disclosure - Stockholders' Equity (Notes) Notes http://www.pdl.com/role/StockholdersEquityNotes Stockholders' Equity (Notes) Notes 25 false false R26.htm 2130100 - Disclosure - Revenue from Contracts with Customers (Notes) Notes http://www.pdl.com/role/RevenueFromContractsWithCustomersNotes Revenue from Contracts with Customers (Notes) Notes 26 false false R27.htm 2132100 - Disclosure - Leases (Notes) Notes http://www.pdl.com/role/LeasesNotes Leases (Notes) Notes 27 false false R28.htm 2133100 - Disclosure - Investment in Evofem (Notes) Notes http://www.pdl.com/role/InvestmentInEvofemNotes Investment in Evofem (Notes) Notes 28 false false R29.htm 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.pdl.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.pdl.com/role/SummaryOfSignificantAccountingPolicies 29 false false R30.htm 2303301 - Disclosure - Net Income per Share (Tables) Sheet http://www.pdl.com/role/NetIncomePerShareTables Net Income per Share (Tables) Tables http://www.pdl.com/role/NetIncomePerShare 30 false false R31.htm 2304301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.pdl.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.pdl.com/role/FairValueMeasurements 31 false false R32.htm 2305301 - Disclosure - Cash Equivalents and Investments (Tables) Sheet http://www.pdl.com/role/CashEquivalentsAndInvestmentsTables Cash Equivalents and Investments (Tables) Tables http://www.pdl.com/role/CashEquivalentsAndInvestments 32 false false R33.htm 2311301 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.pdl.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.pdl.com/role/AccruedLiabilities 33 false false R34.htm 2313301 - Disclosure - Convertible Notes (Tables) Notes http://www.pdl.com/role/ConvertibleNotesTables Convertible Notes (Tables) Tables http://www.pdl.com/role/ConvertibleNotes 34 false false R35.htm 2315301 - Disclosure - Other Long-Term Liabilities (Tables) Sheet http://www.pdl.com/role/OtherLongTermLiabilitiesTables Other Long-Term Liabilities (Tables) Tables http://www.pdl.com/role/OtherLongTermLiabilities 35 false false R36.htm 2318301 - Disclosure - Customer Concentration (Tables) Sheet http://www.pdl.com/role/CustomerConcentrationTables Customer Concentration (Tables) Tables http://www.pdl.com/role/CustomerConcentration 36 false false R37.htm 2326301 - Disclosure - Intangibles and Goodwill (Tables) Sheet http://www.pdl.com/role/IntangiblesAndGoodwillTables Intangibles and Goodwill (Tables) Tables http://www.pdl.com/role/IntangiblesAndGoodwillNotes 37 false false R38.htm 2326302 - Disclosure - Intangibles and Goodwill Remaining Amortization Expense (Tables) Sheet http://www.pdl.com/role/IntangiblesAndGoodwillRemainingAmortizationExpenseTables Intangibles and Goodwill Remaining Amortization Expense (Tables) Tables 38 false false R39.htm 2327301 - Disclosure - Segment Information (Tables) Sheet http://www.pdl.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.pdl.com/role/SegmentInformationNotes 39 false false R40.htm 2328301 - Disclosure - Inventory (Tables) Sheet http://www.pdl.com/role/InventoryTables Inventory (Tables) Tables http://www.pdl.com/role/InventoryNotes 40 false false R41.htm 2330301 - Disclosure - Revenue from Contracts with Customers (Tables) Sheet http://www.pdl.com/role/RevenueFromContractsWithCustomersTables Revenue from Contracts with Customers (Tables) Tables http://www.pdl.com/role/RevenueFromContractsWithCustomersNotes 41 false false R42.htm 2332301 - Disclosure - Leases (Tables) Sheet http://www.pdl.com/role/LeasesTables Leases (Tables) Tables http://www.pdl.com/role/LeasesNotes 42 false false R43.htm 2333301 - Disclosure - Investment in Evofem (Tables) Sheet http://www.pdl.com/role/InvestmentInEvofemTables Investment in Evofem (Tables) Tables http://www.pdl.com/role/InvestmentInEvofemNotes 43 false false R44.htm 2402403 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Detail) Sheet http://www.pdl.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail Summary of Significant Accounting Policies (Narrative) (Detail) Details http://www.pdl.com/role/SummaryOfSignificantAccountingPoliciesPolicies 44 false false R45.htm 2403402 - Disclosure - Net Income per Share (Narrative) (Detail) Sheet http://www.pdl.com/role/NetIncomePerShareNarrativeDetail Net Income per Share (Narrative) (Detail) Details http://www.pdl.com/role/NetIncomePerShareTables 45 false false R46.htm 2403403 - Disclosure - Net Income per Share (Net Income Per Basic and Diluted Share) (Detail) Sheet http://www.pdl.com/role/NetIncomePerShareNetIncomePerBasicAndDilutedShareDetail Net Income per Share (Net Income Per Basic and Diluted Share) (Detail) Details http://www.pdl.com/role/NetIncomePerShareTables 46 false false R47.htm 2404402 - Disclosure - Fair Value Measurements (Narrative) (Detail) Sheet http://www.pdl.com/role/FairValueMeasurementsNarrativeDetail Fair Value Measurements (Narrative) (Detail) Details http://www.pdl.com/role/FairValueMeasurementsTables 47 false false R48.htm 2404403 - Disclosure - Fair Value Measurements (Financial Instruments Measured at Fair Value on a Recurring Basis) (Detail) Sheet http://www.pdl.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail Fair Value Measurements (Financial Instruments Measured at Fair Value on a Recurring Basis) (Detail) Details http://www.pdl.com/role/FairValueMeasurementsTables 48 false false R49.htm 2404404 - Disclosure - Fair Value Measurements (Schedule of Fair Value of Assets and Liabilities not Subject to Fair Value Recognition) (Detail) Sheet http://www.pdl.com/role/FairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesNotSubjectToFairValueRecognitionDetail Fair Value Measurements (Schedule of Fair Value of Assets and Liabilities not Subject to Fair Value Recognition) (Detail) Details http://www.pdl.com/role/FairValueMeasurementsTables 49 false false R50.htm 2404405 - Disclosure - Fair Value Measurements Level 3 Unobservable Input Reconciliation (Details) Sheet http://www.pdl.com/role/FairValueMeasurementsLevel3UnobservableInputReconciliationDetails Fair Value Measurements Level 3 Unobservable Input Reconciliation (Details) Details 50 false false R51.htm 2405402 - Disclosure - Cash Equivalents and Investments (Narrative) (Detail) Sheet http://www.pdl.com/role/CashEquivalentsAndInvestmentsNarrativeDetail Cash Equivalents and Investments (Narrative) (Detail) Details http://www.pdl.com/role/CashEquivalentsAndInvestmentsTables 51 false false R52.htm 2405403 - Disclosure - Cash Equivalents and Investments (Summary of Cash and Available-For-Sale Securities) (Detail) Sheet http://www.pdl.com/role/CashEquivalentsAndInvestmentsSummaryOfCashAndAvailableForSaleSecuritiesDetail Cash Equivalents and Investments (Summary of Cash and Available-For-Sale Securities) (Detail) Details http://www.pdl.com/role/CashEquivalentsAndInvestmentsTables 52 false false R53.htm 2407401 - Disclosure - Notes Receivable and Other Long-term Receivables (Narrative) (Detail) Notes http://www.pdl.com/role/NotesReceivableAndOtherLongTermReceivablesNarrativeDetail Notes Receivable and Other Long-term Receivables (Narrative) (Detail) Details http://www.pdl.com/role/NotesReceivableAndOtherLongTermReceivables 53 false false R54.htm 2411403 - Disclosure - Accrued Liabilities (Narrative) (Detail) Sheet http://www.pdl.com/role/AccruedLiabilitiesNarrativeDetail Accrued Liabilities (Narrative) (Detail) Details http://www.pdl.com/role/AccruedLiabilitiesTables 54 false false R55.htm 2411404 - Disclosure - Accrued Liabilities (Accrued Liabilities) (Detail) Sheet http://www.pdl.com/role/AccruedLiabilitiesAccruedLiabilitiesDetail Accrued Liabilities (Accrued Liabilities) (Detail) Details http://www.pdl.com/role/AccruedLiabilitiesTables 55 false false R56.htm 2412402 - Disclosure - Commitments and Contingencies (Narrative) (Detail) Sheet http://www.pdl.com/role/CommitmentsAndContingenciesNarrativeDetail Commitments and Contingencies (Narrative) (Detail) Details http://www.pdl.com/role/CommitmentsAndContingencies 56 false false R57.htm 2413402 - Disclosure - Convertible Notes (Narrative) (Detail) Notes http://www.pdl.com/role/ConvertibleNotesNarrativeDetail Convertible Notes (Narrative) (Detail) Details http://www.pdl.com/role/ConvertibleNotesTables 57 false false R58.htm 2413403 - Disclosure - Convertible Notes (Summary of Convertible Notes) (Detail) Notes http://www.pdl.com/role/ConvertibleNotesSummaryOfConvertibleNotesDetail Convertible Notes (Summary of Convertible Notes) (Detail) Details http://www.pdl.com/role/ConvertibleNotesTables 58 false false R59.htm 2413404 - Disclosure - Convertible Notes (Summary of Series 2012 Notes) (Detail) Notes http://www.pdl.com/role/ConvertibleNotesSummaryOfSeries2012NotesDetail Convertible Notes (Summary of Series 2012 Notes) (Detail) Details http://www.pdl.com/role/ConvertibleNotesTables 59 false false R60.htm 2413406 - Disclosure - Convertible Notes (Summary of May 2015 Notes) (Detail) Notes http://www.pdl.com/role/ConvertibleNotesSummaryOfMay2015NotesDetail Convertible Notes (Summary of May 2015 Notes) (Detail) Details http://www.pdl.com/role/ConvertibleNotesTables 60 false false R61.htm 2413408 - Disclosure - Convertible Notes Convertible Notes (Summary of February 2018 Notes) (Detail) (Details) Notes http://www.pdl.com/role/ConvertibleNotesConvertibleNotesSummaryOfFebruary2018NotesDetailDetails Convertible Notes Convertible Notes (Summary of February 2018 Notes) (Detail) (Details) Details 61 false false R62.htm 2413409 - Disclosure - Convertible Notes Convertible Notes (Interest Expense for February 2018 Notes) (Detail) (Details) Notes http://www.pdl.com/role/ConvertibleNotesConvertibleNotesInterestExpenseForFebruary2018NotesDetailDetails Convertible Notes Convertible Notes (Interest Expense for February 2018 Notes) (Detail) (Details) Details 62 false false R63.htm 2413410 - Disclosure - Convertible Notes Convertible Notes (Summary of December 2021 Notes) (Details) Notes http://www.pdl.com/role/ConvertibleNotesConvertibleNotesSummaryOfDecember2021NotesDetails Convertible Notes Convertible Notes (Summary of December 2021 Notes) (Details) Details 63 false false R64.htm 2413411 - Disclosure - Convertible Notes Convertible Notes (Interest Expense for December 2021 Notes) (Details) Notes http://www.pdl.com/role/ConvertibleNotesConvertibleNotesInterestExpenseForDecember2021NotesDetails Convertible Notes Convertible Notes (Interest Expense for December 2021 Notes) (Details) Details 64 false false R65.htm 2415402 - Disclosure - Other Long-Term Liabilities (Narrative) (Detail) Sheet http://www.pdl.com/role/OtherLongTermLiabilitiesNarrativeDetail Other Long-Term Liabilities (Narrative) (Detail) Details http://www.pdl.com/role/OtherLongTermLiabilitiesTables 65 false false R66.htm 2415403 - Disclosure - Other Long-Term Liabilities (Other Long-Term Liabilities) (Detail) Sheet http://www.pdl.com/role/OtherLongTermLiabilitiesOtherLongTermLiabilitiesDetail Other Long-Term Liabilities (Other Long-Term Liabilities) (Detail) Details http://www.pdl.com/role/OtherLongTermLiabilitiesTables 66 false false R67.htm 2416405 - Disclosure - Stock-Based Compensation (Summary of Stock Option and Restricted Stock Award Activity) (Detail) Sheet http://www.pdl.com/role/StockBasedCompensationSummaryOfStockOptionAndRestrictedStockAwardActivityDetail Stock-Based Compensation (Summary of Stock Option and Restricted Stock Award Activity) (Detail) Details http://www.pdl.com/role/StockBasedCompensation 67 false false R68.htm 2418403 - Disclosure - Customer Concentration (Percentage of Total Revenue From Licenses Over 10% of Revenue) (Detail) Sheet http://www.pdl.com/role/CustomerConcentrationPercentageOfTotalRevenueFromLicensesOver10OfRevenueDetail Customer Concentration (Percentage of Total Revenue From Licenses Over 10% of Revenue) (Detail) Details http://www.pdl.com/role/CustomerConcentrationTables 68 false false R69.htm 2419402 - Disclosure - Income Taxes (Narrative) (Detail) Sheet http://www.pdl.com/role/IncomeTaxesNarrativeDetail Income Taxes (Narrative) (Detail) Details http://www.pdl.com/role/IncomeTaxes 69 false false R70.htm 2420403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Schedule of Balances of Accumulated Other Comprehensive Income (Loss)) (Detail) Sheet http://www.pdl.com/role/AccumulatedOtherComprehensiveIncomeLossScheduleOfBalancesOfAccumulatedOtherComprehensiveIncomeLossDetail Accumulated Other Comprehensive Income (Loss) (Schedule of Balances of Accumulated Other Comprehensive Income (Loss)) (Detail) Details 70 false false R71.htm 2422401 - Disclosure - Subsequent Events (Narrative) (Detail) Sheet http://www.pdl.com/role/SubsequentEventsNarrativeDetail Subsequent Events (Narrative) (Detail) Details 71 false false R72.htm 2425403 - Disclosure - Business Combinations (Details) Sheet http://www.pdl.com/role/BusinessCombinationsDetails Business Combinations (Details) Details 72 false false R73.htm 2426403 - Disclosure - Intangibles and Goodwill (Details) Sheet http://www.pdl.com/role/IntangiblesAndGoodwillDetails Intangibles and Goodwill (Details) Details http://www.pdl.com/role/IntangiblesAndGoodwillTables 73 false false R74.htm 2426404 - Disclosure - Intangibles and Goodwill Schedule of Finite-Lived Intangible Asset Amortization Expense (Details) Sheet http://www.pdl.com/role/IntangiblesAndGoodwillScheduleOfFiniteLivedIntangibleAssetAmortizationExpenseDetails Intangibles and Goodwill Schedule of Finite-Lived Intangible Asset Amortization Expense (Details) Details 74 false false R75.htm 2427402 - Disclosure - Segment Information (Details) Sheet http://www.pdl.com/role/SegmentInformationDetails Segment Information (Details) Details http://www.pdl.com/role/SegmentInformationTables 75 false false R76.htm 2428402 - Disclosure - Inventory (Details) Sheet http://www.pdl.com/role/InventoryDetails Inventory (Details) Details http://www.pdl.com/role/InventoryTables 76 false false R77.htm 2429402 - Disclosure - Stockholders' Equity (Details) Sheet http://www.pdl.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.pdl.com/role/StockholdersEquityNotes 77 false false R78.htm 2430402 - Disclosure - Revenue from Contracts with Customers (Details) Sheet http://www.pdl.com/role/RevenueFromContractsWithCustomersDetails Revenue from Contracts with Customers (Details) Details http://www.pdl.com/role/RevenueFromContractsWithCustomersTables 78 false false R79.htm 2430403 - Disclosure - Revenue from Contracts with Customers Contract Assets and Liabilities (Details) Sheet http://www.pdl.com/role/RevenueFromContractsWithCustomersContractAssetsAndLiabilitiesDetails Revenue from Contracts with Customers Contract Assets and Liabilities (Details) Details 79 false false R80.htm 2430404 - Disclosure - Revenue from Contracts with Customers Transaction Price Allocated to the Remaining Performance Obligations (Details) Sheet http://www.pdl.com/role/RevenueFromContractsWithCustomersTransactionPriceAllocatedToRemainingPerformanceObligationsDetails Revenue from Contracts with Customers Transaction Price Allocated to the Remaining Performance Obligations (Details) Details 80 false false R81.htm 2431403 - Disclosure - Asset Acquisitions Asset Acquisition Details (Details) Sheet http://www.pdl.com/role/AssetAcquisitionsAssetAcquisitionDetailsDetails Asset Acquisitions Asset Acquisition Details (Details) Details 81 false false R82.htm 2432402 - Disclosure - Leases (Details) Sheet http://www.pdl.com/role/LeasesDetails Leases (Details) Details http://www.pdl.com/role/LeasesTables 82 false false R83.htm 2432403 - Disclosure - Leases Lease expense (Details) Sheet http://www.pdl.com/role/LeasesLeaseExpenseDetails Leases Lease expense (Details) Details 83 false false R84.htm 2433402 - Disclosure - Investment in Evofem (Details) Sheet http://www.pdl.com/role/InvestmentInEvofemDetails Investment in Evofem (Details) Details http://www.pdl.com/role/InvestmentInEvofemTables 84 false false R85.htm 2433403 - Disclosure - Investment in Evofem Narrative (Details) Sheet http://www.pdl.com/role/InvestmentInEvofemNarrativeDetails Investment in Evofem Narrative (Details) Details 85 false false All Reports Book All Reports pdli-20190630.xml pdli-20190630.xsd pdli-20190630_cal.xml pdli-20190630_def.xml pdli-20190630_lab.xml pdli-20190630_pre.xml http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/invest/2013-01-31 true true ZIP 103 0000882104-19-000089-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000882104-19-000089-xbrl.zip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̤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end